

2027

# Fòmilè

(Lis Medikaman ki Kouvri yo oswa “Lis Medikaman”)

Wellcare PA Health & Wellness Dual Liberty Sync (HMO-POS D-SNP),  
Wellcare PA Health & Wellness Dual Select (HMO-POS D-SNP)

42



## TANPRI LI: DOKIMAN SA A GENYEN ENFÒMASYON SOU MEDIKAMAN NOU GARANTI NAN PLAN SA A

**Nimewo Idantite (ID) soumisyon fichye Fòmilè HPMS apwouve a: 27156**

**Fòmilè sa a te aktyalize nan dat 10/15/2026.** Pou plis enfòmasyon ki resan oswa lòt kesyon, tanpri kontakte nou, Sèvis pou Manm Wellcare yo nan **1-833-502-9471** (itilizatè TTY yo ta dwe rele nan **711**), ant 1 Oktòb ak 31 Mas, reprezantan yo disponib sèt jou pa semèn, 8 a.m. jiska 8 p.m., ant 1 Avril ak 30 Septanm, reprezantan yo disponib Lendi jiska Vandredi, 8 a.m. jiska 8 p.m., oswa vizite **[go.wellcare.com/PA](https://go.wellcare.com/PA)**.



With



pa health  
& wellness.

**Nòt pou manm ki deja egziste yo:** Fòmilè sa a te chanje depi ane pase. Tanpri revize dokiman sa a pou asire w li toujou genyen medikaman w ap pran yo.

Lè Lis Medikaman sa a (Fòmilè) fè referans ak "nou," "nou menm" oswa "pa nou," sa vle di Wellcare. Lè li fè referans ak "plan" oswa "plan nou an," sa vle di Wellcare PA Health & Wellness Dual Liberty Sync (HMO-POS D-SNP), Wellcare PA Health & Wellness Dual Select (HMO-POS D-SNP).

Dokiman sa a gen ladann yon Lis Medikaman (fòmilè) pou plan nou an ki aktyalize apati 10/15/2026. Pou yon Lis Medikaman ki aktyalize (fòmilè), tanpri kontakte nou. Enfòmasyon kontak nou yo, ansanm ak dènye dat nou te mete ajou Lis Medikaman an (fòmilè), parèt nan paj kouvèti devan ak do yo.

Ou dwe jeneralman itilize famasi ki nan rezo yo pou itilize avantaj medikaman sou preskripsyon ou an. Avantaj, fòmilè, rezo famasi, ak/oswa kopeman/ko-asirans yo gen dwa chanje nan dat 1 Janvyè 2027, epi detanzantan pandan ane a.

## **Kisa fòmilè Wellcare PA Health & Wellness Dual Liberty Sync (HMO-POS D-SNP), Wellcare PA Health & Wellness Dual Select (HMO-POS D-SNP) la ye?**

Nan dokiman sa a, nou itilize tèm lis medikaman ak fòmilè pou eksprime menm bagay la. Yon fòmilè se yon lis medikaman ki kouvri ki chwazi bò kote plan nou an nan konsiltasyon ak yon ekip founisè swen sante, ki reprezante terapi sou òdonans yo konsidere kòm yon pati nesesè nan yon pwogram tretman kalite. Anjeneral, plan nou an pral garanti medikaman ki endike nan fòmilè nou an toutotan medikaman an nesesè sou plan medikal, preskripsyon an egzekite nan yon famasi nan rezo plan an, epi yo swiv lòt règ plan an. Pou plis enfòmasyon sou fason pou egzekite preskripsyon ou yo, tanpri revize Prèk Kouvèti Asirans ou a.

### **Èske fòmilè a ka chanje?**

Pifò chanjman nan kouvèti medikaman yo rive 1 janvye, men nou gen dwa ajoute oswa retire medikaman nan fòmilè a pandan ane a, nou gen dwa deplase yo nan diferan nivo pataj frè oswa ajoute nouvo restriksyon. Nou dwe swiv règ Medicare yo lè nou fè chanjman sa yo. Nou pibliye mizajou yo nan fòmilè a chak mwa sou sitwèb nou an isit la: [go.wellcare.com/PA](https://go.wellcare.com/PA).

**Chanjman ki ka afekte ou ane sa a: Nan ka ki anba yo, chanjman kouvèti asirans yo pral afekte w pandan ane a:**

- **Ranplasman imedya nan kèk nouvo vèsyon medikaman mak depoze ak pwodwi byolojik orijinal yo.** Nou gen dwa retire imedyatman yon medikaman nan fòmilè nou an si nou ranplase li ak yon sèten nouvo vèsyon medikaman sa a ki pral parèt ak menm oswa mwens nivo pataj frè epi ak menm restriksyon oswa mwens. Lè nou ajoute yon nouvo vèsyon yon medikaman nan fòmilè nou an, nou gen dwa deside kenbe medikaman mak depoze a oswa pwodwi byolojik orijinal la nan fòmilè nou an, men imedyatman deplase l nan yon diferan nivo pataj frè oswa ajoute nouvo restriksyon.

Nou kapab fè chanjman imedya sa yo sèlman si n ap ajoute yon nouvo vèsyon jenerik yon medikaman mak depoze, oswa si nou ajoute nouvo vèsyon byosimilè nan yon pwodwi byolojik orijinal, ki te deja nan fòmilè a (pa egzanp: ajoute yon byosimilè entèchanjab ki pa ka ranplase ak yon pwodui byolojik orijinal ak yon famasi san yon nouvo preskripsyon).

Si w ap pran medikaman mak depoze oswa pwodwi byolojik orijinal la kounye a, nou gen dwa pa di w alavans anvan nou fè yon chanjman imedyata, men pi devan n ap ba w enfòmasyon sou chanjman presi nou te fè a.

Si nou fè yon chanjman konsa, ou menm oswa preskriptè w la ka mande nou pou nou fè yon eksepsyon epi kontinye garanti medikaman y ap chanje a pou ou. Pou plis enfòmasyon, gade seksyon anba a ki rele “Ki jan mwen ka mande yon eksepsyon nan fòmilè Wellcare PA Health & Wellness Dual Liberty Sync (HMO-POS D-SNP), Wellcare PA Health & Wellness Dual Select (HMO-POS D-SNP) a?”

Kèk nan kalite medikaman sa yo gen dwa nouvo pou ou. Kèk nan kalite medikaman sa yo gen dwa nouvo pou ou. Pou plis enfòmasyon, gade seksyon ki anba a ki rele "Kisa pwodwi byolojik orijinal la ye e kijan li lye ak byosimilè yo?"

- **Medikaman yo retire sou mache a.** Si fabrikan an retire yon medikaman nan vant oswa Food and Drug Administration (FDA) decide retire li pou rezon sekirite oswa efikasite, nou gen dwa retire medikaman an imedyatman nan fòmilè nou an epi apresya bay manm yo ki pran medikaman an avètisman.

- **Lòt chanjman.** Nou gen dwa fè lòt chanjman ki afekte manm k ap pran yon medikaman kounye a. Pa egzanp, nou gen dwa retire yon medikaman mak depoze nan fòmilè an lè nou ajoute yon ekivalan jenerik oswa retire yon pwodwi byolojik orijinal lè nou ajoute yon byosimilè. Nou gen dwa aplike tou nouvo restriksyon sou medikaman mak depoze oswa pwodwi byolojik orijinal la, oswa deplase li nan yon nivo pataj frè diferan, oswa toude. Nou gen dwa fè chanjman ki baze sou nouvo direktiv klinik yo. Si nou retire medikaman nan fòmilè nou an, ajoute otorizasyon alavans, limit kantite ak/ oswa restriksyon terapi pa etap sou yon medikaman, oswa yon medikaman nan yon nivo pataj frè ki plis, nou dwe enfòmè manm ki afekte yo sou chanjman an omwen 30 jou anvan chanjman an vin anvigè. Altènativman, lè yon manm mande yon renouvèlman medikaman an, li gen dwa resevwa yon rezèv pou 30 jou nan medikaman an ak avi sou chanjman an.

Si nou fè lòt chanjman sa yo, ou menm oswa preskriptè w la ka mande nou pou fè yon eksepsyon pou ou epi kontinye garanti medikaman w ap pran an. Avi nou ba w la pral gen ladan enfòmasyon sou fason pou mande yon eksepsyon, epi ou ka jwenn tou enfòmasyon nan seksyon anba a ki rele “Ki jan mwen ka mande yon eksepsyon nan fòmilè Wellcare PA Health & Wellness Dual Liberty Sync (HMO-POS D-SNP), Wellcare PA Health & Wellness Dual Select (HMO-POS D-SNP) a?”

**Chanjman ki p ap afekte w si w ap pran medikaman an kounye a.** Anjeneral, si w ap pran yon medikaman nan fòmilè nou an pou lane 2027 ki te garanti nan kòmansman ane a, nou p ap sispann oswa redui kouvèti medikaman an pandan ane kouvèti 2027 la eksepte jan sa dekri pi wo a. Sa vle di medikaman sa yo ap rete disponib nan menm pataj frè an epi pa gen okenn nouvo restriksyon pou manm sa yo k ap pran yo a pandan rès ane kouvèti asirans lan. Ou p ap resevwa avi dirèk ane sa a sou chanjman ki pa afekte w. Sepandan, nan dat 1 janvyè ane k ap vini an, chanjman sa yo ta afekte w, epi li enpòtan pou verifye fòmilè a pou nouvo ane avantaj la pou nenpòt chanjman nan medikaman yo.

Fòmilè ki atache a aktyalize depi 10/15/2026. Pou jwenn enfòmasyon ajou sou medikaman plan nou an garanti, tanpri kontakte nou. Enfòmasyon kontak nou yo parèt nan paj kouvèti devan ak do an.

Fòmilè a pral aktyalize chak mwa epi afiche sou sit entènèt nou an. Pou jwenn yon lis enprime lis medikaman ki kouvri ki ajou a oswa pou w jwenn enfòmasyon sou medikaman plan nou an garanti, tanpri vizite sit entènèt nou an oswa rele Sèvis pou Manm yo nan enfòmasyon kontak nou yo ki nan paj kouvèti ak do yo.

## Kijan pou mwen itilize fòmilè a?

Gen de fason pou jwenn medikaman ou an nan lis medikaman ki kouvri an:

### **Kondisyon Medikal.**

Fòmilè a kòmanse nan paj 1. Medikaman yo ki nan fòmilè sa a gwoupe an kategori selon kalite kondisyon medikal yo sèvi pou trete. Pa egzanp, medikaman yo itilize pou trete yon maladi kè nan lis kategori "Kadyo-vaskilè, Tansyon / Lipid." Si w konnen poukisa medikaman w lan bon, chèche non kategori a nan lis ki kòmanse nan paj 1 an. Apresa, gade anba non kategori medikaman ou a.

### **Lis Alfabetik**

Si w pa sèten ki kategori pou w gade, ou ta dwe chèche medikaman w lan nan Endèks ki kòmanse nan paj INDEX-1. Endèks la bay yon lis alfabetik tout medikaman ki nan dokiman sa a. Alafwa medikaman mak depoze yo ak medikaman jenerik yo nan lis Endèks la. Gade nan endèks la epi jwenn medikaman ou a. Akote medikaman w la, w ap wè nimewo paj la kote w ka jwenn enfòmasyon sou kouvèti a. Ale nan paj ki nan Endèks la epi jwenn non medikaman w lan nan premye kolòn lis la.

## **Kisa medikaman jenerik yo ye?**

Plan nou an garanti alafwa medikaman mak depoze ak medikaman jenerik yo. Yon medikaman jenerik jwenn apwobasyon FDA a kòmkiwa li gen menm engredyan aktif ak medikaman mak depoze la. Anjeneral, medikaman jenerik fonksyone menm jan e yo abityèlman koute mwens pase medikaman ki depoze yo. Gen ranplasan medikaman jenerik ki disponib pou anpil medikaman ki depoze yo. Anjeneral, medikaman jenerik yo ka ranplase medikaman mak depoze la nan famasi san yo pa bezwen yon nouvo preskripsyon, selon lwa Eta a.

## **Kisa pwodwi byolojik orijinal yo ye e kijan yo lye ak byosimilè yo?**

Nan fòmilè a lè nou fè referans ak medikaman, sa ta ka vle di yon medikaman oswa yon pwodwi byolojik. Pwodwi byolojik yo se medikaman ki pi konplèks pase medikaman tipik. Piske pwodwi byolojik yo pi konplèks pase medikaman tipik yo, olye pou yo gen yon fòm jenerik, yo gen lòt posiblite yo rele byosimilè. Anjeneral, byosimilè fonksyone menm jan ak pwodwi byolojik orijinal la epi yo gen dwa koute mwens. Gen lòt posiblite byosimilè pou kèk pwodwi byolojik orijinal yo. Kèk byosimilè yo se byosimilè ki ka ranplase epi, selon lwa Eta a, yo gen dwa ranplase pwodwi byolojik orijinal la nan famasi a san yo pa bezwen yon nouvo preskripsyon, menm jan medikaman jenerik yo ka ranplase medikaman mak depoze yo.

Pou diskisyon sou kalite medikaman yo, tanpri gade Prèv Kouvèti Asirans a, Chapit 5, Seksyon 3.1, "'Lis Medikaman' an di ki medikaman Pati D ki garanti yo."

## Èske gen restriksyon sou pwoteksyon mwen an?

Kèk medikaman ki kouvri gen dwa gen egzijans siplemantè oswa limit sou kouvèti asirans lan. Egzijans ak limit sa yo gen dwa ladan l:

- **Otorizasyon Alavans:** Plan nou an egzije ou menm oswa preskriptè w la pou w jwenn otorizasyon alavans pou kèk medikaman. Sa vle di w ap bezwen jwenn apwobasyon nan men plan nou an dapre kèk kritè espesifik anvan ou egzekite preskripsyon ou yo. Si ou pa jwenn apwobasyon, plan nou an gen dwa pa garanti medikaman an.
- **Limit Kantite:** Pou kèk medikaman, plan nou an limite kantite medikaman ke li pral garanti. Pa egzanp, plan nou an bay 18 konprime pou chak preskripsyon pou rizatriptan 5mg. Sa a gen dwa vin anplis yon rezèv estanda pou yon mwa oswa twa mwa.
- **Terapi pa Etap:** Nan kèk ka, plan nou an mande pou w eseye dabò kèk medikaman pou trete kondisyon medikal ou an anvan nou garanti yon lòt medikaman pou kondisyon sa a. Pa egzanp, si Medikaman A ak Medikaman B toude trete kondisyon medikal ou an, plan nou an gen dwa pa garanti Medikaman B sof si ou eseye Medikaman A dabò. Si Medikaman A pa fonksyone pou ou, plan nou an pral garanti Medikaman B.

Ou ka chèche konnen si medikaman ou a gen nenpòt lòt kondisyon oswa limit lè w gade nan fòmilè ki kòmanse nan paj 1 an. Ou ka jwenn plis enfòmasyon tou sou restriksyon ki aplike pou medikaman presi ki kouvri yo lè w vizite sit entènèt nou an. Nou afiche dokiman sou entènèt ki esplike otorizasyon alavans nou yo ak restriksyon terapi pa etap nou yo. Ou gen dwa mande nou tou pou voye yon kopi ba ou. Enfòmasyon kontak nou yo, ansanm ak dènye dat nou te aktyalize fòmilè a, parèt nan paj kouvèti devan ak do yo.

Ou ka mande plan nou an pou fè yon eksepsyon nan restriksyon oswa limit sa yo oswa pou yon lis lòt medikaman ki sanble ki gen dwa trete kondisyon sante ou. Gade seksyon, “Ki jan mwen ka mande yon eksepsyon nan fòmilè Wellcare PA Health & Wellness Dual Liberty Sync (HMO-POS D-SNP), Wellcare PA Health & Wellness Dual Select (HMO-POS D-SNP) a?” nan paj XI pou jwenn enfòmasyon sou fason pou mande yon eksepsyon.

## **E si medikaman mwen an pa nan fòmilè a?**

Si medikaman ou a pa nan fòmilè sa a (lis medikaman ki kouvri yo), ou ta dwe kontakte Sèvis pou Manm yo dabò epi mande si medikaman ou an garanti.

Si w aprann plan nou an pa garanti medikaman w lan, ou gen de opsyon:

- Ou ka mande Sèvis pou Manm yo yon lis medikaman ki sanble ki garanti nan plan nou an. Lè w resevwa lis la, montre doktè w la epi mande yo pou yo preskri yon medikaman ki menm jan ki garanti nan plan nou an .
- Ou ka mande plan nou an pou fè yon eksepsyon epi garanti medikaman w lan. Gade pi ba a pou enfòmasyon sou fason pou mande yon eksepsyon.

## **Ki jan mwen ka mande yon eksepsyon nan fòmilè Wellcare PA Health & Wellness Dual Liberty Sync (HMO-POS D-SNP), Wellcare PA Health & Wellness Dual Select (HMO-POS D-SNP) a?**

Ou ka mande plan nou an pou fè yon eksepsyon nan règ kouvèti asirans nou an. Gen plizyè kalite eksepsyon ou ka mande nou fè.

- Ou ka mande nou pou garanti yon medikaman menm si li pa nan fòmilè nou an. Si l apwouve, medikaman sa a pral garanti nan yon nivo pataj frè yo te detèmine alavans, epi ou pa ta kapab mande nou bay medikaman an nan yon nivo pataj frè ki pi ba.
- Ou ka mande nou pou nou anile yon restriksyon sou kouvèti ki gen ladan l otorizasyon alavans, terapi pa etap, oswa yon limit nan kantite sou medikaman ou a. Pa egzanp, pou kèk medikaman, plan nou an limite kantite medikaman n ap garanti a. Si medikaman ou a gen yon limit nan kantite, ou ka mande nou anile limit la epi garanti yon pi gwo kantite.
- Ou ka mande nou pou kouvri yon medikaman nan fòmilè a nan yon nivo pataj frè ki pi ba sof si medikaman an nan yon nivo espesyalize. Si apwouve, sa t ap bese montan ou dwe peye pou medikaman w lan.

Anjeneral, plan nou an ap apwouve demann ou an pou yon eksepsyon sèlman si medikaman altènatif yo nan fòmilè plan an, medikaman pataj frè ki pi ba a, oswa si aplikasyon restriksyon an pa ta efikas pou ou epi/oswa ta lakòz ou gen efè negatif.

Ou menm oswa preskriptè w la ta dwe kontakte nou pou mande yon klasifikasyon nan nivo a, eksepsyon a lis medikaman ki kouvri, ki gen ladan yon eksepsyon nan yon restriksyon sou kouvèti a. **Lè w mande yon eksepsyon,**

**preskriptè w la ap bezwen esplike rezon medikal ki fè w bezwen**

**eksepsyon an.** Anjeneral, nou dwe pran desizyon nou an nan espas 72 èdtan apre nou resevwa deklarasyon sipò preskriptè w la. Ou ka mande yon desizyon akselere (rapid) si ou kwè, epi nou dakò, sante ou ta ka vin gravman andomaje lè w tann jiska 72 èdtan pou yon desizyon. Si nou dakò, oswa si preskriptè w la mande pou yon desizyon rapid, nou dwe ba w yon desizyon pa pita pase 24 èdtan apre nou resevwa deklarasyon sipò doktè w la.

## **Kisa mwen ka fè si medikaman mwen an pa nan fòmilè a oswa si gen yon restriksyon?**

Antanke yon nouvo manm oswa yon manm k ap kontinye nan plan nou an, ou gen dwa pran medikaman ki pa nan fòmilè nou an. Oswa, ou gen dwa pran yon medikaman ki nan fòmilè an men ki gen yon restriksyon sou kouvèti, tankou otorizasyon alavans. Ou ta dwe pale ak preskriptè w la sou posibilite pou mande yon desizyon sou kouvèti ki montre w reponn ak kritè apwobasyon an, pou w pase nan yon medikaman altènatif nou garanti, oswa pou w mande yon eksepsyon nan lis medikaman ki kouvri an pou nou ka garanti medikaman w ap pran an. Pandan ou menm ak doktè ou an ap detèmine machaswiv ki ap bon pou ou an, nou gen dwa garanti medikaman ou an nan kèk ka pandan premye 90 jou kòm manm nan plan nou an.

Pou chak medikaman ou yo ki pa nan fòmilè nou an oswa ki gen yon restriksyon sou kouvèti, nou pral garanti yon rezèv tanporè pou 30 jou. Si preskripsyon ou an ekri pou mwens jou, nou pral otorize renouvèlman pou bay rezèv medikaman jiska 30 jou maksimòm. Si yo pa apwouve pwoteksyon, apre premye rezèv ou an pou 30 jou, nou p ap peye pou medikaman sa yo, menm si ou se manm plan an pandan mwens pase 90 jou.

.Si w abite nan yon etablisman swen alongtèm epi w bezwen yon medikaman ki pa nan fòmilè nou an oswa si kapasite w pou jwenn medikaman w yo limite, men w sot pase premye 90 jou afilyasyon nan plan nou an, n ap garanti yon rezèv ijans pou 31 jou nan medikaman sa a pandan w ap chèche yon eksepsyon a lis medikaman ki kouvri.

Si w fè eksperyans yon chanjman nan nivo swen (tankou yo te egzeye oswa ospitalize w nan yon etablisman swen alongtèm), doktè w oswa famasi ou an ka rele Sant Sèvis Founisè nou an epi mande yon ranvwa pou yon sèl fwa. Anilasyon yon sèl fwa sa a ap jiska yon rezèv pou 30 jou (sòf si ou gen yon preskripsyon ekri pou mwens jou).

## Pou plis enfòmasyon

Pou jwenn plis enfòmasyon detaye sou kouvèti plan medikaman preskripsyon ou an, tanpri revize Prèv Kouvèti Asirans ou a ak lòt dokiman plan an.

Si w gen kesyon sou plan nou an, tanpri kontakte nou. Enfòmasyon kontak nou yo, ansanm ak dènye dat nou te aktyalize fòmilè a, parèt nan paj kouvèti devan ak do yo.

Si w gen kesyon jeneral sou kouvèti medikaman preskripsyon Medicare, tanpri rele Medicare nan 1-800-MEDICARE (**1-800-633-4227**) 24 èdtan pa jou/7 jou pa semèn. Itilizatè TTY yo ta dwe rele **1-877-486-2048**. Oswa, vizite [\*\*http://www.medicare.gov\*\*](http://www.medicare.gov).

## Fòmilè plan nou an

Fòmilè ki anba a bay enfòmasyon sou kouvèti medikaman ki kouvri pa plan nou an . Si w gen pwoblèm pou w jwenn medikaman w lan nan lis la, ale nan Endèks ki kòmanse nan paj INDEX-1.

Premye kolòn nan tablo a bay non medikaman an. Medikaman mak depoze yo an lèt majiskil (tankou, ELIQUIS) epi medikaman jenerik yo ekri an italik miniskil (tankou, *simvastatin*).

Enfòmasyon ki nan kolòn Egzijans/Limit yo fè w konnen si plan nou an gen nenpòt egzijans espesyal pou garanti medikaman w lan.

- **NT** vle di Pa Nan Pati D: Medikaman sou preskripsyon sa a pa nòmalman kouvri nan yon Plan Medikaman sou Preskripsyon Medicare. Montan ou peye lè ou egzekite yon preskripsyon pou medikaman sa pa konte sou kou medikaman total ou yo (sa vle di, montan ou peye a pa ede w kalifye pou kouvèti katastwofik la). Anplis, si w ap resevwa èd siplemantè (Extra Help) pou peye pou preskripsyon w yo, ou p ap resevwa okenn lòt èd pou peye pou medikaman sa a.
- **NM** vle di medikaman an pa disponib atravè avantaj sèvis nan lapòs mansyèl ou an. Yo note sa nan kolòn Egzijans/Limit nan kolòn fòmilè a. Ou gen dwa anmezi pou resevwa plis pase yon mwa rezèv pou pifò medikaman ki nan fòmilè ou a atravè sèvis lapòs nan yon pri ki redui. Tanpri gade Chapit 5 Prèy Kouvèti Asirans ou a pou plis enfòmasyon.
- **PA** vle di Otorizasyon Alavans: Tanpri gade paj IX la pou plis detay.

- **PA-NS** vle di Otorizasyon Alavans pou Nouvo Demaraj: Sa vle di si medikaman sa a nouvo pou ou, w ap bezwen jwenn apwobasyon nan men nou anvan ou egzekite preskripsyon w la. Si w ap pran medikaman sa a nan moman enskripsyon an, ou p ap oblije satisfè kritè pou apwobasyon.
- **B/D** vle di Garanti anba Medicare B oswa D: Medikaman sa a ka kalifye pou peman nan kad Medicare Part B oswa Part D. Ou menm (oswa doktè ou an) oblije jwenn otorizasyon alavans nan men nou pou detèmine si medikaman sa a garanti anba Medicare Part D anvan ou egzekite preskripsyon ou pou medikaman sa a. San apwobasyon alavans, nou ka pa garanti medikaman sa a.
- **QL** vle di Limit Kantite: Tanpri gade paj IX la pou plis detay.
- **LA** vle di Medikaman ki gen Aksè Limite. Preskripsyon sa a gen dwa disponib sèlman nan kèk famasi. Pou jwenn plis enfòmasyon, konsilte Lis Famasi ou an oswa rele Sèvis pou Manm yo nan 1-833-502-9471. Itilizatè TTY yo ta dwe rele nan 711, ant 1 Oktòb ak 31 Mas, reprezantan yo disponib sèt jou pa semèn, 8 a.m. to 8 p.m., ant 1 Avril ak 30 Septanm, reprezantan yo disponib Lendi–Vandredi, 8 a.m. rive 8 p.m., oswa vizite [go.wellcare.com/PA](https://go.wellcare.com/PA).
- **ST** vle di Terapi pa Etap: Tanpri gade paj IX la pou plis detay.
- **^** vle di Medikaman gen dwa disponib pou jiska 30 jou sèlman.

## Montan kopeman/ko-asirans nivo medikaman yo

Medikaman sou preskripsyon yo gwoupe nan yon sis nivo. Pou konnen nan ki nivo medikaman w lan ye, gade nan kolòn Nivo Medikaman nan fòmilè an ki kòmanse nan paj 1 a. Pou jwenn plis enfòmasyon detaye sou depans pou w peye pou preskripsyon yo, ansanm ak nenpòt franchiz ki gen dwa aplike, tanpri al gade Prèv Kouvèti Asirans ou a ak lòt dokiman plan an yo.

- Nivo 1 (Jenerik) gen ladan medikaman jenerik prefere yo epi kapab gen ladan kèk medikaman mak.
  - Kopeman Prefere: \$0
  - Kopeman Estanda: \$15
- Nivo 2 (Medikaman Mak Depoze Prefere) gen ladan medikaman ki gen mak prefere epi kapab gen ladan kèk medikaman jenerik.

Ou p ap peye plis pase \$35 pou yon apwovizyonman yon mwa pou chak pwodwi ensilin ki kouvri nan nivo sa a. Si pataj frè nivo a mwens pase \$35, w ap peye frè ki pi ba pou ensilin ou an.

- Prefere Entèval ko-asirans: 20% - 25%
- Ko-asirans Estanda: 25%

- Nivo 3 (Medikaman Non-Prefere) gen ladan medikaman mak ak medikaman jenerik non-prefere.

Ou p ap peye plis pase \$35 pou yon apwovizyonman yon mwa pou chak pwodwi ensilin ki kouvri nan nivo sa a. Si pataj frè nivo a mwens pase \$35, w ap peye frè ki pi ba pou ensilin ou an.

- Entèval ko-asirans Prefere: 28% - 42%
  - Entèval ko-asirans Estanda: 29% - 44%
- Nivo 4 (Medikaman Enjektan yo) gen ladan l kèk medikaman yo bay pa enjeksyon oswa yo sèvi avèk yo pou anpeche moun malad (vaksen).
  - Entèval ko-asirans Prefere: 0% - 25%
  - Entèval ko-asirans Estanda: 15% - 25%
- Nivo 5 (Medikaman ki nan Kategori Espesyal) gen ladan l medikaman mak ak medikaman jenerik ki koute chè anpil. Medikaman yo nan nivo sa a pa elijib pou eksepsyon pou peman nan yon nivo ki pi ba.
  - Ko-asirans Prefere: 25%
  - Ko-asirans Estanda: 25%
- Nivo 6 (Medikaman Select Care yo) gen ladan kèk medikaman jenerik ak oswa medikaman mak yo itilize pou trete kondisyon espesifik.
  - Kopeman Prefere: \$0
  - Kopeman Estanda: \$0

Konsilte Prèk Kouvèti Asirans ou an oswa Rezime Avantaj yo pou ko-peman/ko-asirans ak montan ki aplikab pou ou yo.

## Tabdèmatyè

|                                                         |            |
|---------------------------------------------------------|------------|
| <b>AJAN DYAGNOSTIK / DIVÈS AJAN.....</b>                | <b>3</b>   |
| <b>ANDOKRIN/DYABÈT .....</b>                            | <b>6</b>   |
| <b>ANTI - ENFEKSYE.....</b>                             | <b>18</b>  |
| <b>DIVÈS ATIK REZÈV .....</b>                           | <b>38</b>  |
| <b>GASTWOANTEWOLOJI .....</b>                           | <b>39</b>  |
| <b>IMINOLOJI, VAKSEN / BIOTEKNOLOJI.....</b>            | <b>45</b>  |
| <b>KADYOVASKILÈ, IPÈTANSYON / LIPID YO .....</b>        | <b>53</b>  |
| <b>MEDIKAMAN ANTINEOPLASTIK / IMMINOSIPPRESAN .....</b> | <b>69</b>  |
| <b>MEDIKAMAN OTONOMIK / CNS, NEWOLOJI / PSIK.....</b>   | <b>91</b>  |
| <b>MEDIKAMAN POU ZÒRÈY, NEN / GÒJ .....</b>             | <b>124</b> |
| <b>MISKILOSKELETAL / RIMATOLOJI.....</b>                | <b>125</b> |
| <b>OBSTETRIK / JINEKOLOJI.....</b>                      | <b>130</b> |
| <b>OFTALMOLOJI.....</b>                                 | <b>141</b> |
| <b>PWODUI DÈMATOLOJIK/TERAPI TOPIK.....</b>             | <b>147</b> |
| <b>PWODUI IWOLOJIK.....</b>                             | <b>157</b> |
| <b>RESPIRATWA AK ALÈJI.....</b>                         | <b>159</b> |
| <b>VITAMIN, HEMATINIK / ELEKTWOLIT.....</b>             | <b>167</b> |



| Non Medikaman an | Nivo Medikaman an | Egzijans/Limit yo |
|------------------|-------------------|-------------------|
|------------------|-------------------|-------------------|

## AJAN DYAGNOSTIK / DIVÈS AJAN

### AJAN DIVÈS

|                                                                       |    |    |
|-----------------------------------------------------------------------|----|----|
| <i>acamprosate oral tablet, delayed release (dr/ec) 333 mg</i>        | 1  |    |
| <i>anagrelide oral capsule 0.5 mg, 1 mg</i>                           | 1  |    |
| <i>carglumic acid oral tablet, dispersible 200 mg</i>                 | 5^ | PA |
| <i>cevimeline oral capsule 30 mg</i>                                  | 1  |    |
| CHEMET ORAL CAPSULE 100 MG                                            | 3  | PA |
| <i>d10 %-0.45 % sodium chloride intravenous parenteral solution</i>   | 1  |    |
| <i>d2.5 %-0.45 % sodium chloride intravenous parenteral solution</i>  | 3  |    |
| <i>d5 % and 0.9 % sodium chloride intravenous parenteral solution</i> | 1  |    |
| <i>d5 %-0.45 % sodium chloride intravenous parenteral solution</i>    | 1  |    |
| <i>deferasirox oral tablet 180 mg, 360 mg</i>                         | 3  | PA |
| <i>deferasirox oral tablet 90 mg</i>                                  | 1  | PA |
| <i>deferasirox oral tablet, dispersible 125 mg</i>                    | 3  | PA |
| <i>deferasirox oral tablet, dispersible 250 mg, 500 mg</i>            | 5^ | PA |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                          | Nivo Medikaman an | Egzijans/Limit yo |
|---------------------------------------------------------------------------|-------------------|-------------------|
| <i>dextrose 10 % and 0.2 % nacl intravenous parenteral solution</i>       | 3                 |                   |
| <i>dextrose 10 % in water (d10w) intravenous parenteral solution 10 %</i> | 1                 |                   |
| <i>dextrose 5 % in water (d5w) intravenous parenteral solution</i>        | 1                 |                   |
| <i>dextrose 5%-0.2 % sod chloride intravenous parenteral solution</i>     | 1                 |                   |
| <i>disulfiram oral tablet 250 mg, 500 mg</i>                              | 1                 |                   |
| <i>glutamine (sickle cell) oral powder in packet 5 gram</i>               | 5^                | PA                |
| INCRELEX SUBCUTANEOUS SOLUTION 10 MG/ML                                   | 5^                | PA; LA            |
| <i>kionex oral suspension 15 gram/60 ml</i>                               | 1                 |                   |
| <i>levocarnitine (with sugar) oral solution 100 mg/ml</i>                 | 1                 |                   |
| <i>levocarnitine oral tablet 330 mg</i>                                   | 1                 |                   |
| LOKELMA ORAL POWDER IN PACKET 10 GRAM, 5 GRAM                             | 2                 |                   |
| <i>midodrine oral tablet 10 mg, 2.5 mg, 5 mg</i>                          | 1                 |                   |
| <i>nitisinone oral capsule 10 mg, 2 mg, 20 mg, 5 mg</i>                   | 5^                | PA                |
| <i>pilocarpine hcl oral tablet 5 mg, 7.5 mg</i>                           | 1                 |                   |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                  | Nivo Medikaman an | Egzijans/Limit yo          |
|-------------------------------------------------------------------|-------------------|----------------------------|
| PROLASTIN-C INTRAVENOUS SOLUTION<br>1,000 MG (+/-)/20 ML          | 5^                | PA; LA                     |
| REVCovi INTRAMUSCULAR SOLUTION<br>2.4 MG/1.5 ML (1.6 MG/ML)       | 5^                | PA; LA                     |
| REZDIFFRA ORAL TABLET 100 MG, 60 MG, 80 MG                        | 5^                | PA; QL (30 EA per 30 days) |
| <i>riluzole oral tablet 50 mg</i>                                 | 1                 |                            |
| <i>risedronate oral tablet 30 mg</i>                              | 1                 | QL (30 EA per 30 days)     |
| <i>sevelamer carbonate oral tablet 800 mg</i>                     | 3                 | PA                         |
| <i>sodium chloride 0.9 % intravenous parenteral solution</i>      | 1                 |                            |
| <i>sodium chloride irrigation solution 0.9 %</i>                  | 1                 |                            |
| <i>sodium phenylbutyrate oral powder 0.94 gram/gram</i>           | 5^                | PA                         |
| <i>sodium phenylbutyrate oral tablet 500 mg</i>                   | 5^                | PA                         |
| <i>sodium polystyrene sulfonate oral powder 15 gram</i>           | 1                 |                            |
| <i>sodium polystyrene sulfonate oral suspension 15 gram/60 ml</i> | 1                 |                            |
| <i>sps (with sorbitol) oral suspension 15-20 gram/60 ml</i>       | 1                 |                            |
| <i>trientine oral capsule 250 mg</i>                              | 5^                | PA                         |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                               | Nivo Medikaman an | Egzijans/Limit yo          |
|--------------------------------------------------------------------------------|-------------------|----------------------------|
| WEGOVY ORAL TABLET 1.5 MG, 25 MG, 4 MG, 9 MG                                   | 2                 | PA; QL (30 EA per 30 days) |
| WEGOVY SUBCUTANEOUS PEN INJECTOR 0.25 MG/0.5 ML, 0.5 MG/0.5 ML, 1 MG/0.5 ML    | 2                 | PA; QL (2 ML per 28 days)  |
| WEGOVY SUBCUTANEOUS PEN INJECTOR 1.7 MG/0.75 ML, 2.4 MG/0.75 ML                | 2                 | PA; QL (3 ML per 28 days)  |
| <b>BAGAY KI ANPECHE FIMEN</b>                                                  |                   |                            |
| <i>bupropion hcl (smoking deter) oral tablet extended release 12 hr 150 mg</i> | 1                 | QL (60 EA per 30 days)     |
| NICOTROL NS NASAL SPRAY, NON-AEROSOL 10 MG/ML                                  | 3                 |                            |
| <i>varenicline tartrate oral tablet 0.5 mg, 1 mg, 1 mg (56 pack)</i>           | 1                 |                            |
| <i>varenicline tartrate oral tablets, dose pack 0.5 mg (11)- 1 mg (42)</i>     | 1                 |                            |
| <b>ANDOKRIN/DYABÈT</b>                                                         |                   |                            |
| <b>AJAN ANTI-THYROID</b>                                                       |                   |                            |
| <i>methimazole oral tablet 10 mg, 5 mg</i>                                     | 1                 |                            |
| <i>propylthiouracil oral tablet 50 mg</i>                                      | 1                 |                            |
| <b>DIVÈS ÒMONN</b>                                                             |                   |                            |
| <i>cabergoline oral tablet 0.5 mg</i>                                          | 1                 |                            |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                       | Nivo Medikaman an | Egzijans/Limit yo           |
|------------------------------------------------------------------------|-------------------|-----------------------------|
| <i>calcitonin (salmon) nasal spray, non-aerosol 200 unit/actuation</i> | 1                 |                             |
| <i>calcitriol oral capsule 0.25 mcg, 0.5 mcg</i>                       | 1                 |                             |
| <i>calcitriol oral solution 1 mcg/ml</i>                               | 1                 |                             |
| <i>cinacalcet oral tablet 30 mg</i>                                    | 1                 | PA; QL (60 EA per 30 days)  |
| <i>cinacalcet oral tablet 60 mg</i>                                    | 3                 | PA; QL (60 EA per 30 days)  |
| <i>cinacalcet oral tablet 90 mg</i>                                    | 3                 | PA; QL (120 EA per 30 days) |
| <i>danazol oral capsule 100 mg, 200 mg, 50 mg</i>                      | 1                 |                             |
| <i>desmopressin nasal spray, non-aerosol 10 mcg/spray (0.1 ml)</i>     | 1                 |                             |
| <i>desmopressin oral tablet 0.1 mg, 0.2 mg</i>                         | 1                 |                             |
| <i>doxercalciferol oral capsule 0.5 mcg, 1 mcg, 2.5 mcg</i>            | 1                 |                             |
| <i>mifepristone oral tablet 300 mg</i>                                 | 5^                | PA                          |
| <i>paricalcitol oral capsule 1 mcg, 2 mcg, 4 mcg</i>                   | 1                 |                             |
| <i>sapropterin oral powder in packet 100 mg</i>                        | 5^                | PA                          |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                                       | Nivo Medikaman an | Egzijans/Limit yo           |
|----------------------------------------------------------------------------------------|-------------------|-----------------------------|
| SOMAVERT SUBCUTANEOUS RECON SOLN 10 MG, 15 MG, 20 MG, 25 MG, 30 MG                     | 5^                | PA                          |
| <i>testosterone cypionate intramuscular oil 100 mg/ml, 200 mg/ml, 200 mg/ml (1 ml)</i> | 1                 |                             |
| <i>testosterone enanthate intramuscular oil 200 mg/ml</i>                              | 1                 |                             |
| <i>testosterone transdermal gel in metered-dose pump 12.5 mg/ 1.25 gram (1 %)</i>      | 1                 | PA; QL (300 GM per 30 days) |
| <i>testosterone transdermal gel in metered-dose pump 20.25 mg/1.25 gram (1.62 %)</i>   | 1                 | PA; QL (150 GM per 30 days) |
| <i>testosterone transdermal gel in packet 1 % (25 mg/2.5gram), 1 % (50 mg/5 gram)</i>  | 1                 | PA; QL (300 GM per 30 days) |
| <i>tolvaptan (polycys kidney dis) oral tablet 15 mg, 30 mg</i>                         | 5^                | PA                          |
| <i>tolvaptan oral tablet 15 mg, 30 mg</i>                                              | 5^                | PA                          |
| <b>ÒMONN ADRENAL YO</b>                                                                |                   |                             |
| <i>dexamethasone oral solution 0.5 mg/5 ml</i>                                         | 1                 |                             |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                                                      | Nivo Medikaman an | Egzijans/Limit yo           |
|-------------------------------------------------------------------------------------------------------|-------------------|-----------------------------|
| <i>dexamethasone oral tablet 0.5 mg, 0.75 mg, 1 mg, 1.5 mg, 2 mg, 4 mg, 6 mg</i>                      | 1                 |                             |
| <i>fludrocortisone oral tablet 0.1 mg</i>                                                             | 1                 |                             |
| <i>hydrocortisone oral tablet 10 mg, 20 mg, 5 mg</i>                                                  | 1                 |                             |
| <i>methylprednisolone oral tablet 16 mg, 32 mg, 4 mg, 8 mg</i>                                        | 1                 | B/D                         |
| <i>methylprednisolone oral tablets,dose pack 4 mg</i>                                                 | 1                 |                             |
| <i>prednisolone oral solution 15 mg/5 ml</i>                                                          | 1                 |                             |
| <i>prednisolone sodium phosphate oral solution 25 mg/5 ml (5 mg/ml), 5 mg base/5 ml (6.7 mg/5 ml)</i> | 1                 |                             |
| <i>prednisone intensol oral concentrate 5 mg/ml</i>                                                   | 3                 |                             |
| <i>prednisone oral solution 5 mg/5 ml</i>                                                             | 3                 |                             |
| <i>prednisone oral tablet 1 mg, 10 mg, 2.5 mg, 20 mg, 5 mg, 50 mg</i>                                 | 1                 |                             |
| <i>prednisone oral tablets,dose pack 10 mg, 10 mg (48 pack), 5 mg, 5 mg (48 pack)</i>                 | 1                 |                             |
| TARPEYO ORAL CAPSULE,DELAYED RELEASE(DR/EC) 4 MG                                                      | 5^                | PA; QL (120 EA per 30 days) |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

## Non Medikaman an

## Nivo Egzijans/Limit yo Medikaman an

### ÒMONN TIWOYID

*levothyroxine oral tablet 100 mcg, 112 mcg, 125 mcg, 137 mcg, 150 mcg, 175 mcg, 200 mcg, 25 mcg, 300 mcg, 50 mcg, 75 mcg, 88 mcg*

1

*levoxyl oral tablet 100 mcg, 112 mcg, 125 mcg, 137 mcg, 150 mcg, 175 mcg, 200 mcg, 25 mcg, 50 mcg, 75 mcg, 88 mcg*

1

*liomny oral tablet 25 mcg, 5 mcg, 50 mcg*

1

*liothyronine oral tablet 25 mcg, 5 mcg, 50 mcg*

1

SYNTHROID ORAL TABLET 100 MCG, 112 MCG, 125 MCG, 137 MCG, 150 MCG, 175 MCG, 200 MCG, 25 MCG, 300 MCG, 50 MCG, 75 MCG, 88 MCG

2

*unithroid oral tablet 100 mcg, 112 mcg, 125 mcg, 137 mcg, 150 mcg, 175 mcg, 200 mcg, 25 mcg, 300 mcg, 50 mcg, 75 mcg, 88 mcg*

1

### TERAPI DYABÈT

*acarbose oral tablet 100 mg*

6

QL (90 EA per 30 days)

*acarbose oral tablet 25 mg*

6

QL (360 EA per 30 days)

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                                              | Nivo Medikaman an | Egzijans/Limit yo          |
|-----------------------------------------------------------------------------------------------|-------------------|----------------------------|
| <i>acarbose oral tablet 50 mg</i>                                                             | 6                 | QL (180 EA per 30 days)    |
| <i>alcohol pads topical pads, medicated</i>                                                   | 1                 |                            |
| <i>dapagliflozin oral tablet 10 mg, 5 mg</i>                                                  | 1                 | QL (30 EA per 30 days)     |
| <i>dapagliflozin-metformin oral tablet, ir -<br/>er, biphasic 24hr 10-1,000 mg, 10-500 mg</i> | 1                 | QL (30 EA per 30 days)     |
| <i>dapagliflozin-metformin oral tablet, ir -<br/>er, biphasic 24hr 5-1,000 mg, 5-500 mg</i>   | 1                 | QL (60 EA per 30 days)     |
| <i>diazoxide oral suspension 50 mg/ml</i>                                                     | 5^                |                            |
| FARXIGA ORAL TABLET 10 MG, 5 MG                                                               | 2                 | ST; QL (30 EA per 30 days) |
| <i>glimepiride oral tablet 1 mg</i>                                                           | 6                 | QL (240 EA per 30 days)    |
| <i>glimepiride oral tablet 2 mg</i>                                                           | 6                 | QL (120 EA per 30 days)    |
| <i>glimepiride oral tablet 4 mg</i>                                                           | 6                 | QL (60 EA per 30 days)     |
| <i>glipizide oral tablet 10 mg</i>                                                            | 6                 | QL (120 EA per 30 days)    |
| <i>glipizide oral tablet 5 mg</i>                                                             | 6                 | QL (240 EA per 30 days)    |
| <i>glipizide oral tablet extended release<br/>24hr 10 mg</i>                                  | 6                 | QL (60 EA per 30 days)     |
| <i>glipizide oral tablet extended release<br/>24hr 2.5 mg</i>                                 | 6                 | QL (240 EA per 30 days)    |
| <i>glipizide oral tablet extended release<br/>24hr 5 mg</i>                                   | 6                 | QL (120 EA per 30 days)    |
| <i>glipizide-metformin oral tablet 2.5-250 mg</i>                                             | 6                 | QL (240 EA per 30 days)    |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                                              | Nivo Medikaman an | Egzijans/Limit yo       |
|-----------------------------------------------------------------------------------------------|-------------------|-------------------------|
| <i>glipizide-metformin oral tablet 2.5-500 mg, 5-500 mg</i>                                   | 6                 | QL (120 EA per 30 days) |
| GLYXAMBI ORAL TABLET 10-5 MG, 25-5 MG                                                         | 2                 | QL (30 EA per 30 days)  |
| GVOKE HYPOPEN 2-PACK SUBCUTANEOUS AUTO-INJECTOR 0.5 MG/0.1 ML, 1 MG/0.2 ML                    | 2                 |                         |
| GVOKE PFS 1-PACK SYRINGE SUBCUTANEOUS SYRINGE 1 MG/0.2 ML                                     | 2                 |                         |
| GVOKE SUBCUTANEOUS SOLUTION 1 MG/0.2 ML                                                       | 2                 |                         |
| HUMULIN R U-500 (CONC) KWIKPEN SUBCUTANEOUS INSULIN PEN 500 UNIT/ML (3 ML)                    | 2                 |                         |
| INSULIN GLARGINE U-300 CONC SUBCUTANEOUS INSULIN PEN 300 UNIT/ML (1.5 ML), 300 UNIT/ML (3 ML) | 2                 |                         |
| INSULIN GLARGINE-YFGN SUBCUTANEOUS INSULIN PEN 100 UNIT/ML (3 ML)                             | 2                 |                         |
| INSULIN GLARGINE-YFGN SUBCUTANEOUS SOLUTION 100 UNIT/ML                                       | 2                 |                         |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                          | Nivo Medikaman an | Egzijans/Limit yo                            |
|---------------------------------------------------------------------------|-------------------|----------------------------------------------|
| JANUVIA ORAL TABLET 100 MG, 25 MG, 50 MG                                  | 2                 | QL (30 EA per 30 days)                       |
| JARDIANCE ORAL TABLET 10 MG, 25 MG                                        | 2                 | QL (30 EA per 30 days)                       |
| KIRSTY PEN SUBCUTANEOUS INSULIN PEN 100 UNIT/ML (3 ML)                    | 2                 |                                              |
| KIRSTY SUBCUTANEOUS SOLUTION 100 UNIT/ML                                  | 2                 |                                              |
| LANTUS SOLOSTAR U-100 INSULIN SUBCUTANEOUS INSULIN PEN 100 UNIT/ML (3 ML) | 2                 |                                              |
| LANTUS U-100 INSULIN SUBCUTANEOUS SOLUTION 100 UNIT/ML                    | 2                 |                                              |
| <i>liraglutide subcutaneous pen injector 0.6 mg/0.1 ml (18 mg/3 ml)</i>   | 2                 | PA; QL (9 ML per 30 days)                    |
| MERILOG SOLOSTAR SUBCUTANEOUS INSULIN PEN 100 UNIT/ML (3 ML)              | 2                 |                                              |
| MERILOG SUBCUTANEOUS SOLUTION 100 UNIT/ML                                 | 2                 |                                              |
| <i>metformin er 1,000 mg osm-tab</i>                                      | 1                 | generic of Fortamet; QL (60 EA per 30 days)  |
| <i>metformin er 500 mg osmotic tb</i>                                     | 1                 | generic of Fortamet; QL (120 EA per 30 days) |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                                                                         | Nivo Medikaman an | Egzijans/Limit yo                                      |
|--------------------------------------------------------------------------------------------------------------------------|-------------------|--------------------------------------------------------|
| <i>metformin oral tablet 1,000 mg</i>                                                                                    | 6                 | QL (75 EA per 30 days)                                 |
| <i>metformin oral tablet 500 mg</i>                                                                                      | 6                 | QL (150 EA per 30 days)                                |
| <i>metformin oral tablet 850 mg</i>                                                                                      | 6                 | QL (90 EA per 30 days)                                 |
| <i>metformin oral tablet extended release 24 hr 500 mg</i>                                                               | 6                 | generic for Glucophage XR; QL (120 EA per 30 days)     |
| <i>metformin oral tablet extended release 24 hr 750 mg</i>                                                               | 6                 | generic for Glucophage XR; QL (60 EA per 30 days)      |
| <i>metformin oral tablet extended release 24hr 1,000 mg</i>                                                              | 1                 | (osmotic) generic of Fortamet; QL (60 EA per 30 days)  |
| <i>metformin oral tablet extended release 24hr 500 mg</i>                                                                | 1                 | (osmotic) generic of Fortamet; QL (120 EA per 30 days) |
| MOUNJARO SUBCUTANEOUS PEN INJECTOR 10 MG/0.5 ML, 12.5 MG/0.5 ML, 15 MG/0.5 ML, 2.5 MG/0.5 ML, 5 MG/0.5 ML, 7.5 MG/0.5 ML | 4                 | PA; QL (2 ML per 28 days)                              |
| <i>nateglinide oral tablet 120 mg</i>                                                                                    | 6                 | QL (90 EA per 30 days)                                 |
| <i>nateglinide oral tablet 60 mg</i>                                                                                     | 6                 | QL (180 EA per 30 days)                                |
| NOVOLIN 70/30 U-100 INSULIN SUBCUTANEOUS SUSPENSION 100 UNIT/ML (70-30)                                                  | 2                 |                                                        |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                                                              | Nivo Medikaman an | Egzijans/Limit yo          |
|---------------------------------------------------------------------------------------------------------------|-------------------|----------------------------|
| NOVOLIN 70-30 FLEXPEN U-100 SUBCUTANEOUS INSULIN PEN 100 UNIT/ML (70-30)                                      | 2                 |                            |
| NOVOLIN N FLEXPEN SUBCUTANEOUS INSULIN PEN 100 UNIT/ML (3 ML)                                                 | 2                 |                            |
| NOVOLIN N NPH U-100 INSULIN SUBCUTANEOUS SUSPENSION 100 UNIT/ML                                               | 2                 |                            |
| NOVOLIN R FLEXPEN SUBCUTANEOUS INSULIN PEN 100 UNIT/ML (3 ML)                                                 | 2                 |                            |
| NOVOLIN R REGULAR U100 INSULIN INJECTION SOLUTION 100 UNIT/ML                                                 | 2                 |                            |
| NOVOLOG MIX 70-30 U-100 INSULN SUBCUTANEOUS SOLUTION 100 UNIT/ML (70-30)                                      | 2                 |                            |
| NOVOLOG MIX 70-30FLEXPEN U-100 SUBCUTANEOUS INSULIN PEN 100 UNIT/ML (70-30)                                   | 2                 |                            |
| OZEMPIC ORAL TABLET 1.5 MG, 4 MG, 9 MG                                                                        | 2                 | PA; QL (30 EA per 30 days) |
| OZEMPIC SUBCUTANEOUS PEN INJECTOR 0.25 MG OR 0.5 MG (2 MG/3 ML), 1 MG/DOSE (4 MG/3 ML), 2 MG/DOSE (8 MG/3 ML) | 2                 | PA; QL (3 ML per 28 days)  |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                                          | Nivo Medikaman an | Egzijans/Limit yo       |
|-------------------------------------------------------------------------------------------|-------------------|-------------------------|
| <i>pioglitazone oral tablet 15 mg, 30 mg, 45 mg</i>                                       | 6                 | QL (30 EA per 30 days)  |
| <i>pioglitazone-glimepiride oral tablet 30-2 mg, 30-4 mg</i>                              | 6                 | QL (30 EA per 30 days)  |
| <i>pioglitazone-metformin oral tablet 15-500 mg, 15-850 mg</i>                            | 6                 | QL (90 EA per 30 days)  |
| <i>repaglinide oral tablet 0.5 mg</i>                                                     | 6                 | QL (960 EA per 30 days) |
| <i>repaglinide oral tablet 1 mg</i>                                                       | 6                 | QL (480 EA per 30 days) |
| <i>repaglinide oral tablet 2 mg</i>                                                       | 6                 | QL (240 EA per 30 days) |
| <i>saxagliptin oral tablet 2.5 mg, 5 mg</i>                                               | 2                 | QL (30 EA per 30 days)  |
| <i>saxagliptin-metformin oral tablet, er multiphase 24 hr 2.5-1,000 mg</i>                | 2                 | QL (60 EA per 30 days)  |
| <i>saxagliptin-metformin oral tablet, er multiphase 24 hr 5-1,000 mg, 5-500 mg</i>        | 2                 | QL (30 EA per 30 days)  |
| <i>sitagliptin phos-metformin oral tablet 50-1,000 mg, 50-500 mg</i>                      | 2                 | QL (60 EA per 30 days)  |
| <i>sitagliptin phos-metformin oral tablet, er multiphase 24 hr 100-1,000 mg</i>           | 2                 | QL (30 EA per 30 days)  |
| <i>sitagliptin phos-metformin oral tablet, er multiphase 24 hr 50-1,000 mg, 50-500 mg</i> | 2                 | QL (60 EA per 30 days)  |
| SOLQUA 100/33 SUBCUTANEOUS INSULIN PEN 100 UNIT-33 MCG/ML                                 | 2                 | QL (15 ML per 25 days)  |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                                              | Nivo Medikaman an | Egzijans/Limit yo         |
|-----------------------------------------------------------------------------------------------|-------------------|---------------------------|
| SYNJARDY ORAL TABLET 12.5-1,000 MG, 12.5-500 MG, 5-1,000 MG, 5-500 MG                         | 2                 | QL (60 EA per 30 days)    |
| SYNJARDY XR ORAL TABLET, IR - ER, BIPHASIC 24HR 10-1,000 MG, 25-1,000 MG                      | 2                 | QL (30 EA per 30 days)    |
| SYNJARDY XR ORAL TABLET, IR - ER, BIPHASIC 24HR 12.5-1,000 MG, 5-1,000 MG                     | 2                 | QL (60 EA per 30 days)    |
| TRADJENTA ORAL TABLET 5 MG                                                                    | 2                 | QL (30 EA per 30 days)    |
| TRIJARDY XR ORAL TABLET, IR - ER, BIPHASIC 24HR 10-5-1,000 MG, 25-5-1,000 MG                  | 2                 | QL (30 EA per 30 days)    |
| TRIJARDY XR ORAL TABLET, IR - ER, BIPHASIC 24HR 12.5-2.5-1,000 MG, 5-2.5-1,000 MG             | 2                 | QL (60 EA per 30 days)    |
| TRULICITY SUBCUTANEOUS PEN INJECTOR 0.75 MG/0.5 ML, 1.5 MG/0.5 ML, 3 MG/0.5 ML, 4.5 MG/0.5 ML | 2                 | PA; QL (2 ML per 28 days) |
| XIGDUO XR ORAL TABLET, IR - ER, BIPHASIC 24HR 2.5-1,000 MG                                    | 2                 | QL (60 EA per 30 days)    |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

## Non Medikaman an

## Nivo Egzijans/Limit yo Medikaman an

### ANTI - ENFEKSYE

#### AJAN ANTIFONJIF

|                                                  |   |     |
|--------------------------------------------------|---|-----|
| <i>amphotericin b injection recon soln 50 mg</i> | 1 | B/D |
|--------------------------------------------------|---|-----|

|                                                                                |    |     |
|--------------------------------------------------------------------------------|----|-----|
| <i>amphotericin b liposome intravenous suspension for reconstitution 50 mg</i> | 5^ | B/D |
|--------------------------------------------------------------------------------|----|-----|

|                                                         |   |  |
|---------------------------------------------------------|---|--|
| <i>casprofungin intravenous recon soln 50 mg, 70 mg</i> | 3 |  |
|---------------------------------------------------------|---|--|

|                                                  |   |  |
|--------------------------------------------------|---|--|
| <i>clotrimazole mucous membrane troche 10 mg</i> | 1 |  |
|--------------------------------------------------|---|--|

|                                       |    |    |
|---------------------------------------|----|----|
| CRESEMBA ORAL CAPSULE 186 MG, 74.5 MG | 5^ | PA |
|---------------------------------------|----|----|

|                                                                          |   |    |
|--------------------------------------------------------------------------|---|----|
| <i>fluconazole in nacl (iso-osm) intravenous piggyback 200 mg/100 ml</i> | 3 | PA |
|--------------------------------------------------------------------------|---|----|

|                                                                          |   |    |
|--------------------------------------------------------------------------|---|----|
| <i>fluconazole in nacl (iso-osm) intravenous piggyback 400 mg/200 ml</i> | 1 | PA |
|--------------------------------------------------------------------------|---|----|

|                                                                          |   |  |
|--------------------------------------------------------------------------|---|--|
| <i>fluconazole oral suspension for reconstitution 10 mg/ml, 40 mg/ml</i> | 1 |  |
|--------------------------------------------------------------------------|---|--|

|                                                              |   |  |
|--------------------------------------------------------------|---|--|
| <i>fluconazole oral tablet 100 mg, 150 mg, 200 mg, 50 mg</i> | 1 |  |
|--------------------------------------------------------------|---|--|

|                                                |    |    |
|------------------------------------------------|----|----|
| <i>flucytosine oral capsule 250 mg, 500 mg</i> | 5^ | PA |
|------------------------------------------------|----|----|

|                                                           |   |  |
|-----------------------------------------------------------|---|--|
| <i>griseofulvin microsize oral suspension 125 mg/5 ml</i> | 3 |  |
|-----------------------------------------------------------|---|--|

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                              | Nivo Medikaman an | Egzijans/Limit yo          |
|-------------------------------------------------------------------------------|-------------------|----------------------------|
| <i>griseofulvin microsize oral tablet 500 mg</i>                              | 3                 |                            |
| <i>griseofulvin ultramicrosize oral tablet 125 mg, 250 mg</i>                 | 3                 |                            |
| <i>itraconazole oral capsule 100 mg</i>                                       | 3                 | QL (120 EA per 30 days)    |
| <i>ketoconazole oral tablet 200 mg</i>                                        | 1                 | PA                         |
| <i>miconazole intravenous recon soln 100 mg, 50 mg</i>                        | 3                 |                            |
| <i>nystatin oral suspension 100,000 unit/ml</i>                               | 1                 |                            |
| <i>nystatin oral tablet 500,000 unit</i>                                      | 1                 |                            |
| <i>posaconazole oral tablet, delayed release (dr/ec) 100 mg</i>               | 3                 | PA; QL (96 EA per 30 days) |
| <i>terbinafine hcl oral tablet 250 mg</i>                                     | 1                 |                            |
| <i>voriconazole intravenous recon soln 200 mg</i>                             | 3                 | PA                         |
| <i>voriconazole oral suspension for reconstitution 200 mg/5 ml (40 mg/ml)</i> | 5^                | PA                         |
| <i>voriconazole oral tablet 200 mg, 50 mg</i>                                 | 3                 | PA                         |
| <b>AJAN SULFA'S / KI GEN POU WÈ AK YO</b>                                     |                   |                            |
| <i>sulfadiazine oral tablet 500 mg</i>                                        | 3                 |                            |
| <i>sulfamethoxazole-trimethoprim oral suspension 200-40 mg/5 ml</i>           | 1                 |                            |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                       | Nivo Medikaman an | Egzijans/Limit yo |
|------------------------------------------------------------------------|-------------------|-------------------|
| <i>sulfamethoxazole-trimethoprim oral tablet 400-80 mg, 800-160 mg</i> | 1                 |                   |
| <b>AJAN VWA IRINÈ</b>                                                  |                   |                   |
| <i>fosfomycin tromethamine oral packet 3 gram</i>                      | 3                 |                   |
| <i>methenamine hippurate oral tablet 1 gram</i>                        | 3                 |                   |
| <i>nitrofurantoin macrocrystal oral capsule 100 mg</i>                 | 3                 |                   |
| <i>nitrofurantoin macrocrystal oral capsule 50 mg</i>                  | 1                 |                   |
| <i>nitrofurantoin monohyd/m-cryst oral capsule 100 mg</i>              | 3                 |                   |
| <i>trimethoprim oral tablet 100 mg</i>                                 | 1                 |                   |
| <b>DIVÈS ANTI-ENFEKSYE</b>                                             |                   |                   |
| <i>albendazole oral tablet 200 mg</i>                                  | 3                 |                   |
| <i>amikacin injection solution 500 mg/2 ml</i>                         | 3                 |                   |
| ARIKAYCE INHALATION SUSPENSION FOR NEBULIZATION 590 MG/8.4 ML          | 5^                | PA; LA            |
| <i>atovaquone oral suspension 750 mg/5 ml</i>                          | 1                 |                   |
| <i>atovaquone-proguanil oral tablet 250-100 mg</i>                     | 3                 |                   |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                                                  | Nivo Medikaman an | Egzijans/Limit yo              |
|---------------------------------------------------------------------------------------------------|-------------------|--------------------------------|
| <i>atovaquone-proguanil oral tablet 62.5-25 mg</i>                                                | 1                 |                                |
| <i>aztreonam injection recon soln 1 gram, 2 gram</i>                                              | 3                 |                                |
| CAYSTON INHALATION SOLUTION FOR NEBULIZATION 75 MG/ML                                             | 5^                | PA; LA; QL (84 ML per 56 days) |
| <i>chloroquine phosphate oral tablet 250 mg, 500 mg</i>                                           | 3                 |                                |
| <i>clindamycin hcl oral capsule 150 mg, 300 mg, 75 mg</i>                                         | 1                 |                                |
| <i>clindamycin in 5 % dextrose intravenous piggyback 300 mg/50 ml, 900 mg/50 ml</i>               | 1                 |                                |
| <i>clindamycin in 5 % dextrose intravenous piggyback 600 mg/50 ml</i>                             | 3                 |                                |
| <i>clindamycin phosphate injection solution 150 (mg/ml) (4 ml), 150 (mg/ml) (6 ml), 150 mg/ml</i> | 1                 |                                |
| COARTEM ORAL TABLET 20-120 MG                                                                     | 3                 |                                |
| <i>colistin (colistimethate na) injection recon soln 150 mg</i>                                   | 3                 | QL (30 EA per 10 days)         |
| <i>dapsone oral tablet 100 mg, 25 mg</i>                                                          | 1                 |                                |
| <i>daptomycin intravenous recon soln 500 mg</i>                                                   | 3                 |                                |
| <i>ertapenem injection recon soln 1 gram</i>                                                      | 3                 | QL (14 EA per 14 days)         |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                                                                | Nivo Medikaman an | Egzijans/Limit yo          |
|-----------------------------------------------------------------------------------------------------------------|-------------------|----------------------------|
| <i>ethambutol oral tablet 100 mg, 400 mg</i>                                                                    | 1                 |                            |
| <i>gentamicin in nacl (iso-osm) intravenous piggyback 100 mg/100 ml, 60 mg/50 ml, 80 mg/100 ml, 80 mg/50 ml</i> | 1                 |                            |
| <i>gentamicin injection solution 40 mg/ml</i>                                                                   | 1                 |                            |
| <i>hydroxychloroquine oral tablet 200 mg</i>                                                                    | 1                 |                            |
| <i>imipenem-cilastatin intravenous recon soln 250 mg</i>                                                        | 1                 |                            |
| <i>imipenem-cilastatin intravenous recon soln 500 mg</i>                                                        | 3                 |                            |
| IMPAVIDO ORAL CAPSULE 50 MG                                                                                     | 5^                | PA                         |
| <i>isoniazid oral solution 50 mg/5 ml</i>                                                                       | 1                 |                            |
| <i>isoniazid oral tablet 100 mg, 300 mg</i>                                                                     | 1                 |                            |
| <i>ivermectin oral tablet 3 mg</i>                                                                              | 2                 | PA; QL (20 EA per 30 days) |
| <i>ivermectin oral tablet 6 mg</i>                                                                              | 2                 | PA; QL (8 EA per 30 days)  |
| <i>linezolid in dextrose 5% intravenous piggyback 600 mg/300 ml</i>                                             | 3                 |                            |
| <i>linezolid oral suspension for reconstitution 100 mg/5 ml</i>                                                 | 5^                | QL (1800 ML per 30 days)   |
| <i>linezolid oral tablet 600 mg</i>                                                                             | 3                 | QL (60 EA per 30 days)     |
| <i>mefloquine oral tablet 250 mg</i>                                                                            | 1                 |                            |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                          | Nivo Medikaman an | Egzijans/Limit yo          |
|---------------------------------------------------------------------------|-------------------|----------------------------|
| <i>meropenem intravenous recon soln 1 gram</i>                            | 2                 | QL (30 EA per 10 days)     |
| <i>meropenem intravenous recon soln 500 mg</i>                            | 2                 | QL (10 EA per 10 days)     |
| <i>metronidazole in nacl (iso-os) intravenous piggyback 500 mg/100 ml</i> | 1                 |                            |
| <i>metronidazole oral tablet 250 mg, 500 mg</i>                           | 1                 |                            |
| <i>neomycin oral tablet 500 mg</i>                                        | 1                 |                            |
| <i>nitazoxanide oral tablet 500 mg</i>                                    | 5^                | QL (12 EA per 30 days)     |
| <i>pentamidine inhalation recon soln 300 mg</i>                           | 1                 | B/D; QL (1 EA per 28 days) |
| <i>pentamidine injection recon soln 300 mg</i>                            | 1                 |                            |
| <i>praziquantel oral tablet 600 mg</i>                                    | 3                 |                            |
| PRIFTIN ORAL TABLET 150 MG                                                | 3                 |                            |
| PRIMAQUINE ORAL TABLET 26.3 MG (15 MG BASE)                               | 3                 |                            |
| <i>pyrazinamide oral tablet 500 mg</i>                                    | 1                 |                            |
| <i>pyrimethamine oral tablet 25 mg</i>                                    | 5^                | PA                         |
| <i>quinine sulfate oral capsule 324 mg</i>                                | 3                 | PA                         |
| <i>rifabutin oral capsule 150 mg</i>                                      | 1                 |                            |
| <i>rifampin intravenous recon soln 600 mg</i>                             | 1                 |                            |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                                   | Nivo Medikaman an | Egzijans/Limit yo           |
|------------------------------------------------------------------------------------|-------------------|-----------------------------|
| <i>rifampin oral capsule 150 mg, 300 mg</i>                                        | 1                 |                             |
| SIRTURO ORAL TABLET 100 MG, 20 MG                                                  | 5^                | PA; LA                      |
| STREPTOMYCIN INTRAMUSCULAR RECON SOLN 1 GRAM                                       | 5^                | QL (60 EA per 30 days)      |
| <i>tigecycline intravenous recon soln 50 mg</i>                                    | 3                 |                             |
| <i>tinidazole oral tablet 250 mg, 500 mg</i>                                       | 1                 |                             |
| <i>tobramycin in 0.225 % nacl inhalation solution for nebulization 300 mg/5 ml</i> | 5^                | PA; QL (280 ML per 28 days) |
| <i>tobramycin sulfate injection solution 10 mg/ml, 40 mg/ml</i>                    | 1                 |                             |
| <i>vancomycin intravenous recon soln 1,000 mg</i>                                  | 3                 | QL (20 EA per 10 days)      |
| <i>vancomycin intravenous recon soln 10 gram</i>                                   | 3                 | QL (2 EA per 10 days)       |
| <i>vancomycin intravenous recon soln 500 mg</i>                                    | 1                 | QL (10 EA per 10 days)      |
| <i>vancomycin intravenous recon soln 750 mg</i>                                    | 3                 | QL (27 EA per 10 days)      |
| <i>vancomycin oral capsule 125 mg</i>                                              | 3                 | QL (40 EA per 10 days)      |
| <i>vancomycin oral capsule 250 mg</i>                                              | 3                 | QL (80 EA per 10 days)      |
| XIFAXAN ORAL TABLET 200 MG                                                         | 2                 | PA; QL (9 EA per 30 days)   |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                                         | Nivo Medikaman an | Egzijans/Limit yo          |
|------------------------------------------------------------------------------------------|-------------------|----------------------------|
| XIFAXAN ORAL TABLET 550 MG                                                               | 2                 | PA; QL (90 EA per 30 days) |
| <b><i>ERYTROMISIN / LÒT MAKWOLID</i></b>                                                 |                   |                            |
| <i>azithromycin intravenous recon soln 500 mg</i>                                        | 3                 |                            |
| <i>azithromycin oral suspension for reconstitution 100 mg/5 ml, 200 mg/5 ml</i>          | 1                 |                            |
| <i>azithromycin oral tablet 250 mg, 250 mg (6 pack), 500 mg, 500 mg (3 pack), 600 mg</i> | 1                 |                            |
| <i>clarithromycin oral suspension for reconstitution 125 mg/5 ml</i>                     | 1                 |                            |
| <i>clarithromycin oral suspension for reconstitution 250 mg/5 ml</i>                     | 3                 |                            |
| <i>clarithromycin oral tablet 250 mg, 500 mg</i>                                         | 1                 |                            |
| <i>clarithromycin oral tablet extended release 24 hr 500 mg</i>                          | 1                 |                            |
| <i>erythromycin oral tablet 250 mg, 500 mg</i>                                           | 3                 |                            |
| <i>erythromycin oral tablet, delayed release (dr/ec) 250 mg, 333 mg, 500 mg</i>          | 1                 |                            |
| <i>fidaxomicin oral tablet 200 mg</i>                                                    | 5^                | QL (20 EA per 10 days)     |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an | Nivo Medikaman an | Egzijans/Limit yo |
|------------------|-------------------|-------------------|
|------------------|-------------------|-------------------|

### **KINOLÒN**

|                                                                               |   |
|-------------------------------------------------------------------------------|---|
| <i>ciprofloxacin hcl oral tablet 250 mg, 500 mg, 750 mg</i>                   | 1 |
| <i>ciprofloxacin in 5 % dextrose intravenous piggyback 200 mg/100 ml</i>      | 1 |
| <i>levofloxacin in d5w intravenous piggyback 500 mg/100 ml, 750 mg/150 ml</i> | 1 |
| <i>levofloxacin oral solution 250 mg/10 ml</i>                                | 3 |
| <i>levofloxacin oral tablet 250 mg, 500 mg, 750 mg</i>                        | 1 |
| <i>moxifloxacin oral tablet 400 mg</i>                                        | 1 |
| <i>moxifloxacin-sod.chloride(iso) intravenous piggyback 400 mg/250 ml</i>     | 1 |

### **PENISILIN**

|                                                                                                          |   |
|----------------------------------------------------------------------------------------------------------|---|
| <i>amoxicillin oral capsule 250 mg, 500 mg</i>                                                           | 1 |
| <i>amoxicillin oral suspension for reconstitution 125 mg/5 ml, 200 mg/5 ml, 250 mg/5 ml, 400 mg/5 ml</i> | 1 |
| <i>amoxicillin oral tablet 500 mg, 875 mg</i>                                                            | 1 |
| <i>amoxicillin oral tablet, chewable 125 mg, 250 mg</i>                                                  | 1 |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                                                                                           | Nivo Medikaman an | Egzijans/Limit yo |
|--------------------------------------------------------------------------------------------------------------------------------------------|-------------------|-------------------|
| <i>amoxicillin-pot clavulanate oral suspension for reconstitution 200-28.5 mg/5 ml, 250-62.5 mg/5 ml, 400-57 mg/5 ml, 600-42.9 mg/5 ml</i> | 1                 |                   |
| <i>amoxicillin-pot clavulanate oral tablet 250-125 mg, 500-125 mg, 875-125 mg</i>                                                          | 1                 |                   |
| <i>amoxicillin-pot clavulanate oral tablet extended release 12 hr 1,000-62.5 mg</i>                                                        | 1                 |                   |
| <i>ampicillin oral capsule 500 mg</i>                                                                                                      | 1                 |                   |
| <i>ampicillin sodium injection recon soln 1 gram, 2 gram</i>                                                                               | 3                 |                   |
| <i>ampicillin sodium injection recon soln 10 gram</i>                                                                                      | 1                 |                   |
| <i>ampicillin-sulbactam injection recon soln 1.5 gram, 15 gram, 3 gram</i>                                                                 | 1                 |                   |
| BICILLIN L-A INTRAMUSCULAR SYRINGE<br>1,200,000 UNIT/2 ML, 2,400,000 UNIT/4 ML, 600,000 UNIT/ML                                            | 3                 |                   |
| <i>dicloxacillin oral capsule 250 mg, 500 mg</i>                                                                                           | 1                 |                   |
| <i>nafcillin injection recon soln 1 gram, 2 gram</i>                                                                                       | 1                 |                   |
| <i>nafcillin injection recon soln 10 gram</i>                                                                                              | 5^                |                   |
| <i>oxacillin injection recon soln 1 gram</i>                                                                                               | 1                 |                   |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                                                         | Nivo Medikaman an | Egzijans/Limit yo |
|----------------------------------------------------------------------------------------------------------|-------------------|-------------------|
| <i>oxacillin injection recon soln 10 gram, 2 gram</i>                                                    | 3                 |                   |
| PENICILLIN G POT IN DEXTROSE<br>INTRAVENOUS PIGGYBACK 2 MILLION<br>UNIT/50 ML, 3 MILLION UNIT/50 ML      | 3                 |                   |
| <i>penicillin g potassium injection recon<br/>soln 20 million unit</i>                                   | 3                 |                   |
| <i>penicillin g sodium injection recon soln<br/>5 million unit</i>                                       | 1                 |                   |
| <i>penicillin v potassium oral recon soln<br/>125 mg/5 ml, 250 mg/5 ml</i>                               | 1                 |                   |
| <i>penicillin v potassium oral tablet 250<br/>mg, 500 mg</i>                                             | 1                 |                   |
| <i>piperacillin-tazobactam intravenous<br/>recon soln 2.25 gram, 3.375 gram, 4.5<br/>gram, 40.5 gram</i> | 3                 |                   |
| <b>PWODUI ANTIVIRAL YO</b>                                                                               |                   |                   |
| <i>abacavir oral solution 20 mg/ml</i>                                                                   | 1                 |                   |
| <i>abacavir oral tablet 300 mg</i>                                                                       | 1                 |                   |
| <i>abacavir-lamivudine oral tablet 600-<br/>300 mg</i>                                                   | 1                 |                   |
| <i>acyclovir oral capsule 200 mg</i>                                                                     | 1                 |                   |
| <i>acyclovir oral suspension 200 mg/5 ml</i>                                                             | 3                 |                   |
| <i>acyclovir oral tablet 400 mg, 800 mg</i>                                                              | 1                 |                   |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                      | Nivo Medikaman an | Egzijans/Limit yo      |
|-------------------------------------------------------|-------------------|------------------------|
| <i>acyclovir sodium intravenous solution 50 mg/ml</i> | 3                 | B/D                    |
| <i>adefovir oral tablet 10 mg</i>                     | 3                 |                        |
| <i>amantadine hcl oral capsule 100 mg</i>             | 1                 |                        |
| <i>amantadine hcl oral solution 50 mg/5 ml</i>        | 1                 |                        |
| <i>amantadine hcl oral tablet 100 mg</i>              | 1                 |                        |
| APTIVUS ORAL CAPSULE 250 MG                           | 5^                |                        |
| <i>atazanavir oral capsule 150 mg, 200 mg, 300 mg</i> | 1                 |                        |
| BARACLUDE ORAL SOLUTION 0.05 MG/ML                    | 3                 |                        |
| BIKTARVY ORAL TABLET 30-120-15 MG, 50-200-25 MG       | 5^                |                        |
| CIMDUO ORAL TABLET 300-300 MG                         | 5^                |                        |
| <i>darunavir oral tablet 600 mg</i>                   | 3                 | QL (60 EA per 30 days) |
| <i>darunavir oral tablet 800 mg</i>                   | 3                 | QL (30 EA per 30 days) |
| DELSTRIGO ORAL TABLET 100-300-300 MG                  | 5^                |                        |
| DESCOVY ORAL TABLET 120-15 MG, 200-25 MG              | 5^                | QL (30 EA per 30 days) |
| DOVATO ORAL TABLET 50-300 MG                          | 5^                |                        |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                                    | Nivo Medikaman an | Egzijans/Limit yo      |
|-------------------------------------------------------------------------------------|-------------------|------------------------|
| EDURANT PED ORAL TABLET FOR SUSPENSION 2.5 MG                                       | 3                 |                        |
| <i>efavirenz oral tablet 600 mg</i>                                                 | 1                 |                        |
| <i>efavirenz-emtricitabin-tenofov oral tablet 600-200-300 mg</i>                    | 3                 |                        |
| <i>efavirenz-lamivu-tenofov disop oral tablet 400-300-300 mg, 600-300-300 mg</i>    | 5^                |                        |
| <i>emtricitabine oral capsule 200 mg</i>                                            | 1                 |                        |
| <i>emtricitabine-tenofovir (tdf) oral tablet 100-150 mg, 167-250 mg, 200-300 mg</i> | 3                 | QL (30 EA per 30 days) |
| <i>emtricitabine-tenofovir (tdf) oral tablet 133-200 mg</i>                         | 5^                | QL (30 EA per 30 days) |
| <i>emtricitabine-rilpivirine-tenofovir (tdf) oral tablet 200-25-300 mg</i>          | 5^                |                        |
| EMTRIVA ORAL SOLUTION 10 MG/ML                                                      | 3                 |                        |
| <i>entecavir oral tablet 0.5 mg, 1 mg</i>                                           | 1                 |                        |
| <i>etravirine oral tablet 100 mg, 200 mg</i>                                        | 3                 |                        |
| EVOTAZ ORAL TABLET 300-150 MG                                                       | 5^                |                        |
| <i>famciclovir oral tablet 125 mg, 250 mg, 500 mg</i>                               | 1                 |                        |
| <i>fosamprenavir oral tablet 700 mg</i>                                             | 3                 |                        |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                     | Nivo Medikaman an | Egzijans/Limit yo          |
|------------------------------------------------------|-------------------|----------------------------|
| GENVOYA ORAL TABLET 150-150-200-10 MG                | 5^                |                            |
| IDVYNZO ORAL TABLET 100-0.25 MG                      | 5^                |                            |
| INTELENCE ORAL TABLET 25 MG                          | 2                 |                            |
| ISENTRESS HD ORAL TABLET 600 MG                      | 5^                |                            |
| ISENTRESS ORAL POWDER IN PACKET 100 MG               | 5^                |                            |
| ISENTRESS ORAL TABLET 400 MG                         | 5^                |                            |
| ISENTRESS ORAL TABLET,CHEWABLE 100 MG                | 5^                |                            |
| ISENTRESS ORAL TABLET,CHEWABLE 25 MG                 | 3                 |                            |
| JULUCA ORAL TABLET 50-25 MG                          | 5^                |                            |
| KALETRA ORAL SOLUTION 400-100 MG/5 ML                | 3                 |                            |
| <i>lamivudine oral solution 10 mg/ml</i>             | 1                 |                            |
| <i>lamivudine oral tablet 100 mg, 150 mg, 300 mg</i> | 1                 |                            |
| <i>lamivudine-zidovudine oral tablet 150-300 mg</i>  | 1                 |                            |
| LEDIPASVIR-SOFOSBUVIR ORAL TABLET 90-400 MG          | 5^                | PA; QL (28 EA per 28 days) |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                              | Nivo Medikaman an | Egzijans/Limit yo               |
|---------------------------------------------------------------|-------------------|---------------------------------|
| LIVTENCITY ORAL TABLET 200 MG                                 | 5^                | PA; LA; QL (120 EA per 30 days) |
| <i>lopinavir-ritonavir oral tablet 100-25 mg, 200-50 mg</i>   | 1                 |                                 |
| <i>maraviroc oral tablet 150 mg, 300 mg</i>                   | 5^                |                                 |
| <i>nevirapine oral suspension 50 mg/5 ml</i>                  | 1                 |                                 |
| <i>nevirapine oral tablet 200 mg</i>                          | 1                 |                                 |
| <i>nevirapine oral tablet extended release 24 hr 400 mg</i>   | 1                 |                                 |
| NORVIR ORAL POWDER IN PACKET 100 MG                           | 2                 |                                 |
| ODEFSEY ORAL TABLET 200-25-25 MG                              | 5^                |                                 |
| <i>oseltamivir oral capsule 30 mg</i>                         | 1                 | QL (168 EA per 365 days)        |
| <i>oseltamivir oral capsule 45 mg, 75 mg</i>                  | 1                 | QL (84 EA per 365 days)         |
| <i>oseltamivir oral suspension for reconstitution 6 mg/ml</i> | 1                 | QL (1080 ML per 365 days)       |
| PAXLOVID ORAL TABLETS,DOSE PACK 150 MG (10)- 100 MG (10)      | 2                 | QL (20 EA per 30 days)          |
| PAXLOVID ORAL TABLETS,DOSE PACK 150 MG (6)- 100 MG (5)        | 2                 | QL (11 EA per 30 days)          |
| PAXLOVID ORAL TABLETS,DOSE PACK 300 MG (150 MG X 2)-100 MG    | 2                 | QL (30 EA per 30 days)          |
| PIFELTRO ORAL TABLET 100 MG                                   | 5^                |                                 |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                  | Nivo Medikaman an | Egzijans/Limit yo          |
|---------------------------------------------------|-------------------|----------------------------|
| PREVYMIS ORAL TABLET 240 MG, 480 MG               | 5^                | PA; QL (28 EA per 28 days) |
| PREZCOBIX ORAL TABLET 675-150 MG, 800-150 MG-MG   | 5^                |                            |
| PREZISTA ORAL SUSPENSION 100 MG/ML                | 5^                | QL (400 ML per 30 days)    |
| PREZISTA ORAL TABLET 150 MG                       | 3                 | QL (240 EA per 30 days)    |
| PREZISTA ORAL TABLET 75 MG                        | 3                 | QL (480 EA per 30 days)    |
| REYATAZ ORAL POWDER IN PACKET 50 MG               | 5^                |                            |
| <i>ribavirin oral capsule 200 mg</i>              | 1                 |                            |
| <i>ribavirin oral tablet 200 mg</i>               | 1                 |                            |
| <i>rilpivirine hcl oral tablet 25 mg</i>          | 3                 |                            |
| <i>rimantadine oral tablet 100 mg</i>             | 3                 |                            |
| <i>ritonavir oral tablet 100 mg</i>               | 1                 |                            |
| RUKOBIA ORAL TABLET EXTENDED RELEASE 12 HR 600 MG | 5^                |                            |
| SELZENTRY ORAL SOLUTION 20 MG/ML                  | 5^                |                            |
| SOFOSBUVIR-VELPATASVIR ORAL TABLET 400-100 MG     | 5^                | PA; QL (28 EA per 28 days) |
| STRIBILD ORAL TABLET 150-150-200-300 MG           | 5^                |                            |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                            | Nivo Medikaman an | Egzijans/Limit yo |
|-----------------------------------------------------------------------------|-------------------|-------------------|
| SUNLENCA ORAL TABLET 300 MG, 300 MG (4-TABLET PACK), 300 MG (5-TABLET PACK) | 5^                |                   |
| SYMTUZA ORAL TABLET 800-150-200-10 MG                                       | 5^                |                   |
| <i>tenofovir disoproxil fumarate oral tablet 300 mg</i>                     | 1                 |                   |
| TIVICAY ORAL TABLET 50 MG                                                   | 5^                |                   |
| TIVICAY PD ORAL TABLET FOR SUSPENSION 5 MG                                  | 5^                |                   |
| TRIUMEQ ORAL TABLET 600-50-300 MG                                           | 5^                |                   |
| TRIUMEQ PD ORAL TABLET FOR SUSPENSION 60-5-30 MG                            | 3                 |                   |
| <i>valacyclovir oral tablet 1 gram, 500 mg</i>                              | 1                 |                   |
| <i>valganciclovir oral recon soln 50 mg/ml</i>                              | 5^                |                   |
| <i>valganciclovir oral tablet 450 mg</i>                                    | 2                 |                   |
| VIRACEPT ORAL TABLET 250 MG, 625 MG                                         | 3                 |                   |
| VIREAD ORAL POWDER 40 MG/SCOOP (40 MG/GRAM)                                 | 5^                |                   |
| VIREAD ORAL TABLET 150 MG, 250 MG                                           | 5^                |                   |
| VIREAD ORAL TABLET 200 MG                                                   | 2                 |                   |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                            | Nivo Medikaman an | Egzijans/Limit yo          |
|-----------------------------------------------------------------------------|-------------------|----------------------------|
| VOSEVI ORAL TABLET 400-100-100 MG                                           | 5^                | PA; QL (28 EA per 28 days) |
| XOFLUZA ORAL TABLET 40 MG, 80 MG                                            | 3                 |                            |
| <i>zidovudine oral capsule 100 mg</i>                                       | 1                 |                            |
| <i>zidovudine oral syrup 10 mg/ml</i>                                       | 1                 |                            |
| <i>zidovudine oral tablet 300 mg</i>                                        | 1                 |                            |
| <b>SEFALOSPORINS</b>                                                        |                   |                            |
| <i>cefaclor oral capsule 250 mg, 500 mg</i>                                 | 1                 |                            |
| <i>cefaclor oral suspension for reconstitution 250 mg/5 ml</i>              | 1                 |                            |
| <i>cefadroxil oral capsule 500 mg</i>                                       | 1                 |                            |
| <i>cefadroxil oral suspension for reconstitution 250 mg/5 ml</i>            | 3                 |                            |
| <i>cefadroxil oral suspension for reconstitution 500 mg/5 ml</i>            | 1                 |                            |
| <i>cefazolin injection recon soln 1 gram</i>                                | 3                 |                            |
| <i>cefazolin injection recon soln 500 mg</i>                                | 1                 |                            |
| <i>cefazolin intravenous recon soln 10 gram</i>                             | 3                 |                            |
| <i>cefdinir oral capsule 300 mg</i>                                         | 1                 |                            |
| <i>cefdinir oral suspension for reconstitution 125 mg/5 ml, 250 mg/5 ml</i> | 1                 |                            |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                            | Nivo Medikaman an | Egzijans/Limit yo |
|-----------------------------------------------------------------------------|-------------------|-------------------|
| <i>cefepime injection recon soln 1 gram, 2 gram</i>                         | 3                 |                   |
| <i>cefixime oral capsule 400 mg</i>                                         | 1                 |                   |
| <i>cefixime oral suspension for reconstitution 100 mg/5 ml, 200 mg/5 ml</i> | 3                 |                   |
| <i>cefoxitin intravenous recon soln 1 gram, 10 gram, 2 gram</i>             | 1                 |                   |
| <i>cefpodoxime oral suspension for reconstitution 100 mg/5 ml</i>           | 3                 |                   |
| <i>cefpodoxime oral suspension for reconstitution 50 mg/5 ml</i>            | 1                 |                   |
| <i>cefpodoxime oral tablet 100 mg, 200 mg</i>                               | 3                 |                   |
| <i>cefprozil oral suspension for reconstitution 125 mg/5 ml</i>             | 1                 |                   |
| <i>cefprozil oral suspension for reconstitution 250 mg/5 ml</i>             | 3                 |                   |
| <i>cefprozil oral tablet 250 mg, 500 mg</i>                                 | 1                 |                   |
| <i>ceftaroline fosamil intravenous recon soln 400 mg, 600 mg</i>            | 5^                |                   |
| <i>ceftazidime injection recon soln 1 gram, 2 gram, 6 gram</i>              | 3                 |                   |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                              | Nivo Medikaman an | Egzijans/Limit yo |
|-------------------------------------------------------------------------------|-------------------|-------------------|
| <i>ceftriaxone injection recon soln 1 gram, 10 gram, 2 gram</i>               | 3                 |                   |
| <i>ceftriaxone injection recon soln 250 mg, 500 mg</i>                        | 1                 |                   |
| <i>cefuroxime axetil oral tablet 250 mg, 500 mg</i>                           | 1                 |                   |
| <i>cefuroxime sodium injection recon soln 750 mg</i>                          | 1                 |                   |
| <i>cefuroxime sodium intravenous recon soln 1.5 gram</i>                      | 1                 |                   |
| <i>cephalexin oral capsule 250 mg, 500 mg</i>                                 | 1                 |                   |
| <i>cephalexin oral suspension for reconstitution 125 mg/5 ml, 250 mg/5 ml</i> | 1                 |                   |
| <i>tazicef injection recon soln 1 gram, 2 gram, 6 gram</i>                    | 3                 |                   |
| <b>TETRASIKLIN</b>                                                            |                   |                   |
| <i>demeclocycline oral tablet 150 mg, 300 mg</i>                              | 3                 |                   |
| <i>doxy-100 intravenous recon soln 100 mg</i>                                 | 1                 |                   |
| <i>doxycycline hyclate intravenous recon soln 100 mg</i>                      | 1                 |                   |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                                            | Nivo Medikaman an | Egzijans/Limit yo       |
|---------------------------------------------------------------------------------------------|-------------------|-------------------------|
| <i>doxycycline hyclate oral capsule 100 mg, 50 mg</i>                                       | 1                 |                         |
| <i>doxycycline hyclate oral tablet 100 mg, 20 mg</i>                                        | 1                 |                         |
| <i>doxycycline monohydrate oral capsule 100 mg, 50 mg</i>                                   | 1                 |                         |
| <i>doxycycline monohydrate oral tablet 100 mg, 50 mg, 75 mg</i>                             | 1                 |                         |
| <i>minocycline oral capsule 100 mg, 50 mg, 75 mg</i>                                        | 1                 |                         |
| <i>minocycline oral tablet 100 mg, 50 mg, 75 mg</i>                                         | 3                 |                         |
| <i>tetracycline oral capsule 250 mg, 500 mg</i>                                             | 3                 |                         |
| <b>DIVÈS ATIK REZÈV</b>                                                                     |                   |                         |
| <b><i>DIVÈS ATIK REZÈV</i></b>                                                              |                   |                         |
| ASSURE ID INSULIN SAFETY SYRINGE 1 ML 29 GAUGE X 1/2"                                       | 1                 |                         |
| GAUZE PAD TOPICAL BANDAGE 2 X 2 "                                                           | 2                 |                         |
| INSULIN SYRINGE-NEEDLE U-100 SYRINGE 0.3 ML 29 GAUGE, 1 ML 29 GAUGE X 1/2", 1/2 ML 28 GAUGE | 1                 | BD or Embecta preferred |
| PEN NEEDLE, DIABETIC NEEDLE 29 GAUGE X 1/2"                                                 | 1                 | BD or Embecta preferred |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

## Non Medikaman an

Nivo Egzijans/Limit yo  
Medikaman an

### GASTWOANTEWOLOJI

#### **ANTI-DYAREYIK / ANTISPASMODIK**

|                                       |   |    |
|---------------------------------------|---|----|
| <i>dicyclomine oral capsule 10 mg</i> | 3 | PA |
|---------------------------------------|---|----|

|                                             |   |    |
|---------------------------------------------|---|----|
| <i>dicyclomine oral solution 10 mg/5 ml</i> | 3 | PA |
|---------------------------------------------|---|----|

|                                      |   |    |
|--------------------------------------|---|----|
| <i>dicyclomine oral tablet 20 mg</i> | 3 | PA |
|--------------------------------------|---|----|

|                                                             |   |  |
|-------------------------------------------------------------|---|--|
| <i>diphenoxylate-atropine oral liquid 2.5-0.025 mg/5 ml</i> | 3 |  |
|-------------------------------------------------------------|---|--|

|                                                        |   |  |
|--------------------------------------------------------|---|--|
| <i>diphenoxylate-atropine oral tablet 2.5-0.025 mg</i> | 3 |  |
|--------------------------------------------------------|---|--|

|                                              |   |  |
|----------------------------------------------|---|--|
| <i>glycopyrrolate oral tablet 1 mg, 2 mg</i> | 1 |  |
|----------------------------------------------|---|--|

|                                     |   |  |
|-------------------------------------|---|--|
| <i>loperamide oral capsule 2 mg</i> | 1 |  |
|-------------------------------------|---|--|

#### **DIVÈS AJAN GASTWOENTESTINAL**

|                                           |   |                            |
|-------------------------------------------|---|----------------------------|
| <i>alosetron oral tablet 0.5 mg, 1 mg</i> | 3 | PA; QL (60 EA per 30 days) |
|-------------------------------------------|---|----------------------------|

|                                                     |   |     |
|-----------------------------------------------------|---|-----|
| <i>aprepitant oral capsule 125 mg, 40 mg, 80 mg</i> | 1 | B/D |
|-----------------------------------------------------|---|-----|

|                                                                 |   |     |
|-----------------------------------------------------------------|---|-----|
| <i>aprepitant oral capsule, dose pack 125 mg (1)- 80 mg (2)</i> | 1 | B/D |
|-----------------------------------------------------------------|---|-----|

|                                        |   |  |
|----------------------------------------|---|--|
| <i>balsalazide oral capsule 750 mg</i> | 1 |  |
|----------------------------------------|---|--|

|                                         |    |  |
|-----------------------------------------|----|--|
| <i>betaine oral powder 1 gram/scoop</i> | 5^ |  |
|-----------------------------------------|----|--|

|                                                               |   |  |
|---------------------------------------------------------------|---|--|
| <i>budesonide oral capsule, delayed, extend. release 3 mg</i> | 1 |  |
|---------------------------------------------------------------|---|--|

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                                                                                                                                      | Nivo Medikaman an | Egzijans/Limit yo            |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------|------------------------------|
| <i>budesonide oral tablet, delayed and ext.release 9 mg</i>                                                                                                                           | 5^                | PA; QL (30 EA per 30 days)   |
| <i>compro rectal suppository 25 mg</i>                                                                                                                                                | 1                 |                              |
| <i>constulose oral solution 10 gram/15 ml</i>                                                                                                                                         | 1                 |                              |
| CREON ORAL CAPSULE, DELAYED RELEASE(DR/EC) 12,000-38,000 -60,000 UNIT, 24,000-76,000 -120,000 UNIT, 3,000-9,500- 15,000 UNIT, 36,000-114,000- 180,000 UNIT, 6,000-19,000 -30,000 UNIT | 2                 |                              |
| <i>cromolyn oral concentrate 100 mg/5 ml</i>                                                                                                                                          | 1                 |                              |
| <i>dronabinol oral capsule 10 mg, 2.5 mg, 5 mg</i>                                                                                                                                    | 1                 | PA; QL (60 EA per 30 days)   |
| ENTYVIO PEN SUBCUTANEOUS PEN INJECTOR 108 MG/0.68 ML                                                                                                                                  | 5^                | PA; QL (1.36 ML per 28 days) |
| <i>enulose oral solution 10 gram/15 ml</i>                                                                                                                                            | 1                 |                              |
| <i>gavilyte-c oral recon soln 240-22.72-6.72 -5.84 gram</i>                                                                                                                           | 1                 |                              |
| <i>gavilyte-g oral recon soln 236-22.74-6.74 -5.86 gram</i>                                                                                                                           | 1                 |                              |
| <i>gavilyte-n oral recon soln 420 gram</i>                                                                                                                                            | 1                 |                              |
| <i>generlac oral solution 10 gram/15 ml</i>                                                                                                                                           | 1                 |                              |
| <i>granisetron hcl oral tablet 1 mg</i>                                                                                                                                               | 1                 | B/D                          |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                   | Nivo Medikaman an | Egzijans/Limit yo       |
|--------------------------------------------------------------------|-------------------|-------------------------|
| <i>hydrocortisone rectal enema 100 mg/60 ml</i>                    | 1                 |                         |
| <i>hydrocortisone topical cream with perineal applicator 2.5 %</i> | 1                 |                         |
| <i>lactulose oral solution 10 gram/15 ml</i>                       | 1                 |                         |
| LINZESS ORAL CAPSULE 145 MCG, 290 MCG, 72 MCG                      | 2                 | QL (30 EA per 30 days)  |
| <i>lubiprostone oral capsule 24 mcg</i>                            | 2                 | QL (60 EA per 30 days)  |
| <i>lubiprostone oral capsule 8 mcg</i>                             | 2                 | QL (120 EA per 30 days) |
| <i>meclizine oral tablet 12.5 mg, 25 mg</i>                        | 1                 | PA                      |
| <i>mesalamine oral capsule (with del rel tablets) 400 mg</i>       | 1                 |                         |
| <i>mesalamine oral capsule, extended release 24hr 0.375 gram</i>   | 1                 |                         |
| <i>mesalamine oral tablet, delayed release (dr/ec) 1.2 gram</i>    | 1                 |                         |
| <i>mesalamine oral tablet, delayed release (dr/ec) 800 mg</i>      | 3                 |                         |
| <i>mesalamine rectal enema 4 gram/60 ml</i>                        | 1                 |                         |
| <i>mesalamine rectal suppository 1,000 mg</i>                      | 1                 |                         |
| <i>metoclopramide hcl oral solution 5 mg/5 ml</i>                  | 1                 |                         |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                       | Nivo Medikaman an | Egzijans/Limit yo      |
|------------------------------------------------------------------------|-------------------|------------------------|
| <i>metoclopramide hcl oral tablet 10 mg, 5 mg</i>                      | 1                 |                        |
| MOVANTIK ORAL TABLET 12.5 MG, 25 MG                                    | 2                 | QL (30 EA per 30 days) |
| <i>nitroglycerin rectal ointment 0.4 % (w/w)</i>                       | 3                 | QL (30 GM per 30 days) |
| <i>ondansetron hcl oral solution 4 mg/5 ml</i>                         | 1                 |                        |
| <i>ondansetron hcl oral tablet 4 mg, 8 mg</i>                          | 1                 |                        |
| <i>ondansetron oral tablet, disintegrating 4 mg, 8 mg</i>              | 1                 |                        |
| <i>peg 3350-electrolytes oral recon soln 236-22.74-6.74 -5.86 gram</i> | 1                 |                        |
| <i>peg-electrolyte soln oral recon soln 420 gram</i>                   | 1                 |                        |
| PLENVU ORAL POWDER IN PACKET, SEQUENTIAL 140-9-5.2 GRAM                | 3                 |                        |
| <i>prochlorperazine maleate oral tablet 10 mg, 5 mg</i>                | 1                 |                        |
| <i>prochlorperazine rectal suppository 25 mg</i>                       | 1                 |                        |
| <i>procto-med hc topical cream with perineal applicator 2.5 %</i>      | 1                 |                        |
| <i>proctosol hc topical cream with perineal applicator 2.5 %</i>       | 1                 |                        |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                                                           | Nivo Medikaman an | Egzijans/Limit yo           |
|------------------------------------------------------------------------------------------------------------|-------------------|-----------------------------|
| <i>proctozone-hc topical cream with perineal applicator 2.5 %</i>                                          | 1                 |                             |
| <i>scopolamine base transdermal patch 3 day 1 mg over 3 days</i>                                           | 3                 | QL (10 EA per 30 days)      |
| SKYRIZI SUBCUTANEOUS WEARABLE INJECTOR 180 MG/1.2 ML (150 MG/ML)                                           | 5^                | PA; QL (1.2 ML per 56 days) |
| SKYRIZI SUBCUTANEOUS WEARABLE INJECTOR 360 MG/2.4 ML (150 MG/ML)                                           | 5^                | PA; QL (2.4 ML per 56 days) |
| <i>sodium,potassium,mag sulfates oral recon soln 17.5-3.13-1.6 gram, 17.5-3.13-1.6 gram 2 pack (480ml)</i> | 1                 |                             |
| <i>sulfasalazine oral tablet 500 mg</i>                                                                    | 1                 |                             |
| <i>sulfasalazine oral tablet,delayed release (dr/ec) 500 mg</i>                                            | 1                 |                             |
| <i>ursodiol oral capsule 300 mg</i>                                                                        | 2                 |                             |
| <i>ursodiol oral tablet 250 mg, 500 mg</i>                                                                 | 3                 |                             |
| VELSIPITY ORAL TABLET 2 MG                                                                                 | 3                 | PA; QL (30 EA per 30 days)  |
| VOWST ORAL CAPSULE 1 X 10EXP6 TO 3 X 10EXP7 CELL                                                           | 5^                | PA; LA                      |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                                                                                                                                                                                                                              | Nivo Medikaman an | Egzijans/Limit yo         |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------|---------------------------|
| ZENPEP ORAL CAPSULE, DELAYED RELEASE(DR/EC) 10,000-32,000 -42,000 UNIT, 15,000-47,000 -63,000 UNIT, 20,000-63,000- 84,000 UNIT, 25,000-79,000- 105,000 UNIT, 3,000-10,000 -14,000-UNIT, 40,000-126,000- 168,000 UNIT, 5,000-17,000- 24,000 UNIT, 60,000-189,600- 252,600 UNIT | 2                 |                           |
| ZYMFENTRA SUBCUTANEOUS PEN INJECTOR KIT 120 MG/ML                                                                                                                                                                                                                             | 5^                | PA; QL (2 EA per 28 days) |
| ZYMFENTRA SUBCUTANEOUS SYRINGE KIT 120 MG/ML                                                                                                                                                                                                                                  | 5^                | PA; QL (2 EA per 28 days) |
| <b>TERAPI ILSÈ</b>                                                                                                                                                                                                                                                            |                   |                           |
| <i>bismuth subcit k-metronidz-tcn oral capsule 140-125-125 mg</i>                                                                                                                                                                                                             | 3                 | QL (120 EA per 180 days)  |
| <i>dexlansoprazole oral capsule, biphase delayed releas 30 mg, 60 mg</i>                                                                                                                                                                                                      | 1                 | QL (30 EA per 30 days)    |
| <i>esomeprazole magnesium oral capsule, delayed release(dr/ec) 20 mg, 40 mg</i>                                                                                                                                                                                               | 3                 | QL (60 EA per 30 days)    |
| <i>famotidine oral suspension for reconstitution 40 mg/5 ml (8 mg/ml)</i>                                                                                                                                                                                                     | 1                 |                           |
| <i>famotidine oral tablet 20 mg, 40 mg</i>                                                                                                                                                                                                                                    | 1                 |                           |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                           | Nivo Medikaman an | Egzijans/Limit yo        |
|----------------------------------------------------------------------------|-------------------|--------------------------|
| <i>lansoprazole oral capsule, delayed release(dr/ec) 15 mg, 30 mg</i>      | 1                 | QL (60 EA per 30 days)   |
| <i>misoprostol oral tablet 100 mcg, 200 mcg</i>                            | 1                 |                          |
| <i>omeprazole oral capsule, delayed release(dr/ec) 10 mg, 20 mg, 40 mg</i> | 1                 | QL (60 EA per 30 days)   |
| <i>pantoprazole oral tablet, delayed release (dr/ec) 20 mg, 40 mg</i>      | 1                 | QL (60 EA per 30 days)   |
| <i>rabeprazole oral tablet, delayed release (dr/ec) 20 mg</i>              | 1                 | QL (60 EA per 30 days)   |
| <i>sucralfate oral suspension 100 mg/ml</i>                                | 3                 |                          |
| <i>sucralfate oral tablet 1 gram</i>                                       | 1                 |                          |
| VOQUEZNA DUAL PAK ORAL COMBO PACK 20 MG (28)- 500 MG (84)                  | 3                 | QL (112 EA per 180 days) |
| VOQUEZNA TRIPLE PAK ORAL COMBO PACK 20-500-500 MG                          | 3                 | QL (112 EA per 180 days) |

## IMINOLOJI, VAKSEN / BIOTEKNOLOJI

### MEDIKAMAN BIOTEKNOLOJI

|                                                      |    |           |
|------------------------------------------------------|----|-----------|
| ACTIMMUNE SUBCUTANEOUS SOLUTION 100 MCG/0.5 ML       | 5^ | PA        |
| ARCALYST SUBCUTANEOUS RECON SOLN 220 MG              | 5^ | PA        |
| BESREMI PEN SUBCUTANEOUS PEN INJECTOR 500 MCG/0.5 ML | 5^ | PA-NS; LA |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                                   | Nivo Medikaman an | Egzijans/Limit yo          |
|------------------------------------------------------------------------------------|-------------------|----------------------------|
| BESREMI SUBCUTANEOUS SYRINGE 500 MCG/ML                                            | 5^                | PA-NS; LA                  |
| BETASERON SUBCUTANEOUS KIT 0.3 MG                                                  | 5^                | PA; QL (14 EA per 28 days) |
| FULPHILA SUBCUTANEOUS SYRINGE 6 MG/0.6 ML                                          | 5^                | PA                         |
| LEUKINE INJECTION RECON SOLN 250 MCG                                               | 5^                | PA                         |
| NIVESTYM INJECTION SOLUTION 300 MCG/ML, 480 MCG/1.6 ML                             | 5^                | PA                         |
| NIVESTYM SUBCUTANEOUS SYRINGE 300 MCG/0.5 ML, 480 MCG/0.8 ML                       | 5^                | PA                         |
| OMNITROPE SUBCUTANEOUS CARTRIDGE 10 MG/1.5 ML (6.7 MG/ML), 5 MG/1.5 ML (3.3 MG/ML) | 5^                | PA                         |
| OMNITROPE SUBCUTANEOUS RECON SOLN 5.8 MG                                           | 5^                | PA                         |
| PEGASYS SUBCUTANEOUS SOLUTION 180 MCG/ML                                           | 5^                | QL (4 ML per 28 days)      |
| PEGASYS SUBCUTANEOUS SYRINGE 180 MCG/0.5 ML                                        | 5^                | QL (2 ML per 28 days)      |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                                                                          | Nivo Medikaman an | Egzijans/Limit yo                     |
|---------------------------------------------------------------------------------------------------------------------------|-------------------|---------------------------------------|
| RETACRIT INJECTION SOLUTION 10,000 UNIT/ML, 2,000 UNIT/ML, 20,000 UNIT/2 ML, 20,000 UNIT/ML, 3,000 UNIT/ML, 4,000 UNIT/ML | 2                 | PA                                    |
| RETACRIT INJECTION SOLUTION 40,000 UNIT/ML                                                                                | 5^                | PA                                    |
| <b><i>VAKSEN / DIVÈS PWODUI IMMINOLOJIK</i></b>                                                                           |                   |                                       |
| ABRYSVO (PF) INTRAMUSCULAR RECON SOLN 120 MCG/0.5 ML                                                                      | 4                 | NM; IRA \$0 for age 19 and older      |
| ACTHIB (PF) INTRAMUSCULAR RECON SOLN 10 MCG/0.5 ML                                                                        | 4                 | NM                                    |
| ADACEL(TDAP ADOLESN/ADULT)(PF) INTRAMUSCULAR SUSPENSION 2 LF-(2.5-5-3-5 MCG)-5LF/0.5 ML                                   | 4                 | NM                                    |
| ADACEL(TDAP ADOLESN/ADULT)(PF) INTRAMUSCULAR SYRINGE 2 LF-(2.5-5-3-5 MCG)-5LF/0.5 ML                                      | 4                 | NM                                    |
| AREXVY (PF) INTRAMUSCULAR SUSPENSION FOR RECONSTITUTION 120 MCG/0.5 ML                                                    | 4                 | NM; IRA \$0 for age 50 and older only |
| BCG VACCINE, LIVE (PF) PERCUTANEOUS SUSPENSION FOR RECONSTITUTION 50 MG                                                   | 4                 | NM                                    |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                                | Nivo Medikaman an | Egzijans/Limit yo        |
|---------------------------------------------------------------------------------|-------------------|--------------------------|
| BEXSERO INTRAMUSCULAR SYRINGE 50-50-50-25 MCG/0.5 ML                            | 4                 | NM                       |
| BOOSTRIX TDAP INTRAMUSCULAR SUSPENSION 2.5-8-5 LF-MCG-LF/0.5ML                  | 4                 | NM                       |
| BOOSTRIX TDAP INTRAMUSCULAR SYRINGE 2.5-8-5 LF-MCG-LF/0.5ML                     | 4                 | NM                       |
| DAPTACEL (DTAP PEDIATRIC) (PF) INTRAMUSCULAR SUSPENSION 15-10-5 LF-MCG-LF/0.5ML | 4                 | NM                       |
| ENGRIX-B (PF) INTRAMUSCULAR SUSPENSION 20 MCG/ML                                | 4                 | B/D; NM                  |
| ENGRIX-B (PF) INTRAMUSCULAR SYRINGE 20 MCG/ML                                   | 4                 | B/D; NM                  |
| ENGRIX-B PEDIATRIC (PF) INTRAMUSCULAR SYRINGE 10 MCG/0.5 ML                     | 4                 | B/D; NM                  |
| GAMUNEX-C INJECTION SOLUTION 1 GRAM/10 ML (10 %)                                | 5^                | PA; NM                   |
| GARDASIL 9 (PF) INTRAMUSCULAR SUSPENSION 0.5 ML                                 | 4                 | NM; IRA \$0 up to age 45 |
| GARDASIL 9 (PF) INTRAMUSCULAR SYRINGE 0.5 ML                                    | 4                 | NM; IRA \$0 up to age 45 |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                                   | Nivo Medikaman an | Egzijans/Limit yo |
|------------------------------------------------------------------------------------|-------------------|-------------------|
| HAVRIX (PF) INTRAMUSCULAR SYRINGE<br>1,440 ELISA UNIT/ML, 720 ELISA<br>UNIT/0.5 ML | 4                 | NM                |
| HEPLISAV-B (PF) INTRAMUSCULAR<br>SYRINGE 20 MCG/0.5 ML                             | 4                 | B/D; NM           |
| HIBERIX (PF) INTRAMUSCULAR RECON<br>SOLN 10 MCG/0.5 ML                             | 4                 | NM                |
| IMOVAX RABIES VACCINE (PF)<br>INTRAMUSCULAR RECON SOLN 2.5<br>UNIT                 | 4                 | B/D; NM           |
| INFANRIX (DTAP) (PF) INTRAMUSCULAR<br>SYRINGE 25-58-10 LF-MCG-LF/0.5ML             | 4                 | NM                |
| IPOL INJECTION SUSPENSION 40-8-32<br>UNIT/0.5 ML                                   | 4                 | NM                |
| IXIARO (PF) INTRAMUSCULAR SYRINGE<br>6 MCG/0.5 ML                                  | 4                 | NM                |
| JYNNEOS (PF) SUBCUTANEOUS<br>SUSPENSION 0.5X TO 3.95X 10EXP8<br>UNIT/0.5           | 4                 | B/D; NM           |
| KINRIX (PF) INTRAMUSCULAR SYRINGE<br>25 LF-58 MCG-10 LF/0.5 ML                     | 4                 | NM                |
| MENQUADFI (PF) INTRAMUSCULAR<br>SOLUTION 10 MCG/0.5 ML                             | 4                 | NM                |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                                            | Nivo Medikaman an | Egzijans/Limit yo                        |
|---------------------------------------------------------------------------------------------|-------------------|------------------------------------------|
| MENVEO A-C-Y-W-135-DIP (PF)<br>INTRAMUSCULAR KIT 10-5 MCG/0.5 ML                            | 4                 | NM                                       |
| M-M-R II (PF) SUBCUTANEOUS RECON<br>SOLN 1,000-12,500 TCID50/0.5 ML                         | 4                 | NM                                       |
| MRESVIA (PF) INTRAMUSCULAR<br>SYRINGE 50 MCG/0.5 ML                                         | 4                 | NM; IRA \$0 for age 50<br>and older only |
| PEDIARIX (PF) INTRAMUSCULAR<br>SYRINGE 10 MCG-25LF-25 MCG-<br>10LF/0.5 ML                   | 4                 | NM                                       |
| PEDVAX HIB (PF) INTRAMUSCULAR<br>SOLUTION 7.5 MCG/0.5 ML                                    | 4                 | NM                                       |
| PENBRAYA (PF) INTRAMUSCULAR KIT 5-<br>120 MCG/0.5 ML                                        | 4                 | NM                                       |
| PENMENVY MEN A-B-C-W-Y (PF)<br>INTRAMUSCULAR KIT 0.5 ML                                     | 4                 | NM                                       |
| PENTACEL (PF) INTRAMUSCULAR KIT<br>15LF-20MCG-5LF- 62 DU/0.5 ML                             | 4                 | NM                                       |
| PRIORIX (PF) SUBCUTANEOUS<br>SUSPENSION FOR RECONSTITUTION<br>10EXP3.4-4.2- 3.3CCID50/0.5ML | 4                 | NM                                       |
| PROQUAD (PF) SUBCUTANEOUS<br>SUSPENSION FOR RECONSTITUTION<br>10EXP3-4.3-3- 3.99 TCID50/0.5 | 4                 | NM                                       |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                                     | Nivo Medikaman an | Egzijans/Limit yo                                                                                                 |
|--------------------------------------------------------------------------------------|-------------------|-------------------------------------------------------------------------------------------------------------------|
| QUADRACEL (PF) INTRAMUSCULAR<br>SUSPENSION 15 LF-48 MCG- 5 LF<br>UNIT/0.5ML          | 4                 | NM                                                                                                                |
| QUADRACEL (PF) INTRAMUSCULAR<br>SYRINGE 15 LF-48 MCG- 5 LF<br>UNIT/0.5ML             | 4                 | NM                                                                                                                |
| RABAVERT (PF) INTRAMUSCULAR<br>SUSPENSION FOR RECONSTITUTION 2.5<br>UNIT             | 4                 | B/D; NM                                                                                                           |
| RECOMBIVAX HB (PF) INTRAMUSCULAR<br>SUSPENSION 10 MCG/ML, 40 MCG/ML,<br>5 MCG/0.5 ML | 4                 | B/D; NM                                                                                                           |
| RECOMBIVAX HB (PF) INTRAMUSCULAR<br>SYRINGE 10 MCG/ML, 5 MCG/0.5 ML                  | 4                 | B/D; NM                                                                                                           |
| ROTARIX ORAL SUSPENSION 10EXP6<br>CCID50 /1.5 ML                                     | 6                 | NM                                                                                                                |
| ROTATEQ VACCINE ORAL SOLUTION 2<br>ML                                                | 6                 | NM                                                                                                                |
| SHINGRIX (PF) INTRAMUSCULAR<br>SUSPENSION FOR RECONSTITUTION 50<br>MCG/0.5 ML        | 4                 | NM; A third dose may be<br>considered in post-<br>transplant members (PA<br>required).; QL (2 EA per<br>720 days) |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                 | Nivo Medikaman an | Egzijans/Limit yo                                                                                    |
|------------------------------------------------------------------|-------------------|------------------------------------------------------------------------------------------------------|
| SHINGRIX (PF) INTRAMUSCULAR SYRINGE 50 MCG/0.5 ML                | 4                 | NM; A third dose may be considered in post-transplant members (PA required).; QL (1 ML per 720 days) |
| TENIVAC (PF) INTRAMUSCULAR SUSPENSION 5 LF UNIT- 2 LF UNIT/0.5ML | 4                 | NM                                                                                                   |
| TENIVAC (PF) INTRAMUSCULAR SYRINGE 5-2 LF UNIT/0.5 ML            | 4                 | NM                                                                                                   |
| TICOVAC INTRAMUSCULAR SYRINGE 1.2 MCG/0.25 ML, 2.4 MCG/0.5 ML    | 4                 | NM                                                                                                   |
| TRUMENBA INTRAMUSCULAR SYRINGE 120 MCG/0.5 ML                    | 4                 | NM                                                                                                   |
| TWINRIX (PF) INTRAMUSCULAR SYRINGE 720 ELISA UNIT- 20 MCG/ML     | 4                 | NM                                                                                                   |
| TYPHIM VI INTRAMUSCULAR SYRINGE 25 MCG/0.5 ML                    | 4                 | NM                                                                                                   |
| VAQTA (PF) INTRAMUSCULAR SUSPENSION 25 UNIT/0.5 ML, 50 UNIT/ML   | 4                 | NM                                                                                                   |
| VAQTA (PF) INTRAMUSCULAR SYRINGE 25 UNIT/0.5 ML, 50 UNIT/ML      | 4                 | NM                                                                                                   |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                                        | Nivo Medikaman an | Egzijans/Limit yo |
|-----------------------------------------------------------------------------------------|-------------------|-------------------|
| VARIVAX (PF) SUBCUTANEOUS<br>SUSPENSION FOR RECONSTITUTION<br>1,350 UNIT/0.5 ML         | 4                 | NM                |
| VAXCHORA VACCINE ORAL<br>SUSPENSION FOR RECONSTITUTION<br>4X10EXP8 TO 2X 10EXP9 CF UNIT | 6                 | NM                |
| VIMKUNYA (PF) INTRAMUSCULAR<br>SYRINGE 40 MCG/0.8 ML                                    | 4                 | NM                |
| VIVOTIF ORAL CAPSULE, DELAYED<br>RELEASE(DR/EC) 2 BILLION UNIT                          | 6                 | NM                |
| YF-VAX (PF) SUBCUTANEOUS<br>SUSPENSION FOR RECONSTITUTION 10<br>EXP4.74 UNIT/0.5 ML     | 4                 | NM                |
| <b>KADYOVASKILÈ, IPÈTANSYON / LIPID<br/>YO</b>                                          |                   |                   |
| <b>AJAN ANTI-ARRHYTHMIK</b>                                                             |                   |                   |
| <i>amiodarone oral tablet 100 mg, 200<br/>mg, 400 mg</i>                                | 1                 |                   |
| <i>disopyramide phosphate oral capsule<br/>100 mg, 150 mg</i>                           | 3                 |                   |
| <i>dofetilide oral capsule 125 mcg, 250<br/>mcg, 500 mcg</i>                            | 1                 |                   |
| <i>flecainide oral tablet 100 mg, 150 mg,<br/>50 mg</i>                                 | 1                 |                   |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                                       | Nivo Medikaman an | Egzijans/Limit yo          |
|----------------------------------------------------------------------------------------|-------------------|----------------------------|
| <i>mexiletine oral capsule 150 mg, 200 mg, 250 mg</i>                                  | 3                 |                            |
| MULTAQ ORAL TABLET 400 MG                                                              | 3                 |                            |
| <i>pacerone oral tablet 100 mg, 200 mg</i>                                             | 1                 |                            |
| <i>propafenone oral capsule, extended release 12 hr 225 mg, 325 mg, 425 mg</i>         | 1                 |                            |
| <i>propafenone oral tablet 150 mg, 225 mg, 300 mg</i>                                  | 1                 |                            |
| <i>quinidine sulfate oral tablet 200 mg, 300 mg</i>                                    | 1                 |                            |
| <i>sotalol af oral tablet 120 mg, 160 mg, 80 mg</i>                                    | 1                 |                            |
| <i>sotalol oral tablet 120 mg, 160 mg, 240 mg, 80 mg</i>                               | 1                 |                            |
| <b>AJAN KADYOVASKILÈ DIVÈS</b>                                                         |                   |                            |
| <i>digoxin oral solution 50 mcg/ml (0.05 mg/ml)</i>                                    | 1                 |                            |
| <i>digoxin oral tablet 125 mcg (0.125 mg), 250 mcg (0.25 mg), 62.5 mcg (0.0625 mg)</i> | 1                 | QL (60 EA per 30 days)     |
| FILSPARI ORAL TABLET 200 MG, 400 MG                                                    | 5 <sup>^</sup>    | PA; QL (30 EA per 30 days) |
| <i>ivabradine oral tablet 5 mg, 7.5 mg</i>                                             | 3                 | QL (60 EA per 30 days)     |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                                                                                                       | Nivo Medikaman an | Egzijans/Limit yo       |
|--------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------|-------------------------|
| <i>ranolazine oral tablet extended release 12 hr 1,000 mg, 500 mg</i>                                                                                  | 3                 |                         |
| <i>sacubitril-valsartan oral tablet 24-26 mg</i>                                                                                                       | 2                 | QL (180 EA per 30 days) |
| <i>sacubitril-valsartan oral tablet 49-51 mg, 97-103 mg</i>                                                                                            | 2                 | QL (60 EA per 30 days)  |
| VERQUVO ORAL TABLET 10 MG, 2.5 MG, 5 MG                                                                                                                | 2                 | QL (30 EA per 30 days)  |
| <b>AJAN KI BESE LIPID/KOLESTEWÒL</b>                                                                                                                   |                   |                         |
| <i>amlodipine-atorvastatin oral tablet 10-10 mg, 10-20 mg, 10-40 mg, 10-80 mg, 2.5-10 mg, 2.5-20 mg, 2.5-40 mg, 5-10 mg, 5-20 mg, 5-40 mg, 5-80 mg</i> | 6                 | QL (30 EA per 30 days)  |
| <i>atorvastatin oral tablet 10 mg, 20 mg, 40 mg, 80 mg</i>                                                                                             | 6                 | QL (30 EA per 30 days)  |
| <i>cholestyramine (with sugar) oral powder in packet 4 gram</i>                                                                                        | 1                 |                         |
| <i>cholestyramine light oral powder in packet 4 gram</i>                                                                                               | 1                 |                         |
| <i>colesevelam oral powder in packet 3.75 gram</i>                                                                                                     | 1                 |                         |
| <i>colesevelam oral tablet 625 mg</i>                                                                                                                  | 1                 |                         |
| <i>colestipol oral packet 5 gram</i>                                                                                                                   | 1                 |                         |
| <i>colestipol oral tablet 1 gram</i>                                                                                                                   | 1                 |                         |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                                    | Nivo Medikaman an | Egzijans/Limit yo      |
|-------------------------------------------------------------------------------------|-------------------|------------------------|
| <i>ezetimibe oral tablet 10 mg</i>                                                  | 1                 |                        |
| <i>ezetimibe-simvastatin oral tablet 10-10 mg, 10-20 mg, 10-40 mg, 10-80 mg</i>     | 6                 | QL (30 EA per 30 days) |
| <i>fenofibrate micronized oral capsule 134 mg, 200 mg, 43 mg, 67 mg</i>             | 1                 |                        |
| <i>fenofibrate nanocrystallized oral tablet 145 mg, 48 mg</i>                       | 1                 |                        |
| <i>fenofibrate oral tablet 160 mg, 54 mg</i>                                        | 1                 |                        |
| <i>fenofibric acid (choline) oral capsule, delayed release(dr/ec) 135 mg, 45 mg</i> | 1                 |                        |
| <i>fluvastatin oral capsule 20 mg, 40 mg</i>                                        | 6                 | QL (60 EA per 30 days) |
| <i>fluvastatin oral tablet extended release 24 hr 80 mg</i>                         | 6                 | QL (30 EA per 30 days) |
| <i>gemfibrozil oral tablet 600 mg</i>                                               | 1                 |                        |
| <i>icosapent ethyl oral capsule 0.5 gram, 1 gram</i>                                | 3                 |                        |
| <i>lovastatin oral tablet 10 mg, 20 mg, 40 mg</i>                                   | 6                 | QL (60 EA per 30 days) |
| NEXLETOL ORAL TABLET 180 MG                                                         | 2                 | PA                     |
| <i>niacin oral tablet extended release 24 hr 1,000 mg, 500 mg, 750 mg</i>           | 1                 |                        |
| <i>pitavastatin calcium oral tablet 1 mg, 2 mg, 4 mg</i>                            | 2                 | QL (30 EA per 30 days) |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                                          | Nivo Medikaman an | Egzijans/Limit yo      |
|-------------------------------------------------------------------------------------------|-------------------|------------------------|
| PRALUENT PEN SUBCUTANEOUS PEN INJECTOR 150 MG/ML, 75 MG/ML                                | 2                 | PA                     |
| <i>pravastatin oral tablet 10 mg, 20 mg, 40 mg, 80 mg</i>                                 | 6                 | QL (30 EA per 30 days) |
| <i>rosuvastatin oral tablet 10 mg, 20 mg, 40 mg, 5 mg</i>                                 | 6                 | QL (30 EA per 30 days) |
| <i>simvastatin oral tablet 10 mg, 20 mg, 40 mg, 5 mg, 80 mg</i>                           | 6                 | QL (30 EA per 30 days) |
| <b>NITRAT</b>                                                                             |                   |                        |
| <i>isosorbide dinitrate oral tablet 10 mg, 20 mg, 30 mg, 5 mg</i>                         | 1                 |                        |
| <i>isosorbide mononitrate oral tablet 10 mg, 20 mg</i>                                    | 1                 |                        |
| <i>isosorbide mononitrate oral tablet extended release 24 hr 120 mg, 30 mg, 60 mg</i>     | 1                 |                        |
| <i>nitro-bid transdermal ointment 2 %</i>                                                 | 3                 |                        |
| <i>nitroglycerin sublingual tablet 0.3 mg, 0.4 mg, 0.6 mg</i>                             | 1                 |                        |
| <i>nitroglycerin transdermal patch 24 hour 0.1 mg/hr, 0.2 mg/hr, 0.4 mg/hr, 0.6 mg/hr</i> | 1                 |                        |
| <b>TERAPI ANTI-IPÈTANSIF</b>                                                              |                   |                        |
| <i>acebutolol oral capsule 200 mg, 400 mg</i>                                             | 1                 |                        |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                                                                         | Nivo Medikaman an | Egzijans/Limit yo      |
|--------------------------------------------------------------------------------------------------------------------------|-------------------|------------------------|
| <i>aliskiren oral tablet 150 mg, 300 mg</i>                                                                              | 1                 |                        |
| <i>amiloride oral tablet 5 mg</i>                                                                                        | 1                 |                        |
| <i>amiloride-hydrochlorothiazide oral tablet 5-50 mg</i>                                                                 | 1                 |                        |
| <i>amlodipine oral tablet 10 mg, 2.5 mg, 5 mg</i>                                                                        | 1                 |                        |
| <i>amlodipine-benazepril oral capsule 10-20 mg, 10-40 mg, 2.5-10 mg, 5-10 mg, 5-20 mg, 5-40 mg</i>                       | 6                 |                        |
| <i>amlodipine-olmesartan oral tablet 10-20 mg, 10-40 mg, 5-20 mg, 5-40 mg</i>                                            | 6                 | QL (30 EA per 30 days) |
| <i>amlodipine-valsartan oral tablet 10-160 mg, 10-320 mg, 5-160 mg, 5-320 mg</i>                                         | 6                 | QL (30 EA per 30 days) |
| <i>amlodipine-valsartan-hcthiazyd oral tablet 10-160-12.5 mg, 10-160-25 mg, 10-320-25 mg, 5-160-12.5 mg, 5-160-25 mg</i> | 6                 | QL (30 EA per 30 days) |
| <i>atenolol oral tablet 100 mg, 25 mg, 50 mg</i>                                                                         | 1                 |                        |
| <i>atenolol-chlorthalidone oral tablet 100-25 mg, 50-25 mg</i>                                                           | 1                 |                        |
| <i>benazepril oral tablet 10 mg, 20 mg, 40 mg, 5 mg</i>                                                                  | 6                 |                        |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                                              | Nivo Medikaman an | Egzijans/Limit yo      |
|-----------------------------------------------------------------------------------------------|-------------------|------------------------|
| <i>benazepril-hydrochlorothiazide oral tablet 10-12.5 mg, 20-12.5 mg, 20-25 mg, 5-6.25 mg</i> | 6                 |                        |
| <i>betaxolol oral tablet 10 mg, 20 mg</i>                                                     | 1                 |                        |
| <i>bisoprolol fumarate oral tablet 10 mg, 5 mg</i>                                            | 1                 |                        |
| <i>bisoprolol-hydrochlorothiazide oral tablet 10-6.25 mg, 2.5-6.25 mg, 5-6.25 mg</i>          | 1                 |                        |
| <i>bumetanide injection solution 0.25 mg/ml</i>                                               | 1                 |                        |
| <i>bumetanide oral tablet 0.5 mg, 1 mg, 2 mg</i>                                              | 1                 |                        |
| <i>candesartan oral tablet 16 mg, 4 mg, 8 mg</i>                                              | 6                 | QL (60 EA per 30 days) |
| <i>candesartan oral tablet 32 mg</i>                                                          | 6                 | QL (30 EA per 30 days) |
| <i>candesartan-hydrochlorothiazid oral tablet 16-12.5 mg</i>                                  | 6                 | QL (60 EA per 30 days) |
| <i>candesartan-hydrochlorothiazid oral tablet 32-12.5 mg, 32-25 mg</i>                        | 6                 | QL (30 EA per 30 days) |
| <i>captopril oral tablet 100 mg, 12.5 mg, 25 mg, 50 mg</i>                                    | 6                 |                        |
| <i>cartia xt oral capsule, extended release 24hr 120 mg, 180 mg, 240 mg, 300 mg</i>           | 1                 |                        |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                                                       | Nivo Medikaman an | Egzijans/Limit yo      |
|--------------------------------------------------------------------------------------------------------|-------------------|------------------------|
| <i>carvedilol oral tablet 12.5 mg, 25 mg, 3.125 mg, 6.25 mg</i>                                        | 1                 |                        |
| <i>chlorthalidone oral tablet 25 mg, 50 mg</i>                                                         | 1                 |                        |
| <i>clonidine hcl oral tablet 0.1 mg, 0.2 mg, 0.3 mg</i>                                                | 1                 |                        |
| <i>clonidine transdermal patch weekly 0.1 mg/24 hr, 0.2 mg/24 hr, 0.3 mg/24 hr</i>                     | 1                 | QL (4 EA per 28 days)  |
| <i>diltiazem hcl oral capsule, extended release 12 hr 120 mg, 60 mg, 90 mg</i>                         | 1                 |                        |
| <i>diltiazem hcl oral capsule, extended release 24 hr 360 mg, 420 mg</i>                               | 1                 |                        |
| <i>diltiazem hcl oral capsule, extended release 24hr 120 mg, 180 mg, 240 mg, 300 mg</i>                | 1                 |                        |
| <i>diltiazem hcl oral tablet 120 mg, 30 mg, 60 mg, 90 mg</i>                                           | 1                 |                        |
| <i>diltiazem hcl oral tablet extended release 24 hr 120 mg, 180 mg, 240 mg, 300 mg, 360 mg, 420 mg</i> | 1                 |                        |
| <i>dilt-xr oral capsule, ext. rel 24h degradable 120 mg, 180 mg, 240 mg</i>                            | 1                 |                        |
| <i>doxazosin oral tablet 1 mg, 2 mg, 4 mg, 8 mg</i>                                                    | 1                 |                        |
| EDARBI ORAL TABLET 40 MG, 80 MG                                                                        | 2                 | QL (30 EA per 30 days) |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                         | Nivo Medikaman an | Egzijans/Limit yo      |
|--------------------------------------------------------------------------|-------------------|------------------------|
| EDARBYCLOR ORAL TABLET 40-12.5 MG, 40-25 MG                              | 2                 | QL (30 EA per 30 days) |
| <i>enalapril maleate oral tablet 10 mg, 2.5 mg, 20 mg, 5 mg</i>          | 6                 |                        |
| <i>enalapril-hydrochlorothiazide oral tablet 10-25 mg, 5-12.5 mg</i>     | 6                 |                        |
| <i>eplerenone oral tablet 25 mg, 50 mg</i>                               | 1                 |                        |
| <i>felodipine oral tablet extended release 24 hr 10 mg, 2.5 mg, 5 mg</i> | 1                 |                        |
| <i>fosinopril oral tablet 10 mg, 20 mg, 40 mg</i>                        | 6                 |                        |
| <i>fosinopril-hydrochlorothiazide oral tablet 10-12.5 mg, 20-12.5 mg</i> | 6                 |                        |
| <i>furosemide injection solution 10 mg/ml</i>                            | 1                 |                        |
| <i>furosemide oral solution 10 mg/ml, 40 mg/5 ml (8 mg/ml)</i>           | 1                 |                        |
| <i>furosemide oral tablet 20 mg, 40 mg, 80 mg</i>                        | 1                 |                        |
| <i>guanfacine oral tablet 1 mg, 2 mg</i>                                 | 3                 |                        |
| <i>hydralazine oral tablet 10 mg, 100 mg, 25 mg, 50 mg</i>               | 1                 |                        |
| <i>hydrochlorothiazide oral capsule 12.5 mg</i>                          | 1                 |                        |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                                   | Nivo Medikaman an | Egzijans/Limit yo      |
|------------------------------------------------------------------------------------|-------------------|------------------------|
| <i>hydrochlorothiazide oral tablet 12.5 mg, 25 mg, 50 mg</i>                       | 1                 |                        |
| <i>indapamide oral tablet 1.25 mg, 2.5 mg</i>                                      | 1                 |                        |
| <i>irbesartan oral tablet 150 mg, 300 mg, 75 mg</i>                                | 6                 | QL (30 EA per 30 days) |
| <i>irbesartan-hydrochlorothiazide oral tablet 150-12.5 mg</i>                      | 6                 | QL (60 EA per 30 days) |
| <i>irbesartan-hydrochlorothiazide oral tablet 300-12.5 mg</i>                      | 6                 | QL (30 EA per 30 days) |
| <i>isradipine oral capsule 2.5 mg, 5 mg</i>                                        | 1                 |                        |
| KERENDIA ORAL TABLET 10 MG, 20 MG, 40 MG                                           | 2                 | QL (30 EA per 30 days) |
| <i>labetalol oral tablet 100 mg, 200 mg, 300 mg</i>                                | 1                 |                        |
| <i>lisinopril oral tablet 10 mg, 2.5 mg, 20 mg, 30 mg, 40 mg, 5 mg</i>             | 6                 |                        |
| <i>lisinopril-hydrochlorothiazide oral tablet 10-12.5 mg, 20-12.5 mg, 20-25 mg</i> | 6                 |                        |
| <i>losartan oral tablet 100 mg</i>                                                 | 6                 | QL (30 EA per 30 days) |
| <i>losartan oral tablet 25 mg, 50 mg</i>                                           | 6                 | QL (60 EA per 30 days) |
| <i>losartan-hydrochlorothiazide oral tablet 100-12.5 mg, 100-25 mg</i>             | 6                 | QL (30 EA per 30 days) |
| <i>losartan-hydrochlorothiazide oral tablet 50-12.5 mg</i>                         | 6                 | QL (60 EA per 30 days) |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                                            | Nivo Medikaman an | Egzijans/Limit yo |
|---------------------------------------------------------------------------------------------|-------------------|-------------------|
| <i>matzim la oral tablet extended release 24 hr 180 mg, 240 mg, 300 mg, 360 mg, 420 mg</i>  | 1                 |                   |
| <i>metolazone oral tablet 10 mg, 2.5 mg, 5 mg</i>                                           | 1                 |                   |
| <i>metoprolol succinate oral tablet extended release 24 hr 100 mg, 200 mg, 25 mg, 50 mg</i> | 1                 |                   |
| <i>metoprolol ta-hydrochlorothiaz oral tablet 100-25 mg, 100-50 mg, 50-25 mg</i>            | 1                 |                   |
| <i>metoprolol tartrate oral tablet 100 mg, 25 mg, 37.5 mg, 50 mg, 75 mg</i>                 | 1                 |                   |
| <i>metyrosine oral capsule 250 mg</i>                                                       | 5^                | PA                |
| <i>minoxidil oral tablet 10 mg, 2.5 mg</i>                                                  | 1                 |                   |
| <i>moexipril oral tablet 15 mg, 7.5 mg</i>                                                  | 6                 |                   |
| <i>nadolol oral tablet 20 mg, 40 mg, 80 mg</i>                                              | 1                 |                   |
| <i>nebivolol oral tablet 10 mg, 2.5 mg, 20 mg, 5 mg</i>                                     | 1                 |                   |
| <i>nicardipine oral capsule 20 mg, 30 mg</i>                                                | 1                 |                   |
| <i>nifedipine oral tablet extended release 24hr 30 mg, 60 mg, 90 mg</i>                     | 1                 |                   |
| <i>nifedipine oral tablet extended release 30 mg, 60 mg, 90 mg</i>                          | 1                 |                   |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                                                                     | Nivo Medikaman an | Egzijans/Limit yo      |
|----------------------------------------------------------------------------------------------------------------------|-------------------|------------------------|
| <i>nimodipine oral capsule 30 mg</i>                                                                                 | 1                 |                        |
| <i>olmesartan oral tablet 20 mg, 40 mg</i>                                                                           | 6                 | QL (30 EA per 30 days) |
| <i>olmesartan oral tablet 5 mg</i>                                                                                   | 6                 | QL (60 EA per 30 days) |
| <i>olmesartan-amlodipin-hcthiazyd oral tablet 20-5-12.5 mg, 40-10-12.5 mg, 40-10-25 mg, 40-5-12.5 mg, 40-5-25 mg</i> | 6                 | QL (30 EA per 30 days) |
| <i>olmesartan-hydrochlorothiazide oral tablet 20-12.5 mg, 40-12.5 mg, 40-25 mg</i>                                   | 6                 | QL (30 EA per 30 days) |
| <i>perindopril erbumine oral tablet 2 mg, 4 mg, 8 mg</i>                                                             | 6                 |                        |
| <i>pindolol oral tablet 10 mg, 5 mg</i>                                                                              | 1                 |                        |
| <i>prazosin oral capsule 1 mg, 2 mg, 5 mg</i>                                                                        | 1                 |                        |
| <i>propranolol oral capsule, extended release 24 hr 120 mg, 160 mg, 60 mg, 80 mg</i>                                 | 1                 |                        |
| <i>propranolol oral solution 20 mg/5 ml (4 mg/ml), 40 mg/5 ml (8 mg/ml)</i>                                          | 1                 |                        |
| <i>propranolol oral tablet 10 mg, 20 mg, 40 mg, 60 mg, 80 mg</i>                                                     | 1                 |                        |
| <i>quinapril oral tablet 10 mg, 20 mg, 40 mg, 5 mg</i>                                                               | 6                 |                        |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                                                     | Nivo Medikaman an | Egzijans/Limit yo      |
|------------------------------------------------------------------------------------------------------|-------------------|------------------------|
| <i>quinapril-hydrochlorothiazide oral tablet 10-12.5 mg, 20-12.5 mg, 20-25 mg</i>                    | 6                 |                        |
| <i>ramipril oral capsule 1.25 mg, 10 mg, 2.5 mg, 5 mg</i>                                            | 6                 |                        |
| <i>spironolactone oral tablet 100 mg, 25 mg, 50 mg</i>                                               | 1                 |                        |
| <i>spironolacton-hydrochlorothiaz oral tablet 25-25 mg</i>                                           | 1                 |                        |
| <i>telmisartan oral tablet 20 mg, 40 mg, 80 mg</i>                                                   | 6                 | QL (30 EA per 30 days) |
| <i>telmisartan-amlodipine oral tablet 40-10 mg, 40-5 mg, 80-10 mg, 80-5 mg</i>                       | 6                 | QL (30 EA per 30 days) |
| <i>telmisartan-hydrochlorothiazid oral tablet 40-12.5 mg, 80-25 mg</i>                               | 6                 | QL (30 EA per 30 days) |
| <i>telmisartan-hydrochlorothiazid oral tablet 80-12.5 mg</i>                                         | 6                 | QL (60 EA per 30 days) |
| <i>terazosin oral capsule 1 mg, 10 mg, 2 mg, 5 mg</i>                                                | 1                 |                        |
| <i>tiadylt er oral capsule,extended release 24 hr 120 mg, 180 mg, 240 mg, 300 mg, 360 mg, 420 mg</i> | 1                 |                        |
| <i>timolol maleate oral tablet 10 mg, 20 mg, 5 mg</i>                                                | 1                 |                        |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                                                            | Nivo Medikaman an | Egzijans/Limit yo      |
|-------------------------------------------------------------------------------------------------------------|-------------------|------------------------|
| <i>torse mide oral tablet 10 mg, 100 mg, 20 mg, 5 mg</i>                                                    | 1                 |                        |
| <i>trandolapril oral tablet 1 mg, 2 mg, 4 mg</i>                                                            | 6                 |                        |
| <i>triamterene-hydrochlorothiazid oral capsule 37.5-25 mg</i>                                               | 1                 |                        |
| <i>triamterene-hydrochlorothiazid oral tablet 37.5-25 mg, 75-50 mg</i>                                      | 1                 |                        |
| <i>valsartan oral tablet 160 mg, 40 mg, 80 mg</i>                                                           | 6                 | QL (60 EA per 30 days) |
| <i>valsartan oral tablet 320 mg</i>                                                                         | 6                 | QL (30 EA per 30 days) |
| <i>valsartan-hydrochlorothiazide oral tablet 160-12.5 mg, 160-25 mg, 320-12.5 mg, 320-25 mg, 80-12.5 mg</i> | 6                 | QL (30 EA per 30 days) |
| <i>verapamil oral capsule, 24 hr er pellet ct 100 mg, 200 mg, 300 mg</i>                                    | 1                 |                        |
| <i>verapamil oral capsule, ext rel. pellets 24 hr 120 mg, 180 mg, 240 mg, 360 mg</i>                        | 1                 |                        |
| <i>verapamil oral tablet 120 mg, 40 mg, 80 mg</i>                                                           | 1                 |                        |
| <i>verapamil oral tablet extended release 120 mg, 180 mg, 240 mg</i>                                        | 1                 |                        |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

## Non Medikaman an

## Nivo Egzijans/Limit yo Medikaman an

### TERAPI KOWAGILASYON

|                                                                         |                |                             |
|-------------------------------------------------------------------------|----------------|-----------------------------|
| <i>aspirin-dipyridamole oral capsule, er multiphase 12 hr 25-200 mg</i> | 1              |                             |
| <i>cilostazol oral tablet 100 mg, 50 mg</i>                             | 1              |                             |
| <i>clopidogrel oral tablet 75 mg</i>                                    | 1              |                             |
| <i>dabigatran etexilate oral capsule 110 mg, 150 mg, 75 mg</i>          | 1              | QL (60 EA per 30 days)      |
| <i>dipyridamole oral tablet 25 mg, 50 mg, 75 mg</i>                     | 3              |                             |
| ELIQUIS DVT-PE TREAT 30D START ORAL TABLETS,DOSE PACK 5 MG (74 TABS)    | 2              | QL (74 EA per 180 days)     |
| ELIQUIS ORAL TABLET 2.5 MG                                              | 2              | QL (60 EA per 30 days)      |
| ELIQUIS ORAL TABLET 5 MG                                                | 2              | QL (74 EA per 30 days)      |
| ELIQUIS ORAL TABLET FOR SUSPENSION 0.5 MG                               | 2              | QL (140 EA per 28 days)     |
| ELIQUIS ORAL TABLET FOR SUSPENSION 1.5 MG (0.5 MG X 3)                  | 2              | QL (420 EA per 28 days)     |
| ELIQUIS ORAL TABLET FOR SUSPENSION 2 MG (0.5 MG X 4)                    | 2              | QL (560 EA per 28 days)     |
| ELIQUIS SPRINKLE ORAL CAPSULE, SPRINKLE 0.15 MG                         | 2              | QL (70 EA per 28 days)      |
| <i>eltrombopag olamine oral powder in packet 12.5 mg, 25 mg</i>         | 5 <sup>^</sup> | PA; QL (180 EA per 30 days) |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                                                                                   | Nivo Medikaman an | Egzijans/Limit yo          |
|------------------------------------------------------------------------------------------------------------------------------------|-------------------|----------------------------|
| <i>eltrombopag olamine oral tablet 12.5 mg, 25 mg</i>                                                                              | 5^                | PA; QL (30 EA per 30 days) |
| <i>eltrombopag olamine oral tablet 50 mg, 75 mg</i>                                                                                | 5^                | PA; QL (60 EA per 30 days) |
| <i>enoxaparin subcutaneous syringe 100 mg/ml, 120 mg/0.8 ml, 150 mg/ml, 30 mg/0.3 ml, 40 mg/0.4 ml, 60 mg/0.6 ml, 80 mg/0.8 ml</i> | 3                 |                            |
| <i>heparin (porcine) injection solution 1,000 unit/ml, 10,000 unit/ml, 20,000 unit/ml, 5,000 unit/ml</i>                           | 1                 |                            |
| <i>jantoven oral tablet 1 mg, 10 mg, 2 mg, 2.5 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7.5 mg</i>                                              | 1                 |                            |
| <i>pentoxifylline oral tablet extended release 400 mg</i>                                                                          | 1                 |                            |
| <i>prasugrel hcl oral tablet 10 mg, 5 mg</i>                                                                                       | 1                 |                            |
| <i>rivaroxaban oral suspension for reconstitution 1 mg/ml</i>                                                                      | 1                 |                            |
| <i>rivaroxaban oral tablet 2.5 mg</i>                                                                                              | 1                 |                            |
| <i>ticagrelor oral tablet 60 mg, 90 mg</i>                                                                                         | 2                 |                            |
| <i>warfarin oral tablet 1 mg, 10 mg, 2 mg, 2.5 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7.5 mg</i>                                              | 1                 |                            |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                           | Nivo Medikaman an | Egzijans/Limit yo              |
|----------------------------------------------------------------------------|-------------------|--------------------------------|
| XARELTO DVT-PE TREAT 30D START ORAL TABLETS,DOSE PACK 15 MG (42)-20 MG (9) | 2                 | QL (51 EA per 180 days)        |
| XARELTO ORAL TABLET 10 MG, 20 MG                                           | 2                 | QL (30 EA per 30 days)         |
| XARELTO ORAL TABLET 15 MG                                                  | 2                 | QL (60 EA per 30 days)         |
| <b>MEDIKAMAN ANTINEOPLASTIK / IMMINOSIPPRESAN</b>                          |                   |                                |
| <b>AJAN ADJONKTIF</b>                                                      |                   |                                |
| BOMYNTRA SUBCUTANEOUS SOLUTION 120 MG/1.7 ML (70 MG/ML)                    | 5^                | PA-NS                          |
| BOMYNTRA SUBCUTANEOUS SYRINGE 120 MG/1.7 ML (70 MG/ML)                     | 5^                | PA-NS                          |
| <i>leucovorin calcium oral tablet 10 mg, 15 mg, 25 mg, 5 mg</i>            | 1                 |                                |
| <i>mesna oral tablet 400 mg</i>                                            | 3                 |                                |
| OSENVELT SUBCUTANEOUS SOLUTION 120 MG/1.7 ML (70 MG/ML)                    | 5^                | PA-NS                          |
| <b>MEDIKAMAN ANTINEOPLASTIK / IMMINOSIPPRESAN</b>                          |                   |                                |
| <i>abiraterone oral tablet 250 mg</i>                                      | 5^                | PA-NS; QL (120 EA per 30 days) |
| <i>abirtega oral tablet 250 mg</i>                                         | 3                 | PA-NS; QL (120 EA per 30 days) |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                         | Nivo Medikaman an | Egzijans/Limit yo                 |
|----------------------------------------------------------|-------------------|-----------------------------------|
| AKEEGA ORAL TABLET 100-500 MG, 50-500 MG                 | 5^                | PA-NS; LA; QL (60 EA per 30 days) |
| ALECENSA ORAL CAPSULE 150 MG                             | 5^                | PA-NS; QL (240 EA per 30 days)    |
| ALUNBRIG ORAL TABLET 180 MG, 90 MG                       | 5^                | PA-NS; QL (30 EA per 30 days)     |
| ALUNBRIG ORAL TABLET 30 MG                               | 5^                | PA-NS; QL (60 EA per 30 days)     |
| ALUNBRIG ORAL TABLETS,DOSE PACK 90 MG (7)- 180 MG (23)   | 5^                | PA-NS; QL (30 EA per 180 days)    |
| <i>anastrozole oral tablet 1 mg</i>                      | 1                 |                                   |
| AUGTYRO ORAL CAPSULE 160 MG                              | 5^                | PA-NS; QL (60 EA per 30 days)     |
| AUGTYRO ORAL CAPSULE 40 MG                               | 5^                | PA-NS; QL (240 EA per 30 days)    |
| AVMAPKI-FAKZYNJA ORAL COMBO PACK 0.8-200 MG              | 5^                | PA-NS; QL (66 EA per 28 days)     |
| AYVAKIT ORAL TABLET 100 MG, 200 MG, 25 MG, 300 MG, 50 MG | 5^                | PA-NS; LA; QL (30 EA per 30 days) |
| <i>azathioprine oral tablet 50 mg</i>                    | 1                 | B/D                               |
| BALVERSA ORAL TABLET 3 MG, 4 MG, 5 MG                    | 5^                | PA-NS; LA                         |
| <i>bexarotene oral capsule 75 mg</i>                     | 5^                | PA-NS                             |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                 | Nivo Medikaman an | Egzijans/Limit yo                  |
|--------------------------------------------------|-------------------|------------------------------------|
| <i>bexarotene topical gel 1 %</i>                | 5^                | PA-NS; QL (60 GM per 30 days)      |
| <i>bicalutamide oral tablet 50 mg</i>            | 1                 |                                    |
| BOSULIF ORAL CAPSULE 100 MG                      | 5^                | PA-NS; QL (180 EA per 30 days)     |
| BOSULIF ORAL CAPSULE 50 MG                       | 5^                | PA-NS; QL (330 EA per 30 days)     |
| BOSULIF ORAL TABLET 100 MG                       | 5^                | PA-NS; QL (90 EA per 30 days)      |
| BOSULIF ORAL TABLET 500 MG                       | 5^                | PA-NS; QL (30 EA per 30 days)      |
| <i>bosutinib oral tablet 400 mg</i>              | 5^                | PA-NS; QL (30 EA per 30 days)      |
| BRAFTOVI ORAL CAPSULE 75 MG                      | 5^                | PA-NS; LA; QL (180 EA per 30 days) |
| BRUKINSA ORAL TABLET 160 MG                      | 5^                | PA-NS; LA; QL (60 EA per 30 days)  |
| CABOMETYX ORAL TABLET 20 MG, 40 MG, 60 MG        | 5^                | PA-NS; LA; QL (30 EA per 30 days)  |
| CALQUENCE (ACALABRUTINIB MAL) ORAL TABLET 100 MG | 5^                | PA-NS; LA; QL (60 EA per 30 days)  |
| CAPRELSA ORAL TABLET 100 MG                      | 5^                | PA-NS; LA; QL (60 EA per 30 days)  |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                               | Nivo Medikaman an | Egzijans/Limit yo                 |
|----------------------------------------------------------------|-------------------|-----------------------------------|
| CAPRELSA ORAL TABLET 300 MG                                    | 5^                | PA-NS; LA; QL (30 EA per 30 days) |
| COMETRIQ ORAL CAPSULE 100 MG/DAY(80 MG X1-20 MG X1)            | 5^                | PA-NS; QL (56 EA per 28 days)     |
| COMETRIQ ORAL CAPSULE 140 MG/DAY(80 MG X1-20 MG X3)            | 5^                | PA-NS; QL (112 EA per 28 days)    |
| COMETRIQ ORAL CAPSULE 60 MG/DAY (20 MG X 3/DAY)                | 5^                | PA-NS; QL (84 EA per 28 days)     |
| COPIKTRA ORAL CAPSULE 15 MG, 25 MG                             | 5^                | PA-NS; LA; QL (56 EA per 28 days) |
| COTELLIC ORAL TABLET 20 MG                                     | 5^                | PA-NS; LA; QL (63 EA per 28 days) |
| <i>cyclophosphamide oral capsule 25 mg, 50 mg</i>              | 1                 | B/D                               |
| CYCLOPHOSPHAMIDE ORAL TABLET 50 MG                             | 3                 | B/D                               |
| <i>cyclosporine modified oral capsule 100 mg, 25 mg, 50 mg</i> | 1                 | B/D                               |
| <i>cyclosporine modified oral solution 100 mg/ml</i>           | 1                 | B/D                               |
| <i>cyclosporine oral capsule 100 mg, 25 mg</i>                 | 1                 | B/D                               |
| DANZITEN ORAL TABLET 71 MG, 95 MG                              | 5^                | PA-NS; QL (112 EA per 28 days)    |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                    | Nivo Medikaman an | Egzijans/Limit yo                 |
|---------------------------------------------------------------------|-------------------|-----------------------------------|
| <i>dasatinib oral tablet 100 mg, 140 mg, 50 mg, 80 mg</i>           | 5^                | PA-NS; QL (30 EA per 30 days)     |
| <i>dasatinib oral tablet 20 mg</i>                                  | 5^                | PA-NS; QL (90 EA per 30 days)     |
| <i>dasatinib oral tablet 70 mg</i>                                  | 5^                | PA-NS; QL (60 EA per 30 days)     |
| DAURISMO ORAL TABLET 100 MG                                         | 5^                | PA-NS; QL (30 EA per 30 days)     |
| DAURISMO ORAL TABLET 25 MG                                          | 5^                | PA-NS; QL (60 EA per 30 days)     |
| DROXIA ORAL CAPSULE 200 MG, 300 MG, 400 MG                          | 2                 |                                   |
| ELIGARD (3 MONTH) SUBCUTANEOUS SYRINGE 22.5 MG                      | 2                 | PA-NS                             |
| ELIGARD (4 MONTH) SUBCUTANEOUS SYRINGE 30 MG                        | 2                 | PA-NS                             |
| ELIGARD (6 MONTH) SUBCUTANEOUS SYRINGE 45 MG                        | 2                 | PA-NS                             |
| ELIGARD SUBCUTANEOUS SYRINGE 7.5 MG (1 MONTH)                       | 2                 | PA-NS                             |
| ENSACOVE ORAL CAPSULE 100 MG, 25 MG                                 | 5^                | PA-NS; LA; QL (60 EA per 30 days) |
| ENVARUSUS XR ORAL TABLET EXTENDED RELEASE 24 HR 0.75 MG, 1 MG, 4 MG | 3                 | B/D                               |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                           | Nivo Medikaman an | Egzijans/Limit yo              |
|----------------------------------------------------------------------------|-------------------|--------------------------------|
| ERIVEDGE ORAL CAPSULE 150 MG                                               | 5^                | PA-NS; QL (30 EA per 30 days)  |
| ERLEADA ORAL TABLET 240 MG                                                 | 5^                | PA-NS; QL (30 EA per 30 days)  |
| ERLEADA ORAL TABLET 60 MG                                                  | 5^                | PA-NS; QL (120 EA per 30 days) |
| <i>erlotinib oral tablet 100 mg, 150 mg</i>                                | 5^                | PA-NS; QL (30 EA per 30 days)  |
| <i>erlotinib oral tablet 25 mg</i>                                         | 5^                | PA-NS; QL (60 EA per 30 days)  |
| EULEXIN ORAL CAPSULE 125 MG                                                | 5^                |                                |
| <i>everolimus (antineoplastic) oral tablet 10 mg, 2.5 mg, 5 mg, 7.5 mg</i> | 5^                | PA-NS; QL (30 EA per 30 days)  |
| <i>everolimus (antineoplastic) oral tablet for suspension 2 mg</i>         | 5^                | PA-NS; QL (150 EA per 30 days) |
| <i>everolimus (antineoplastic) oral tablet for suspension 3 mg</i>         | 5^                | PA-NS; QL (90 EA per 30 days)  |
| <i>everolimus (antineoplastic) oral tablet for suspension 5 mg</i>         | 5^                | PA-NS; QL (60 EA per 30 days)  |
| <i>everolimus (immunosuppressive) oral tablet 0.25 mg</i>                  | 2                 | B/D                            |
| <i>everolimus (immunosuppressive) oral tablet 0.5 mg, 0.75 mg, 1 mg</i>    | 5^                | B/D                            |
| <i>exemestane oral tablet 25 mg</i>                                        | 1                 |                                |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                 | Nivo Medikaman an | Egzijans/Limit yo                  |
|------------------------------------------------------------------|-------------------|------------------------------------|
| FIRMAGON KIT W DILUENT SYRINGE<br>SUBCUTANEOUS RECON SOLN 120 MG | 5 <sup>^</sup>    | PA-NS                              |
| FIRMAGON KIT W DILUENT SYRINGE<br>SUBCUTANEOUS RECON SOLN 80 MG  | 3                 | PA-NS                              |
| FOTIVDA ORAL CAPSULE 0.89 MG, 1.34 MG                            | 5 <sup>^</sup>    | PA-NS; LA; QL (21 EA per 28 days)  |
| FRUZAQLA ORAL CAPSULE 1 MG                                       | 5 <sup>^</sup>    | PA-NS; QL (84 EA per 28 days)      |
| FRUZAQLA ORAL CAPSULE 5 MG                                       | 5 <sup>^</sup>    | PA-NS; QL (21 EA per 28 days)      |
| GAVRETO ORAL CAPSULE 100 MG                                      | 5 <sup>^</sup>    | PA-NS; LA; QL (120 EA per 30 days) |
| <i>gefitinib oral tablet 250 mg</i>                              | 5 <sup>^</sup>    | PA-NS; QL (30 EA per 30 days)      |
| <i>gengraf oral capsule 100 mg, 25 mg</i>                        | 1                 | B/D                                |
| GILOTRIF ORAL TABLET 20 MG, 30 MG, 40 MG                         | 5 <sup>^</sup>    | PA-NS; QL (30 EA per 30 days)      |
| GOMEKLI ORAL CAPSULE 1 MG                                        | 5 <sup>^</sup>    | PA-NS; QL (126 EA per 28 days)     |
| GOMEKLI ORAL CAPSULE 2 MG                                        | 5 <sup>^</sup>    | PA-NS; QL (84 EA per 28 days)      |
| GOMEKLI ORAL TABLET FOR<br>SUSPENSION 1 MG                       | 5 <sup>^</sup>    | PA-NS; QL (168 EA per 28 days)     |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                               | Nivo Medikaman an | Egzijans/Limit yo                 |
|------------------------------------------------|-------------------|-----------------------------------|
| HERNEXEOS ORAL TABLET 60 MG                    | 5 <sup>^</sup>    | PA-NS; QL (90 EA per 30 days)     |
| <i>hydroxyurea oral capsule 500 mg</i>         | 1                 |                                   |
| HYRNUO ORAL TABLET 10 MG                       | 5 <sup>^</sup>    | PA-NS; QL (120 EA per 30 days)    |
| IBRANCE ORAL CAPSULE 125 MG                    | 5 <sup>^</sup>    | PA-NS; QL (21 EA per 28 days)     |
| IBRANCE ORAL TABLET 100 MG, 125 MG, 75 MG      | 5 <sup>^</sup>    | PA-NS; QL (21 EA per 28 days)     |
| IBTROZI ORAL CAPSULE 200 MG                    | 5 <sup>^</sup>    | PA-NS; QL (90 EA per 30 days)     |
| ICLUSIG ORAL TABLET 10 MG, 15 MG, 30 MG, 45 MG | 5 <sup>^</sup>    | PA-NS; QL (30 EA per 30 days)     |
| IDHIFA ORAL TABLET 100 MG, 50 MG               | 5 <sup>^</sup>    | PA-NS; LA; QL (30 EA per 30 days) |
| <i>imatinib oral tablet 100 mg</i>             | 2                 | PA-NS; QL (180 EA per 30 days)    |
| <i>imatinib oral tablet 400 mg</i>             | 5 <sup>^</sup>    | PA-NS; QL (60 EA per 30 days)     |
| IMBRUVICA ORAL CAPSULE 140 MG                  | 5 <sup>^</sup>    | PA-NS; QL (90 EA per 30 days)     |
| IMBRUVICA ORAL CAPSULE 70 MG                   | 5 <sup>^</sup>    | PA-NS; QL (28 EA per 28 days)     |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                    | Nivo Medikaman an | Egzijans/Limit yo                  |
|-----------------------------------------------------|-------------------|------------------------------------|
| IMBRUVICA ORAL SUSPENSION 70 MG/ML                  | 5 <sup>^</sup>    | PA-NS; QL (324 ML per 30 days)     |
| IMBRUVICA ORAL TABLET 140 MG, 280 MG, 420 MG        | 5 <sup>^</sup>    | PA-NS; QL (28 EA per 28 days)      |
| IMKELDI ORAL SOLUTION 80 MG/ML                      | 5 <sup>^</sup>    | PA-NS; QL (280 ML per 28 days)     |
| INLURIYO ORAL TABLET 200 MG                         | 5 <sup>^</sup>    | PA-NS                              |
| INLYTA ORAL TABLET 1 MG                             | 5 <sup>^</sup>    | PA-NS; QL (180 EA per 30 days)     |
| INLYTA ORAL TABLET 5 MG                             | 5 <sup>^</sup>    | PA-NS; QL (120 EA per 30 days)     |
| INQOVI ORAL TABLET 35-100 MG                        | 5 <sup>^</sup>    | PA-NS; QL (5 EA per 28 days)       |
| INREBIC ORAL CAPSULE 100 MG                         | 5 <sup>^</sup>    | PA-NS; LA; QL (120 EA per 30 days) |
| ITOVEBI ORAL TABLET 3 MG                            | 5 <sup>^</sup>    | PA-NS; QL (60 EA per 30 days)      |
| ITOVEBI ORAL TABLET 9 MG                            | 5 <sup>^</sup>    | PA-NS; QL (30 EA per 30 days)      |
| IWILFIN ORAL TABLET 192 MG                          | 5 <sup>^</sup>    | PA-NS; LA; QL (240 EA per 30 days) |
| JAKAFI ORAL TABLET 10 MG, 15 MG, 20 MG, 25 MG, 5 MG | 5 <sup>^</sup>    | PA-NS; QL (60 EA per 30 days)      |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                               | Nivo Medikaman an | Egzijans/Limit yo                 |
|--------------------------------------------------------------------------------|-------------------|-----------------------------------|
| JAKAFI XR ORAL TABLET EXTENDED RELEASE 24 HR 11 MG, 22 MG, 33 MG, 44 MG, 55 MG | 5 <sup>^</sup>    | PA-NS; QL (30 EA per 30 days)     |
| JAYPIRCA ORAL TABLET 100 MG                                                    | 5 <sup>^</sup>    | PA-NS; QL (60 EA per 30 days)     |
| JAYPIRCA ORAL TABLET 50 MG                                                     | 5 <sup>^</sup>    | PA-NS; QL (30 EA per 30 days)     |
| JIDEYTRO ORAL TABLET 100 MG                                                    | 5 <sup>^</sup>    | PA-NS; LA; QL (30 EA per 30 days) |
| JIDEYTRO ORAL TABLET 25 MG                                                     | 5 <sup>^</sup>    | PA-NS; LA; QL (90 EA per 30 days) |
| JYLAMVO ORAL SOLUTION 2 MG/ML                                                  | 2                 |                                   |
| KISQALI ORAL TABLET 200 MG/DAY (200 MG X 1)                                    | 5 <sup>^</sup>    | PA-NS; QL (21 EA per 28 days)     |
| KISQALI ORAL TABLET 400 MG/DAY (200 MG X 2)                                    | 5 <sup>^</sup>    | PA-NS; QL (42 EA per 28 days)     |
| KISQALI ORAL TABLET 600 MG/DAY (200 MG X 3)                                    | 5 <sup>^</sup>    | PA-NS; QL (63 EA per 28 days)     |
| KOMZIFTI ORAL CAPSULE 200 MG                                                   | 5 <sup>^</sup>    | PA-NS; QL (90 EA per 30 days)     |
| KOSELUGO ORAL CAPSULE 10 MG, 25 MG                                             | 5 <sup>^</sup>    | PA-NS                             |
| KOSELUGO ORAL CAPSULE, SPRINKLE 5 MG, 7.5 MG                                   | 5 <sup>^</sup>    | PA-NS                             |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                                                        | Nivo Medikaman an | Egzijans/Limit yo                 |
|---------------------------------------------------------------------------------------------------------|-------------------|-----------------------------------|
| KRAZATI ORAL TABLET 200 MG                                                                              | 5^                | PA-NS; QL (180 EA per 30 days)    |
| <i>lapatinib oral tablet 250 mg</i>                                                                     | 5^                | PA-NS; QL (180 EA per 30 days)    |
| LAZCLUZE ORAL TABLET 240 MG                                                                             | 5^                | PA-NS; LA; QL (30 EA per 30 days) |
| LAZCLUZE ORAL TABLET 80 MG                                                                              | 5^                | PA-NS; LA; QL (60 EA per 30 days) |
| <i>lenalidomide oral capsule 10 mg, 15 mg, 2.5 mg, 20 mg, 25 mg, 5 mg</i>                               | 5^                | PA-NS; QL (28 EA per 28 days)     |
| LENVIMA ORAL CAPSULE 10 MG/DAY (10 MG X 1), 4 MG                                                        | 5^                | PA-NS; QL (30 EA per 30 days)     |
| LENVIMA ORAL CAPSULE 12 MG/DAY (4 MG X 3), 18 MG/DAY (10 MG X 1-4 MG X2), 24 MG/DAY(10 MG X 2-4 MG X 1) | 5^                | PA-NS; QL (90 EA per 30 days)     |
| LENVIMA ORAL CAPSULE 14 MG/DAY(10 MG X 1-4 MG X 1), 20 MG/DAY (10 MG X 2), 8 MG/DAY (4 MG X 2)          | 5^                | PA-NS; QL (60 EA per 30 days)     |
| <i>letrozole oral tablet 2.5 mg</i>                                                                     | 1                 |                                   |
| LEUKERAN ORAL TABLET 2 MG                                                                               | 5^                |                                   |
| <i>leuprolide subcutaneous kit 1 mg/0.2 ml</i>                                                          | 3                 | PA-NS                             |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                                                                  | Nivo Medikaman an | Egzijans/Limit yo                 |
|-------------------------------------------------------------------------------------------------------------------|-------------------|-----------------------------------|
| LIFYORLI ORAL CAPSULE 125 MG/DAY(100 MG X1-25MG X1), 125 MG/DAY(100 MG X1-25MG X3), 125 MG/DAY(100 MG X1-25MG X9) | 5^                | PA-NS; LA; QL (18 EA per 28 days) |
| LIFYORLI ORAL CAPSULE 150 MG/DAY(100 MG X1-25MG X2), 150 MG/DAY(100 MG X1-25MG X3), 150 MG/DAY(100 MG X1-25MG X9) | 5^                | PA-NS; LA; QL (27 EA per 28 days) |
| <i>lomustine oral capsule 10 mg, 40 mg</i>                                                                        | 3                 |                                   |
| <i>lomustine oral capsule 100 mg</i>                                                                              | 5^                |                                   |
| LONSURF ORAL TABLET 15-6.14 MG, 20-8.19 MG                                                                        | 5^                | PA-NS                             |
| LORBRENA ORAL TABLET 100 MG                                                                                       | 5^                | PA-NS; QL (30 EA per 30 days)     |
| LORBRENA ORAL TABLET 25 MG                                                                                        | 5^                | PA-NS; QL (90 EA per 30 days)     |
| LUMAKRAS ORAL TABLET 120 MG                                                                                       | 5^                | PA-NS; QL (240 EA per 30 days)    |
| LUMAKRAS ORAL TABLET 240 MG                                                                                       | 5^                | PA-NS; QL (120 EA per 30 days)    |
| LUMAKRAS ORAL TABLET 320 MG                                                                                       | 5^                | PA-NS; QL (90 EA per 30 days)     |
| LUPRON DEPOT INTRAMUSCULAR SYRINGE KIT 3.75 MG, 7.5 MG                                                            | 5^                | PA-NS                             |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                                  | Nivo Medikaman an | Egzijans/Limit yo                  |
|-----------------------------------------------------------------------------------|-------------------|------------------------------------|
| LYNPARZA ORAL TABLET 100 MG, 150 MG                                               | 5^                | PA-NS; QL (120 EA per 30 days)     |
| LYSODREN ORAL TABLET 500 MG                                                       | 5^                |                                    |
| LYTGOBI ORAL TABLET 12 MG/DAY (4 MG X 3)                                          | 5^                | PA-NS; LA; QL (84 EA per 28 days)  |
| LYTGOBI ORAL TABLET 16 MG/DAY (4 MG X 4)                                          | 5^                | PA-NS; LA; QL (112 EA per 28 days) |
| LYTGOBI ORAL TABLET 20 MG/DAY (4 MG X 5)                                          | 5^                | PA-NS; LA; QL (140 EA per 28 days) |
| MATULANE ORAL CAPSULE 50 MG                                                       | 5^                |                                    |
| <i>megestrol oral suspension 400 mg/10 ml (40 mg/ml), 625 mg/5 ml (125 mg/ml)</i> | 3                 | PA                                 |
| <i>megestrol oral tablet 20 mg, 40 mg</i>                                         | 3                 |                                    |
| MEKINIST ORAL RECON SOLN 0.05 MG/ML                                               | 5^                | PA-NS; QL (1260 ML per 30 days)    |
| MEKINIST ORAL TABLET 0.5 MG                                                       | 5^                | PA-NS; QL (90 EA per 30 days)      |
| MEKINIST ORAL TABLET 2 MG                                                         | 5^                | PA-NS; QL (30 EA per 30 days)      |
| MEKTOVI ORAL TABLET 15 MG                                                         | 5^                | PA-NS; LA; QL (180 EA per 30 days) |
| <i>mercaptopurine oral suspension 20 mg/ml</i>                                    | 5^                |                                    |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                                | Nivo Medikaman an | Egzijans/Limit yo                             |
|---------------------------------------------------------------------------------|-------------------|-----------------------------------------------|
| <i>mercaptopurine oral tablet 50 mg</i>                                         | 1                 |                                               |
| <i>methotrexate sodium (pf) injection solution 25 mg/ml</i>                     | 1                 | B/D                                           |
| <i>methotrexate sodium injection solution 25 mg/ml</i>                          | 1                 | B/D                                           |
| <i>methotrexate sodium oral tablet 2.5 mg</i>                                   | 1                 |                                               |
| MODEYSO ORAL CAPSULE 125 MG                                                     | 5^                | PA-NS; QL (20 EA per 28 days)                 |
| <i>mycophenolate mofetil oral capsule 250 mg</i>                                | 1                 | B/D                                           |
| <i>mycophenolate mofetil oral suspension for reconstitution 200 mg/ml</i>       | 5^                | B/D                                           |
| <i>mycophenolate mofetil oral tablet 500 mg</i>                                 | 1                 | B/D                                           |
| <i>mycophenolate sodium oral tablet, delayed release (dr/ec) 180 mg, 360 mg</i> | 1                 | B/D; mycophenolate sodium = mycophenolic acid |
| <i>mycophenolic acid dr 180 mg tb</i>                                           | 1                 | B/D                                           |
| <i>mycophenolic acid dr 360 mg tb</i>                                           | 1                 | B/D                                           |
| NERLYNX ORAL TABLET 40 MG                                                       | 5^                | PA-NS; LA                                     |
| <i>nilotinib hcl oral capsule 150 mg, 200 mg</i>                                | 5^                | PA-NS; QL (112 EA per 28 days)                |
| <i>nilotinib hcl oral capsule 50 mg</i>                                         | 5^                | PA-NS; QL (120 EA per 30 days)                |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                               | Nivo Medikaman an | Egzijans/Limit yo                  |
|--------------------------------------------------------------------------------|-------------------|------------------------------------|
| <i>nilutamide oral tablet 150 mg</i>                                           | 5^                |                                    |
| NINLARO ORAL CAPSULE 2.3 MG, 3 MG, 4 MG                                        | 5^                | PA-NS; QL (3 EA per 28 days)       |
| NUBEQA ORAL TABLET 300 MG                                                      | 5^                | PA-NS; LA; QL (120 EA per 30 days) |
| <i>octreotide acetate injection solution 1,000 mcg/ml, 500 mcg/ml</i>          | 5^                | PA                                 |
| <i>octreotide acetate injection solution 100 mcg/ml, 200 mcg/ml, 50 mcg/ml</i> | 3                 | PA                                 |
| ODOMZO ORAL CAPSULE 200 MG                                                     | 5^                | PA-NS; LA; QL (30 EA per 30 days)  |
| OGSIVEO ORAL TABLET 100 MG, 150 MG                                             | 5^                | PA-NS; QL (56 EA per 28 days)      |
| OJEMDA ORAL SUSPENSION FOR RECONSTITUTION 25 MG/ML                             | 5^                | PA-NS; QL (96 ML per 28 days)      |
| OJEMDA ORAL TABLET 400 MG/WEEK (100 MG X 4)                                    | 5^                | PA-NS; QL (16 EA per 28 days)      |
| OJEMDA ORAL TABLET 500 MG/WEEK (100 MG X 5)                                    | 5^                | PA-NS; QL (20 EA per 28 days)      |
| OJEMDA ORAL TABLET 600 MG/WEEK (100 MG X 6)                                    | 5^                | PA-NS; QL (24 EA per 28 days)      |
| OJJAARA ORAL TABLET 100 MG, 150 MG, 200 MG                                     | 5^                | PA-NS; QL (30 EA per 30 days)      |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                            | Nivo Medikaman an | Egzijans/Limit yo                 |
|-----------------------------------------------------------------------------|-------------------|-----------------------------------|
| ONUREG ORAL TABLET 200 MG, 300 MG                                           | 5 <sup>^</sup>    | PA-NS; QL (14 EA per 28 days)     |
| ORGOVYX ORAL TABLET 120 MG                                                  | 5 <sup>^</sup>    | PA-NS; LA; QL (30 EA per 28 days) |
| ORSERDU ORAL TABLET 345 MG                                                  | 5 <sup>^</sup>    | PA-NS; QL (30 EA per 30 days)     |
| ORSERDU ORAL TABLET 86 MG                                                   | 5 <sup>^</sup>    | PA-NS; QL (90 EA per 30 days)     |
| <i>pazopanib oral tablet 200 mg</i>                                         | 5 <sup>^</sup>    | PA-NS; QL (120 EA per 30 days)    |
| PEMAZYRE ORAL TABLET 13.5 MG, 4.5 MG, 9 MG                                  | 5 <sup>^</sup>    | PA-NS; LA; QL (28 EA per 28 days) |
| PIQRAY ORAL TABLET 200 MG/DAY (200 MG X 1)                                  | 5 <sup>^</sup>    | PA-NS; QL (28 EA per 28 days)     |
| PIQRAY ORAL TABLET 250 MG/DAY (200 MG X1-50 MG X1), 300 MG/DAY (150 MG X 2) | 5 <sup>^</sup>    | PA-NS; QL (56 EA per 28 days)     |
| <i>pomalidomide oral capsule 1 mg, 2 mg, 3 mg, 4 mg</i>                     | 5 <sup>^</sup>    | PA-NS; QL (21 EA per 28 days)     |
| POMALYST ORAL CAPSULE 1 MG, 2 MG, 3 MG, 4 MG                                | 5 <sup>^</sup>    | PA-NS; LA; QL (21 EA per 28 days) |
| PROGRAF ORAL GRANULES IN PACKET 0.2 MG, 1 MG                                | 3                 | B/D                               |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                           | Nivo Medikaman an | Egzijans/Limit yo                  |
|--------------------------------------------|-------------------|------------------------------------|
| QINLOCK ORAL TABLET 50 MG                  | 5 <sup>^</sup>    | PA-NS; LA; QL (90 EA per 30 days)  |
| RETEVMO ORAL TABLET 120 MG, 160 MG, 80 MG  | 5 <sup>^</sup>    | PA-NS; LA; QL (60 EA per 30 days)  |
| RETEVMO ORAL TABLET 40 MG                  | 5 <sup>^</sup>    | PA-NS; LA; QL (90 EA per 30 days)  |
| REVUFORJ ORAL TABLET 110 MG                | 5 <sup>^</sup>    | PA-NS; QL (120 EA per 30 days)     |
| REVUFORJ ORAL TABLET 160 MG                | 5 <sup>^</sup>    | PA-NS; QL (60 EA per 30 days)      |
| REVUFORJ ORAL TABLET 25 MG                 | 5 <sup>^</sup>    | PA-NS; QL (240 EA per 30 days)     |
| REZLIDHIA ORAL CAPSULE 150 MG              | 5 <sup>^</sup>    | PA-NS; QL (60 EA per 30 days)      |
| ROMVIMZA ORAL CAPSULE 14 MG, 20 MG, 30 MG  | 5 <sup>^</sup>    | PA-NS; LA; QL (8 EA per 28 days)   |
| ROZLYTREK ORAL CAPSULE 100 MG              | 5 <sup>^</sup>    | PA-NS; QL (150 EA per 30 days)     |
| ROZLYTREK ORAL CAPSULE 200 MG              | 5 <sup>^</sup>    | PA-NS; QL (90 EA per 30 days)      |
| ROZLYTREK ORAL PELLETS IN PACKET 50 MG     | 5 <sup>^</sup>    | PA-NS; QL (336 EA per 28 days)     |
| RUBRACA ORAL TABLET 200 MG, 250 MG, 300 MG | 5 <sup>^</sup>    | PA-NS; LA; QL (120 EA per 30 days) |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                                    | Nivo Medikaman an | Egzijans/Limit yo              |
|-------------------------------------------------------------------------------------|-------------------|--------------------------------|
| RYDAPT ORAL CAPSULE 25 MG                                                           | 5^                | PA-NS; QL (224 EA per 28 days) |
| SCEMBLIX ORAL TABLET 100 MG                                                         | 5^                | PA-NS; QL (120 EA per 30 days) |
| SCEMBLIX ORAL TABLET 20 MG                                                          | 5^                | PA-NS; QL (60 EA per 30 days)  |
| SCEMBLIX ORAL TABLET 40 MG                                                          | 5^                | PA-NS; QL (300 EA per 30 days) |
| SIGNIFOR SUBCUTANEOUS SOLUTION 0.3 MG/ML (1 ML), 0.6 MG/ML (1 ML), 0.9 MG/ML (1 ML) | 5^                | PA                             |
| <i>sirolimus oral solution 1 mg/ml</i>                                              | 3                 | B/D                            |
| <i>sirolimus oral tablet 0.5 mg, 1 mg, 2 mg</i>                                     | 1                 | B/D                            |
| SOLTAMOX ORAL SOLUTION 20 MG/10 ML                                                  | 5^                |                                |
| <i>sorafenib oral tablet 200 mg</i>                                                 | 5^                | PA-NS; QL (120 EA per 30 days) |
| STIVARGA ORAL TABLET 40 MG                                                          | 5^                | PA-NS; QL (84 EA per 28 days)  |
| <i>sunitinib malate oral capsule 12.5 mg, 25 mg, 37.5 mg, 50 mg</i>                 | 5^                | PA-NS; QL (28 EA per 28 days)  |
| TABLOID ORAL TABLET 40 MG                                                           | 3                 |                                |
| TABRECTA ORAL TABLET 150 MG, 200 MG                                                 | 5^                | PA-NS                          |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                      | Nivo Medikaman an | Egzijans/Limit yo                  |
|-----------------------------------------------------------------------|-------------------|------------------------------------|
| <i>tacrolimus oral capsule 0.5 mg, 1 mg, 5 mg</i>                     | 1                 | B/D                                |
| TAFINLAR ORAL CAPSULE 50 MG, 75 MG                                    | 5^                | PA-NS; QL (120 EA per 30 days)     |
| TAFINLAR ORAL TABLET FOR SUSPENSION 10 MG                             | 5^                | PA-NS; QL (840 EA per 28 days)     |
| TAGRISSO ORAL TABLET 40 MG, 80 MG                                     | 5^                | PA-NS; LA; QL (30 EA per 30 days)  |
| TALZENNA ORAL CAPSULE 0.1 MG, 0.25 MG, 0.35 MG, 0.5 MG, 0.75 MG, 1 MG | 5^                | PA-NS; QL (30 EA per 30 days)      |
| <i>tamoxifen oral tablet 10 mg, 20 mg</i>                             | 1                 |                                    |
| TEPMETKO ORAL TABLET 225 MG                                           | 5^                | PA-NS; LA                          |
| THALOMID ORAL CAPSULE 100 MG                                          | 5^                | PA-NS; QL (112 EA per 28 days)     |
| THALOMID ORAL CAPSULE 50 MG                                           | 5^                | PA-NS; QL (28 EA per 28 days)      |
| TIBSOVO ORAL TABLET 250 MG                                            | 5^                | PA-NS                              |
| <i>toremifene oral tablet 60 mg</i>                                   | 3                 |                                    |
| <i>tretinoin (antineoplastic) oral capsule 10 mg</i>                  | 5^                |                                    |
| TRUQAP ORAL TABLET 160 MG, 200 MG                                     | 5^                | PA-NS; QL (64 EA per 28 days)      |
| TUKYSA ORAL TABLET 150 MG                                             | 5^                | PA-NS; LA; QL (120 EA per 30 days) |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                  | Nivo Medikaman an | Egzijans/Limit yo                  |
|-------------------------------------------------------------------|-------------------|------------------------------------|
| TUKYSA ORAL TABLET 50 MG                                          | 5 <sup>^</sup>    | PA-NS; LA; QL (300 EA per 30 days) |
| TURALIO ORAL CAPSULE 125 MG                                       | 5 <sup>^</sup>    | PA-NS; LA; QL (120 EA per 30 days) |
| VANFLYTA ORAL TABLET 17.7 MG, 26.5 MG                             | 5 <sup>^</sup>    | PA-NS; QL (56 EA per 28 days)      |
| VENCLEXTA ORAL TABLET 10 MG                                       | 2                 | PA-NS; LA; QL (14 EA per 7 days)   |
| VENCLEXTA ORAL TABLET 100 MG                                      | 5 <sup>^</sup>    | PA-NS; LA; QL (180 EA per 30 days) |
| VENCLEXTA ORAL TABLET 50 MG                                       | 5 <sup>^</sup>    | PA-NS; LA; QL (7 EA per 7 days)    |
| VENCLEXTA STARTING PACK ORAL TABLETS,DOSE PACK 10 MG-50 MG-100 MG | 5 <sup>^</sup>    | PA-NS; LA; QL (42 EA per 180 days) |
| VERZENIO ORAL TABLET 100 MG, 150 MG, 200 MG, 50 MG                | 5 <sup>^</sup>    | PA-NS; LA; QL (56 EA per 28 days)  |
| VITRAKVI ORAL CAPSULE 100 MG                                      | 5 <sup>^</sup>    | PA-NS; LA; QL (60 EA per 30 days)  |
| VITRAKVI ORAL CAPSULE 25 MG                                       | 5 <sup>^</sup>    | PA-NS; LA; QL (180 EA per 30 days) |
| VITRAKVI ORAL SOLUTION 20 MG/ML                                   | 5 <sup>^</sup>    | PA-NS; LA; QL (300 ML per 30 days) |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                         | Nivo Medikaman an | Egzijans/Limit yo                 |
|------------------------------------------|-------------------|-----------------------------------|
| VIZIMPRO ORAL TABLET 15 MG, 30 MG, 45 MG | 5^                | PA-NS; QL (30 EA per 30 days)     |
| VONJO ORAL CAPSULE 100 MG                | 5^                | PA-NS; QL (120 EA per 30 days)    |
| VORANIGO ORAL TABLET 10 MG               | 5^                | PA-NS; QL (60 EA per 30 days)     |
| VORANIGO ORAL TABLET 40 MG               | 5^                | PA-NS; QL (30 EA per 30 days)     |
| WELIREG ORAL TABLET 40 MG                | 5^                | PA-NS; LA                         |
| XALKORI ORAL CAPSULE 200 MG, 250 MG      | 5^                | PA-NS; QL (60 EA per 30 days)     |
| XALKORI ORAL PELLETT 150 MG              | 5^                | PA-NS; QL (180 EA per 30 days)    |
| XALKORI ORAL PELLETT 20 MG, 50 MG        | 5^                | PA-NS; QL (120 EA per 30 days)    |
| XATMEP ORAL SOLUTION 2.5 MG/ML           | 2                 |                                   |
| XERMELO ORAL TABLET 250 MG               | 5^                | PA; LA; QL (84 EA per 28 days)    |
| XOSPATA ORAL TABLET 40 MG                | 5^                | PA-NS; LA; QL (90 EA per 30 days) |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                                                                                                                                                                                      | Nivo Medikaman an | Egzijans/Limit yo                 |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------|-----------------------------------|
| XPOVIO ORAL TABLET 100 MG/WEEK (50 MG X 2), 40 MG/WEEK (10 MG X 4), 40MG TWICE WEEK (40 MG X 2), 60 MG/WEEK (60 MG X 1), 60MG TWICE WEEK (120 MG/WEEK), 80 MG/WEEK (40 MG X 2), 80 MG/WEEK (80 MG X 1), 80MG TWICE WEEK (160 MG/WEEK) | 5^                | PA-NS; LA                         |
| XTANDI ORAL CAPSULE 40 MG                                                                                                                                                                                                             | 5^                | PA-NS; QL (120 EA per 30 days)    |
| XTANDI ORAL TABLET 40 MG                                                                                                                                                                                                              | 5^                | PA-NS; QL (120 EA per 30 days)    |
| XTANDI ORAL TABLET 80 MG                                                                                                                                                                                                              | 5^                | PA-NS; QL (60 EA per 30 days)     |
| <i>yulithira oral tablet 10 mg, 2.5 mg, 5 mg, 7.5 mg</i>                                                                                                                                                                              | 3                 | PA-NS; QL (30 EA per 30 days)     |
| ZEJULA ORAL TABLET 100 MG, 200 MG, 300 MG                                                                                                                                                                                             | 5^                | PA-NS; LA; QL (30 EA per 30 days) |
| ZELBORAF ORAL TABLET 240 MG                                                                                                                                                                                                           | 5^                | PA-NS; QL (224 EA per 28 days)    |
| ZENBEXUS ORAL CAPSULE 0.75 MG, 1 MG                                                                                                                                                                                                   | 5^                | PA-NS; QL (21 EA per 28 days)     |
| ZOLINZA ORAL CAPSULE 100 MG                                                                                                                                                                                                           | 5^                | PA-NS; QL (120 EA per 30 days)    |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                                                                                                  | Nivo Medikaman an | Egzijans/Limit yo             |
|---------------------------------------------------------------------------------------------------------------------------------------------------|-------------------|-------------------------------|
| ZYKADIA ORAL TABLET 150 MG                                                                                                                        | 5^                | PA-NS; QL (90 EA per 30 days) |
| <b>MEDIKAMAN OTONOMIK / CNS, NEWOLOJI / PSIK</b>                                                                                                  |                   |                               |
| <b>AJAN ANTI-PARKINSONISM</b>                                                                                                                     |                   |                               |
| <i>benztropine oral tablet 0.5 mg, 1 mg, 2 mg</i>                                                                                                 | 3                 | PA                            |
| <i>bromocriptine oral capsule 5 mg</i>                                                                                                            | 1                 |                               |
| <i>bromocriptine oral tablet 2.5 mg</i>                                                                                                           | 1                 |                               |
| <i>carbidopa oral tablet 25 mg</i>                                                                                                                | 1                 |                               |
| <i>carbidopa-levodopa oral tablet 10-100 mg, 25-100 mg, 25-250 mg</i>                                                                             | 1                 |                               |
| <i>carbidopa-levodopa oral tablet extended release 25-100 mg, 50-200 mg</i>                                                                       | 1                 |                               |
| <i>carbidopa-levodopa oral tablet, disintegrating 10-100 mg, 25-100 mg, 25-250 mg</i>                                                             | 1                 |                               |
| <i>carbidopa-levodopa-entacapone oral tablet 12.5-50-200 mg, 18.75-75-200 mg, 25-100-200 mg, 31.25-125-200 mg, 37.5-150-200 mg, 50-200-200 mg</i> | 1                 |                               |
| <i>entacapone oral tablet 200 mg</i>                                                                                                              | 1                 |                               |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                                                                    | Nivo Medikaman an | Egzijans/Limit yo |
|---------------------------------------------------------------------------------------------------------------------|-------------------|-------------------|
| NEUPRO TRANSDERMAL PATCH 24 HOUR 1 MG/24 HOUR, 2 MG/24 HOUR, 3 MG/24 HOUR, 4 MG/24 HOUR, 6 MG/24 HOUR, 8 MG/24 HOUR | 3                 |                   |
| <i>pramipexole oral tablet 0.125 mg, 0.25 mg, 0.5 mg, 0.75 mg, 1 mg, 1.5 mg</i>                                     | 1                 |                   |
| <i>pramipexole oral tablet extended release 24 hr 0.375 mg, 0.75 mg, 1.5 mg, 2.25 mg, 3 mg</i>                      | 1                 |                   |
| <i>rasagiline oral tablet 0.5 mg, 1 mg</i>                                                                          | 1                 |                   |
| <i>ropinirole oral tablet 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg, 5 mg</i>                                         | 1                 |                   |
| <i>ropinirole oral tablet extended release 24 hr 12 mg, 2 mg, 4 mg, 6 mg, 8 mg</i>                                  | 1                 |                   |
| <i>selegiline hcl oral capsule 5 mg</i>                                                                             | 1                 |                   |
| <i>selegiline hcl oral tablet 5 mg</i>                                                                              | 1                 |                   |
| <i>trihexyphenidyl oral tablet 2 mg, 5 mg</i>                                                                       | 2                 |                   |

### **ANALJEZIK NAKOTIK**

|                                                               |   |                          |
|---------------------------------------------------------------|---|--------------------------|
| <i>acetaminophen-codeine oral solution 120-12 mg/5 ml</i>     | 1 | QL (2700 ML per 30 days) |
| <i>acetaminophen-codeine oral tablet 300-15 mg, 300-30 mg</i> | 1 | QL (360 EA per 30 days)  |
| <i>acetaminophen-codeine oral tablet 300-60 mg</i>            | 1 | QL (180 EA per 30 days)  |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                                                 | Nivo Medikaman an | Egzijans/Limit yo           |
|--------------------------------------------------------------------------------------------------|-------------------|-----------------------------|
| <i>buprenorphine hcl sublingual tablet 2 mg, 8 mg</i>                                            | 1                 |                             |
| <i>fentanyl transdermal patch 72 hour 100 mcg/hr, 12 mcg/hr, 25 mcg/hr, 50 mcg/hr, 75 mcg/hr</i> | 3                 | PA; QL (10 EA per 30 days)  |
| <i>hydrocodone-acetaminophen oral solution 7.5-325 mg/15 ml</i>                                  | 3                 | QL (2700 ML per 30 days)    |
| <i>hydrocodone-acetaminophen oral tablet 10-325 mg, 7.5-325 mg</i>                               | 3                 | QL (180 EA per 30 days)     |
| <i>hydrocodone-acetaminophen oral tablet 5-325 mg</i>                                            | 3                 | QL (240 EA per 30 days)     |
| <i>hydrocodone-ibuprofen oral tablet 7.5-200 mg</i>                                              | 3                 | QL (50 EA per 30 days)      |
| <i>hydromorphone oral liquid 1 mg/ml</i>                                                         | 1                 | QL (600 ML per 30 days)     |
| <i>hydromorphone oral tablet 2 mg, 4 mg, 8 mg</i>                                                | 1                 | QL (180 EA per 30 days)     |
| <i>methadone oral solution 10 mg/5 ml, 5 mg/5 ml</i>                                             | 1                 | PA; QL (450 ML per 30 days) |
| <i>methadone oral tablet 10 mg, 5 mg</i>                                                         | 1                 | PA; QL (90 EA per 30 days)  |
| <i>morphine concentrate oral solution 100 mg/5 ml (20 mg/ml)</i>                                 | 1                 | QL (180 ML per 30 days)     |
| <i>morphine oral solution 10 mg/5 ml (2 mg/ml), 20 mg/5 ml (4 mg/ml)</i>                         | 1                 | QL (900 ML per 30 days)     |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                                 | Nivo Medikaman an | Egzijans/Limit yo          |
|----------------------------------------------------------------------------------|-------------------|----------------------------|
| <i>morphine oral tablet 15 mg, 30 mg</i>                                         | 1                 | QL (180 EA per 30 days)    |
| <i>morphine oral tablet extended release 100 mg, 15 mg, 200 mg, 30 mg, 60 mg</i> | 1                 | PA; QL (90 EA per 30 days) |
| <i>oxycodone oral capsule 5 mg</i>                                               | 1                 | QL (180 EA per 30 days)    |
| <i>oxycodone oral concentrate 20 mg/ml</i>                                       | 1                 | QL (180 ML per 30 days)    |
| <i>oxycodone oral solution 5 mg/5 ml</i>                                         | 1                 | QL (900 ML per 30 days)    |
| <i>oxycodone oral tablet 10 mg, 15 mg, 20 mg, 30 mg, 5 mg</i>                    | 1                 | QL (180 EA per 30 days)    |
| <i>oxycodone-acetaminophen oral tablet 10-325 mg</i>                             | 3                 | QL (180 EA per 30 days)    |
| <i>oxycodone-acetaminophen oral tablet 2.5-325 mg, 5-325 mg</i>                  | 3                 | QL (360 EA per 30 days)    |
| <i>oxycodone-acetaminophen oral tablet 7.5-325 mg</i>                            | 3                 | QL (240 EA per 30 days)    |
| <b>ANALJEZIK NON-NAKOTIK</b>                                                     |                   |                            |
| <i>buprenorphine-naloxone sublingual film 12-3 mg, 2-0.5 mg, 4-1 mg, 8-2 mg</i>  | 1                 |                            |
| <i>buprenorphine-naloxone sublingual tablet 2-0.5 mg, 8-2 mg</i>                 | 1                 |                            |
| <i>butorphanol nasal spray, non-aerosol 10 mg/ml</i>                             | 1                 | QL (10 ML per 28 days)     |
| <i>celecoxib oral capsule 100 mg, 200 mg, 400 mg, 50 mg</i>                      | 1                 |                            |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                                                  | Nivo Medikaman an | Egzijans/Limit yo       |
|---------------------------------------------------------------------------------------------------|-------------------|-------------------------|
| <i>diclofenac potassium oral tablet 50 mg</i>                                                     | 1                 |                         |
| <i>diclofenac sodium oral tablet extended release 24 hr 100 mg</i>                                | 1                 |                         |
| <i>diclofenac sodium oral tablet, delayed release (dr/ec) 25 mg, 50 mg, 75 mg</i>                 | 1                 |                         |
| <i>diclofenac sodium topical drops 1.5 %</i>                                                      | 1                 | QL (300 ML per 28 days) |
| <i>diclofenac-misoprostol oral tablet, ir, delayed rel, biphasic 50-200 mg-mcg, 75-200 mg-mcg</i> | 1                 |                         |
| <i>diflunisal oral tablet 500 mg</i>                                                              | 1                 |                         |
| <i>etodolac oral capsule 200 mg, 300 mg</i>                                                       | 1                 |                         |
| <i>etodolac oral tablet 400 mg, 500 mg</i>                                                        | 1                 |                         |
| <i>etodolac oral tablet extended release 24 hr 400 mg, 500 mg, 600 mg</i>                         | 1                 |                         |
| <i>flurbiprofen oral tablet 100 mg</i>                                                            | 1                 |                         |
| <i>ibu oral tablet 600 mg, 800 mg</i>                                                             | 1                 |                         |
| <i>ibuprofen oral suspension 100 mg/5 ml</i>                                                      | 1                 |                         |
| <i>ibuprofen oral tablet 400 mg, 600 mg, 800 mg</i>                                               | 1                 |                         |
| JOURNAVX ORAL TABLET 50 MG                                                                        | 2                 | QL (30 EA per 90 days)  |
| KLOXXADO NASAL SPRAY, NON-AEROSOL 8 MG/ACTUATION                                                  | 3                 |                         |
| <i>meloxicam oral tablet 15 mg, 7.5 mg</i>                                                        | 1                 |                         |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                   | Nivo Medikaman an | Egzijans/Limit yo       |
|--------------------------------------------------------------------|-------------------|-------------------------|
| <i>nabumetone oral tablet 500 mg, 750 mg</i>                       | 1                 |                         |
| <i>naloxone injection solution 0.4 mg/ml</i>                       | 1                 |                         |
| <i>naloxone injection syringe 0.4 mg/ml, 1 mg/ml</i>               | 1                 |                         |
| <i>naltrexone oral tablet 50 mg</i>                                | 1                 |                         |
| <i>naproxen oral tablet 250 mg, 375 mg, 500 mg</i>                 | 1                 |                         |
| <i>naproxen oral tablet, delayed release (dr/ec) 375 mg</i>        | 1                 |                         |
| <i>naproxen sodium oral tablet 275 mg, 550 mg</i>                  | 1                 |                         |
| <i>oxaprozin oral tablet 600 mg</i>                                | 1                 |                         |
| <i>piroxicam oral capsule 10 mg, 20 mg</i>                         | 1                 |                         |
| <i>sulindac oral tablet 150 mg, 200 mg</i>                         | 1                 |                         |
| <i>tramadol oral tablet 50 mg</i>                                  | 1                 | QL (240 EA per 30 days) |
| <i>tramadol-acetaminophen oral tablet 37.5-325 mg</i>              | 1                 | QL (240 EA per 30 days) |
| <b>ANTIKONVILZIF</b>                                               |                   |                         |
| <i>brivaracetam oral solution 10 mg/ml</i>                         | 5^                | QL (600 ML per 30 days) |
| <i>brivaracetam oral tablet 10 mg, 100 mg, 25 mg, 50 mg, 75 mg</i> | 5^                | QL (60 EA per 30 days)  |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                               | Nivo Medikaman an | Egzijans/Limit yo                  |
|--------------------------------------------------------------------------------|-------------------|------------------------------------|
| <i>carbamazepine oral capsule, er multiphase 12 hr 100 mg, 200 mg, 300 mg</i>  | 1                 |                                    |
| <i>carbamazepine oral suspension 100 mg/5 ml</i>                               | 1                 |                                    |
| <i>carbamazepine oral tablet 200 mg</i>                                        | 1                 |                                    |
| <i>carbamazepine oral tablet extended release 12 hr 100 mg, 200 mg, 400 mg</i> | 1                 |                                    |
| <i>carbamazepine oral tablet, chewable 100 mg</i>                              | 1                 |                                    |
| <i>clobazam oral suspension 2.5 mg/ml</i>                                      | 3                 | PA-NS; QL (480 ML per 30 days)     |
| <i>clobazam oral tablet 10 mg, 20 mg</i>                                       | 3                 | PA-NS; QL (60 EA per 30 days)      |
| <i>clonazepam oral tablet 0.5 mg, 1 mg</i>                                     | 1                 | QL (90 EA per 30 days)             |
| <i>clonazepam oral tablet 2 mg</i>                                             | 1                 | QL (300 EA per 30 days)            |
| <i>clonazepam oral tablet, disintegrating 0.125 mg, 0.25 mg, 0.5 mg, 1 mg</i>  | 1                 | QL (90 EA per 30 days)             |
| <i>clonazepam oral tablet, disintegrating 2 mg</i>                             | 1                 | QL (300 EA per 30 days)            |
| DIACOMIT ORAL CAPSULE 250 MG                                                   | 5 <sup>^</sup>    | PA-NS; LA; QL (360 EA per 30 days) |
| DIACOMIT ORAL CAPSULE 500 MG                                                   | 5 <sup>^</sup>    | PA-NS; LA; QL (180 EA per 30 days) |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                              | Nivo Medikaman an | Egzijans/Limit yo                  |
|-------------------------------------------------------------------------------|-------------------|------------------------------------|
| DIACOMIT ORAL POWDER IN PACKET 250 MG                                         | 5^                | PA-NS; LA; QL (360 EA per 30 days) |
| DIACOMIT ORAL POWDER IN PACKET 500 MG                                         | 5^                | PA-NS; LA; QL (180 EA per 30 days) |
| <i>diazepam rectal kit 12.5-15-17.5-20 mg, 2.5 mg, 5-7.5-10 mg</i>            | 3                 |                                    |
| DILANTIN EXTENDED ORAL CAPSULE 100 MG                                         | 3                 |                                    |
| DILANTIN INFATABS ORAL TABLET,CHEWABLE 50 MG                                  | 3                 |                                    |
| DILANTIN ORAL CAPSULE 30 MG                                                   | 3                 |                                    |
| DILANTIN-125 ORAL SUSPENSION 125 MG/5 ML                                      | 3                 |                                    |
| <i>divalproex oral capsule, delayed rel sprinkle 125 mg</i>                   | 1                 |                                    |
| <i>divalproex oral tablet extended release 24 hr 250 mg, 500 mg</i>           | 1                 |                                    |
| <i>divalproex oral tablet, delayed release (dr/ec) 125 mg, 250 mg, 500 mg</i> | 1                 |                                    |
| EPIDIOLEX ORAL SOLUTION 100 MG/ML                                             | 5^                | PA-NS; LA                          |
| <i>eslicarbazepine oral tablet 200 mg, 400 mg</i>                             | 3                 | QL (60 EA per 30 days)             |
| <i>eslicarbazepine oral tablet 600 mg, 800 mg</i>                             | 5^                | QL (60 EA per 30 days)             |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                             | Nivo Medikaman an | Egzijans/Limit yo                  |
|--------------------------------------------------------------|-------------------|------------------------------------|
| <i>ethosuximide oral capsule 250 mg</i>                      | 1                 |                                    |
| <i>ethosuximide oral solution 250 mg/5 ml</i>                | 1                 |                                    |
| <i>felbamate oral suspension 600 mg/5 ml</i>                 | 3                 |                                    |
| <i>felbamate oral tablet 400 mg, 600 mg</i>                  | 1                 |                                    |
| FINTEPLA ORAL SOLUTION 2.2 MG/ML                             | 5^                | PA-NS; LA; QL (360 ML per 30 days) |
| <i>gabapentin oral capsule 100 mg, 400 mg</i>                | 1                 | QL (270 EA per 30 days)            |
| <i>gabapentin oral capsule 300 mg</i>                        | 1                 | QL (360 EA per 30 days)            |
| <i>gabapentin oral solution 250 mg/5 ml</i>                  | 1                 | QL (2160 ML per 30 days)           |
| <i>gabapentin oral tablet 600 mg</i>                         | 1                 | QL (180 EA per 30 days)            |
| <i>gabapentin oral tablet 800 mg</i>                         | 1                 | QL (120 EA per 30 days)            |
| <i>gabapentin oral tablet extended release 24 hr 300 mg</i>  | 3                 | PA; QL (180 EA per 30 days)        |
| <i>gabapentin oral tablet extended release 24 hr 600 mg</i>  | 3                 | PA; QL (90 EA per 30 days)         |
| <i>lacosamide oral solution 10 mg/ml</i>                     | 1                 | QL (1200 ML per 30 days)           |
| <i>lacosamide oral tablet 100 mg, 150 mg, 200 mg</i>         | 1                 | QL (60 EA per 30 days)             |
| <i>lacosamide oral tablet 50 mg</i>                          | 1                 | QL (120 EA per 30 days)            |
| <i>lamotrigine oral tablet 100 mg, 150 mg, 200 mg, 25 mg</i> | 1                 |                                    |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                                                  | Nivo Medikaman an | Egzijans/Limit yo             |
|---------------------------------------------------------------------------------------------------|-------------------|-------------------------------|
| <i>lamotrigine oral tablet extended release 24hr 100 mg, 200 mg, 25 mg, 250 mg, 300 mg, 50 mg</i> | 1                 |                               |
| <i>lamotrigine oral tablet, chewable dispersible 25 mg, 5 mg</i>                                  | 1                 |                               |
| <i>lamotrigine oral tablet, disintegrating 100 mg, 200 mg, 25 mg, 50 mg</i>                       | 1                 |                               |
| <i>levetiracetam oral solution 100 mg/ml</i>                                                      | 1                 |                               |
| <i>levetiracetam oral tablet 1,000 mg, 250 mg, 500 mg, 750 mg</i>                                 | 1                 |                               |
| <i>levetiracetam oral tablet extended release 24 hr 500 mg, 750 mg</i>                            | 1                 |                               |
| LEVETIRACETAM ORAL TABLET FOR SUSPENSION 250 MG, 500 MG                                           | 3                 |                               |
| <i>methsuximide oral capsule 300 mg</i>                                                           | 3                 |                               |
| NAYZILAM NASAL SPRAY, NON-AEROSOL 5 MG/SPRAY (0.1 ML)                                             | 3                 | PA-NS; QL (10 EA per 30 days) |
| <i>oxcarbazepine oral suspension 300 mg/5 ml (60 mg/ml)</i>                                       | 1                 |                               |
| <i>oxcarbazepine oral tablet 150 mg, 300 mg, 600 mg</i>                                           | 1                 |                               |
| <i>perampanel oral suspension 0.5 mg/ml</i>                                                       | 5^                | QL (680 ML per 28 days)       |
| <i>perampanel oral tablet 10 mg, 12 mg, 2 mg, 4 mg, 6 mg, 8 mg</i>                                | 3                 | QL (30 EA per 30 days)        |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                                                 | Nivo Medikaman an | Egzijans/Limit yo               |
|--------------------------------------------------------------------------------------------------|-------------------|---------------------------------|
| <i>phenobarbital oral elixir 20 mg/5 ml (4 mg/ml)</i>                                            | 3                 | PA-NS                           |
| <i>phenobarbital oral tablet 100 mg, 15 mg, 16.2 mg, 30 mg, 32.4 mg, 60 mg, 64.8 mg, 97.2 mg</i> | 1                 | PA-NS                           |
| <i>phenytoin oral suspension 125 mg/5 ml</i>                                                     | 1                 |                                 |
| <i>phenytoin oral tablet, chewable 50 mg</i>                                                     | 1                 |                                 |
| <i>phenytoin sodium extended oral capsule 100 mg</i>                                             | 1                 |                                 |
| <i>pregabalin oral capsule 100 mg, 150 mg, 200 mg, 25 mg, 50 mg, 75 mg</i>                       | 3                 | QL (90 EA per 30 days)          |
| <i>pregabalin oral capsule 225 mg, 300 mg</i>                                                    | 3                 | QL (60 EA per 30 days)          |
| <i>pregabalin oral solution 20 mg/ml</i>                                                         | 3                 | QL (900 ML per 30 days)         |
| PRIMIDONE ORAL TABLET 125 MG                                                                     | 3                 |                                 |
| <i>primidone oral tablet 250 mg, 50 mg</i>                                                       | 1                 |                                 |
| <i>roweepra oral tablet 500 mg</i>                                                               | 1                 |                                 |
| <i>rufinamide oral suspension 40 mg/ml</i>                                                       | 5 <sup>^</sup>    | PA-NS; QL (2760 ML per 30 days) |
| <i>rufinamide oral tablet 200 mg</i>                                                             | 1                 | PA-NS; QL (480 EA per 30 days)  |
| <i>rufinamide oral tablet 400 mg</i>                                                             | 5 <sup>^</sup>    | PA-NS; QL (240 EA per 30 days)  |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                                                                                         | Nivo Medikaman an | Egzijans/Limit yo                  |
|------------------------------------------------------------------------------------------------------------------------------------------|-------------------|------------------------------------|
| SUBVENITE ORAL SUSPENSION 10 MG/ML                                                                                                       | 5^                |                                    |
| SYMPAZAN ORAL FILM 10 MG, 20 MG                                                                                                          | 5^                | PA-NS; QL (60 EA per 30 days)      |
| SYMPAZAN ORAL FILM 5 MG                                                                                                                  | 3                 | PA-NS; QL (60 EA per 30 days)      |
| <i>tiagabine oral tablet 12 mg, 16 mg, 2 mg, 4 mg</i>                                                                                    | 1                 |                                    |
| <i>topiramate oral capsule, sprinkle 15 mg, 25 mg</i>                                                                                    | 1                 |                                    |
| <i>topiramate oral solution 25 mg/ml</i>                                                                                                 | 2                 | PA-NS                              |
| <i>topiramate oral tablet 100 mg, 200 mg, 25 mg, 50 mg</i>                                                                               | 1                 |                                    |
| <i>valproic acid (as sodium salt) oral solution 250 mg/5 ml</i>                                                                          | 1                 |                                    |
| <i>valproic acid oral capsule 250 mg</i>                                                                                                 | 1                 |                                    |
| VALTOCO NASAL SPRAY, NON-AEROSOL 10 MG/SPRAY (0.1 ML), 15 MG/2 SPRAY (7.5/0.1ML X 2), 20 MG/2 SPRAY (10MG/0.1ML X2), 5 MG/SPRAY (0.1 ML) | 3                 | PA-NS; QL (10 EA per 30 days)      |
| <i>vigabatrin oral powder in packet 500 mg</i>                                                                                           | 5^                | PA-NS; LA; QL (150 EA per 25 days) |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                                                   | Nivo Medikaman an | Egzijans/Limit yo                  |
|----------------------------------------------------------------------------------------------------|-------------------|------------------------------------|
| <i>vigabatrin oral tablet 500 mg</i>                                                               | 5^                | PA-NS; LA; QL (180 EA per 30 days) |
| <i>vigadrone oral powder in packet 500 mg</i>                                                      | 5^                | PA-NS; LA; QL (150 EA per 25 days) |
| <i>vigadrone oral tablet 500 mg</i>                                                                | 5^                | PA-NS; LA; QL (180 EA per 30 days) |
| XCOPRI MAINTENANCE PACK ORAL TABLET 250MG/DAY(150 MG X1-100MG X1), 350 MG/DAY (200 MG X1-150MG X1) | 5^                | QL (56 EA per 28 days)             |
| XCOPRI ORAL TABLET 100 MG, 25 MG, 50 MG                                                            | 5^                | QL (30 EA per 30 days)             |
| XCOPRI ORAL TABLET 150 MG, 200 MG                                                                  | 5^                | QL (60 EA per 30 days)             |
| XCOPRI TITRATION PACK ORAL TABLETS,DOSE PACK 12.5 MG (14)- 25 MG (14)                              | 3                 | QL (28 EA per 180 days)            |
| XCOPRI TITRATION PACK ORAL TABLETS,DOSE PACK 150 MG (14)- 200 MG (14), 50 MG (14)- 100 MG (14)     | 5^                | QL (28 EA per 180 days)            |
| ZONISADE ORAL SUSPENSION 100 MG/5 ML                                                               | 5^                | PA-NS                              |
| <i>zonisamide oral capsule 100 mg, 25 mg, 50 mg</i>                                                | 1                 |                                    |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                                                    | Nivo Medikaman an | Egzijans/Limit yo                   |
|-----------------------------------------------------------------------------------------------------|-------------------|-------------------------------------|
| ZTALMY ORAL SUSPENSION 50 MG/ML                                                                     | 5^                | PA-NS; LA; QL (1100 ML per 30 days) |
| <b><i>DIVÈS TERAPI NEWOLOJIK</i></b>                                                                |                   |                                     |
| AUSTEDO ORAL TABLET 12 MG, 9 MG                                                                     | 5^                | PA; QL (120 EA per 30 days)         |
| AUSTEDO ORAL TABLET 6 MG                                                                            | 5^                | PA; QL (60 EA per 30 days)          |
| AUSTEDO XR ORAL TABLET EXTENDED RELEASE 24 HR 12 MG, 18 MG, 24 MG, 30 MG, 36 MG, 42 MG, 48 MG, 6 MG | 5^                | PA; QL (30 EA per 30 days)          |
| AUSTEDO XR TITRATION KT(WK1-4) ORAL TABLET, EXT REL 24HR DOSE PACK 12-18-24-30 MG                   | 5^                | PA; QL (28 EA per 180 days)         |
| <i>dalfampridine oral tablet extended release 12 hr 10 mg</i>                                       | 1                 | PA; QL (60 EA per 30 days)          |
| <i>dimethyl fumarate oral capsule, delayed release(dr/ec) 120 mg</i>                                | 3                 | PA; QL (56 EA per 28 days)          |
| <i>dimethyl fumarate oral capsule, delayed release(dr/ec) 120 mg (14)- 240 mg (46)</i>              | 3                 | PA; QL (120 EA per 180 days)        |
| <i>dimethyl fumarate oral capsule, delayed release(dr/ec) 240 mg</i>                                | 3                 | PA; QL (60 EA per 30 days)          |
| <i>donepezil oral tablet 10 mg, 5 mg</i>                                                            | 1                 |                                     |
| <i>donepezil oral tablet 23 mg</i>                                                                  | 3                 | QL (30 EA per 30 days)              |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                             | Nivo Medikaman an | Egzijans/Limit yo               |
|------------------------------------------------------------------------------|-------------------|---------------------------------|
| <i>donepezil oral tablet, disintegrating 10 mg, 5 mg</i>                     | 1                 |                                 |
| <i>fingolimod oral capsule 0.5 mg</i>                                        | 5^                | PA; QL (30 EA per 30 days)      |
| <i>galantamine oral capsule, ext rel. pellets 24 hr 16 mg, 24 mg, 8 mg</i>   | 1                 | QL (30 EA per 30 days)          |
| <i>galantamine oral solution 4 mg/ml</i>                                     | 1                 | QL (200 ML per 30 days)         |
| <i>galantamine oral tablet 12 mg, 4 mg, 8 mg</i>                             | 1                 | QL (60 EA per 30 days)          |
| <i>glatiramer subcutaneous syringe 20 mg/ml</i>                              | 5^                | PA; QL (30 ML per 30 days)      |
| <i>glatiramer subcutaneous syringe 40 mg/ml</i>                              | 5^                | PA; QL (12 ML per 28 days)      |
| <i>glatopa subcutaneous syringe 20 mg/ml</i>                                 | 5^                | PA; QL (30 ML per 30 days)      |
| <i>glatopa subcutaneous syringe 40 mg/ml</i>                                 | 5^                | PA; QL (12 ML per 28 days)      |
| INGREZZA INITIATION PK(TARDIV) ORAL CAPSULE, DOSE PACK 40 MG (7)- 80 MG (21) | 5^                | PA; LA; QL (28 EA per 180 days) |
| INGREZZA ORAL CAPSULE 40 MG, 60 MG, 80 MG                                    | 5^                | PA; LA; QL (30 EA per 30 days)  |
| LEQEMBI IQLIK SUBCUTANEOUS AUTO-INJECTOR 360 MG/1.8 ML                       | 5^                | PA                              |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                                              | Nivo Medikaman an | Egzijans/Limit yo           |
|-----------------------------------------------------------------------------------------------|-------------------|-----------------------------|
| <i>memantine oral capsule, sprinkle, er 24hr 14 mg, 21 mg, 28 mg, 7 mg</i>                    | 1                 | PA                          |
| <i>memantine oral solution 2 mg/ml</i>                                                        | 1                 | PA                          |
| <i>memantine oral tablet 10 mg, 5 mg</i>                                                      | 1                 | PA                          |
| NAMZARIC ORAL CAPSULE, SPRINKLE, ER 24HR 14-10 MG, 21-10 MG, 28-10 MG, 7-10 MG                | 2                 |                             |
| NUEDEXTA ORAL CAPSULE 20-10 MG                                                                | 2                 | PA; QL (60 EA per 30 days)  |
| <i>rivastigmine tartrate oral capsule 1.5 mg, 3 mg, 4.5 mg, 6 mg</i>                          | 1                 | QL (60 EA per 30 days)      |
| <i>rivastigmine transdermal patch 24 hour 13.3 mg/24 hour, 4.6 mg/24 hour, 9.5 mg/24 hour</i> | 1                 | QL (30 EA per 30 days)      |
| <i>teriflunomide oral tablet 14 mg, 7 mg</i>                                                  | 5^                | PA; QL (30 EA per 30 days)  |
| <i>tetrabenazine oral tablet 12.5 mg</i>                                                      | 3                 | PA; QL (240 EA per 30 days) |
| <i>tetrabenazine oral tablet 25 mg</i>                                                        | 5^                | PA; QL (120 EA per 30 days) |
| <b>MEDIKAMAN SIKOTERAPETIK</b>                                                                |                   |                             |
| ABILIFY ASIMTUFII INTRAMUSCULAR SUSPENSION, EXTENDED REL SYRING 720 MG/2.4 ML                 | 5^                | QL (2.4 ML per 56 days)     |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                             | Nivo Medikaman an | Egzijans/Limit yo           |
|------------------------------------------------------------------------------|-------------------|-----------------------------|
| ABILIFY ASIMTUFII INTRAMUSCULAR SUSPENSION,EXTENDED REL SYRING 960 MG/3.2 ML | 5^                | QL (3.2 ML per 56 days)     |
| ABILIFY MAINTENA INTRAMUSCULAR SUSPENSION,EXTENDED REL RECON 300 MG, 400 MG  | 5^                | QL (1 EA per 28 days)       |
| ABILIFY MAINTENA INTRAMUSCULAR SUSPENSION,EXTENDED REL SYRING 300 MG, 400 MG | 5^                | QL (1 EA per 28 days)       |
| <i>alprazolam oral tablet 0.25 mg, 0.5 mg, 1 mg</i>                          | 3                 | PA; QL (120 EA per 30 days) |
| <i>alprazolam oral tablet 2 mg</i>                                           | 3                 | PA; QL (150 EA per 30 days) |
| <i>amitriptyline oral tablet 10 mg, 100 mg, 150 mg, 25 mg, 50 mg, 75 mg</i>  | 3                 |                             |
| <i>amoxapine oral tablet 100 mg, 150 mg, 25 mg, 50 mg</i>                    | 3                 |                             |
| <i>aripiprazole oral solution 1 mg/ml</i>                                    | 3                 | QL (900 ML per 30 days)     |
| <i>aripiprazole oral tablet 10 mg, 15 mg, 2 mg, 20 mg, 30 mg, 5 mg</i>       | 3                 | QL (30 EA per 30 days)      |
| <i>aripiprazole oral tablet,disintegrating 10 mg, 15 mg</i>                  | 3                 | QL (60 EA per 30 days)      |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                                 | Nivo Medikaman an | Egzijans/Limit yo             |
|----------------------------------------------------------------------------------|-------------------|-------------------------------|
| ARISTADA INITIO INTRAMUSCULAR<br>SUSPENSION,EXTENDED REL SYRING<br>675 MG/2.4 ML | 5^                | QL (2.4 ML per 180 days)      |
| ARISTADA INTRAMUSCULAR<br>SUSPENSION,EXTENDED REL SYRING<br>1,064 MG/3.9 ML      | 5^                | QL (3.9 ML per 56 days)       |
| ARISTADA INTRAMUSCULAR<br>SUSPENSION,EXTENDED REL SYRING<br>441 MG/1.6 ML        | 5^                | QL (1.6 ML per 28 days)       |
| ARISTADA INTRAMUSCULAR<br>SUSPENSION,EXTENDED REL SYRING<br>662 MG/2.4 ML        | 5^                | QL (2.4 ML per 28 days)       |
| ARISTADA INTRAMUSCULAR<br>SUSPENSION,EXTENDED REL SYRING<br>882 MG/3.2 ML        | 5^                | QL (3.2 ML per 28 days)       |
| <i>armodafinil oral tablet 150 mg, 200 mg,<br/>250 mg</i>                        | 1                 | PA; QL (30 EA per 30<br>days) |
| <i>armodafinil oral tablet 50 mg</i>                                             | 1                 | PA; QL (60 EA per 30<br>days) |
| <i>asenapine maleate sublingual tablet 10<br/>mg, 2.5 mg, 5 mg</i>               | 1                 | QL (60 EA per 30 days)        |
| <i>atomoxetine oral capsule 10 mg, 18<br/>mg, 25 mg, 40 mg</i>                   | 1                 | QL (60 EA per 30 days)        |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                                | Nivo Medikaman an | Egzijans/Limit yo          |
|---------------------------------------------------------------------------------|-------------------|----------------------------|
| <i>atomoxetine oral capsule 100 mg, 60 mg, 80 mg</i>                            | 1                 | QL (30 EA per 30 days)     |
| AUVELITY ORAL TABLET, IR AND ER, BIPHASIC 45-105 MG                             | 3                 | ST; QL (60 EA per 30 days) |
| BELSOMRA ORAL TABLET 10 MG, 15 MG, 20 MG, 5 MG                                  | 2                 | QL (30 EA per 30 days)     |
| <i>bupropion hcl oral tablet 100 mg, 75 mg</i>                                  | 1                 |                            |
| <i>bupropion hcl oral tablet extended release 24 hr 150 mg</i>                  | 1                 | QL (90 EA per 30 days)     |
| <i>bupropion hcl oral tablet extended release 24 hr 300 mg</i>                  | 1                 | QL (30 EA per 30 days)     |
| <i>bupropion hcl oral tablet sustained-release 12 hr 100 mg, 150 mg, 200 mg</i> | 1                 | QL (60 EA per 30 days)     |
| <i>bupirone oral tablet 10 mg, 15 mg, 30 mg, 5 mg, 7.5 mg</i>                   | 1                 |                            |
| CAPLYTA ORAL CAPSULE 10.5 MG, 21 MG, 42 MG                                      | 5^                | QL (30 EA per 30 days)     |
| <i>chlorpromazine oral concentrate 100 mg/ml, 30 mg/ml</i>                      | 3                 |                            |
| <i>chlorpromazine oral tablet 10 mg, 50 mg</i>                                  | 1                 |                            |
| <i>chlorpromazine oral tablet 100 mg, 200 mg, 25 mg</i>                         | 3                 |                            |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                                    | Nivo Medikaman an | Egzijans/Limit yo              |
|-------------------------------------------------------------------------------------|-------------------|--------------------------------|
| <i>citalopram oral solution 10 mg/5 ml</i>                                          | 1                 |                                |
| <i>citalopram oral tablet 10 mg, 20 mg, 40 mg</i>                                   | 1                 |                                |
| <i>clomipramine oral capsule 25 mg, 50 mg, 75 mg</i>                                | 3                 | PA-NS                          |
| <i>clorazepate dipotassium oral tablet 15 mg</i>                                    | 3                 | PA-NS; QL (180 EA per 30 days) |
| <i>clorazepate dipotassium oral tablet 3.75 mg</i>                                  | 3                 | PA-NS; QL (90 EA per 30 days)  |
| <i>clorazepate dipotassium oral tablet 7.5 mg</i>                                   | 3                 | PA-NS; QL (360 EA per 30 days) |
| <i>clozapine oral tablet 100 mg, 200 mg, 25 mg, 50 mg</i>                           | 1                 |                                |
| <i>clozapine oral tablet, disintegrating 100 mg, 12.5 mg, 150 mg, 200 mg, 25 mg</i> | 3                 |                                |
| COBENFY ORAL CAPSULE 100-20 MG, 125-30 MG, 50-20 MG                                 | 5^                | QL (60 EA per 30 days)         |
| COBENFY STARTER PACK ORAL CAPSULE, DOSE PACK 50 MG-20 MG /100 MG-20 MG              | 5^                | QL (56 EA per 180 days)        |
| <i>desipramine oral tablet 10 mg, 100 mg, 150 mg, 25 mg, 50 mg, 75 mg</i>           | 3                 |                                |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                                                                | Nivo Medikaman an | Egzijans/Limit yo       |
|-----------------------------------------------------------------------------------------------------------------|-------------------|-------------------------|
| <i>desvenlafaxine succinate oral tablet extended release 24 hr 100 mg, 25 mg, 50 mg</i>                         | 1                 | QL (30 EA per 30 days)  |
| <i>dexmethylphenidate oral capsule,er biphasic 50-50 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 5 mg</i>  | 1                 | QL (30 EA per 30 days)  |
| <i>dexmethylphenidate oral tablet 10 mg, 2.5 mg, 5 mg</i>                                                       | 1                 | QL (60 EA per 30 days)  |
| <i>dextroamphetamine sulfate oral capsule, extended release 10 mg, 15 mg, 5 mg</i>                              | 3                 | QL (120 EA per 30 days) |
| <i>dextroamphetamine sulfate oral tablet 10 mg, 5 mg</i>                                                        | 1                 | QL (180 EA per 30 days) |
| <i>dextroamphetamine sulfate oral tablet 15 mg</i>                                                              | 1                 | QL (120 EA per 30 days) |
| <i>dextroamphetamine sulfate oral tablet 20 mg</i>                                                              | 1                 | QL (90 EA per 30 days)  |
| <i>dextroamphetamine sulfate oral tablet 30 mg</i>                                                              | 1                 | QL (60 EA per 30 days)  |
| <i>dextroamphetamine-amphetamine oral capsule,extended release 24hr 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 5 mg</i> | 1                 | QL (30 EA per 30 days)  |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                                            | Nivo Medikaman an | Egzijans/Limit yo               |
|---------------------------------------------------------------------------------------------|-------------------|---------------------------------|
| <i>dextroamphetamine-amphetamine oral tablet 10 mg, 12.5 mg, 15 mg, 30 mg, 5 mg, 7.5 mg</i> | 1                 | QL (60 EA per 30 days)          |
| <i>dextroamphetamine-amphetamine oral tablet 20 mg</i>                                      | 1                 | QL (90 EA per 30 days)          |
| <i>diazepam intensol oral concentrate 5 mg/ml</i>                                           | 3                 | PA-NS; QL (240 ML per 30 days)  |
| <i>diazepam oral solution 5 mg/5 ml (1 mg/ml)</i>                                           | 3                 | PA-NS; QL (1200 ML per 30 days) |
| <i>diazepam oral tablet 10 mg, 2 mg, 5 mg</i>                                               | 3                 | PA-NS; QL (120 EA per 30 days)  |
| <i>doxepin oral capsule 10 mg, 100 mg, 150 mg, 25 mg, 50 mg, 75 mg</i>                      | 3                 |                                 |
| <i>doxepin oral concentrate 10 mg/ml</i>                                                    | 3                 |                                 |
| <i>doxepin oral tablet 3 mg, 6 mg</i>                                                       | 3                 | QL (30 EA per 30 days)          |
| DRIZALMA SPRINKLE ORAL CAPSULE, DELAYED REL SPRINKLE 20 MG, 30 MG, 40 MG, 60 MG             | 3                 | QL (60 EA per 30 days)          |
| <i>duloxetine oral capsule, delayed release(dr/ec) 20 mg, 30 mg, 40 mg, 60 mg</i>           | 1                 | QL (60 EA per 30 days)          |
| EMSAM TRANSDERMAL PATCH 24 HOUR 12 MG/24 HR, 6 MG/24 HR, 9 MG/24 HR                         | 5^                | QL (30 EA per 30 days)          |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                              | Nivo Medikaman an | Egzijans/Limit yo           |
|-------------------------------------------------------------------------------|-------------------|-----------------------------|
| <i>escitalopram oxalate oral solution 5 mg/5 ml</i>                           | 1                 |                             |
| <i>escitalopram oxalate oral tablet 10 mg, 20 mg, 5 mg</i>                    | 1                 |                             |
| EXXUA ORAL TABLET EXTENDED RELEASE 24 HR 18.2 MG, 36.3 MG, 54.5 MG, 72.6 MG   | 5^                | ST; QL (30 EA per 30 days)  |
| EXXUA ORAL TABLET, EXT REL 24HR DOSE PACK 18.2 MG (32 TABS)                   | 5^                | ST; QL (32 EA per 180 days) |
| FANAPT ORAL TABLET 1 MG, 10 MG, 12 MG, 2 MG, 4 MG, 6 MG, 8 MG                 | 3                 | ST; QL (60 EA per 30 days)  |
| FANAPT TITRATION PACK A ORAL TABLETS,DOSE PACK 1MG(2)-2MG(2)-4MG(2)-6MG(2)    | 3                 | ST; QL (8 EA per 180 days)  |
| FANAPT TITRATION PACK B ORAL TABLETS,DOSE PACK 1 MG(6)-2MG(2)-6 MG(2)-8 MG(2) | 3                 | ST; QL (12 EA per 180 days) |
| FANAPT TITRATION PACK C ORAL TABLETS,DOSE PACK 1 MG(4)-2 MG(2) - 6 MG (2)     | 3                 | ST; QL (8 EA per 180 days)  |
| FETZIMA ORAL CAPSULE,EXT REL 24HR DOSE PACK 20 MG (2)- 40 MG (26)             | 2                 | QL (28 EA per 180 days)     |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                         | Nivo Medikaman an | Egzijans/Limit yo      |
|--------------------------------------------------------------------------|-------------------|------------------------|
| FETZIMA ORAL CAPSULE, EXTENDED RELEASE 24 HR 120 MG, 20 MG, 40 MG, 80 MG | 2                 | QL (30 EA per 30 days) |
| <i>fluoxetine oral capsule 10 mg, 20 mg, 40 mg</i>                       | 1                 |                        |
| <i>fluoxetine oral solution 20 mg/5 ml (4 mg/ml)</i>                     | 1                 |                        |
| <i>fluphenazine decanoate injection solution 25 mg/ml</i>                | 1                 |                        |
| <i>fluphenazine hcl injection solution 2.5 mg/ml</i>                     | 1                 |                        |
| <i>fluphenazine hcl oral concentrate 5 mg/ml</i>                         | 1                 |                        |
| <i>fluphenazine hcl oral elixir 2.5 mg/5 ml</i>                          | 1                 |                        |
| <i>fluphenazine hcl oral tablet 1 mg, 10 mg, 2.5 mg, 5 mg</i>            | 1                 |                        |
| <i>fluvoxamine oral tablet 100 mg, 25 mg, 50 mg</i>                      | 1                 |                        |
| <i>guanfacine oral tablet extended release 24 hr 1 mg, 2 mg, 4 mg</i>    | 3                 | QL (30 EA per 30 days) |
| <i>guanfacine oral tablet extended release 24 hr 3 mg</i>                | 3                 | QL (60 EA per 30 days) |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                                                         | Nivo Medikaman an | Egzijans/Limit yo        |
|----------------------------------------------------------------------------------------------------------|-------------------|--------------------------|
| <i>haloperidol decanoate intramuscular solution 100 mg/ml, 100 mg/ml (1 ml), 50 mg/ml, 50 mg/ml(1ml)</i> | 1                 |                          |
| <i>haloperidol lactate injection solution 5 mg/ml</i>                                                    | 1                 |                          |
| <i>haloperidol lactate oral concentrate 2 mg/ml</i>                                                      | 1                 |                          |
| <i>haloperidol oral tablet 0.5 mg, 1 mg, 10 mg, 2 mg, 20 mg, 5 mg</i>                                    | 1                 |                          |
| <i>imipramine hcl oral tablet 10 mg, 25 mg, 50 mg</i>                                                    | 1                 |                          |
| INVEGA HAFYERA INTRAMUSCULAR SYRINGE 1,092 MG/3.5 ML                                                     | 5^                | QL (3.5 ML per 180 days) |
| INVEGA HAFYERA INTRAMUSCULAR SYRINGE 1,560 MG/5 ML                                                       | 5^                | QL (5 ML per 180 days)   |
| INVEGA SUSTENNA INTRAMUSCULAR SYRINGE 117 MG/0.75 ML                                                     | 5^                | QL (0.75 ML per 28 days) |
| INVEGA SUSTENNA INTRAMUSCULAR SYRINGE 156 MG/ML                                                          | 5^                | QL (1 ML per 28 days)    |
| INVEGA SUSTENNA INTRAMUSCULAR SYRINGE 234 MG/1.5 ML                                                      | 5^                | QL (1.5 ML per 28 days)  |
| INVEGA SUSTENNA INTRAMUSCULAR SYRINGE 39 MG/0.25 ML                                                      | 2                 | QL (0.25 ML per 28 days) |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                                       | Nivo Medikaman an | Egzijans/Limit yo           |
|----------------------------------------------------------------------------------------|-------------------|-----------------------------|
| INVEGA SUSTENNA INTRAMUSCULAR SYRINGE 78 MG/0.5 ML                                     | 5^                | QL (0.5 ML per 28 days)     |
| INVEGA TRINZA INTRAMUSCULAR SYRINGE 273 MG/0.88 ML                                     | 5^                | QL (0.88 ML per 90 days)    |
| INVEGA TRINZA INTRAMUSCULAR SYRINGE 410 MG/1.32 ML                                     | 5^                | QL (1.32 ML per 90 days)    |
| INVEGA TRINZA INTRAMUSCULAR SYRINGE 546 MG/1.75 ML                                     | 5^                | QL (1.75 ML per 90 days)    |
| INVEGA TRINZA INTRAMUSCULAR SYRINGE 819 MG/2.63 ML                                     | 5^                | QL (2.63 ML per 90 days)    |
| <i>lisdexamfetamine oral capsule 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg</i>   | 3                 | QL (30 EA per 30 days)      |
| <i>lisdexamfetamine oral tablet, chewable 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg</i> | 3                 | QL (30 EA per 30 days)      |
| <i>lithium carbonate oral capsule 150 mg, 300 mg, 600 mg</i>                           | 1                 |                             |
| <i>lithium carbonate oral tablet 300 mg</i>                                            | 1                 |                             |
| <i>lithium carbonate oral tablet extended release 300 mg, 450 mg</i>                   | 1                 |                             |
| <i>lithium citrate oral solution 8 meq/5 ml</i>                                        | 1                 |                             |
| <i>lorazepam intensol oral concentrate 2 mg/ml</i>                                     | 1                 | PA; QL (150 ML per 30 days) |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                                                           | Nivo Medikaman an | Egzijans/Limit yo           |
|------------------------------------------------------------------------------------------------------------|-------------------|-----------------------------|
| <i>lorazepam oral tablet 0.5 mg, 1 mg, 2 mg</i>                                                            | 1                 | PA; QL (150 EA per 30 days) |
| <i>loxapine succinate oral capsule 10 mg, 25 mg, 5 mg, 50 mg</i>                                           | 1                 |                             |
| <i>lurasidone oral tablet 120 mg, 20 mg, 40 mg, 60 mg</i>                                                  | 3                 | QL (30 EA per 30 days)      |
| <i>lurasidone oral tablet 80 mg</i>                                                                        | 3                 | QL (60 EA per 30 days)      |
| LYBALVI ORAL TABLET 10-10 MG, 15-10 MG, 20-10 MG, 5-10 MG                                                  | 5^                | QL (30 EA per 30 days)      |
| MARPLAN ORAL TABLET 10 MG                                                                                  | 3                 |                             |
| <i>methylphenidate hcl oral solution 10 mg/5 ml</i>                                                        | 1                 | QL (900 ML per 30 days)     |
| <i>methylphenidate hcl oral solution 5 mg/5 ml</i>                                                         | 1                 | QL (1800 ML per 30 days)    |
| <i>methylphenidate hcl oral tablet 10 mg, 20 mg, 5 mg</i>                                                  | 1                 | QL (90 EA per 30 days)      |
| <i>methylphenidate hcl oral tablet extended release 10 mg, 20 mg</i>                                       | 1                 | QL (90 EA per 30 days)      |
| <i>methylphenidate hcl oral tablet extended release 24hr 18 mg, 18 mg (bx rating), 27 mg, 36 mg, 54 mg</i> | 1                 | QL (30 EA per 30 days)      |
| <i>methylphenidate hcl oral tablet, chewable 10 mg, 2.5 mg, 5 mg</i>                                       | 1                 | QL (180 EA per 30 days)     |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                    | Nivo Medikaman an | Egzijans/Limit yo             |
|---------------------------------------------------------------------|-------------------|-------------------------------|
| <i>mirtazapine oral tablet 15 mg, 30 mg, 45 mg, 7.5 mg</i>          | 1                 |                               |
| <i>mirtazapine oral tablet, disintegrating 15 mg, 30 mg, 45 mg</i>  | 1                 |                               |
| <i>modafinil oral tablet 100 mg</i>                                 | 1                 | PA; QL (30 EA per 30 days)    |
| <i>modafinil oral tablet 200 mg</i>                                 | 1                 | PA; QL (60 EA per 30 days)    |
| <i>molindone oral tablet 10 mg, 25 mg, 5 mg</i>                     | 1                 |                               |
| <i>nefazodone oral tablet 100 mg, 150 mg, 200 mg, 250 mg, 50 mg</i> | 3                 |                               |
| <i>nortriptyline oral capsule 10 mg, 25 mg, 50 mg, 75 mg</i>        | 1                 |                               |
| <i>nortriptyline oral solution 10 mg/5 ml</i>                       | 3                 |                               |
| NUPLAZID ORAL CAPSULE 34 MG                                         | 5 <sup>^</sup>    | PA-NS; QL (30 EA per 30 days) |
| NUPLAZID ORAL TABLET 10 MG                                          | 5 <sup>^</sup>    | PA-NS; QL (30 EA per 30 days) |
| <i>olanzapine intramuscular recon soln 10 mg</i>                    | 1                 | QL (3 EA per 1 day)           |
| <i>olanzapine oral tablet 10 mg, 2.5 mg, 5 mg</i>                   | 1                 | QL (60 EA per 30 days)        |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                                 | Nivo Medikaman an | Egzijans/Limit yo       |
|----------------------------------------------------------------------------------|-------------------|-------------------------|
| <i>olanzapine oral tablet 15 mg, 20 mg, 7.5 mg</i>                               | 1                 | QL (30 EA per 30 days)  |
| <i>olanzapine oral tablet, disintegrating 10 mg</i>                              | 3                 | QL (60 EA per 30 days)  |
| <i>olanzapine oral tablet, disintegrating 15 mg, 20 mg, 5 mg</i>                 | 3                 | QL (30 EA per 30 days)  |
| OPIPZA ORAL FILM 10 MG                                                           | 3                 | QL (90 EA per 30 days)  |
| OPIPZA ORAL FILM 2 MG                                                            | 3                 | QL (30 EA per 30 days)  |
| OPIPZA ORAL FILM 5 MG                                                            | 3                 | QL (180 EA per 30 days) |
| <i>paliperidone oral tablet extended release 24hr 1.5 mg, 3 mg, 9 mg</i>         | 3                 | QL (30 EA per 30 days)  |
| <i>paliperidone oral tablet extended release 24hr 6 mg</i>                       | 3                 | QL (60 EA per 30 days)  |
| <i>paroxetine hcl oral suspension 10 mg/5 ml</i>                                 | 3                 | QL (900 ML per 30 days) |
| <i>paroxetine hcl oral tablet 10 mg, 20 mg, 40 mg</i>                            | 3                 | QL (30 EA per 30 days)  |
| <i>paroxetine hcl oral tablet 30 mg</i>                                          | 3                 | QL (60 EA per 30 days)  |
| <i>paroxetine hcl oral tablet extended release 24 hr 12.5 mg, 25 mg, 37.5 mg</i> | 3                 | QL (60 EA per 30 days)  |
| <i>perphenazine oral tablet 16 mg, 2 mg, 4 mg, 8 mg</i>                          | 1                 |                         |
| <i>phenelzine oral tablet 15 mg</i>                                              | 1                 |                         |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                                                      | Nivo Medikaman an | Egzijans/Limit yo      |
|-------------------------------------------------------------------------------------------------------|-------------------|------------------------|
| <i>pimozide oral tablet 1 mg, 2 mg</i>                                                                | 1                 |                        |
| <i>protriptyline oral tablet 10 mg, 5 mg</i>                                                          | 3                 |                        |
| <i>quetiapine oral tablet 100 mg, 200 mg, 25 mg, 300 mg, 400 mg, 50 mg</i>                            | 1                 |                        |
| QUETIAPINE ORAL TABLET 150 MG                                                                         | 1                 |                        |
| <i>quetiapine oral tablet extended release 24 hr 150 mg, 200 mg</i>                                   | 1                 | QL (30 EA per 30 days) |
| <i>quetiapine oral tablet extended release 24 hr 300 mg, 400 mg, 50 mg</i>                            | 1                 | QL (60 EA per 30 days) |
| RALDESY ORAL SOLUTION 10 MG/ML                                                                        | 3                 | ST                     |
| REXULTI ORAL TABLET 0.25 MG, 0.5 MG, 1 MG, 2 MG, 3 MG, 4 MG                                           | 5^                | QL (30 EA per 30 days) |
| <i>risperidone microspheres intramuscular suspension, extended rel recon 12.5 mg/2 ml, 25 mg/2 ml</i> | 3                 | QL (2 EA per 28 days)  |
| <i>risperidone microspheres intramuscular suspension, extended rel recon 37.5 mg/2 ml, 50 mg/2 ml</i> | 5^                | QL (2 EA per 28 days)  |
| <i>risperidone oral solution 1 mg/ml</i>                                                              | 1                 |                        |
| <i>risperidone oral tablet 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg</i>                                | 1                 |                        |
| <i>risperidone oral tablet, disintegrating 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg</i>                      | 1                 | QL (60 EA per 30 days) |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                                 | Nivo Medikaman an | Egzijans/Limit yo               |
|----------------------------------------------------------------------------------|-------------------|---------------------------------|
| <i>risperidone oral tablet, disintegrating 4 mg</i>                              | 1                 | QL (120 EA per 30 days)         |
| SECUADO TRANSDERMAL PATCH 24 HOUR 3.8 MG/24 HOUR, 5.7 MG/24 HOUR, 7.6 MG/24 HOUR | 5^                | QL (30 EA per 30 days)          |
| <i>sertraline oral concentrate 20 mg/ml</i>                                      | 1                 |                                 |
| <i>sertraline oral tablet 100 mg, 25 mg, 50 mg</i>                               | 1                 |                                 |
| <i>sodium oxybate oral solution 500 mg/ml</i>                                    | 5^                | PA; LA; QL (540 ML per 30 days) |
| <i>temazepam oral capsule 15 mg, 30 mg, 7.5 mg</i>                               | 3                 | PA; QL (30 EA per 30 days)      |
| <i>thioridazine oral tablet 10 mg, 100 mg, 25 mg, 50 mg</i>                      | 1                 |                                 |
| <i>thiothixene oral capsule 1 mg, 10 mg, 2 mg, 5 mg</i>                          | 1                 |                                 |
| <i>tranylcypromine oral tablet 10 mg</i>                                         | 1                 |                                 |
| <i>trazodone oral tablet 100 mg, 150 mg, 50 mg</i>                               | 1                 |                                 |
| <i>trifluoperazine oral tablet 1 mg, 10 mg, 2 mg, 5 mg</i>                       | 1                 |                                 |
| <i>trimipramine oral capsule 100 mg, 25 mg, 50 mg</i>                            | 3                 |                                 |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                              | Nivo Medikaman an | Egzijans/Limit yo              |
|-------------------------------------------------------------------------------|-------------------|--------------------------------|
| TRINTELLIX ORAL TABLET 10 MG, 20 MG, 5 MG                                     | 3                 | QL (30 EA per 30 days)         |
| <i>venlafaxine oral capsule, extended release 24hr 150 mg, 37.5 mg, 75 mg</i> | 1                 |                                |
| <i>venlafaxine oral tablet 100 mg, 25 mg, 37.5 mg, 50 mg, 75 mg</i>           | 1                 |                                |
| VERSACLOZ ORAL SUSPENSION 50 MG/ML                                            | 5^                | PA-NS; QL (600 ML per 30 days) |
| <i>vilazodone oral tablet 10 mg, 20 mg, 40 mg</i>                             | 1                 | QL (30 EA per 30 days)         |
| VRAYLAR ORAL CAPSULE 0.5 MG, 0.75 MG, 1.5 MG, 3 MG, 4.5 MG, 6 MG              | 2                 | QL (30 EA per 30 days)         |
| <i>ziprasidone hcl oral capsule 20 mg, 40 mg, 60 mg, 80 mg</i>                | 1                 | QL (60 EA per 30 days)         |
| <i>ziprasidone mesylate intramuscular recon soln 20 mg/ml (final conc.)</i>   | 1                 |                                |
| <i>zolpidem oral tablet 10 mg, 5 mg</i>                                       | 1                 | QL (30 EA per 30 days)         |
| ZURZUVAE ORAL CAPSULE 20 MG, 25 MG                                            | 5^                | PA-NS; QL (28 EA per 365 days) |
| ZURZUVAE ORAL CAPSULE 30 MG                                                   | 5^                | PA-NS; QL (14 EA per 365 days) |
| <b>RELAKSAN POU MISKL / TERAPI ANTI-SPASMODIK</b>                             |                   |                                |
| <i>baclofen oral tablet 10 mg, 20 mg, 5 mg</i>                                | 1                 |                                |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                                        | Nivo Medikaman an | Egzijans/Limit yo          |
|-----------------------------------------------------------------------------------------|-------------------|----------------------------|
| <i>cyclobenzaprine oral tablet 10 mg, 5 mg</i>                                          | 3                 | PA                         |
| <i>dantrolene oral capsule 100 mg, 25 mg, 50 mg</i>                                     | 1                 |                            |
| <i>pyridostigmine bromide oral tablet 60 mg</i>                                         | 1                 |                            |
| <i>tizanidine oral tablet 2 mg, 4 mg</i>                                                | 1                 |                            |
| <b>TERAPI POU MIGRÈN / MALTÈT KI RELE ALJI VASKILÈ NAN FIGI (CLUSTER HEADACHE, AVF)</b> |                   |                            |
| AIMOVIG AUTOINJECTOR<br>SUBCUTANEOUS AUTO-INJECTOR 140 MG/ML, 70 MG/ML                  | 2                 | PA; QL (1 ML per 30 days)  |
| <i>dihydroergotamine nasal spray, non-aerosol 0.5 mg/pump act. (4 mg/ml)</i>            | 3                 | QL (8 ML per 28 days)      |
| EMGALITY PEN SUBCUTANEOUS PEN INJECTOR 120 MG/ML                                        | 2                 | PA; QL (2 ML per 30 days)  |
| EMGALITY SYRINGE SUBCUTANEOUS SYRINGE 120 MG/ML                                         | 2                 | PA; QL (2 ML per 30 days)  |
| <i>ergotamine-caffeine oral tablet 1-100 mg</i>                                         | 1                 | QL (40 EA per 28 days)     |
| <i>naratriptan oral tablet 1 mg, 2.5 mg</i>                                             | 1                 | QL (18 EA per 28 days)     |
| NURTEC ODT ORAL<br>TABLET, DISINTEGRATING 75 MG                                         | 2                 | PA; QL (16 EA per 30 days) |
| <i>rizatriptan oral tablet 10 mg, 5 mg</i>                                              | 1                 | QL (12 EA per 28 days)     |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                            | Nivo Medikaman an | Egzijans/Limit yo      |
|-----------------------------------------------------------------------------|-------------------|------------------------|
| <i>rizatriptan oral tablet, disintegrating 10 mg, 5 mg</i>                  | 1                 | QL (12 EA per 28 days) |
| <i>sumatriptan nasal spray, non-aerosol 20 mg/actuation, 5 mg/actuation</i> | 1                 | QL (18 EA per 28 days) |
| <i>sumatriptan succinate oral tablet 100 mg, 25 mg, 50 mg</i>               | 1                 | QL (18 EA per 28 days) |
| <i>sumatriptan succinate subcutaneous pen injector 6 mg/0.5 ml</i>          | 1                 | QL (8 ML per 28 days)  |
| <i>sumatriptan succinate subcutaneous solution 6 mg/0.5 ml</i>              | 1                 | QL (8 ML per 28 days)  |
| <i>zolmitriptan oral tablet 2.5 mg, 5 mg</i>                                | 1                 | QL (18 EA per 28 days) |
| <i>zolmitriptan oral tablet, disintegrating 2.5 mg, 5 mg</i>                | 1                 | QL (18 EA per 28 days) |
| <b>MEDIKAMAN POU ZÒRÈY, NEN / GÒJ</b>                                       |                   |                        |
| <b>AJAN DIVÈS</b>                                                           |                   |                        |
| <i>azelastine nasal spray, non-aerosol 137 mcg (0.1 %)</i>                  | 1                 | QL (60 ML per 30 days) |
| <i>chlorhexidine gluconate mucous membrane mouthwash 0.12 %</i>             | 1                 |                        |
| <i>ipratropium bromide nasal spray, non-aerosol 21 mcg (0.03 %)</i>         | 1                 | QL (30 ML per 28 days) |
| <i>ipratropium bromide nasal spray, non-aerosol 42 mcg (0.06 %)</i>         | 1                 | QL (30 ML per 20 days) |
| <i>kourzeq dental paste 0.1 %</i>                                           | 2                 |                        |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                                       | Nivo Medikaman an | Egzijans/Limit yo         |
|----------------------------------------------------------------------------------------|-------------------|---------------------------|
| <i>olopatadine nasal spray, non-aerosol 0.6 %</i>                                      | 1                 |                           |
| <i>periogard mucous membrane mouthwash 0.12 %</i>                                      | 1                 |                           |
| <i>triamcinolone acetonide dental paste 0.1 %</i>                                      | 2                 |                           |
| <b>DIVÈS PREPARASYON OTIK</b>                                                          |                   |                           |
| <i>acetic acid otic (ear) solution 2 %</i>                                             | 1                 |                           |
| <i>fluocinolone acetonide oil otic (ear) drops 0.01 %</i>                              | 1                 |                           |
| <i>ofloxacin otic (ear) drops 0.3 %</i>                                                | 1                 |                           |
| <b>ESTEWOYIKD OTIK / ANTIBIOTIK</b>                                                    |                   |                           |
| <i>ciprofloxacin-dexamethasone otic (ear) drops, suspension 0.3-0.1 %</i>              | 3                 | QL (7.5 ML per 7 days)    |
| <i>neomycin-polymyxin-hc otic (ear) drops, suspension 3.5-10,000-1 mg/ml-unit/ml-%</i> | 1                 |                           |
| <i>neomycin-polymyxin-hc otic (ear) solution 3.5-10,000-1 mg/ml-unit/ml-%</i>          | 1                 |                           |
| <b>MISKILOSKELETAL / RIMATOLOJI</b>                                                    |                   |                           |
| <b>LÒT PWODUI RIMATOLOJIK</b>                                                          |                   |                           |
| ADALIMUMAB-AATY SUBCUTANEOUS AUTO-INJECTOR, KIT 40 MG/0.4 ML                           | 5^                | PA; QL (4 EA per 28 days) |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                           | Nivo Medikaman an | Egzijans/Limit yo           |
|----------------------------------------------------------------------------|-------------------|-----------------------------|
| ADALIMUMAB-AATY SUBCUTANEOUS AUTO-INJECTOR, KIT 80 MG/0.8 ML               | 5^                | PA; QL (2 EA per 28 days)   |
| ADALIMUMAB-AATY SUBCUTANEOUS SYRINGE KIT 20 MG/0.2 ML                      | 5^                | PA; QL (2 EA per 28 days)   |
| ADALIMUMAB-AATY SUBCUTANEOUS SYRINGE KIT 40 MG/0.4 ML                      | 5^                | PA; QL (4 EA per 28 days)   |
| ADALIMUMAB-AATY(CF) AI CROHNS SUBCUTANEOUS AUTO-INJECTOR, KIT 80 MG/0.8 ML | 5^                | PA; QL (3 EA per 180 days)  |
| ADALIMUMAB-ADBM SUBCUTANEOUS PEN INJECTOR KIT 40 MG/0.4 ML, 40 MG/0.8 ML   | 5^                | PA; QL (4 EA per 28 days)   |
| ADALIMUMAB-ADBM SUBCUTANEOUS SYRINGE KIT 40 MG/0.4 ML, 40 MG/0.8 ML        | 5^                | PA; QL (4 EA per 28 days)   |
| AVTOZMA AUTOINJECTOR SUBCUTANEOUS PEN INJECTOR 162 MG/0.9 ML               | 5^                | PA; QL (3.6 ML per 28 days) |
| AVTOZMA SUBCUTANEOUS SYRINGE 162 MG/0.9 ML                                 | 5^                | PA; QL (3.6 ML per 28 days) |
| BENLYSTA SUBCUTANEOUS AUTO-INJECTOR 200 MG/ML                              | 5^                | PA; QL (8 ML per 28 days)   |
| BENLYSTA SUBCUTANEOUS SYRINGE 200 MG/ML                                    | 5^                | PA; QL (8 ML per 28 days)   |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                                             | Nivo Medikaman an | Egzijans/Limit yo           |
|----------------------------------------------------------------------------------------------|-------------------|-----------------------------|
| ENBREL MINI SUBCUTANEOUS CARTRIDGE 50 MG/ML (1 ML)                                           | 5^                | PA; QL (8 ML per 28 days)   |
| ENBREL SUBCUTANEOUS SOLUTION 25 MG/0.5 ML                                                    | 5^                | PA; QL (8 ML per 28 days)   |
| ENBREL SUBCUTANEOUS SYRINGE 25 MG/0.5 ML (0.5), 50 MG/ML (1 ML)                              | 5^                | PA; QL (8 ML per 28 days)   |
| ENBREL SURECLICK SUBCUTANEOUS PEN INJECTOR 50 MG/ML (1 ML)                                   | 5^                | PA; QL (8 ML per 28 days)   |
| <i>leflunomide oral tablet 10 mg, 20 mg</i>                                                  | 1                 | QL (30 EA per 30 days)      |
| <i>milnacipran oral tablet 100 mg, 12.5 mg, 25 mg, 50 mg</i>                                 | 2                 | QL (60 EA per 30 days)      |
| OTEZLA ORAL TABLET 20 MG, 30 MG                                                              | 5^                | PA; QL (60 EA per 30 days)  |
| OTEZLA STARTER ORAL TABLETS, DOSE PACK 10 MG (4)- 20 MG (51), 10 MG (4)-20 MG (4)-30 MG (47) | 5^                | PA; QL (55 EA per 180 days) |
| OTEZLA XR INITIATION ORAL TABLET AND TABLET ER DOSE PACK 10-20-30-75 MG                      | 5^                | PA; QL (41 EA per 180 days) |
| OTEZLA XR ORAL TABLET EXTENDED RELEASE 24 HR 75 MG                                           | 5^                | PA; QL (30 EA per 30 days)  |
| <i>penicillamine oral tablet 250 mg</i>                                                      | 5^                | PA                          |
| RINVOQ LQ ORAL SOLUTION 1 MG/ML                                                              | 5^                | PA; QL (360 ML per 30 days) |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                   | Nivo Medikaman an | Egzijans/Limit yo            |
|--------------------------------------------------------------------|-------------------|------------------------------|
| RINVOQ ORAL TABLET EXTENDED RELEASE 24 HR 15 MG, 30 MG             | 5^                | PA; QL (30 EA per 30 days)   |
| RINVOQ ORAL TABLET EXTENDED RELEASE 24 HR 45 MG                    | 5^                | PA; QL (84 EA per 180 days)  |
| <i>tofacitinib oral solution 1 mg/ml</i>                           | 5^                | PA; QL (480 ML per 30 days)  |
| <i>tofacitinib oral tablet 10 mg, 5 mg</i>                         | 5^                | PA; QL (60 EA per 30 days)   |
| <i>tofacitinib oral tablet extended release 24 hr 11 mg, 22 mg</i> | 5^                | PA; QL (30 EA per 30 days)   |
| TYENNE AUTOINJECTOR SUBCUTANEOUS PEN INJECTOR 162 MG/0.9 ML        | 5^                | PA; QL (3.6 ML per 28 days)  |
| TYENNE SUBCUTANEOUS SYRINGE 162 MG/0.9 ML                          | 5^                | PA; QL (3.6 ML per 28 days)  |
| <b>TERAPI OSTEYOPOWOZ</b>                                          |                   |                              |
| <i>alendronate oral solution 70 mg/75 ml</i>                       | 1                 | QL (300 ML per 28 days)      |
| <i>alendronate oral tablet 10 mg</i>                               | 1                 | QL (30 EA per 30 days)       |
| <i>alendronate oral tablet 35 mg, 70 mg</i>                        | 1                 | QL (4 EA per 28 days)        |
| BONSITY SUBCUTANEOUS PEN INJECTOR 20 MCG/DOSE (560MCG/2.24ML)      | 5^                | PA; QL (2.24 ML per 28 days) |
| CONEXXENCE SUBCUTANEOUS SYRINGE 60 MG/ML                           | 3                 | QL (1 ML per 180 days)       |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                          | Nivo Medikaman an | Egzijans/Limit yo                                                          |
|---------------------------------------------------------------------------|-------------------|----------------------------------------------------------------------------|
| <i>ibandronate oral tablet 150 mg</i>                                     | 1                 | QL (1 EA per 30 days)                                                      |
| <i>raloxifene oral tablet 60 mg</i>                                       | 1                 |                                                                            |
| <i>risedronate oral tablet 150 mg</i>                                     | 1                 | QL (1 EA per 30 days)                                                      |
| <i>risedronate oral tablet 35 mg, 35 mg (12 pack), 35 mg (4 pack)</i>     | 1                 | QL (4 EA per 28 days)                                                      |
| <i>risedronate oral tablet 5 mg</i>                                       | 1                 | QL (30 EA per 30 days)                                                     |
| <i>risedronate oral tablet, delayed release (dr/ec) 35 mg</i>             | 1                 | QL (4 EA per 28 days)                                                      |
| STOBOCLO SUBCUTANEOUS SYRINGE 60 MG/ML                                    | 3                 | QL (1 ML per 180 days)                                                     |
| <i>teriparatide subcutaneous pen injector 20 mcg/dose (560mcg/2.24ml)</i> | 5^                | PA; Only Teriparatide NDC 47781065289 is covered; QL (2.24 ML per 28 days) |
| <b>TERAPI POU GOUT</b>                                                    |                   |                                                                            |
| <i>allopurinol oral tablet 100 mg, 300 mg</i>                             | 1                 |                                                                            |
| <i>colchicine oral capsule 0.6 mg</i>                                     | 3                 | QL (120 EA per 30 days)                                                    |
| <i>colchicine oral tablet 0.6 mg</i>                                      | 3                 | QL (120 EA per 30 days)                                                    |
| <i>febuxostat oral tablet 40 mg, 80 mg</i>                                | 1                 |                                                                            |
| <i>probenecid oral tablet 500 mg</i>                                      | 1                 |                                                                            |
| <i>probenecid-colchicine oral tablet 500-0.5 mg</i>                       | 1                 |                                                                            |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

## Non Medikaman an

## Nivo Egzijans/Limit yo Medikaman an

### OBSTETRIK / JINEKOLOJI

#### ***DIVÈS OB/GYN***

*clindamycin phosphate vaginal cream 2 %*

3

*eluryng vaginal ring 0.12-0.015 mg/24 hr*

1

*enilloring vaginal ring 0.12-0.015 mg/24 hr*

1

*etonogestrel-ethinyl estradiol vaginal ring 0.12-0.015 mg/24 hr*

1

LILETTA INTRAUTERINE INTRAUTERINE DEVICE 20.4 MCG/24 HR (8 YRS) 52 MG

2

*metronidazole vaginal gel 0.75 % (37.5mg/5 gram)*

1

NEXPLANON SUBDERMAL IMPLANT 68 MG

2

*norelgestromin-ethin.estradiol transdermal patch weekly 150-35 mcg/24 hr*

1

*terconazole vaginal cream 0.4 %, 0.8 %*

1

*terconazole vaginal suppository 80 mg*

3

*tranexamic acid oral tablet 650 mg*

1

*xulane transdermal patch weekly 150-35 mcg/24 hr*

1

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                                                                                      | Nivo Medikaman an | Egzijans/Limit yo     |
|---------------------------------------------------------------------------------------------------------------------------------------|-------------------|-----------------------|
| <i>zafemy transdermal patch weekly 150-35 mcg/24 hr</i>                                                                               | 1                 |                       |
| <b>ESTWOJÈN / PROJESTE WÒN</b>                                                                                                        |                   |                       |
| <i>abigale lo oral tablet 0.5-0.1 mg</i>                                                                                              | 3                 |                       |
| <i>abigale oral tablet 1-0.5 mg</i>                                                                                                   | 3                 |                       |
| <i>camila oral tablet 0.35 mg</i>                                                                                                     | 1                 |                       |
| <i>deblitane oral tablet 0.35 mg</i>                                                                                                  | 1                 |                       |
| DEPO-SUBQ PROVERA 104<br>SUBCUTANEOUS SYRINGE 104 MG/0.65 ML                                                                          | 2                 |                       |
| <i>dotti transdermal patch semiweekly 0.025 mg/24 hr, 0.0375 mg/24 hr, 0.05 mg/24 hr, 0.075 mg/24 hr, 0.1 mg/24 hr</i>                | 3                 | QL (8 EA per 28 days) |
| <i>errin oral tablet 0.35 mg</i>                                                                                                      | 1                 |                       |
| <i>estradiol oral tablet 0.5 mg, 1 mg, 2 mg</i>                                                                                       | 1                 |                       |
| <i>estradiol transdermal patch semiweekly 0.025 mg/24 hr, 0.0375 mg/24 hr, 0.05 mg/24 hr, 0.075 mg/24 hr, 0.1 mg/24 hr</i>            | 3                 | QL (8 EA per 28 days) |
| <i>estradiol transdermal patch weekly 0.025 mg/24 hr, 0.0375 mg/24 hr, 0.05 mg/24 hr, 0.06 mg/24 hr, 0.075 mg/24 hr, 0.1 mg/24 hr</i> | 3                 | QL (4 EA per 28 days) |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                                                                         | Nivo Medikaman an | Egzijans/Limit yo     |
|--------------------------------------------------------------------------------------------------------------------------|-------------------|-----------------------|
| <i>estradiol vaginal cream 0.01 % (0.1 mg/gram)</i>                                                                      | 3                 |                       |
| <i>estradiol vaginal tablet 10 mcg</i>                                                                                   | 1                 |                       |
| <i>estradiol valerate intramuscular oil 10 mg/ml, 20 mg/ml, 40 mg/ml</i>                                                 | 1                 |                       |
| <i>estradiol-norethindrone acet oral tablet 0.5-0.1 mg, 1-0.5 mg</i>                                                     | 3                 |                       |
| <i>fyavolv oral tablet 0.5-2.5 mg-mcg, 1-5 mg-mcg</i>                                                                    | 3                 |                       |
| <i>gallifrey oral tablet 5 mg</i>                                                                                        | 1                 |                       |
| <i>heather oral tablet 0.35 mg</i>                                                                                       | 1                 |                       |
| <i>incassia oral tablet 0.35 mg</i>                                                                                      | 1                 |                       |
| <i>jinteli oral tablet 1-5 mg-mcg</i>                                                                                    | 3                 |                       |
| <i>lyleq oral tablet 0.35 mg</i>                                                                                         | 1                 |                       |
| <i>lyllana transdermal patch semiweekly 0.025 mg/24 hr, 0.0375 mg/24 hr, 0.05 mg/24 hr, 0.075 mg/24 hr, 0.1 mg/24 hr</i> | 3                 | QL (8 EA per 28 days) |
| <i>lyza oral tablet 0.35 mg</i>                                                                                          | 1                 |                       |
| <i>medroxyprogesterone intramuscular suspension 150 mg/ml</i>                                                            | 1                 |                       |
| <i>medroxyprogesterone intramuscular syringe 150 mg/ml</i>                                                               | 1                 |                       |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                             | Nivo Medikaman an | Egzijans/Limit yo |
|------------------------------------------------------------------------------|-------------------|-------------------|
| <i>medroxyprogesterone oral tablet 10 mg, 2.5 mg, 5 mg</i>                   | 1                 |                   |
| <i>meleya oral tablet 0.35 mg</i>                                            | 1                 |                   |
| <i>mimvey oral tablet 1-0.5 mg</i>                                           | 3                 |                   |
| <i>nora-be oral tablet 0.35 mg</i>                                           | 1                 |                   |
| <i>norethindrone (contraceptive) oral tablet 0.35 mg</i>                     | 1                 |                   |
| <i>norethindrone acetate oral tablet 5 mg</i>                                | 1                 |                   |
| <i>norethindrone ac-eth estradiol oral tablet 0.5-2.5 mg-mcg, 1-5 mg-mcg</i> | 3                 |                   |
| <i>orquidea oral tablet 0.35 mg</i>                                          | 1                 |                   |
| PREMARIN VAGINAL CREAM 0.625 MG/GRAM                                         | 2                 |                   |
| <i>progesterone micronized oral capsule 100 mg, 200 mg</i>                   | 1                 |                   |
| <i>sharobel oral tablet 0.35 mg</i>                                          | 1                 |                   |
| <i>yuvafem vaginal tablet 10 mcg</i>                                         | 1                 |                   |
| <b>KONTRASEPTIF ORAL / AJAN KI AN RAPÒ AK GRENN PLANING SA YO</b>            |                   |                   |
| <i>altavera (28) oral tablet 0.15-0.03 mg</i>                                | 1                 |                   |
| <i>alyacen 1/35 (28) oral tablet 1-35 mg-mcg</i>                             | 1                 |                   |
| <i>apri oral tablet 0.15-0.03 mg</i>                                         | 1                 |                   |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                               | Nivo Medikaman an | Egzijans/Limit yo |
|--------------------------------------------------------------------------------|-------------------|-------------------|
| <i>aranelle (28) oral tablet 0.5/1/0.5-35 mg-mcg</i>                           | 1                 |                   |
| <i>ashlyna oral tablets,dose pack,3 month 0.15 mg-30 mcg (84)/10 mcg (7)</i>   | 1                 |                   |
| <i>aubra eq oral tablet 0.1-20 mg-mcg</i>                                      | 1                 |                   |
| <i>aviane oral tablet 0.1-20 mg-mcg</i>                                        | 1                 |                   |
| <i>azurette (28) oral tablet 0.15-0.02 mgx21 /0.01 mg x 5</i>                  | 1                 |                   |
| <i>balziva (28) oral tablet 0.4-35 mg-mcg</i>                                  | 1                 |                   |
| <i>blisovi 24 fe oral tablet 1 mg-20 mcg (24)/75 mg (4)</i>                    | 1                 |                   |
| <i>blisovi fe 1.5/30 (28) oral tablet 1.5 mg-30 mcg (21)/75 mg (7)</i>         | 1                 |                   |
| <i>briellyn oral tablet 0.4-35 mg-mcg</i>                                      | 1                 |                   |
| <i>camrese lo oral tablets,dose pack,3 month 0.1 mg-20 mcg (84)/10 mcg (7)</i> | 1                 |                   |
| <i>cryselle (28) oral tablet 0.3-30 mg-mcg</i>                                 | 1                 |                   |
| <i>cyred eq oral tablet 0.15-0.03 mg</i>                                       | 1                 |                   |
| <i>dolishale oral tablet 90-20 mcg (28)</i>                                    | 1                 |                   |
| <i>drospirenone-e.estradiol-lm.fa oral tablet 3-0.02-0.451 mg (24) (4)</i>     | 1                 |                   |
| <i>drospirenone-ethinyl estradiol oral tablet 3-0.02 mg, 3-0.03 mg</i>         | 1                 |                   |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                                   | Nivo Egzijans/Limit yo Medikaman an |
|------------------------------------------------------------------------------------|-------------------------------------|
| <i>enskyce oral tablet 0.15-0.03 mg</i>                                            | 1                                   |
| <i>estarylla oral tablet 0.25-0.035 mg</i>                                         | 1                                   |
| <i>falmina (28) oral tablet 0.1-20 mg-mcg</i>                                      | 1                                   |
| <i>feirza oral tablet 1 mg-20 mcg (21)/75 mg (7), 1.5 mg-30 mcg (21)/75 mg (7)</i> | 1                                   |
| <i>finzala oral tablet, chewable 1 mg-20 mcg(24) /75 mg (4)</i>                    | 1                                   |
| <i>galbriela oral tablet, chewable 0.8mg-25mcg(24) and 75 mg (4)</i>               | 1                                   |
| <i>hailey 24 fe oral tablet 1 mg-20 mcg (24)/75 mg (4)</i>                         | 1                                   |
| <i>hailey fe 1/20 (28) oral tablet 1 mg-20 mcg (21)/75 mg (7)</i>                  | 1                                   |
| <i>iclevia oral tablets, dose pack, 3 month 0.15 mg-30 mcg (91)</i>                | 1                                   |
| <i>introvale oral tablets, dose pack, 3 month 0.15 mg-30 mcg (91)</i>              | 1                                   |
| <i>isibloom oral tablet 0.15-0.03 mg</i>                                           | 1                                   |
| <i>jaimiess oral tablets, dose pack, 3 month 0.15 mg-30 mcg (84)/10 mcg (7)</i>    | 1                                   |
| <i>jasmiel (28) oral tablet 3-0.02 mg</i>                                          | 1                                   |
| <i>juleber oral tablet 0.15-0.03 mg</i>                                            | 1                                   |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                                                      | Nivo Medikaman an | Egzijans/Limit yo |
|-------------------------------------------------------------------------------------------------------|-------------------|-------------------|
| <i>junel 1.5/30 (21) oral tablet 1.5-30 mg-mcg</i>                                                    | 1                 |                   |
| <i>junel 1/20 (21) oral tablet 1-20 mg-mcg</i>                                                        | 1                 |                   |
| <i>junel fe 1.5/30 (28) oral tablet 1.5 mg-30 mcg (21)/75 mg (7)</i>                                  | 1                 |                   |
| <i>junel fe 1/20 (28) oral tablet 1 mg-20 mcg (21)/75 mg (7)</i>                                      | 1                 |                   |
| <i>junel fe 24 oral tablet 1 mg-20 mcg (24)/75 mg (4)</i>                                             | 1                 |                   |
| <i>kaitlib fe oral tablet,chewable 0.8mg-25mcg(24) and 75 mg (4)</i>                                  | 1                 |                   |
| <i>kariva (28) oral tablet 0.15-0.02 mgx21 /0.01 mg x 5</i>                                           | 1                 |                   |
| <i>kelnor 1/35 (28) oral tablet 1-35 mg-mcg</i>                                                       | 1                 |                   |
| <i>kurvelo (28) oral tablet 0.15-0.03 mg</i>                                                          | 1                 |                   |
| <i>l norgest/e.estradiol-e.estradiol oral tablets,dose pack,3 month 0.1 mg-20 mcg (84)/10 mcg (7)</i> | 1                 |                   |
| <i>larin 1.5/30 (21) oral tablet 1.5-30 mg-mcg</i>                                                    | 1                 |                   |
| <i>larin 1/20 (21) oral tablet 1-20 mg-mcg</i>                                                        | 1                 |                   |
| <i>larin fe 1.5/30 (28) oral tablet 1.5 mg-30 mcg (21)/75 mg (7)</i>                                  | 1                 |                   |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                                        | Nivo Medikaman an | Egzijans/Limit yo |
|-----------------------------------------------------------------------------------------|-------------------|-------------------|
| <i>larin fe 1/20 (28) oral tablet 1 mg-20 mcg (21)/75 mg (7)</i>                        | 1                 |                   |
| <i>lessina oral tablet 0.1-20 mg-mcg</i>                                                | 1                 |                   |
| <i>levonest (28) oral tablet 50-30 (6)/75-40 (5)/125-30(10)</i>                         | 1                 |                   |
| <i>levonorgestrel-ethinyl estrad oral tablet 0.1-20 mg-mcg, 90-20 mcg (28)</i>          | 1                 |                   |
| <i>levonorgestrel-ethinyl estrad oral tablets,dose pack,3 month 0.15 mg-30 mcg (91)</i> | 1                 |                   |
| <i>levonorg-eth estrad triphasic oral tablet 50-30 (6)/75-40 (5)/125-30(10)</i>         | 1                 |                   |
| <i>lojaimiess oral tablets,dose pack,3 month 0.1 mg-20 mcg (84)/10 mcg (7)</i>          | 1                 |                   |
| <i>loryna (28) oral tablet 3-0.02 mg</i>                                                | 1                 |                   |
| <i>luizza oral tablet 1-20 mg-mcg, 1.5-30 mg-mcg</i>                                    | 1                 |                   |
| <i>marlissa (28) oral tablet 0.15-0.03 mg</i>                                           | 1                 |                   |
| <i>mibelas 24 fe oral tablet,chewable 1 mg-20 mcg(24) /75 mg (4)</i>                    | 1                 |                   |
| <i>microgestin 1.5/30 (21) oral tablet 1.5-30 mg-mcg</i>                                | 1                 |                   |
| <i>microgestin 1/20 (21) oral tablet 1-20 mg-mcg</i>                                    | 1                 |                   |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                                                                              | Nivo Medikaman an | Egzijans/Limit yo |
|-------------------------------------------------------------------------------------------------------------------------------|-------------------|-------------------|
| <i>microgestin fe 1.5/30 (28) oral tablet 1.5 mg-30 mcg (21)/75 mg (7)</i>                                                    | 1                 |                   |
| <i>microgestin fe 1/20 (28) oral tablet 1 mg-20 mcg (21)/75 mg (7)</i>                                                        | 1                 |                   |
| <i>mili oral tablet 0.25-0.035 mg</i>                                                                                         | 1                 |                   |
| <i>necon 0.5/35 (28) oral tablet 0.5-35 mg-mcg</i>                                                                            | 1                 |                   |
| <i>nikki (28) oral tablet 3-0.02 mg</i>                                                                                       | 1                 |                   |
| <i>norethindrone ac-eth estradiol oral tablet 1-20 mg-mcg</i>                                                                 | 1                 |                   |
| <i>norethindrone-e.estradiol-iron oral tablet,chewable 1 mg-20 mcg(24) /75 mg (4)</i>                                         | 1                 |                   |
| <i>norgestimate-ethinyl estradiol oral tablet 0.18/0.215/0.25 mg-0.025 mg, 0.18/0.215/0.25 mg-0.035mg (28), 0.25-0.035 mg</i> | 1                 |                   |
| <i>nortrel 0.5/35 (28) oral tablet 0.5-35 mg-mcg</i>                                                                          | 1                 |                   |
| <i>nortrel 1/35 (21) oral tablet 1-35 mg-mcg (21)</i>                                                                         | 1                 |                   |
| <i>nortrel 1/35 (28) oral tablet 1-35 mg-mcg</i>                                                                              | 1                 |                   |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                             | Nivo Medikaman an | Egzijans/Limit yo |
|------------------------------------------------------------------------------|-------------------|-------------------|
| <i>nortrel 7/7/7 (28) oral tablet 0.5/0.75/1 mg- 35 mcg</i>                  | 1                 |                   |
| <i>nylia 1/35 (28) oral tablet 1-35 mg-mcg</i>                               | 1                 |                   |
| <i>nylia 7/7/7 (28) oral tablet 0.5/0.75/1 mg- 35 mcg</i>                    | 1                 |                   |
| <i>pimtrea (28) oral tablet 0.15-0.02 mgx21 /0.01 mg x 5</i>                 | 1                 |                   |
| <i>portia 28 oral tablet 0.15-0.03 mg</i>                                    | 1                 |                   |
| <i>reclipsen (28) oral tablet 0.15-0.03 mg</i>                               | 1                 |                   |
| <i>rivelsa oral tablets,dose pack,3 month 0.15 mg-20 mcg/ 0.15 mg-25 mcg</i> | 1                 |                   |
| <i>rosyrah oral tablets,dose pack,3 month 0.15 mg-20 mcg/ 0.15 mg-25 mcg</i> | 1                 |                   |
| <i>setlakin oral tablets,dose pack,3 month 0.15 mg-30 mcg (91)</i>           | 1                 |                   |
| <i>sprintec (28) oral tablet 0.25-0.035 mg</i>                               | 1                 |                   |
| <i>syeda oral tablet 3-0.03 mg</i>                                           | 1                 |                   |
| <i>tarina 24 fe oral tablet 1 mg-20 mcg (24)/75 mg (4)</i>                   | 1                 |                   |
| <i>tarina fe 1-20 eq (28) oral tablet 1 mg-20 mcg (21)/75 mg (7)</i>         | 1                 |                   |
| <i>tilia fe oral tablet 1-20(5)/1-30(7) /1mg-35mcg (9)</i>                   | 1                 |                   |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                         | Nivo Medikaman an | Egzijans/Limit yo |
|--------------------------------------------------------------------------|-------------------|-------------------|
| <i>tri-estarylla oral tablet 0.18/0.215/0.25 mg-0.035mg (28)</i>         | 1                 |                   |
| <i>tri-legest fe oral tablet 1-20(5)/1-30(7) /1mg-35mcg (9)</i>          | 1                 |                   |
| <i>tri-lo-estarylla oral tablet 0.18/0.215/0.25 mg-0.025 mg</i>          | 1                 |                   |
| <i>tri-lo-sprintec oral tablet 0.18/0.215/0.25 mg-0.025 mg</i>           | 1                 |                   |
| <i>tri-mili oral tablet 0.18/0.215/0.25 mg-0.035mg (28)</i>              | 1                 |                   |
| <i>tri-sprintec (28) oral tablet 0.18/0.215/0.25 mg-0.035mg (28)</i>     | 1                 |                   |
| <i>tri-vylibra lo oral tablet 0.18/0.215/0.25 mg-0.025 mg</i>            | 1                 |                   |
| <i>tri-vylibra oral tablet 0.18/0.215/0.25 mg-0.035mg (28)</i>           | 1                 |                   |
| <i>turqoz (28) oral tablet 0.3-30 mg-mcg</i>                             | 1                 |                   |
| <i>valtya oral tablet 1-35 mg-mcg, 1-50 mg-mcg</i>                       | 1                 |                   |
| <i>velivet triphasic regimen (28) oral tablet 0.1/.125/.15-25 mg-mcg</i> | 1                 |                   |
| <i>vestura (28) oral tablet 3-0.02 mg</i>                                | 1                 |                   |
| <i>vienva oral tablet 0.1-20 mg-mcg</i>                                  | 1                 |                   |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                     | Nivo Medikaman an | Egzijans/Limit yo |
|----------------------------------------------------------------------|-------------------|-------------------|
| <i>viorele (28) oral tablet 0.15-0.02 mgx21 /0.01 mg x 5</i>         | 1                 |                   |
| <i>vyfemla (28) oral tablet 0.4-35 mg-mcg</i>                        | 1                 |                   |
| <i>vylibra oral tablet 0.25-0.035 mg</i>                             | 1                 |                   |
| <i>wymzya fe oral tablet, chewable 0.4mg-35mcg(21) and 75 mg (7)</i> | 1                 |                   |
| <i>xarah fe oral tablet 1-20(5)/1-30(7) /1mg-35mcg (9)</i>           | 1                 |                   |
| <i>xelria fe oral tablet, chewable 0.4mg-35mcg(21) and 75 mg (7)</i> | 1                 |                   |
| <i>zovia 1-35 (28) oral tablet 1-35 mg-mcg</i>                       | 1                 |                   |

## OFTALMOLOJI

### AJAN ANTI-ENFLAMATWA NON-STEROYIDAL

|                                                          |   |  |
|----------------------------------------------------------|---|--|
| <i>bromfenac ophthalmic (eye) drops 0.075 %, 0.09 %</i>  | 3 |  |
| <i>diclofenac sodium ophthalmic (eye) drops 0.1 %</i>    | 1 |  |
| <i>flurbiprofen sodium ophthalmic (eye) drops 0.03 %</i> | 1 |  |
| <i>ketorolac ophthalmic (eye) drops 0.4 %, 0.5 %</i>     | 1 |  |
| PROLENSA OPHTHALMIC (EYE) DROPS 0.07 %                   | 2 |  |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an | Nivo Medikaman an | Egzijans/Limit yo |
|------------------|-------------------|-------------------|
|------------------|-------------------|-------------------|

### **ANTIBIOTIK**

|                                                                                              |   |  |
|----------------------------------------------------------------------------------------------|---|--|
| <i>bacitracin-polymyxin b ophthalmic (eye) ointment 500-10,000 unit/gram</i>                 | 1 |  |
| <i>ciprofloxacin hcl ophthalmic (eye) drops 0.3 %</i>                                        | 1 |  |
| <i>erythromycin ophthalmic (eye) ointment 5 mg/gram (0.5 %)</i>                              | 1 |  |
| <i>gatifloxacin ophthalmic (eye) drops 0.5 %</i>                                             | 1 |  |
| <i>gentamicin ophthalmic (eye) drops 0.3 %</i>                                               | 1 |  |
| <i>moxifloxacin ophthalmic (eye) drops 0.5 %</i>                                             | 1 |  |
| NATACYN OPHTHALMIC (EYE)<br>DROPS,SUSPENSION 5 %                                             | 3 |  |
| <i>neomycin-bacitracin-polymyxin ophthalmic (eye) ointment 3.5-400-10,000 mg-unit-unit/g</i> | 1 |  |
| <i>neomycin-polymyxin-gramicidin ophthalmic (eye) drops 1.75 mg-10,000 unit-0.025mg/ml</i>   | 1 |  |
| <i>ofloxacin ophthalmic (eye) drops 0.3 %</i>                                                | 1 |  |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                                 | Nivo Medikaman an | Egzijans/Limit yo      |
|----------------------------------------------------------------------------------|-------------------|------------------------|
| <i>polymyxin b sulf-trimethoprim ophthalmic (eye) drops 10,000 unit- 1 mg/ml</i> | 1                 |                        |
| <i>tobramycin ophthalmic (eye) drops 0.3 %</i>                                   | 1                 |                        |
| <b>BETA-BLOKÈ</b>                                                                |                   |                        |
| <i>betaxolol ophthalmic (eye) drops 0.5 %</i>                                    | 1                 |                        |
| <i>carteolol ophthalmic (eye) drops 1 %</i>                                      | 1                 |                        |
| <i>levobunolol ophthalmic (eye) drops 0.5 %</i>                                  | 1                 |                        |
| <i>timolol maleate ophthalmic (eye) drops 0.25 %, 0.5 %</i>                      | 1                 |                        |
| <i>timolol maleate ophthalmic (eye) gel forming solution 0.25 %, 0.5 %</i>       | 1                 |                        |
| <b>DIVÈS PWODUI OFTAMOLOJIK</b>                                                  |                   |                        |
| <i>atropine ophthalmic (eye) drops 1 %</i>                                       | 1                 |                        |
| <i>azelastine ophthalmic (eye) drops 0.05 %</i>                                  | 1                 |                        |
| <i>cromolyn ophthalmic (eye) drops 4 %</i>                                       | 1                 |                        |
| <i>cyclosporine ophthalmic (eye) dropperette 0.05 %</i>                          | 2                 | QL (60 EA per 30 days) |
| CYSTARAN OPHTHALMIC (EYE) DROPS 0.44 %                                           | 5^                | PA                     |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                              | Nivo Medikaman an | Egzijans/Limit yo          |
|-------------------------------------------------------------------------------|-------------------|----------------------------|
| <i>pilocarpine hcl ophthalmic (eye) drops 1 %, 2 %, 4 %</i>                   | 1                 |                            |
| <i>sulfacetamide sodium ophthalmic (eye) drops 10 %</i>                       | 1                 |                            |
| <i>sulfacetamide-prednisolone ophthalmic (eye) drops 10 %-0.23 % (0.25 %)</i> | 1                 |                            |
| XDEMVIY OPTHALMIC (EYE) DROPS 0.25 %                                          | 5^                | PA; QL (10 ML per 42 days) |
| <b>ESTEWOYID</b>                                                              |                   |                            |
| <i>dexamethasone sodium phosphate ophthalmic (eye) drops 0.1 %</i>            | 3                 |                            |
| <i>difluprednate ophthalmic (eye) drops 0.05 %</i>                            | 3                 |                            |
| <i>fluorometholone ophthalmic (eye) drops,suspension 0.1 %</i>                | 1                 |                            |
| <i>loteprednol etabonate ophthalmic (eye) drops,suspension 0.2 %</i>          | 3                 |                            |
| <i>prednisolone acetate ophthalmic (eye) drops,suspension 1 %</i>             | 1                 |                            |
| <i>prednisolone sodium phosphate ophthalmic (eye) drops 1 %</i>               | 3                 |                            |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an | Nivo Medikaman an | Egzijans/Limit yo |
|------------------|-------------------|-------------------|
|------------------|-------------------|-------------------|

### **KONBINEZON ESTEWOYID-ANTIBIOTIK**

*neomycin-bacitracin-poly-hc ophthalmic (eye) ointment 3.5-400-10,000 mg-unit/g-1%*

1

*neomycin-polymyxin b-dexameth ophthalmic (eye) drops,suspension 3.5mg/ml-10,000 unit/ml-0.1 %*

1

*neomycin-polymyxin b-dexameth ophthalmic (eye) ointment 3.5 mg/g-10,000 unit/g-0.1 %*

1

*neomycin-polymyxin-hc ophthalmic (eye) drops,suspension 3.5-10,000-10 mg-unit-mg/ml*

1

TOBRADEX OPHTHALMIC (EYE) OINTMENT 0.3-0.1 %

2

*tobramycin-dexamethasone ophthalmic (eye) drops,suspension 0.3-0.1 %*

3

### **LÒT MEDIKAMAN POU GLOKOM**

*bimatoprost ophthalmic (eye) drops 0.01 %*

2

*brinzolamide ophthalmic (eye) drops,suspension 1 %*

1

COMBIGAN OPHTHALMIC (EYE) DROPS 0.2-0.5 %

2

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                 | Nivo Medikaman an | Egzijans/Limit yo |
|------------------------------------------------------------------|-------------------|-------------------|
| <i>dorzolamide ophthalmic (eye) drops 2 %</i>                    | 1                 |                   |
| <i>dorzolamide-timolol ophthalmic (eye) drops 22.3-6.8 mg/ml</i> | 1                 |                   |
| <i>latanoprost ophthalmic (eye) drops 0.005 %</i>                | 1                 |                   |
| RHOPRESSA OPHTHALMIC (EYE) DROPS 0.02 %                          | 2                 |                   |
| ROCKLATAN OPHTHALMIC (EYE) DROPS 0.02-0.005 %                    | 2                 |                   |
| <i>travoprost ophthalmic (eye) drops 0.004 %</i>                 | 1                 |                   |
| VYZULTA OPHTHALMIC (EYE) DROPS 0.024 %                           | 3                 |                   |
| <b>MEDIKAMAN ORAL POU GLOKOM</b>                                 |                   |                   |
| <i>acetazolamide oral capsule, extended release 500 mg</i>       | 1                 |                   |
| <i>acetazolamide oral tablet 125 mg, 250 mg</i>                  | 1                 |                   |
| <i>methazolamide oral tablet 25 mg, 50 mg</i>                    | 1                 |                   |
| <b>PWODUI ANTIVIRAL YO</b>                                       |                   |                   |
| <i>trifluridine ophthalmic (eye) drops 1 %</i>                   | 1                 |                   |
| ZIRGAN OPHTHALMIC (EYE) GEL 0.15 %                               | 3                 |                   |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

## Non Medikaman an

## Nivo Egzijans/Limit yo Medikaman an

### SENPATOMIMETIK

ALPHAGAN P OPHTHALMIC (EYE)  
DROPS 0.1 %

2

*apraclonidine ophthalmic (eye) drops*  
0.5 %

3

*brimonidine ophthalmic (eye) drops*  
0.15 %, 0.2 %

1

### PWODUI DÈMATOLOJIK/TERAPI TOPIK

#### ANTI-FONJIV TOPIK

*ciclopirox topical cream 0.77 %*

1

QL (90 GM per 28 days)

*ciclopirox topical gel 0.77 %*

1

QL (100 GM per 28 days)

*ciclopirox topical suspension 0.77 %*

3

QL (60 ML per 28 days)

*clotrimazole topical cream 1 %*

1

QL (45 GM per 28 days)

*clotrimazole topical solution 1 %*

1

QL (30 ML per 28 days)

*clotrimazole-betamethasone topical cream 1-0.05 %*

3

QL (45 GM per 28 days)

*clotrimazole-betamethasone topical lotion 1-0.05 %*

3

QL (60 ML per 28 days)

*ketconazole topical cream 2 %*

1

QL (60 GM per 28 days)

*ketconazole topical shampoo 2 %*

1

QL (120 ML per 28 days)

*naftifine topical cream 1 %*

3

QL (90 GM per 28 days)

*naftifine topical cream 2 %*

3

QL (60 GM per 28 days)

*naftifine topical gel 2 %*

3

QL (60 GM per 28 days)

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                             | Nivo Medikaman an | Egzijans/Limit yo           |
|--------------------------------------------------------------|-------------------|-----------------------------|
| <i>nyamyc topical powder 100,000 unit/gram</i>               | 1                 | QL (120 GM per 30 days)     |
| <i>nystatin topical cream 100,000 unit/gram</i>              | 1                 | QL (30 GM per 28 days)      |
| <i>nystatin topical ointment 100,000 unit/gram</i>           | 1                 | QL (30 GM per 28 days)      |
| <i>nystatin topical powder 100,000 unit/gram</i>             | 1                 | QL (120 GM per 30 days)     |
| <i>nystop topical powder 100,000 unit/gram</i>               | 1                 | QL (120 GM per 30 days)     |
| <b>ANTIPSORIATIK / ANTISEBORRHEYIK</b>                       |                   |                             |
| <i>acitretin oral capsule 10 mg, 17.5 mg, 25 mg</i>          | 3                 |                             |
| <i>calcipotriene scalp solution 0.005 %</i>                  | 3                 | QL (120 ML per 30 days)     |
| <i>calcipotriene topical ointment 0.005 %</i>                | 3                 | QL (120 GM per 30 days)     |
| COSENTYX (2 SYRINGES)<br>SUBCUTANEOUS SYRINGE 150 MG/ML      | 5 <sup>^</sup>    | PA; QL (10 ML per 28 days)  |
| COSENTYX PEN (2 PENS)<br>SUBCUTANEOUS PEN INJECTOR 150 MG/ML | 5 <sup>^</sup>    | PA; QL (10 ML per 28 days)  |
| COSENTYX SUBCUTANEOUS SYRINGE 75 MG/0.5 ML                   | 5 <sup>^</sup>    | PA; QL (2.5 ML per 28 days) |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                           | Nivo Medikaman an | Egzijans/Limit yo               |
|----------------------------------------------------------------------------|-------------------|---------------------------------|
| COSENTYX UNOREADY PEN<br>SUBCUTANEOUS PEN INJECTOR 300<br>MG/2 ML          | 5 <sup>^</sup>    | PA; QL (10 ML per 28<br>days)   |
| <i>selenium sulfide topical lotion 2.5 %</i>                               | 1                 |                                 |
| SKYRIZI SUBCUTANEOUS PEN INJECTOR<br>150 MG/ML                             | 5 <sup>^</sup>    | PA; QL (6 ML per 365<br>days)   |
| SKYRIZI SUBCUTANEOUS SYRINGE 150<br>MG/ML                                  | 5 <sup>^</sup>    | PA; QL (6 ML per 365<br>days)   |
| SKYRIZI SUBCUTANEOUS SYRINGE 55<br>MG/0.37 ML                              | 5 <sup>^</sup>    | PA; QL (0.74 ML per 84<br>days) |
| STEQEYMA SUBCUTANEOUS SOLUTION<br>45 MG/0.5 ML                             | 2                 | PA; QL (0.5 ML per 28<br>days)  |
| STEQEYMA SUBCUTANEOUS SYRINGE<br>45 MG/0.5 ML                              | 2                 | PA; QL (0.5 ML per 28<br>days)  |
| STEQEYMA SUBCUTANEOUS SYRINGE<br>90 MG/ML                                  | 5 <sup>^</sup>    | PA; QL (1 ML per 28 days)       |
| TREMFYA ONE-PRESS SUBCUTANEOUS<br>AUTO-INJECTOR 100 MG/ML                  | 5 <sup>^</sup>    | PA; QL (2 ML per 28 days)       |
| TREMFYA PEN INDUCTION PK(2PEN)<br>SUBCUTANEOUS PEN INJECTOR 200<br>MG/2 ML | 5 <sup>^</sup>    | PA; QL (12 ML per 180<br>days)  |
| TREMFYA PEN SUBCUTANEOUS PEN<br>INJECTOR 200 MG/2 ML                       | 5 <sup>^</sup>    | PA; QL (2 ML per 28 days)       |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                      | Nivo Medikaman an | Egzijans/Limit yo            |
|-------------------------------------------------------|-------------------|------------------------------|
| TREMFYA SUBCUTANEOUS SYRINGE 100 MG/ML, 200 MG/2 ML   | 5^                | PA; QL (2 ML per 28 days)    |
| USTEKINUMAB-TTWE SUBCUTANEOUS SOLUTION 45 MG/0.5 ML   | 2                 | PA; QL (0.5 ML per 28 days)  |
| USTEKINUMAB-TTWE SUBCUTANEOUS SYRINGE 45 MG/0.5 ML    | 2                 | PA; QL (0.5 ML per 28 days)  |
| USTEKINUMAB-TTWE SUBCUTANEOUS SYRINGE 90 MG/ML        | 5^                | PA; QL (1 ML per 28 days)    |
| <b><i>DIVÈS PWODUI DÈMATOLOJIK</i></b>                |                   |                              |
| <i>ammonium lactate topical cream 12 %</i>            | 1                 |                              |
| <i>ammonium lactate topical lotion 12 %</i>           | 1                 |                              |
| DUPIXENT PEN SUBCUTANEOUS PEN INJECTOR 200 MG/1.14 ML | 5^                | PA; QL (4.56 ML per 28 days) |
| DUPIXENT PEN SUBCUTANEOUS PEN INJECTOR 300 MG/2 ML    | 5^                | PA; QL (8 ML per 28 days)    |
| DUPIXENT SYRINGE SUBCUTANEOUS SYRINGE 200 MG/1.14 ML  | 5^                | PA; QL (4.56 ML per 28 days) |
| DUPIXENT SYRINGE SUBCUTANEOUS SYRINGE 300 MG/2 ML     | 5^                | PA; QL (8 ML per 28 days)    |
| EUCRISA TOPICAL OINTMENT 2 %                          | 3                 | PA; QL (120 GM per 30 days)  |
| <i>fluorouracil topical cream 5 %</i>                 | 1                 | QL (40 GM per 30 days)       |
| <i>fluorouracil topical solution 2 %, 5 %</i>         | 1                 | QL (10 ML per 30 days)       |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                             | Nivo Medikaman an | Egzijans/Limit yo             |
|--------------------------------------------------------------|-------------------|-------------------------------|
| <i>imiquimod topical cream in packet 5 %</i>                 | 1                 | QL (24 EA per 28 days)        |
| <i>lidocaine hcl mucous membrane solution 2 %</i>            | 1                 |                               |
| <i>lidocaine hcl mucous membrane solution 4 % (40 mg/ml)</i> | 3                 | QL (50 ML per 30 days)        |
| <i>lidocaine topical adhesive patch,medicated 5 %</i>        | 3                 | PA; QL (90 EA per 30 days)    |
| <i>lidocaine topical ointment 5 %</i>                        | 1                 | QL (50 GM per 30 days)        |
| <i>lidocaine-prilocaine topical cream 2.5-2.5 %</i>          | 1                 | QL (30 GM per 30 days)        |
| <i>lidocan iii topical adhesive patch,medicated 5 %</i>      | 3                 | PA; QL (90 EA per 30 days)    |
| PANRETIN TOPICAL GEL 0.1 %                                   | 5 <sup>^</sup>    | PA-NS; QL (60 GM per 30 days) |
| <i>pimecrolimus topical cream 1 %</i>                        | 3                 | QL (100 GM per 30 days)       |
| <i>podofilox topical solution 0.5 %</i>                      | 3                 | QL (7 ML per 28 days)         |
| SANTYL TOPICAL OINTMENT 250 UNIT/GRAM                        | 3                 | QL (180 GM per 30 days)       |
| <i>silver sulfadiazine topical cream 1 %</i>                 | 1                 |                               |
| <i>ssd topical cream 1 %</i>                                 | 1                 |                               |
| <i>tacrolimus topical ointment 0.03 %, 0.1 %</i>             | 3                 | QL (100 GM per 30 days)       |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                          | Nivo Medikaman an | Egzijans/Limit yo             |
|-----------------------------------------------------------|-------------------|-------------------------------|
| <i>tridacaine ii topical adhesive patch,medicated 5 %</i> | 3                 | PA; QL (90 EA per 30 days)    |
| VALCHLOR TOPICAL GEL 0.016 %                              | 5^                | PA-NS; QL (60 GM per 30 days) |
| <b>KÒTIKOESTEWYID</b>                                     |                   |                               |
| <i>ala-cort topical cream 1 %</i>                         | 1                 |                               |
| <i>alclometasone topical cream 0.05 %</i>                 | 3                 | QL (120 GM per 30 days)       |
| <i>alclometasone topical ointment 0.05 %</i>              | 3                 | QL (120 GM per 30 days)       |
| <i>betamethasone dipropionate topical cream 0.05 %</i>    | 1                 | QL (135 GM per 30 days)       |
| <i>betamethasone dipropionate topical lotion 0.05 %</i>   | 1                 | QL (120 ML per 30 days)       |
| <i>betamethasone dipropionate topical ointment 0.05 %</i> | 3                 | QL (135 GM per 30 days)       |
| <i>betamethasone valerate topical cream 0.1 %</i>         | 1                 | QL (135 GM per 30 days)       |
| <i>betamethasone valerate topical lotion 0.1 %</i>        | 3                 | QL (120 ML per 30 days)       |
| <i>betamethasone valerate topical ointment 0.1 %</i>      | 1                 | QL (135 GM per 30 days)       |
| <i>betamethasone, augmented topical cream 0.05 %</i>      | 1                 | QL (150 GM per 30 days)       |
| <i>betamethasone, augmented topical gel 0.05 %</i>        | 1                 | QL (150 GM per 30 days)       |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                        | Nivo Medikaman an | Egzijans/Limit yo          |
|---------------------------------------------------------|-------------------|----------------------------|
| <i>betamethasone, augmented topical lotion 0.05 %</i>   | 1                 | QL (120 ML per 30 days)    |
| <i>betamethasone, augmented topical ointment 0.05 %</i> | 1                 | QL (150 GM per 30 days)    |
| <i>clobetasol scalp solution 0.05 %</i>                 | 3                 | QL (100 ML per 28 days)    |
| <i>clobetasol topical cream 0.05 %</i>                  | 3                 | QL (120 GM per 28 days)    |
| <i>clobetasol topical gel 0.05 %</i>                    | 3                 | QL (120 GM per 28 days)    |
| <i>clobetasol topical ointment 0.05 %</i>               | 3                 | QL (120 GM per 28 days)    |
| <i>clobetasol topical shampoo 0.05 %</i>                | 3                 | QL (236 ML per 28 days)    |
| <i>clobetasol-emollient topical cream 0.05 %</i>        | 3                 | QL (120 GM per 28 days)    |
| <i>clodan topical shampoo 0.05 %</i>                    | 3                 | QL (236 ML per 28 days)    |
| <i>desonide topical cream 0.05 %</i>                    | 1                 | QL (120 GM per 30 days)    |
| <i>desonide topical lotion 0.05 %</i>                   | 3                 | QL (118 ML per 30 days)    |
| <i>desonide topical ointment 0.05 %</i>                 | 1                 | QL (120 GM per 30 days)    |
| <i>fluocinolone and shower cap scalp oil 0.01 %</i>     | 1                 | QL (118.28 ML per 30 days) |
| <i>fluocinolone topical cream 0.01 %, 0.025 %</i>       | 3                 | QL (120 GM per 30 days)    |
| <i>fluocinolone topical ointment 0.025 %</i>            | 3                 | QL (120 GM per 30 days)    |
| <i>fluocinolone topical solution 0.01 %</i>             | 1                 | QL (120 ML per 30 days)    |
| <i>fluocinonide topical cream 0.05 %</i>                | 3                 | QL (120 GM per 30 days)    |
| <i>fluocinonide topical gel 0.05 %</i>                  | 3                 | QL (120 GM per 30 days)    |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                      | Nivo Medikaman an | Egzijans/Limit yo       |
|-----------------------------------------------------------------------|-------------------|-------------------------|
| <i>fluocinonide topical ointment 0.05 %</i>                           | 1                 | QL (120 GM per 30 days) |
| <i>fluocinonide topical solution 0.05 %</i>                           | 1                 | QL (120 ML per 30 days) |
| <i>fluocinonide-emollient topical cream 0.05 %</i>                    | 3                 | QL (120 GM per 30 days) |
| <i>fluticasone propionate topical cream 0.05 %</i>                    | 1                 |                         |
| <i>halobetasol propionate topical cream 0.05 %</i>                    | 1                 | QL (100 GM per 30 days) |
| <i>halobetasol propionate topical ointment 0.05 %</i>                 | 3                 | QL (100 GM per 30 days) |
| <i>hydrocortisone topical cream 1 %</i>                               | 1                 |                         |
| <i>hydrocortisone topical lotion 2.5 %</i>                            | 1                 |                         |
| <i>hydrocortisone topical ointment 2.5 %</i>                          | 1                 |                         |
| <i>mometasone topical cream 0.1 %</i>                                 | 1                 |                         |
| <i>mometasone topical ointment 0.1 %</i>                              | 1                 |                         |
| <i>mometasone topical solution 0.1 %</i>                              | 1                 |                         |
| <i>triamcinolone acetonide topical cream 0.025 %, 0.1 %, 0.5 %</i>    | 1                 |                         |
| <i>triamcinolone acetonide topical lotion 0.025 %, 0.1 %</i>          | 1                 |                         |
| <i>triamcinolone acetonide topical ointment 0.025 %, 0.1 %, 0.5 %</i> | 1                 |                         |
| <i>triderm topical cream 0.5 %</i>                                    | 1                 |                         |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

## Non Medikaman an

## Nivo Egzijans/Limit yo Medikaman an

### PWODUI ANTI-BAKTERYEN TOPIK

|                                                            |   |                        |
|------------------------------------------------------------|---|------------------------|
| <i>gentamicin topical cream 0.1 %</i>                      | 1 | QL (60 GM per 30 days) |
| <i>gentamicin topical ointment 0.1 %</i>                   | 3 | QL (60 GM per 30 days) |
| <i>mupirocin topical ointment 2 %</i>                      | 1 | QL (44 GM per 30 days) |
| <i>sulfacetamide sodium (acne) topical suspension 10 %</i> | 3 |                        |

### SKABISID / PEDICULISID TOPIK

|                                       |   |                        |
|---------------------------------------|---|------------------------|
| <i>malathion topical lotion 0.5 %</i> | 1 |                        |
| <i>permethrin topical cream 5 %</i>   | 1 | QL (60 GM per 30 days) |

### TERAPI POU AKNE

|                                                          |   |                         |
|----------------------------------------------------------|---|-------------------------|
| <i>accutane oral capsule 10 mg, 20 mg, 40 mg</i>         | 1 |                         |
| <i>adapalene topical cream 0.1 %</i>                     | 3 | QL (45 GM per 30 days)  |
| <i>adapalene topical gel 0.3 %</i>                       | 3 | QL (45 GM per 30 days)  |
| <i>amnesteem oral capsule 10 mg, 20 mg, 30 mg, 40 mg</i> | 1 |                         |
| <i>azelaic acid topical gel 15 %</i>                     | 3 | QL (50 GM per 30 days)  |
| <i>claravis oral capsule 10 mg, 20 mg, 30 mg, 40 mg</i>  | 1 |                         |
| <i>clindamycin phosphate topical gel 1 %</i>             | 3 | QL (120 GM per 30 days) |
| <i>clindamycin phosphate topical gel, once daily 1 %</i> | 3 | QL (75 ML per 30 days)  |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                          | Nivo Medikaman an | Egzijans/Limit yo          |
|---------------------------------------------------------------------------|-------------------|----------------------------|
| <i>clindamycin phosphate topical lotion 1 %</i>                           | 3                 | QL (120 ML per 30 days)    |
| <i>clindamycin phosphate topical solution 1 %</i>                         | 1                 | QL (120 ML per 30 days)    |
| <i>clindamycin phosphate topical swab 1 %</i>                             | 1                 | QL (60 EA per 30 days)     |
| <i>clindamycin-benzoyl peroxide topical gel 1.2 %(1 % base) -5 %</i>      | 1                 | QL (45 GM per 30 days)     |
| <i>clindamycin-benzoyl peroxide topical gel 1-5 %</i>                     | 1                 | QL (50 GM per 30 days)     |
| <i>ery pads topical swab 2 %</i>                                          | 3                 | QL (60 EA per 30 days)     |
| <i>erythromycin with ethanol topical solution 2 %</i>                     | 1                 | QL (60 ML per 30 days)     |
| <i>erythromycin-benzoyl peroxide topical gel 3-5 %</i>                    | 1                 | QL (46.6 GM per 30 days)   |
| <i>isotretinoin oral capsule 10 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg</i> | 3                 |                            |
| <i>metronidazole topical cream 0.75 %</i>                                 | 3                 | QL (45 GM per 30 days)     |
| <i>metronidazole topical gel 0.75 %</i>                                   | 3                 | QL (45 GM per 30 days)     |
| <i>metronidazole topical lotion 0.75 %</i>                                | 3                 | QL (59 ML per 30 days)     |
| <i>neuac topical gel 1.2 %(1 % base) -5 %</i>                             | 1                 | QL (45 GM per 30 days)     |
| <i>tazarotene topical cream 0.1 %</i>                                     | 2                 | PA; QL (60 GM per 30 days) |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                                                | Nivo Medikaman an | Egzijans/Limit yo           |
|-------------------------------------------------------------------------------------------------|-------------------|-----------------------------|
| <i>tazarotene topical gel 0.05 %, 0.1 %</i>                                                     | 3                 | PA; QL (100 GM per 30 days) |
| <i>tretinoin microspheres topical gel 0.04 %, 0.1 %</i>                                         | 3                 | PA; QL (50 GM per 30 days)  |
| <i>tretinoin topical cream 0.025 %, 0.05 %, 0.1 %</i>                                           | 3                 | PA; QL (45 GM per 30 days)  |
| <i>tretinoin topical gel 0.01 %, 0.025 %, 0.05 %</i>                                            | 3                 | PA; QL (45 GM per 30 days)  |
| <i>trilitas topical gel 0.1 %</i>                                                               | 3                 | PA; QL (90 GM per 30 days)  |
| <i>zenatane oral capsule 10 mg, 20 mg, 30 mg, 40 mg</i>                                         | 1                 |                             |
| <b>PWODUI IWOLOJIK</b>                                                                          |                   |                             |
| <b><i>DIVÈS PWODUI IWOLOJIK</i></b>                                                             |                   |                             |
| <i>bethanechol chloride oral tablet 10 mg, 25 mg, 5 mg, 50 mg</i>                               | 1                 |                             |
| CYSTAGON ORAL CAPSULE 150 MG, 50 MG                                                             | 3                 | PA; LA                      |
| ELMIRON ORAL CAPSULE 100 MG                                                                     | 3                 |                             |
| <i>potassium citrate oral tablet extended release 10 meq (1,080 mg), 15 meq, 5 meq (540 mg)</i> | 1                 |                             |
| <i>sildenafil oral tablet 100 mg, 25 mg, 50 mg</i>                                              | 1                 | NT; QL (6 EA per 30 days)   |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                          | Nivo Medikaman an | Egzijans/Limit yo          |
|---------------------------------------------------------------------------|-------------------|----------------------------|
| <i>tadalafil oral tablet 2.5 mg</i>                                       | 3                 | PA; QL (60 EA per 30 days) |
| <i>tadalafil oral tablet 5 mg</i>                                         | 3                 | PA; QL (30 EA per 30 days) |
| <i>vardenafil oral tablet 10 mg, 2.5 mg, 20 mg, 5 mg</i>                  | 1                 | NT; QL (6 EA per 30 days)  |
| <b>PWODUI ANTI-KOLINÈJIK /<br/>ANTISPASMODIK</b>                          |                   |                            |
| <i>mirabegron oral tablet extended release 24 hr 25 mg, 50 mg</i>         | 2                 | QL (30 EA per 30 days)     |
| <i>oxybutynin chloride oral syrup 5 mg/5 ml</i>                           | 1                 | QL (600 ML per 30 days)    |
| <i>oxybutynin chloride oral tablet 5 mg</i>                               | 1                 | QL (120 EA per 30 days)    |
| <i>oxybutynin chloride oral tablet extended release 24hr 10 mg, 15 mg</i> | 3                 | QL (60 EA per 30 days)     |
| <i>oxybutynin chloride oral tablet extended release 24hr 5 mg</i>         | 3                 | QL (30 EA per 30 days)     |
| <i>solifenacin oral tablet 10 mg, 5 mg</i>                                | 3                 | QL (30 EA per 30 days)     |
| <i>tolterodine oral capsule, extended release 24hr 2 mg, 4 mg</i>         | 3                 | QL (30 EA per 30 days)     |
| <i>tolterodine oral tablet 1 mg, 2 mg</i>                                 | 3                 | QL (60 EA per 30 days)     |
| <i>trospium oral capsule, extended release 24hr 60 mg</i>                 | 3                 | QL (30 EA per 30 days)     |
| <i>trospium oral tablet 20 mg</i>                                         | 3                 | QL (60 EA per 30 days)     |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

## Non Medikaman an

## Nivo Egzijans/Limit yo Medikaman an

### TERAPI IPÈPLAZI PWOSTATIK BENIN (BPH)

*alfuzosin oral tablet extended release 24 hr 10 mg*

1

*dutasteride oral capsule 0.5 mg*

1

*dutasteride-tamsulosin oral capsule, er multiphase 24 hr 0.5-0.4 mg*

1

*finasteride oral tablet 5 mg*

1

*tamsulosin oral capsule 0.4 mg*

1

### RESPIRATWA AK ALÈJI

#### AJAN PILMONÈ

*acetylcysteine solution 100 mg/ml (10 %), 200 mg/ml (20 %)*

1

B/D

ADEMPAS ORAL TABLET 0.5 MG, 1 MG, 1.5 MG, 2 MG, 2.5 MG

5^

PA; LA; QL (90 EA per 30 days)

ADVAIR HFA INHALATION HFA

AEROSOL INHALER 115-21

MCG/ACTUATION, 230-21

MCG/ACTUATION, 45-21

MCG/ACTUATION

2

QL (12 GM per 30 days)

AIRSUPRA INHALATION HFA AEROSOL INHALER 90-80 MCG/ACTUATION

2

QL (32.1 GM per 30 days)

*albuterol sulfate inhalation hfa aerosol inhaler 90 mcg/actuation*

1

8.5 gm inhaler; QL (17 GM per 30 days)

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                                                                                | Nivo Medikaman an | Egzijans/Limit yo                        |
|---------------------------------------------------------------------------------------------------------------------------------|-------------------|------------------------------------------|
| <i>albuterol sulfate inhalation hfa aerosol inhaler 90 mcg/actuation (nda020503)</i>                                            | 1                 | 6.7 gm inhaler; QL (13.4 GM per 30 days) |
| <i>albuterol sulfate inhalation hfa aerosol inhaler 90 mcg/actuation (nda020983)</i>                                            | 1                 | 18 gm inhaler; QL (36 GM per 30 days)    |
| <i>albuterol sulfate inhalation solution for nebulization 0.63 mg/3 ml, 1.25 mg/3 ml, 2.5 mg /3 ml (0.083 %), 2.5 mg/0.5 ml</i> | 1                 | B/D                                      |
| <i>albuterol sulfate oral syrup 2 mg/5 ml</i>                                                                                   | 1                 |                                          |
| <i>albuterol sulfate oral tablet 2 mg, 4 mg</i>                                                                                 | 1                 |                                          |
| <i>ambrisentan oral tablet 10 mg, 5 mg</i>                                                                                      | 5^                | PA; LA; QL (30 EA per 30 days)           |
| ANORO ELLIPTA INHALATION BLISTER WITH DEVICE 62.5-25 MCG/ACTUATION                                                              | 2                 | QL (60 EA per 30 days)                   |
| <i>arformoterol inhalation solution for nebulization 15 mcg/2 ml</i>                                                            | 3                 | B/D; QL (120 ML per 30 days)             |
| ARNUITY ELLIPTA INHALATION BLISTER WITH DEVICE 100 MCG/ACTUATION, 200 MCG/ACTUATION, 50 MCG/ACTUATION                           | 2                 | QL (30 EA per 30 days)                   |
| ATROVENT HFA INHALATION HFA AEROSOL INHALER 17 MCG/ACTUATION                                                                    | 3                 | QL (25.8 GM per 30 days)                 |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                                                    | Nivo Medikaman an | Egzijans/Limit yo                                         |
|-----------------------------------------------------------------------------------------------------|-------------------|-----------------------------------------------------------|
| BEVESPI AEROSPHERE INHALATION HFA AEROSOL INHALER 9-4.8 MCG                                         | 2                 | QL (10.7 GM per 30 days)                                  |
| <i>bosentan oral tablet 125 mg, 62.5 mg</i>                                                         | 5^                | PA; LA; QL (60 EA per 30 days)                            |
| BREO ELLIPTA INHALATION BLISTER WITH DEVICE 100-25 MCG/DOSE, 200-25 MCG/DOSE, 50-25 MCG/DOSE        | 2                 | QL (60 EA per 30 days)                                    |
| <i>breyna inhalation hfa aerosol inhaler 160-4.5 mcg/actuation, 80-4.5 mcg/actuation</i>            | 2                 | Breyna is generic for Symbicort; QL (30.9 GM per 30 days) |
| BREZTRI AEROSPHERE INHALATION HFA AEROSOL INHALER 160-18-4.8 MCG/ACTUATION, 160-9-4.8 MCG/ACTUATION | 2                 | QL (10.7 GM per 30 days)                                  |
| <i>budesonide inhalation suspension for nebulization 0.25 mg/2 ml, 0.5 mg/2 ml</i>                  | 3                 | B/D; QL (120 ML per 30 days)                              |
| COMBIVENT RESPIMAT INHALATION MIST 20-100 MCG/ACTUATION                                             | 2                 | QL (8 GM per 30 days)                                     |
| <i>cromolyn inhalation solution for nebulization 20 mg/2 ml</i>                                     | 2                 | B/D                                                       |
| FASENRA PEN SUBCUTANEOUS AUTO-INJECTOR 30 MG/ML                                                     | 5^                | PA; QL (1 ML per 28 days)                                 |
| FASENRA SUBCUTANEOUS SYRINGE 10 MG/0.5 ML                                                           | 5^                | PA; QL (0.5 ML per 28 days)                               |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                                                                       | Nivo Medikaman an | Egzijans/Limit yo              |
|------------------------------------------------------------------------------------------------------------------------|-------------------|--------------------------------|
| FASENRA SUBCUTANEOUS SYRINGE 30 MG/ML                                                                                  | 5^                | PA; QL (1 ML per 28 days)      |
| <i>flunisolide nasal spray, non-aerosol 25 mcg (0.025 %)</i>                                                           | 1                 | QL (50 ML per 30 days)         |
| FLUTICASONE FUROATE-VILANTEROL INHALATION BLISTER WITH DEVICE 100-25 MCG/DOSE, 200-25 MCG/DOSE                         | 2                 | QL (60 EA per 30 days)         |
| <i>fluticasone propionate nasal spray, suspension 50 mcg/actuation</i>                                                 | 1                 | QL (16 GM per 30 days)         |
| <i>fluticasone propion-salmeterol inhalation blister with device 100-50 mcg/dose, 250-50 mcg/dose, 500-50 mcg/dose</i> | 1                 | QL (60 EA per 30 days)         |
| <i>formoterol fumarate inhalation solution for nebulization 20 mcg/2 ml</i>                                            | 3                 | B/D; QL (120 ML per 30 days)   |
| HAEGARDA SUBCUTANEOUS RECON SOLN 2,000 UNIT                                                                            | 5^                | PA; LA; QL (30 EA per 30 days) |
| HAEGARDA SUBCUTANEOUS RECON SOLN 3,000 UNIT                                                                            | 5^                | PA; LA; QL (20 EA per 30 days) |
| <i>icatibant subcutaneous syringe 30 mg/3 ml</i>                                                                       | 5^                | PA; QL (27 ML per 30 days)     |
| INCRUSE ELLIPTA INHALATION BLISTER WITH DEVICE 62.5 MCG/ACTUATION                                                      | 2                 | QL (30 EA per 30 days)         |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                                                                      | Nivo Medikaman an | Egzijans/Limit yo             |
|-----------------------------------------------------------------------------------------------------------------------|-------------------|-------------------------------|
| <i>ipratropium bromide inhalation solution 0.02 %</i>                                                                 | 1                 | B/D                           |
| <i>ipratropium-albuterol inhalation solution for nebulization 0.5 mg-3 mg(2.5 mg base)/3 ml</i>                       | 1                 | B/D                           |
| <i>levalbuterol hcl inhalation solution for nebulization 0.31 mg/3 ml, 0.63 mg/3 ml, 1.25 mg/0.5 ml, 1.25 mg/3 ml</i> | 1                 | B/D                           |
| <i>mometasone nasal spray,non-aerosol 50 mcg/actuation</i>                                                            | 1                 | QL (34 GM per 30 days)        |
| <i>montelukast oral granules in packet 4 mg</i>                                                                       | 1                 |                               |
| <i>montelukast oral tablet 10 mg</i>                                                                                  | 1                 |                               |
| <i>montelukast oral tablet,chewable 4 mg, 5 mg</i>                                                                    | 1                 |                               |
| <i>nintedanib oral capsule 100 mg, 150 mg</i>                                                                         | 5^                | PA; QL (60 EA per 30 days)    |
| NUCALA SUBCUTANEOUS AUTO-INJECTOR 100 MG/ML                                                                           | 5^                | PA; LA; QL (3 ML per 28 days) |
| NUCALA SUBCUTANEOUS RECON SOLN 100 MG                                                                                 | 5^                | PA; LA; QL (3 EA per 28 days) |
| NUCALA SUBCUTANEOUS SYRINGE 100 MG/ML                                                                                 | 5^                | PA; LA; QL (3 ML per 28 days) |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                       | Nivo Medikaman an | Egzijans/Limit yo                               |
|------------------------------------------------------------------------|-------------------|-------------------------------------------------|
| NUCALA SUBCUTANEOUS SYRINGE 40 MG/0.4 ML                               | 5^                | PA; LA; QL (0.4 ML per 28 days)                 |
| OFEV ORAL CAPSULE 100 MG, 150 MG                                       | 5^                | PA; QL (60 EA per 30 days)                      |
| <i>pirfenidone oral tablet 267 mg</i>                                  | 5^                | PA; QL (270 EA per 30 days)                     |
| <i>pirfenidone oral tablet 801 mg</i>                                  | 5^                | PA; QL (90 EA per 30 days)                      |
| PULMOZYME INHALATION SOLUTION 1 MG/ML                                  | 5^                | B/D                                             |
| <i>roflumilast oral tablet 250 mcg, 500 mcg</i>                        | 1                 | QL (30 EA per 30 days)                          |
| SEREVENT DISKUS INHALATION BLISTER WITH DEVICE 50 MCG/DOSE             | 2                 | QL (60 EA per 30 days)                          |
| <i>sildenafil (pulm.hypertension) oral tablet 20 mg</i>                | 1                 | PA; generic for Revatio; QL (90 EA per 30 days) |
| SPIRIVA RESPIMAT INHALATION MIST 1.25 MCG/ACTUATION, 2.5 MCG/ACTUATION | 3                 | QL (4 GM per 30 days)                           |
| <i>tadalafil (pulm. hypertension) oral tablet 20 mg</i>                | 3                 | PA; generic for Adcirca; QL (60 EA per 30 days) |
| <i>terbutaline oral tablet 2.5 mg, 5 mg</i>                            | 1                 |                                                 |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                                                      | Nivo Medikaman an | Egzijans/Limit yo             |
|-------------------------------------------------------------------------------------------------------|-------------------|-------------------------------|
| THEO-24 ORAL CAPSULE, EXTENDED RELEASE 24HR 100 MG, 200 MG, 300 MG, 400 MG                            | 3                 |                               |
| <i>theophylline oral solution 80 mg/15 ml</i>                                                         | 1                 |                               |
| <i>theophylline oral tablet extended release 12 hr 100 mg, 200 mg, 300 mg, 450 mg</i>                 | 1                 |                               |
| <i>theophylline oral tablet extended release 24 hr 400 mg, 600 mg</i>                                 | 1                 |                               |
| TRELEGY ELLIPTA INHALATION BLISTER WITH DEVICE 100-62.5-25 MCG, 200-62.5-25 MCG                       | 2                 | QL (60 EA per 30 days)        |
| TRIKAFTA ORAL GRANULES IN PACKET, SEQUENTIAL 100-50-75MG (D) /75 MG (N), 80-40-60 MG (D) /59.5 MG (N) | 5^                | PA; QL (56 EA per 28 days)    |
| TRIKAFTA ORAL TABLETS, SEQUENTIAL 100-50-75 MG(D) /150 MG (N), 50-25-37.5 MG (D)/75 MG (N)            | 5^                | PA; QL (84 EA per 28 days)    |
| WINREVAIR SUBCUTANEOUS KIT 120 MG (60 MG X 2), 45 MG, 60 MG, 90 MG (45 MG X 2)                        | 5^                | PA; QL (1 EA per 21 days)     |
| XOLAIR SUBCUTANEOUS AUTO-INJECTOR 150 MG/ML, 300 MG/2 ML                                              | 5^                | PA; LA; QL (8 ML per 28 days) |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                         | Nivo Medikaman an | Egzijans/Limit yo                                                                      |
|--------------------------------------------------------------------------|-------------------|----------------------------------------------------------------------------------------|
| XOLAIR SUBCUTANEOUS AUTO-INJECTOR 75 MG/0.5 ML                           | 5 <sup>^</sup>    | PA; LA; QL (1 ML per 28 days)                                                          |
| XOLAIR SUBCUTANEOUS RECON SOLN 150 MG                                    | 5 <sup>^</sup>    | PA; LA; QL (8 EA per 28 days)                                                          |
| XOLAIR SUBCUTANEOUS SYRINGE 150 MG/ML, 300 MG/2 ML                       | 5 <sup>^</sup>    | PA; LA; QL (8 ML per 28 days)                                                          |
| XOLAIR SUBCUTANEOUS SYRINGE 75 MG/0.5 ML                                 | 5 <sup>^</sup>    | PA; LA; QL (1 ML per 28 days)                                                          |
| <i>zafirlukast oral tablet 10 mg, 20 mg</i>                              | 1                 |                                                                                        |
| <b>ANTI-HISTAMIN / AJAN ANTI-ALÈRJENIK</b>                               |                   |                                                                                        |
| <i>cetirizine oral solution 1 mg/ml</i>                                  | 1                 |                                                                                        |
| <i>cyproheptadine oral tablet 4 mg</i>                                   | 3                 | PA                                                                                     |
| <i>desloratadine oral tablet 5 mg</i>                                    | 1                 |                                                                                        |
| <i>epinephrine injection auto-injector 0.15 mg/0.3 ml, 0.3 mg/0.3 ml</i> | 1                 | Only Epinephrine NDCs starting with 00093 and 49502 are covered; QL (4 EA per 30 days) |
| <i>hydroxyzine hcl oral tablet 10 mg, 25 mg, 50 mg</i>                   | 3                 | PA                                                                                     |
| <i>hydroxyzine pamoate oral capsule 25 mg, 50 mg</i>                     | 3                 | PA                                                                                     |
| <i>levocetirizine oral solution 2.5 mg/5 ml</i>                          | 1                 |                                                                                        |
| <i>levocetirizine oral tablet 5 mg</i>                                   | 1                 |                                                                                        |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                          | Nivo Medikaman an | Egzijans/Limit yo |
|-----------------------------------------------------------|-------------------|-------------------|
| <i>promethazine oral syrup 6.25 mg/5 ml</i>               | 3                 | PA                |
| <i>promethazine oral tablet 12.5 mg, 25 mg, 50 mg</i>     | 3                 | PA                |
| <b>VITAMIN, HEMATINIK / ELEKTWOLIT</b>                    |                   |                   |
| <b><i>DIVÈS PWODUI NITRISYON</i></b>                      |                   |                   |
| <i>electrolyte-a intravenous parenteral solution</i>      | 1                 |                   |
| PLENAMINE INTRAVENOUS PARENTERAL SOLUTION 15 %            | 3                 | B/D               |
| <i>premasol 10 % intravenous parenteral solution 10 %</i> | 3                 | B/D               |
| <i>travasol 10 % intravenous parenteral solution 10 %</i> | 3                 | B/D               |
| TROPHAMINE 10 % INTRAVENOUS PARENTERAL SOLUTION 10 %      | 3                 | B/D               |
| <b><i>ELEKTWOLIT</i></b>                                  |                   |                   |
| <i>calcium acetate(phosphat bind) oral capsule 667 mg</i> | 2                 | PA                |
| <i>calcium acetate(phosphat bind) oral tablet 667 mg</i>  | 2                 | PA                |
| <i>klor-con 10 oral tablet extended release 10 meq</i>    | 1                 |                   |
| <i>klor-con 8 oral tablet extended release 8 meq</i>      | 1                 |                   |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                                                   | Nivo Medikaman an | Egzijans/Limit yo |
|----------------------------------------------------------------------------------------------------|-------------------|-------------------|
| <i>klor-con m10 oral tablet,er particles/crystals 10 meq</i>                                       | 1                 |                   |
| <i>klor-con m15 oral tablet,er particles/crystals 15 meq</i>                                       | 1                 |                   |
| <i>klor-con m20 oral tablet,er particles/crystals 20 meq</i>                                       | 1                 |                   |
| <i>klor-con oral packet 20 meq</i>                                                                 | 1                 |                   |
| <i>magnesium sulfate injection solution 500 mg/ml (50 %)</i>                                       | 3                 |                   |
| <i>magnesium sulfate injection syringe 500 mg/ml (50 %)</i>                                        | 3                 |                   |
| <i>potassium chlorid-d5-0.45%nacl intravenous parenteral solution 10 meq/l, 20 meq/l, 40 meq/l</i> | 1                 |                   |
| <i>potassium chloride in 0.9%nacl intravenous parenteral solution 20 meq/l, 40 meq/l</i>           | 1                 |                   |
| <i>potassium chloride intravenous solution 2 meq/ml, 2 meq/ml (20 ml)</i>                          | 1                 |                   |
| <i>potassium chloride oral capsule, extended release 10 meq, 8 meq</i>                             | 1                 |                   |
| <i>potassium chloride oral liquid 20 meq/15 ml, 40 meq/15 ml</i>                                   | 1                 |                   |
| <i>potassium chloride oral packet 20 meq</i>                                                       | 1                 |                   |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

| Non Medikaman an                                                                   | Nivo Medikaman an | Egzijans/Limit yo |
|------------------------------------------------------------------------------------|-------------------|-------------------|
| <i>potassium chloride oral tablet extended release 10 meq, 20 meq, 8 meq</i>       | 1                 |                   |
| <i>potassium chloride oral tablet,er particles/crystals 10 meq, 15 meq, 20 meq</i> | 1                 |                   |
| <i>potassium chloride-0.45 % nacl intravenous parenteral solution 20 meq/l</i>     | 1                 |                   |
| <i>sodium chloride 0.45 % intravenous parenteral solution 0.45 %</i>               | 1                 |                   |
| <i>sodium chloride 3 % hypertonic intravenous parenteral solution 3 %</i>          | 1                 |                   |
| <i>sodium chloride 5 % hypertonic intravenous parenteral solution 5 %</i>          | 1                 |                   |
| <b>VITAMIN / HEMATINIK</b>                                                         |                   |                   |
| <i>cyanocobalamin (vitamin b-12) injection solution</i>                            | 1                 | NT                |
| <i>fluoride (sodium) oral tablet 1 mg (2.2 mg sod. fluoride)</i>                   | 1                 |                   |
| <i>folic acid oral tablet 1 mg</i>                                                 | 1                 | NT                |
| <i>prenatal vitamin plus low iron oral tablet 27 mg iron- 1 mg</i>                 | 1                 |                   |
| <i>vitamin d2 oral capsule 1,250 mcg (50,000 unit)</i>                             | 1                 | NT                |

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

Ou ka jwenn enfòmasyon sou kisa senbòl ak abrevyasyon yo vle di nan tablo a lè w ale nan kòmansman tablo sa a. 10/15/2026

## Endèks Medikaman yo

|                                  |                                 |                                  |
|----------------------------------|---------------------------------|----------------------------------|
| <i>abacavir</i> ..... 28         | ADALIMUMAB-                     | <i>ambrisentan</i> ..... 160     |
| <i>abacavir-</i>                 | AATY(CF) AI                     | <i>amikacin</i> ..... 20         |
| <i>lamivudine</i> ..... 28       | CROHNS..... 126                 | <i>amiloride</i> .....58         |
| <i>abigale</i> .....131          | ADALIMUMAB-                     | <i>amiloride-</i>                |
| <i>abigale lo</i> ..... 131      | ADBM..... 126                   | <i>hydrochlorothiazide</i> .58   |
| ABILIFY ASIMTUFII                | <i>adapalene</i> .....155       | <i>amiodarone</i> ..... 53       |
| ..... 106, 107                   | <i>adefovir</i> ..... 29        | <i>amitriptyline</i> ..... 107   |
| ABILIFY MAINTENA 107             | ADEMPAS.....159                 | <i>amlodipine</i> .....58        |
| <i>abiraterone</i> .....69       | ADVAIR HFA.....159              | <i>amlodipine-</i>               |
| <i>abirtega</i> ..... 69         | AIMOVIG                         | <i>atorvastatin</i> ..... 55     |
| ABRYSVO (PF)..... 47             | AUTOINJECTOR.....123            | <i>amlodipine-</i>               |
| <i>acamprosate</i> .....3        | AIRSUPRA..... 159               | <i>benazepril</i> ..... 58       |
| <i>acarbose</i> ..... 10, 11     | AKEEGA.....70                   | <i>amlodipine-</i>               |
| <i>accutane</i> ..... 155        | <i>ala-cort</i> ..... 152       | <i>olmesartan</i> ..... 58       |
| <i>acebutolol</i> .....57        | <i>albendazole</i> ..... 20     | <i>amlodipine-</i>               |
| <i>acetaminophen-</i>            | <i>albuterol sulfate</i>        | <i>valsartan</i> .....58         |
| <i>codeine</i> ..... 92          | ..... 159, 160                  | <i>amlodipine-</i>               |
| <i>acetazolamide</i> ..... 146   | <i>alclometasone</i> ..... 152  | <i>valsartan-hcthiazyd</i> ..58  |
| <i>acetic acid</i> .....125      | <i>alcohol pads</i> .....11     | <i>ammonium lactate</i> 150      |
| <i>acetylcysteine</i> ..... 159  | ALECENSA..... 70                | <i>amnestem</i> .....155         |
| <i>acitretin</i> ..... 148       | <i>alendronate</i> ..... 128    | <i>amoxapine</i> .....107        |
| ACTHIB (PF).....47               | <i>alfuzosin</i> ..... 159      | <i>amoxicillin</i> .....26       |
| ACTIMMUNE.....45                 | <i>aliskiren</i> ..... 58       | <i>amoxicillin-pot</i>           |
| <i>acyclovir</i> .....28         | <i>allopurinol</i> .....129     | <i>clavulanate</i> ..... 27      |
| <i>acyclovir sodium</i> ..... 29 | <i>alose tron</i> .....39       | <i>amphotericin b</i> ..... 18   |
| ADACEL(TDAP                      | ALPHAGAN P.....147              | <i>amphotericin b</i>            |
| ADOLESN/ADULT)(P                 | <i>alprazolam</i> .....107      | <i>liposome</i> ..... 18         |
| F).....47                        | <i>altavera (28)</i> ..... 133  | <i>ampicillin</i> ..... 27       |
| ADALIMUMAB-                      | ALUNBRIG..... 70                | <i>ampicillin sodium</i> .....27 |
| AATY..... 125, 126               | <i>alyacen 1/35 (28)</i> ...133 | <i>ampicillin-</i>               |
|                                  | <i>amantadine hcl</i> .....29   | <i>sulbactam</i> ..... 27        |

10/15/2026

|                                |                                 |                                |
|--------------------------------|---------------------------------|--------------------------------|
| <i>anagrelide</i> .....3       | <i>atropine</i> ..... 143       | BELSOMRA.....109               |
| <i>anastrozole</i> ..... 70    | ATROVENT HFA.....160            | <i>benazepril</i> ..... 58     |
| ANORO ELLIPTA..... 160         | <i>aubra eq</i> ..... 134       | <i>benazepril-</i>             |
| <i>apraclonidine</i> .....147  | AUGTYRO.....70                  | <i>hydrochlorothiazide</i> .59 |
| <i>aprepitant</i> .....39      | AUSTEDO..... 104                | BENLYSTA..... 126              |
| <i>apri</i> ..... 133          | AUSTEDO XR..... 104             | <i>benztropine</i> .....91     |
| APTIVUS.....29                 | AUSTEDO XR                      | BESREMI..... 46                |
| <i>aranelle (28)</i> ..... 134 | TITRATION KT(WK1-               | BESREMI PEN.....45             |
| ARCALYST.....45                | 4).....104                      | <i>betaine</i> .....39         |
| AREXVY (PF)..... 47            | AUVELITY..... 109               | <i>betamethasone</i>           |
| <i>arformoterol</i> ..... 160  | <i>aviane</i> ..... 134         | <i>dipropionate</i> ..... 152  |
| ARIKAYCE..... 20               | AVMAPKI-                        | <i>betamethasone</i>           |
| <i>aripiprazole</i> .....107   | FAKZYNJA.....70                 | <i>valerate</i> .....152       |
| ARISTADA.....108               | AVTOZMA..... 126                | <i>betamethasone,</i>          |
| ARISTADA INITIO... 108         | AVTOZMA                         | <i>augmented</i> .... 152, 153 |
| <i>armodafinil</i> ..... 108   | AUTOINJECTOR.....126            | BETASERON..... 46              |
| ARNUITY ELLIPTA... 160         | AYVAKIT..... 70                 | <i>betaxolol</i> ..... 59, 143 |
| <i>asenapine maleate</i> 108   | <i>azathioprine</i> .....70     | <i>bethanechol</i>             |
| <i>ashlyna</i> ..... 134       | <i>azelaic acid</i> ..... 155   | <i>chloride</i> .....157       |
| <i>aspirin-</i>                | <i>azelastine</i> .....124, 143 | BEVESPI                        |
| <i>dipyridamole</i> .....67    | <i>azithromycin</i> ..... 25    | AEROSPHERE..... 161            |
| ASSURE ID INSULIN              | <i>aztreonam</i> ..... 21       | <i>bexarotene</i> .....70, 71  |
| SAFETY..... 38                 | <i>azurette (28)</i> ..... 134  | BEXSERO..... 48                |
| <i>atazanavir</i> .....29      | <i>bacitracin-</i>              | <i>bicalutamide</i> .....71    |
| <i>atenolol</i> .....58        | <i>polymyxin b</i> ..... 142    | BICILLIN L-A.....27            |
| <i>atenolol-</i>               | <i>baclofen</i> .....122        | BIKTARVY..... 29               |
| <i>chlorthalidone</i> .....58  | <i>balsalazide</i> .....39      | <i>bimatoprost</i> ..... 145   |
| <i>atomoxetine</i> .. 108, 109 | BALVERSA..... 70                | <i>bismuth subcit k-</i>       |
| <i>atorvastatin</i> ..... 55   | <i>balziva (28)</i> ..... 134   | <i>metronidz-tcn</i> ..... 44  |
| <i>atovaquone</i> ..... 20     | BARACLUDE..... 29               | <i>bisoprolol fumarate</i> .59 |
| <i>atovaquone-</i>             | BCG VACCINE, LIVE               | <i>bisoprolol-</i>             |
| <i>proguanil</i> ..... 20, 21  | (PF)..... 47                    | <i>hydrochlorothiazide</i> .59 |

|                                 |                                   |                                  |
|---------------------------------|-----------------------------------|----------------------------------|
| <i>blisovi 24 fe</i> .....134   | CABOMETYX..... 71                 | <i>cefazolin</i> .....35         |
| <i>blisovi fe 1.5/30</i>        | <i>calcipotriene</i> ..... 148    | <i>cefdinir</i> .....35          |
| (28)..... 134                   | <i>calcitonin (salmon)</i> .... 7 | <i>cefepime</i> ..... 36         |
| BOMYNTRA.....69                 | <i>calcitriol</i> ..... 7         | <i>cefixime</i> ..... 36         |
| BONSITY.....128                 | <i>calcium</i>                    | <i>cefoxitin</i> ..... 36        |
| BOOSTRIX TDAP.....48            | <i>acetate(phosphat</i>           | <i>cefpodoxime</i> ..... 36      |
| <i>bosentan</i> .....161        | <i>bind)</i> .....167             | <i>cefprozil</i> ..... 36        |
| BOSULIF..... 71                 | CALQUENCE                         | <i>ceftaroline fosamil</i> ...36 |
| <i>bosutinib</i> ..... 71       | (ACALABRUTINIB                    | <i>ceftazidime</i> ..... 36      |
| BRAFTOVI.....71                 | MAL)..... 71                      | <i>ceftriaxone</i> .....37       |
| BREO ELLIPTA..... 161           | <i>camila</i> ..... 131           | <i>cefuroxime axetil</i> .... 37 |
| <i>breyana</i> .....161         | <i>camrese lo</i> ..... 134       | <i>cefuroxime sodium</i> .. 37   |
| BREZTRI                         | <i>candesartan</i> .....59        | <i>celecoxib</i> ..... 94        |
| AEROSPHERE..... 161             | <i>candesartan-</i>               | <i>cephalexin</i> .....37        |
| <i>briellyn</i> ..... 134       | <i>hydrochlorothiazid</i> ...59   | <i>cetirizine</i> ..... 166      |
| <i>brimonidine</i> ..... 147    | CAPLYTA..... 109                  | <i>cevimeline</i> .....3         |
| <i>brinzolamide</i> .....145    | CAPRELSA.....71, 72               | CHEMET..... 3                    |
| <i>brivaracetam</i> ..... 96    | <i>captopril</i> ..... 59         | <i>chlorhexidine</i>             |
| <i>bromfenac</i> ..... 141      | <i>carbamazepine</i> ..... 97     | <i>gluconate</i> .....124        |
| <i>bromocriptine</i> ..... 91   | <i>carbidopa</i> .....91          | <i>chloroquine</i>               |
| BRUKINSA..... 71                | <i>carbidopa-levodopa</i> .91     | <i>phosphate</i> .....21         |
| <i>budesonide</i> 39, 40, 161   | <i>carbidopa-</i>                 | <i>chlorpromazine</i> .....109   |
| <i>bumetanide</i> ..... 59      | <i>levodopa-</i>                  | <i>chlorthalidone</i> .....60    |
| <i>buprenorphine hcl</i> ....93 | <i>entacapone</i> .....91         | <i>cholestyramine</i>            |
| <i>buprenorphine-</i>           | <i>carglumic acid</i> ..... 3     | <i>(with sugar)</i> ..... 55     |
| <i>naloxone</i> ..... 94        | <i>carteolol</i> .....143         | <i>cholestyramine</i>            |
| <i>bupropion hcl</i> .....109   | <i>cartia xt</i> ..... 59         | <i>light</i> .....55             |
| <i>bupropion hcl</i>            | <i>carvedilol</i> ..... 60        | <i>ciclopirox</i> .....147       |
| <i>(smoking deter)</i> ..... 6  | <i>caspofungin</i> ..... 18       | <i>cilostazol</i> .....67        |
| <i>buspirone</i> .....109       | CAYSTON..... 21                   | CIMDUO.....29                    |
| <i>butorphanol</i> .....94      | <i>cefaclor</i> ..... 35          | <i>cinacalcet</i> .....7         |
| <i>cabergoline</i> ..... 6      | <i>cefadroxil</i> ..... 35        |                                  |

10/15/2026

|                                                                   |                                                           |                                                         |
|-------------------------------------------------------------------|-----------------------------------------------------------|---------------------------------------------------------|
| <i>ciprofloxacin hcl</i><br>..... 26, 142                         | <i>clozapine</i> .....110                                 | <i>cyclobenzaprine</i> .....123                         |
| <i>ciprofloxacin in 5 %</i><br><i>dextrose</i> ..... 26           | COARTEM..... 21                                           | <i>cyclophosphamide</i> ... 72                          |
| <i>ciprofloxacin-</i><br><i>dexamethasone</i> ..... 125           | COBENFY.....110                                           | CYCLOPHOSPHAMI<br>DE..... 72                            |
| <i>citalopram</i> ..... 110                                       | COBENFY STARTER<br>PACK..... 110                          | <i>cyclosporine</i> ..... 72, 143                       |
| <i>claravis</i> .....155                                          | <i>colchicine</i> ..... 129                               | <i>cyclosporine</i><br><i>modified</i> .....72          |
| <i>clarithromycin</i> .....25                                     | <i>colesevelam</i> ..... 55                               | <i>cyproheptadine</i> .....166                          |
| <i>clindamycin hcl</i> ..... 21                                   | <i>colestipol</i> .....55                                 | <i>cyred eq</i> ..... 134                               |
| <i>clindamycin in 5 %</i><br><i>dextrose</i> ..... 21             | <i>colistin</i><br>( <i>colistimethate na</i> ).. 21      | CYSTAGON.....157                                        |
| <i>clindamycin</i><br><i>phosphate</i><br>..... 21, 130, 155, 156 | COMBIGAN..... 145                                         | CYSTARAN.....143                                        |
| <i>clindamycin-</i><br><i>benzoyl peroxide</i> ....156            | COMBIVENT<br>RESPIMAT..... 161                            | <i>d10 %-0.45 %</i><br><i>sodium chloride</i> ..... 3   |
| <i>clobazam</i> ..... 97                                          | COMETRIQ..... 72                                          | <i>d2.5 %-0.45 %</i><br><i>sodium chloride</i> ..... 3  |
| <i>clobetasol</i> ..... 153                                       | <i>compro</i> ..... 40                                    | <i>d5 % and 0.9 %</i><br><i>sodium chloride</i> ..... 3 |
| <i>clobetasol-</i><br><i>emollient</i> .....153                   | CONEXXENCE.....128                                        | <i>d5 %-0.45 % sodium</i><br><i>chloride</i> .....3     |
| <i>clodan</i> ..... 153                                           | <i>constulose</i> .....40                                 | <i>dabigatran</i><br><i>etexilate</i> .....67           |
| <i>clomipramine</i> .....110                                      | COPIKTRA.....72                                           | <i>dalfampridine</i> ..... 104                          |
| <i>clonazepam</i> ..... 97                                        | COSENTYX.....148                                          | <i>danazol</i> ..... 7                                  |
| <i>clonidine</i> ..... 60                                         | COSENTYX (2<br>SYRINGES).....148                          | <i>dantrolene</i> ..... 123                             |
| <i>clonidine hcl</i> .....60                                      | COSENTYX PEN (2<br>PENS)..... 148                         | DANZITEN..... 72                                        |
| <i>clopidogrel</i> ..... 67                                       | COSENTYX<br>UNOREADY PEN.....149                          | <i>dapagliflozin</i> ..... 11                           |
| <i>clorazepate</i><br><i>dipotassium</i> ..... 110                | COTELLIC.....72                                           | <i>dapagliflozin-</i><br><i>metformin</i> .....11       |
| <i>clotrimazole</i> ..... 18, 147                                 | CREON..... 40                                             | <i>dapsone</i> ..... 21                                 |
| <i>clotrimazole-</i><br><i>betamethasone</i> ..... 147            | CRESEMBA..... 18                                          | DAPTACEL (DTAP<br>PEDIATRIC) (PF)..... 48               |
| 10/15/2026                                                        | <i>cromolyn</i> .. 40, 143, 161                           | <i>daptomycin</i> .....21                               |
|                                                                   | <i>cryselle (28)</i> ..... 134                            |                                                         |
|                                                                   | <i>cyanocobalamin</i><br>( <i>vitamin b-12</i> )..... 169 |                                                         |

|                                 |                                |                                    |
|---------------------------------|--------------------------------|------------------------------------|
| <i>darunavir</i> ..... 29       | <i>dextrose 5 % in</i>         | <i>disopyramide</i>                |
| <i>dasatinib</i> ..... 73       | <i>water (d5w)</i> ..... 4     | <i>phosphate</i> ..... 53          |
| DAURISMO..... 73                | <i>dextrose 5%-0.2 %</i>       | <i>disulfiram</i> ..... 4          |
| <i>deblitane</i> ..... 131      | <i>sod chloride</i> ..... 4    | <i>divalproex</i> ..... 98         |
| <i>deferasirox</i> ..... 3      | DIACOMIT..... 97, 98           | <i>dofetilide</i> ..... 53         |
| DELSTRIGO..... 29               | <i>diazepam</i> ..... 98, 112  | <i>dolishale</i> ..... 134         |
| <i>demeclocycline</i> ..... 37  | <i>diazepam intensol</i> . 112 | <i>donepezil</i> ..... 104, 105    |
| DEPO-SUBQ                       | <i>diazoxide</i> ..... 11      | <i>dorzolamide</i> ..... 146       |
| PROVERA 104..... 131            | <i>diclofenac</i>              | <i>dorzolamide-timolol</i>         |
| DESCOVY..... 29                 | <i>potassium</i> ..... 95      | ..... 146                          |
| <i>desipramine</i> ..... 110    | <i>diclofenac sodium</i>       | <i>dotti</i> ..... 131             |
| <i>desloratadine</i> ..... 166  | ..... 95, 141                  | DOVATO..... 29                     |
| <i>desmopressin</i> ..... 7     | <i>diclofenac-</i>             | <i>doxazosin</i> ..... 60          |
| <i>desonide</i> ..... 153       | <i>misoprostol</i> ..... 95    | <i>doxepin</i> ..... 112           |
| <i>desvenlafaxine</i>           | <i>dicloxacillin</i> ..... 27  | <i>doxercalciferol</i> ..... 7     |
| <i>succinate</i> ..... 111      | <i>dicyclomine</i> ..... 39    | <i>doxy-100</i> ..... 37           |
| <i>dexamethasone</i> ..... 8, 9 | <i>diflunisal</i> ..... 95     | <i>doxycycline hyclate</i>         |
| <i>dexamethasone</i>            | <i>difluprednate</i> ..... 144 | ..... 37, 38                       |
| <i>sodium phosphate</i> . 144   | <i>digoxin</i> ..... 54        | <i>doxycycline</i>                 |
| <i>dexlansoprazole</i> ..... 44 | <i>dihydroergotamine</i> 123   | <i>monohydrate</i> ..... 38        |
| <i>dexmethylphenidat</i>        | DILANTIN..... 98               | DRIZALMA                           |
| <i>e</i> ..... 111              | DILANTIN                       | SPRINKLE..... 112                  |
| <i>dextroamphetamin</i>         | EXTENDED..... 98               | <i>dronabinol</i> ..... 40         |
| <i>e sulfate</i> ..... 111      | DILANTIN INFATABS. 98          | <i>drospirenone-</i>               |
| <i>dextroamphetamin</i>         | DILANTIN-125..... 98           | <i>e.estradiol-lm.fa</i> .... 134  |
| <i>e-amphetamine</i>            | <i>diltiazem hcl</i> ..... 60  | <i>drospirenone-</i>               |
| ..... 111, 112                  | <i>dilt-xr</i> ..... 60        | <i>ethinyl estradiol</i> ..... 134 |
| <i>dextrose 10 % and</i>        | <i>dimethyl fumarate</i> . 104 | DROXIA..... 73                     |
| <i>0.2 % nacl</i> ..... 4       | <i>diphenoxylate-</i>          | <i>duloxetine</i> ..... 112        |
| <i>dextrose 10 % in</i>         | <i>atropine</i> ..... 39       | DUPIXENT PEN..... 150              |
| <i>water (d10w)</i> ..... 4     | <i>dipyridamole</i> ..... 67   | DUPIXENT SYRINGE 150               |
|                                 |                                | <i>dutasteride</i> ..... 159       |

10/15/2026

|                                      |                                  |                                  |
|--------------------------------------|----------------------------------|----------------------------------|
| <i>dutasteride-</i>                  | <i>emtricitabine-</i>            | <i>ertapenem</i> ..... 21        |
| <i>tamsulosin</i> ..... 159          | <i>tenofovir (tdf)</i> ..... 30  | <i>ery pads</i> ..... 156        |
| EDARBI.....60                        | <i>emtricitabine-</i>            | <i>erythromycin</i> ....25, 142  |
| EDARBYCLOR..... 61                   | <i>tenofovir</i> ..... 30        | <i>erythromycin with</i>         |
| EDURANT PED.....30                   | EMTRIVA.....30                   | <i>ethanol</i> ..... 156         |
| <i>efavirenz</i> ..... 30            | <i>enalapril maleate</i> .... 61 | <i>erythromycin-</i>             |
| <i>efavirenz-</i>                    | <i>enalapril-</i>                | <i>benzoyl peroxide</i> ....156  |
| <i>emtricitabine-</i>                | <i>hydrochlorothiazide</i> .61   | <i>escitalopram</i>              |
| <i>tenofovir</i> ..... 30            | ENBREL..... 127                  | <i>oxalate</i> .....113          |
| <i>efavirenz-lamivudine-</i>         | ENBREL MINI..... 127             | <i>eslicarbazepine</i> ..... 98  |
| <i>tenofovir disoproxil</i> ..... 30 | ENBREL SURECLICK 127             | <i>esomeprazole</i>              |
| <i>electrolyte-a</i> .....167        | ENGERIX-B (PF)..... 48           | <i>magnesium</i> ..... 44        |
| ELIGARD.....73                       | ENGERIX-B                        | <i>estarylla</i> .....135        |
| ELIGARD (3                           | PEDIATRIC (PF).....48            | <i>estradiol</i> .....131, 132   |
| MONTH).....73                        | <i>enilofing</i> .....130        | <i>estradiol valerate</i> ...132 |
| ELIGARD (4                           | <i>enoxaparin</i> .....68        | <i>estradiol-</i>                |
| MONTH).....73                        | ENSACOVE..... 73                 | <i>norethindrone acet</i> 132    |
| ELIGARD (6                           | <i>enskyce</i> ..... 135         | <i>ethambutol</i> ..... 22       |
| MONTH).....73                        | <i>entacapone</i> .....91        | <i>ethosuximide</i> ..... 99     |
| ELIQUIS..... 67                      | <i>entecavir</i> .....30         | <i>etodolac</i> .....95          |
| ELIQUIS DVT-PE                       | ENTYVIO PEN..... 40              | <i>etonogestrel-ethinyl</i>      |
| TREAT 30D START.... 67               | <i>enulose</i> ..... 40          | <i>estradiol</i> .....130        |
| ELIQUIS SPRINKLE.... 67              | ENVARSUS XR..... 73              | <i>etravirine</i> ..... 30       |
| ELMIRON..... 157                     | EPIDIOLEX..... 98                | EUCRISA.....150                  |
| <i>eltrombopag</i>                   | <i>epinephrine</i> .....166      | EULEXIN..... 74                  |
| <i>olamine</i> .....67, 68           | <i>eplerenone</i> .....61        | <i>everolimus</i>                |
| <i>eluryng</i> .....130              | <i>ergotamine-</i>               | <i>(antineoplastic)</i> .....74  |
| EMGALITY PEN.....123                 | <i>caffeine</i> .....123         | <i>everolimus</i>                |
| EMGALITY SYRINGE                     | ERIVEDGE.....74                  | <i>(immunosuppressiv</i>         |
| ..... 123                            | ERLEADA..... 74                  | <i>e)</i> .....74                |
| EMSAM.....112                        | <i>erlotinib</i> ..... 74        | EVOTAZ.....30                    |
| <i>emtricitabine</i> ..... 30        | <i>errin</i> ..... 131           | <i>exemestane</i> ..... 74       |

10/15/2026

|                               |          |                                 |          |                               |          |
|-------------------------------|----------|---------------------------------|----------|-------------------------------|----------|
| EXXUA.....                    | 113      | <i>finasteride</i> .....        | 159      | FLUTICASONE                   |          |
| <i>ezetimibe</i> .....        | 56       | <i>fingolimod</i> .....         | 105      | FUROATE-                      |          |
| <i>ezetimibe-</i>             |          | FINTEPLA.....                   | 99       | VILANTEROL.....               | 162      |
| <i>simvastatin</i> .....      | 56       | <i>finzala</i> .....            | 135      | <i>fluticasone</i>            |          |
| <i>falmina (28)</i> .....     | 135      | FIRMAGON KIT W                  |          | <i>propionate</i> .....       | 154, 162 |
| <i>famciclovir</i> .....      | 30       | DILUENT SYRINGE....             | 75       | <i>fluticasone propion-</i>   |          |
| <i>famotidine</i> .....       | 44       | <i>flecainide</i> .....         | 53       | <i>salmeterol</i> .....       | 162      |
| FANAPT.....                   | 113      | <i>fluconazole</i> .....        | 18       | <i>fluvastatin</i> .....      | 56       |
| FANAPT TITRATION              |          | <i>fluconazole in nacl</i>      |          | <i>fluvoxamine</i> .....      | 114      |
| PACK A.....                   | 113      | <i>(iso-osm)</i> .....          | 18       | <i>folic acid</i> .....       | 169      |
| FANAPT TITRATION              |          | <i>flucytosine</i> .....        | 18       | <i>formoterol</i>             |          |
| PACK B.....                   | 113      | <i>fludrocortisone</i> .....    | 9        | <i>fumarate</i> .....         | 162      |
| FANAPT TITRATION              |          | <i>flunisolide</i> .....        | 162      | <i>fosamprenavir</i> .....    | 30       |
| PACK C.....                   | 113      | <i>fluocinolone</i> .....       | 153      | <i>fosfomycin</i>             |          |
| FARXIGA.....                  | 11       | <i>fluocinolone</i>             |          | <i>tromethamine</i> .....     | 20       |
| FASENRA.....                  | 161, 162 | <i>acetonide oil</i> .....      | 125      | <i>fosinopril</i> .....       | 61       |
| FASENRA PEN.....              | 161      | <i>fluocinolone and</i>         |          | <i>fosinopril-</i>            |          |
| <i>febuxostat</i> .....       | 129      | <i>shower cap</i> .....         | 153      | <i>hydrochlorothiazide</i> .. | 61       |
| <i>feirza</i> .....           | 135      | <i>fluocinonide</i> ... ..      | 153, 154 | FOTIVDA.....                  | 75       |
| <i>felbamate</i> .....        | 99       | <i>fluocinonide-</i>            |          | FRUZAQLA.....                 | 75       |
| <i>felodipine</i> .....       | 61       | <i>emollient</i> .....          | 154      | FULPHILA.....                 | 46       |
| <i>fenofibrate</i> .....      | 56       | <i>fluoride (sodium)</i> ... .. | 169      | <i>furosemide</i> .....       | 61       |
| <i>fenofibrate</i>            |          | <i>fluorometholone</i> ....     | 144      | <i>fyavolv</i> .....          | 132      |
| <i>micronized</i> .....       | 56       | <i>fluorouracil</i> .....       | 150      | <i>gabapentin</i> .....       | 99       |
| <i>fenofibrate</i>            |          | <i>fluoxetine</i> .....         | 114      | <i>galantamine</i> .....      | 105      |
| <i>nanocrystallized</i> ..... | 56       | <i>fluphenazine</i>             |          | <i>galbriela</i> .....        | 135      |
| <i>fenofibric acid</i>        |          | <i>decanoate</i> .....          | 114      | <i>gallifrey</i> .....        | 132      |
| <i>(choline)</i> .....        | 56       | <i>fluphenazine hcl</i> ....    | 114      | GAMUNEX-C.....                | 48       |
| <i>fentanyl</i> .....         | 93       | <i>flurbiprofen</i> .....       | 95       | GARDASIL 9 (PF).....          | 48       |
| FETZIMA.....                  | 113, 114 | <i>flurbiprofen sodium</i>      |          | <i>gatifloxacin</i> .....     | 142      |
| <i>fidaxomicin</i> .....      | 25       | .....                           | 141      | GAUZE PAD.....                | 38       |
| FILSPARI.....                 | 54       |                                 |          | <i>gavilyte-c</i> .....       | 40       |

10/15/2026

|                                                       |                                                     |                                               |
|-------------------------------------------------------|-----------------------------------------------------|-----------------------------------------------|
| <i>gavilyte-g</i> .....40                             | GVOKE HYPOPEN 2-<br>PACK.....12                     | <i>hydroxyurea</i> .....76                    |
| <i>gavilyte-n</i> .....40                             | GVOKE PFS 1-PACK<br>SYRINGE.....12                  | <i>hydroxyzine hcl</i> .....166               |
| GAVRETO.....75                                        | HAEGARDA.....162                                    | <i>hydroxyzine</i><br><i>pamoate</i> .....166 |
| <i>gefitinib</i> .....75                              | <i>hailey 24 fe</i> .....135                        | HYRNUO.....76                                 |
| <i>gemfibrozil</i> .....56                            | <i>hailey fe 1/20 (28)</i> .135                     | <i>ibandronate</i> .....129                   |
| <i>generlac</i> .....40                               | <i>halobetasol</i><br><i>propionate</i> .....154    | IBRANCE.....76                                |
| <i>gengraf</i> .....75                                | <i>haloperidol</i> .....115                         | IBTROZI.....76                                |
| <i>gentamicin</i><br>.....22, 142, 155                | <i>haloperidol</i><br><i>decanoate</i> .....115     | <i>ibu</i> .....95                            |
| <i>gentamicin in nacl</i><br><i>(iso-osm)</i> .....22 | <i>haloperidol lactate</i> 115                      | <i>ibuprofen</i> .....95                      |
| GENVOYA.....31                                        | HAVRIX (PF).....49                                  | <i>icatibant</i> .....162                     |
| GILOTRIF.....75                                       | <i>heather</i> .....132                             | <i>iclevia</i> .....135                       |
| <i>glatiramer</i> .....105                            | <i>heparin (porcine)</i> .....68                    | ICLUSIG.....76                                |
| <i>glatopa</i> .....105                               | HEPLISAV-B (PF).....49                              | <i>icosapent ethyl</i> .....56                |
| <i>glimepiride</i> .....11                            | HERNEXEOS.....76                                    | IDHIFA.....76                                 |
| <i>glipizide</i> .....11                              | HIBERIX (PF).....49                                 | IDVYNOS.....31                                |
| <i>glipizide-metformin</i><br>.....11, 12             | HUMULIN R U-500<br>(CONC) KWIKPEN.....12            | <i>imatinib</i> .....76                       |
| <i>glutamine (sickle</i><br><i>cell)</i> .....4       | <i>hydralazine</i> .....61                          | IMBRUVICA.....76, 77                          |
| <i>glycopyrrolate</i> .....39                         | <i>hydrochlorothiazide</i><br>.....61, 62           | <i>imipenem-cilastatin</i> .22                |
| GLYXAMBI.....12                                       | <i>hydrocodone-</i><br><i>acetaminophen</i> .....93 | <i>imipramine hcl</i> .....115                |
| GOMEKLI.....75                                        | <i>hydrocodone-</i><br><i>ibuprofen</i> .....93     | <i>imiquimod</i> .....151                     |
| <i>granisetron hcl</i> .....40                        | <i>hydrocortisone</i><br>.....9, 41, 154            | IMKELDI.....77                                |
| <i>griseofulvin</i><br><i>microsize</i> .....18, 19   | <i>hydromorphone</i> .....93                        | IMOVAX RABIES<br>VACCINE (PF).....49          |
| <i>griseofulvin</i><br><i>ultramicrosize</i> .....19  | <i>hydroxychloroquine</i> .22                       | IMPAVIDO.....22                               |
| <i>guanfacine</i> .....61, 114                        |                                                     | <i>incassia</i> .....132                      |
| GVOKE.....12                                          |                                                     | INCRELEX.....4                                |
|                                                       |                                                     | INCRUSE ELLIPTA...162                         |
|                                                       |                                                     | <i>indapamide</i> .....62                     |
|                                                       |                                                     | INFANRIX (DTAP)<br>(PF).....49                |
|                                                       |                                                     | INGREZZA.....105                              |

10/15/2026

|                                  |                                   |                                   |
|----------------------------------|-----------------------------------|-----------------------------------|
| INGREZZA                         | <i>isosorbide</i>                 | <i>kariva (28)</i> ..... 136      |
| INITIATION                       | <i>mononitrate</i> .....57        | <i>kelnor 1/35 (28)</i> ..... 136 |
| PK(TARDIV)..... 105              | <i>isotretinoin</i> ..... 156     | KERENDIA..... 62                  |
| INLURIYO..... 77                 | <i>isradipine</i> ..... 62        | <i>ketoconazole</i> ....19, 147   |
| INLYTA..... 77                   | ITOVEBI..... 77                   | <i>ketorolac</i> .....141         |
| INQOVI.....77                    | <i>itraconazole</i> ..... 19      | KINRIX (PF).....49                |
| INREBIC.....77                   | <i>ivabradine</i> .....54         | <i>kionex</i> ..... 4             |
| INSULIN GLARGINE                 | <i>ivermectin</i> ..... 22        | KIRSTY..... 13                    |
| U-300 CONC.....12                | IWILFIN..... 77                   | KIRSTY PEN..... 13                |
| INSULIN GLARGINE-                | IXIARO (PF)..... 49               | KISQALI..... 78                   |
| YFGN..... 12                     | <i>jaimiess</i> .....135          | <i>klor-con</i> .....168          |
| INSULIN SYRINGE-                 | JAKAFI..... 77                    | <i>klor-con 10</i> .....167       |
| NEEDLE U-100.....38              | JAKAFI XR..... 78                 | <i>klor-con 8</i> .....167        |
| INTELENCE..... 31                | <i>jantoven</i> .....68           | <i>klor-con m10</i> .....168      |
| <i>introvale</i> ..... 135       | JANUVIA.....13                    | <i>klor-con m15</i> .....168      |
| INVEGA HAFYERA.. 115             | JARDIANCE.....13                  | <i>klor-con m20</i> .....168      |
| INVEGA SUSTENNA                  | <i>jasmiel (28)</i> ..... 135     | KLOXXADO..... 95                  |
| ..... 115, 116                   | JAYPIRCA.....78                   | KOMZIFTI..... 78                  |
| INVEGA TRINZA..... 116           | JIDEYTRO..... 78                  | KOSELUGO..... 78                  |
| IPOL..... 49                     | <i>jinteli</i> .....132           | <i>kourzeq</i> ..... 124          |
| <i>ipratropium</i>               | JOURNAVX..... 95                  | KRAZATI..... 79                   |
| <i>bromide</i> ..... 124, 163    | <i>juleber</i> .....135           | <i>kurvelo (28)</i> .....136      |
| <i>ipratropium-</i>              | JULUCA..... 31                    | <i>I</i>                          |
| <i>albuterol</i> ..... 163       | <i>junel 1.5/30 (21)</i> ... 136  | <i>norgest/e.estradiol-</i>       |
| <i>irbesartan</i> ..... 62       | <i>junel 1/20 (21)</i> ..... 136  | <i>e.estrad</i> .....136          |
| <i>irbesartan-</i>               | <i>junel fe 1.5/30 (28)</i> 136   | <i>labetalol</i> .....62          |
| <i>hydrochlorothiazide</i> .62   | <i>junel fe 1/20 (28)</i> ... 136 | <i>lacosamide</i> .....99         |
| ISENTRESS.....31                 | <i>junel fe 24</i> ..... 136      | <i>lactulose</i> ..... 41         |
| ISENTRESS HD..... 31             | JYLAMVO..... 78                   | <i>lamivudine</i> ..... 31        |
| <i>isibloom</i> ..... 135        | JYNNEOS (PF).....49               | <i>lamivudine-</i>                |
| <i>isoniazid</i> .....22         | <i>kaitlib fe</i> .....136        | <i>zidovudine</i> .....31         |
| <i>isosorbide dinitrate</i> ..57 | KALETRA..... 31                   | <i>lamotrigine</i> ..... 99, 100  |

10/15/2026

|                                |     |                               |     |                                 |     |
|--------------------------------|-----|-------------------------------|-----|---------------------------------|-----|
| <i>lansoprazole</i> .....      | 45  | <i>levofloxacin</i> .....     | 26  | LONSURF.....                    | 80  |
| LANTUS SOLOSTAR                |     | <i>levofloxacin in d5w</i> .. | 26  | <i>loperamide</i> .....         | 39  |
| U-100 INSULIN.....             | 13  | <i>levonest (28)</i> .....    | 137 | <i>lopinavir-ritonavir</i> .... | 32  |
| LANTUS U-100                   |     | <i>levonorgestrel-</i>        |     | <i>lorazepam</i> .....          | 117 |
| INSULIN.....                   | 13  | <i>ethinyl estrad</i> .....   | 137 | <i>lorazepam intensol</i>       | 116 |
| <i>lapatinib</i> .....         | 79  | <i>levonorg-eth estrad</i>    |     | LORBRENA.....                   | 80  |
| <i>larin 1.5/30 (21)</i> ....  | 136 | <i>triphasic</i> .....        | 137 | <i>loryna (28)</i> .....        | 137 |
| <i>larin 1/20 (21)</i> .....   | 136 | <i>levothyroxine</i> .....    | 10  | <i>losartan</i> .....           | 62  |
| <i>larin fe 1.5/30 (28)</i> .  | 136 | <i>levoxyl</i> .....          | 10  | <i>losartan-</i>                |     |
| <i>larin fe 1/20 (28)</i> .... | 137 | <i>lidocaine</i> .....        | 151 | <i>hydrochlorothiazide</i> .    | 62  |
| <i>latanoprost</i> .....       | 146 | <i>lidocaine hcl</i> .....    | 151 | <i>loteprednol</i>              |     |
| LAZCLUZE.....                  | 79  | <i>lidocaine-prilocaine</i>   | 151 | <i>etabonate</i> .....          | 144 |
| LEDIPASVIR-                    |     | <i>lidocan iii</i> .....      | 151 | <i>lovastatin</i> .....         | 56  |
| SOFOSBUVIR.....                | 31  | LIFYORLI.....                 | 80  | <i>loxapine succinate</i> .     | 117 |
| <i>leflunomide</i> .....       | 127 | LILETTA.....                  | 130 | <i>lubiprostone</i> .....       | 41  |
| <i>lenalidomide</i> .....      | 79  | <i>linezolid</i> .....        | 22  | <i>luizza</i> .....             | 137 |
| LENVIMA.....                   | 79  | <i>linezolid in dextrose</i>  |     | LUMAKRAS.....                   | 80  |
| LEQEMBI IQLIK.....             | 105 | 5%.....                       | 22  | LUPRON DEPOT.....               | 80  |
| <i>lessina</i> .....           | 137 | LINZESS.....                  | 41  | <i>lurasidone</i> .....         | 117 |
| <i>letrozole</i> .....         | 79  | <i>liomny</i> .....           | 10  | LYBALVI.....                    | 117 |
| <i>leucovorin calcium</i> ...  | 69  | <i>liothyronine</i> .....     | 10  | <i>lyleq</i> .....              | 132 |
| LEUKERAN.....                  | 79  | <i>liraglutide</i> .....      | 13  | <i>lyllana</i> .....            | 132 |
| LEUKINE.....                   | 46  | <i>lisdexamfetamine</i> ..    | 116 | LYNPARZA.....                   | 81  |
| <i>leuprolide</i> .....        | 79  | <i>lisinopril</i> .....       | 62  | LYSODREN.....                   | 81  |
| <i>levalbuterol hcl</i> .....  | 163 | <i>lisinopril-</i>            |     | LYTGOBI.....                    | 81  |
| <i>levetiracetam</i> .....     | 100 | <i>hydrochlorothiazide</i> .  | 62  | <i>lyza</i> .....               | 132 |
| LEVETIRACETAM....              | 100 | <i>lithium carbonate</i> ..   | 116 | <i>magnesium sulfate</i>        | 168 |
| <i>levobunolol</i> .....       | 143 | <i>lithium citrate</i> .....  | 116 | <i>malathion</i> .....          | 155 |
| <i>levocarnitine</i> .....     | 4   | LIVTENCITY.....               | 32  | <i>maraviroc</i> .....          | 32  |
| <i>levocarnitine (with</i>     |     | <i>lojaimiess</i> .....       | 137 | <i>marlissa (28)</i> .....      | 137 |
| <i>sugar</i> ).....            | 4   | LOKELMA.....                  | 4   | MARPLAN.....                    | 117 |
| <i>levocetirizine</i> .....    | 166 | <i>lomustine</i> .....        | 80  | MATULANE.....                   | 81  |

10/15/2026

|                                          |                                 |                                  |
|------------------------------------------|---------------------------------|----------------------------------|
| <i>matzim la</i> .....63                 | <i>methylphenidate</i>          | <i>minocycline</i> .....38       |
| <i>meclizine</i> .....41                 | <i>hcl</i> .....117             | <i>minoxidil</i> .....63         |
| <i>medroxyprogesterone</i> .....132, 133 | <i>methylprednisolone</i> ...9  | <i>mirabegron</i> .....158       |
| <i>mefloquine</i> .....22                | <i>metoclopramide hcl</i>       | <i>mirtazapine</i> .....118      |
| <i>megestrol</i> .....81                 | .....41, 42                     | <i>misoprostol</i> .....45       |
| MEKINIST.....81                          | <i>metolazone</i> .....63       | M-M-R II (PF).....50             |
| MEKTOVI.....81                           | <i>metoprolol</i>               | <i>modafinil</i> .....118        |
| <i>meleya</i> .....133                   | <i>succinate</i> .....63        | MODEYSO.....82                   |
| <i>meloxicam</i> .....95                 | <i>metoprolol ta-</i>           | <i>moexipril</i> .....63         |
| <i>memantine</i> .....106                | <i>hydrochlorothiaz</i> .....63 | <i>molindone</i> .....118        |
| MENQUADFI (PF).....49                    | <i>metoprolol tartrate</i> . 63 | <i>mometasone</i> ..154, 163     |
| MENVEO A-C-Y-W-135-DIP (PF).....50       | <i>metronidazole</i>            | <i>montelukast</i> .....163      |
| <i>mercaptapurine</i> . 81, 82           | .....23, 130, 156               | <i>morphine</i> .....93, 94      |
| MERILOG.....13                           | <i>metronidazole in</i>         | <i>morphine</i>                  |
| MERILOG                                  | <i>nacl (iso-os)</i> .....23    | <i>concentrate</i> .....93       |
| SOLOSTAR.....13                          | <i>metyrosine</i> .....63       | MOUNJARO.....14                  |
| <i>meropenem</i> .....23                 | <i>mexiletine</i> .....54       | MOVANTIK.....42                  |
| <i>mesalamine</i> .....41                | <i>mibelas 24 fe</i> .....137   | <i>moxifloxacin</i> .....26, 142 |
| <i>mesna</i> .....69                     | <i>micafungin</i> .....19       | <i>moxifloxacin-</i>             |
| <i>metformin</i> .....13, 14             | <i>microgestin 1.5/30</i>       | <i>sod.chloride(iso)</i> .....26 |
| <i>methadone</i> .....93                 | (21).....137                    | MRESVIA (PF).....50              |
| <i>methazolamide</i> .....146            | <i>microgestin 1/20</i>         | MULTAQ.....54                    |
| <i>methenamine</i>                       | (21).....137                    | <i>mupirocin</i> .....155        |
| <i>hippurate</i> .....20                 | <i>microgestin fe</i>           | <i>mycophenolate</i>             |
| <i>methimazole</i> .....6                | <i>1.5/30 (28)</i> .....138     | <i>mofetil</i> .....82           |
| <i>methotrexate</i>                      | <i>microgestin fe 1/20</i>      | <i>mycophenolate</i>             |
| <i>sodium</i> .....82                    | (28).....138                    | <i>sodium</i> .....82            |
| <i>methotrexate</i>                      | <i>midodrine</i> .....4         | <i>nabumetone</i> .....96        |
| <i>sodium (pf)</i> .....82               | <i>mifepristone</i> .....7      | <i>nadolol</i> .....63           |
| <i>methsuximide</i> .....100             | <i>mili</i> .....138            | <i>nafcillin</i> .....27         |
| 10/15/2026                               | <i>milnacipran</i> .....127     | <i>naftifine</i> .....147        |
|                                          | <i>mimvey</i> .....133          | <i>naloxone</i> .....96          |

|                                  |                                   |                                   |
|----------------------------------|-----------------------------------|-----------------------------------|
| <i>naltrexone</i> ..... 96       | <i>nicardipine</i> ..... 63       | <i>nortrel 1/35 (21)</i> .... 138 |
| NAMZARIC..... 106                | NICOTROL NS..... 6                | <i>nortrel 1/35 (28)</i> .... 138 |
| <i>naproxen</i> ..... 96         | <i>nifedipine</i> ..... 63        | <i>nortrel 7/7/7 (28)</i> .. 139  |
| <i>naproxen sodium</i> .... 96   | <i>nikki (28)</i> ..... 138       | <i>nortriptyline</i> ..... 118    |
| <i>naratriptan</i> ..... 123     | <i>nilotinib hcl</i> ..... 82     | NORVIR..... 32                    |
| NATACYN..... 142                 | <i>nilutamide</i> ..... 83        | NOVOLIN 70/30 U-                  |
| <i>nateglinide</i> ..... 14      | <i>nimodipine</i> ..... 64        | 100 INSULIN..... 14               |
| NAYZILAM..... 100                | NINLARO..... 83                   | NOVOLIN 70-30                     |
| <i>nebivolol</i> ..... 63        | <i>nintedanib</i> ..... 163       | FLEXPEN U-100..... 15             |
| <i>necon 0.5/35 (28)</i> .. 138  | <i>nitazoxanide</i> ..... 23      | NOVOLIN N                         |
| <i>nefazodone</i> ..... 118      | <i>nitisinone</i> ..... 4         | FLEXPEN..... 15                   |
| <i>neomycin</i> ..... 23         | <i>nitro-bid</i> ..... 57         | NOVOLIN N NPH U-                  |
| <i>neomycin-</i>                 | <i>nitrofurantoin</i>             | 100 INSULIN..... 15               |
| <i>bacitracin-poly-hc</i> .. 145 | <i>macrocrystal</i> ..... 20      | NOVOLIN R                         |
| <i>neomycin-</i>                 | <i>nitrofurantoin</i>             | FLEXPEN..... 15                   |
| <i>bacitracin-</i>               | <i>monohyd/m-cryst</i> .... 20    | NOVOLIN R                         |
| <i>polymyxin</i> ..... 142       | <i>nitroglycerin</i> ..... 42, 57 | REGULAR U100                      |
| <i>neomycin-</i>                 | NIVESTYM..... 46                  | INSULIN..... 15                   |
| <i>polymyxin b-</i>              | <i>nora-be</i> ..... 133          | NOVOLOG MIX 70-                   |
| <i>dexameth</i> ..... 145        | <i>norelgestromin-</i>            | 30 U-100 INSULN.... 15            |
| <i>neomycin-</i>                 | <i>ethin.estradiol</i> ..... 130  | NOVOLOG MIX 70-                   |
| <i>polymyxin-</i>                | <i>norethindrone</i>              | 30FLEXPEN U-100.... 15            |
| <i>gramicidin</i> ..... 142      | <i>(contraceptive)</i> ..... 133  | NUBEQA..... 83                    |
| <i>neomycin-</i>                 | <i>norethindrone</i>              | NUCALA..... 163, 164              |
| <i>polymyxin-hc</i> .. 125, 145  | <i>acetate</i> ..... 133          | NUDEXTA..... 106                  |
| NERLYNX..... 82                  | <i>norethindrone ac-</i>          | NUPLAZID..... 118                 |
| <i>neuac</i> ..... 156           | <i>eth estradiol</i> ... 133, 138 | NURTEC ODT..... 123               |
| NEUPRO..... 92                   | <i>norethindrone-</i>             | <i>nyamyc</i> ..... 148           |
| <i>nevirapine</i> ..... 32       | <i>e.estradiol-iron</i> ..... 138 | <i>nylia 1/35 (28)</i> ..... 139  |
| NEXLETOL..... 56                 | <i>norgestimate-</i>              | <i>nylia 7/7/7 (28)</i> ..... 139 |
| NEXPLANON..... 130               | <i>ethinyl estradiol</i> .... 138 | <i>nystatin</i> ..... 19, 148     |
| <i>niacin</i> ..... 56           | <i>nortrel 0.5/35 (28)</i> . 138  | <i>nystop</i> ..... 148           |

10/15/2026

|                               |          |                                |     |                             |        |
|-------------------------------|----------|--------------------------------|-----|-----------------------------|--------|
| <i>octreotide acetate</i> ... | 83       | <i>oxaprozin</i> .....         | 96  | <i>penicillin v</i>         |        |
| ODEFSEY.....                  | 32       | <i>oxcarbazepine</i> .....     | 100 | <i>potassium</i> .....      | 28     |
| ODOMZO.....                   | 83       | <i>oxybutynin chloride</i>     | 158 | PENMENVY MEN A-             |        |
| OFEV.....                     | 164      | <i>oxycodone</i> .....         | 94  | B-C-W-Y (PF).....           | 50     |
| <i>ofloxacin</i> .....        | 125, 142 | <i>oxycodone-</i>              |     | PENTACEL (PF).....          | 50     |
| OGSIVEO.....                  | 83       | <i>acetaminophen</i> .....     | 94  | <i>pentamidine</i> .....    | 23     |
| OJEMDA.....                   | 83       | OZEMPIC.....                   | 15  | <i>pentoxifylline</i> ..... | 68     |
| OJJAARA.....                  | 83       | <i>pacerone</i> .....          | 54  | <i>perampanel</i> .....     | 100    |
| <i>olanzapine</i> .....       | 118, 119 | <i>paliperidone</i> .....      | 119 | <i>perindopril</i>          |        |
| <i>olmesartan</i> .....       | 64       | PANRETIN.....                  | 151 | <i>erbumine</i> .....       | 64     |
| <i>olmesartan-</i>            |          | <i>pantoprazole</i> .....      | 45  | <i>periogard</i> .....      | 125    |
| <i>amlodipin-hcthiazid</i> .  | 64       | <i>paricalcitol</i> .....      | 7   | <i>permethrin</i> .....     | 155    |
| <i>olmesartan-</i>            |          | <i>paroxetine hcl</i> .....    | 119 | <i>perphenazine</i> .....   | 119    |
| <i>hydrochlorothiazide</i> .  | 64       | PAXLOVID.....                  | 32  | <i>phenelzine</i> .....     | 119    |
| <i>olopatadine</i> .....      | 125      | <i>pazopanib</i> .....         | 84  | <i>phenobarbital</i> .....  | 101    |
| <i>omeprazole</i> .....       | 45       | PEDIARIX (PF).....             | 50  | <i>phenytoin</i> .....      | 101    |
| OMNITROPE.....                | 46       | PEDVAX HIB (PF).....           | 50  | <i>phenytoin sodium</i>     |        |
| <i>ondansetron</i> .....      | 42       | <i>peg 3350-</i>               |     | <i>extended</i> .....       | 101    |
| <i>ondansetron hcl</i> .....  | 42       | <i>electrolytes</i> .....      | 42  | PIFELTRO.....               | 32     |
| ONUREG.....                   | 84       | PEGASYS.....                   | 46  | <i>pilocarpine hcl</i> .... | 4, 144 |
| OPIPZA.....                   | 119      | <i>peg-electrolyte soln</i> .  | 42  | <i>pimecrolimus</i> .....   | 151    |
| ORGOVYX.....                  | 84       | PEMAZYRE.....                  | 84  | <i>pimozide</i> .....       | 120    |
| <i>orquidea</i> .....         | 133      | PEN NEEDLE,                    |     | <i>pimtrea (28)</i> .....   | 139    |
| ORSERDU.....                  | 84       | DIABETIC.....                  | 38  | <i>pindolol</i> .....       | 64     |
| <i>oseltamivir</i> .....      | 32       | PENBRAYA (PF).....             | 50  | <i>pioglitazone</i> .....   | 16     |
| OSENVELT.....                 | 69       | <i>penicillamine</i> .....     | 127 | <i>pioglitazone-</i>        |        |
| OTEZLA.....                   | 127      | PENICILLIN G POT               |     | <i>glimepiride</i> .....    | 16     |
| OTEZLA STARTER...             | 127      | IN DEXTROSE.....               | 28  | <i>pioglitazone-</i>        |        |
| OTEZLA XR.....                | 127      | <i>penicillin g</i>            |     | <i>metformin</i> .....      | 16     |
| OTEZLA XR                     |          | <i>potassium</i> .....         | 28  | <i>piperacillin-</i>        |        |
| INITIATION.....               | 127      | <i>penicillin g sodium</i> ... | 28  | <i>tazobactam</i> .....     | 28     |
| <i>oxacillin</i> .....        | 27, 28   |                                |     | PIQRAY.....                 | 84     |

10/15/2026

|                              |          |                                |        |                                  |     |
|------------------------------|----------|--------------------------------|--------|----------------------------------|-----|
| <i>pirfenidone</i> .....     | 164      | <i>prednisolone</i>            |        | <i>promethazine</i> .....        | 167 |
| <i>piroxicam</i> .....       | 96       | <i>sodium phosphate</i>        |        | <i>propafenone</i> .....         | 54  |
| <i>pitavastatin</i>          |          | .....                          | 9, 144 | <i>propranolol</i> .....         | 64  |
| <i>calcium</i> .....         | 56       | <i>prednisone</i> .....        | 9      | <i>propylthiouracil</i> .....    | 6   |
| PLENAMINE.....               | 167      | <i>prednisone intensol</i> ... | 9      | PROQUAD (PF).....                | 50  |
| PLENVU.....                  | 42       | <i>pregabalin</i> .....        | 101    | <i>protriptyline</i> .....       | 120 |
| <i>podofilox</i> .....       | 151      | PREMARIN.....                  | 133    | PULMOZYME.....                   | 164 |
| <i>polymyxin b sulf-</i>     |          | <i>premasol 10 %</i> .....     | 167    | <i>pyrazinamide</i> .....        | 23  |
| <i>trimethoprim</i> .....    | 143      | <i>prenatal vitamin</i>        |        | <i>pyridostigmine</i>            |     |
| <i>pomalidomide</i> .....    | 84       | <i>plus low iron</i> .....     | 169    | <i>bromide</i> .....             | 123 |
| POMALYST.....                | 84       | PREVYMIS.....                  | 33     | <i>pyrimethamine</i> .....       | 23  |
| <i>portia 28</i> .....       | 139      | PREZCOBIX.....                 | 33     | QINLOCK.....                     | 85  |
| <i>posaconazole</i> .....    | 19       | PREZISTA.....                  | 33     | QUADRACEL (PF).....              | 51  |
| <i>potassium chlorid-</i>    |          | PRIFTIN.....                   | 23     | <i>quetiapine</i> .....          | 120 |
| <i>d5-0.45%nacl</i> .....    | 168      | PRIMAQUINE.....                | 23     | QUETIAPINE.....                  | 120 |
| <i>potassium chloride</i>    |          | PRIMIDONE.....                 | 101    | <i>quinapril</i> .....           | 64  |
| .....                        | 168, 169 | <i>primidone</i> .....         | 101    | <i>quinapril-</i>                |     |
| <i>potassium chloride</i>    |          | PRIORIX (PF).....              | 50     | <i>hydrochlorothiazide</i> ..... | 65  |
| <i>in 0.9%nacl</i> .....     | 168      | <i>probenecid</i> .....        | 129    | <i>quinidine sulfate</i> .....   | 54  |
| <i>potassium chloride-</i>   |          | <i>probenecid-</i>             |        | <i>quinine sulfate</i> .....     | 23  |
| <i>0.45 % nacl</i> .....     | 169      | <i>colchicine</i> .....        | 129    | RABAVERT (PF).....               | 51  |
| <i>potassium citrate</i> ... | 157      | <i>prochlorperazine</i> .....  | 42     | <i>rabeprazole</i> .....         | 45  |
| PRALUENT PEN.....            | 57       | <i>prochlorperazine</i>        |        | RALDESY.....                     | 120 |
| <i>pramipexole</i> .....     | 92       | <i>maleate</i> .....           | 42     | <i>raloxifene</i> .....          | 129 |
| <i>prasugrel hcl</i> .....   | 68       | <i>procto-med hc</i> .....     | 42     | <i>ramipril</i> .....            | 65  |
| <i>pravastatin</i> .....     | 57       | <i>proctosol hc</i> .....      | 42     | <i>ranolazine</i> .....          | 55  |
| <i>praziquantel</i> .....    | 23       | <i>proctozone-hc</i> .....     | 43     | <i>rasagiline</i> .....          | 92  |
| <i>prazosin</i> .....        | 64       | <i>progesterone</i>            |        | <i>reclipsen (28)</i> .....      | 139 |
| <i>prednisolone</i> .....    | 9        | <i>micronized</i> .....        | 133    | RECOMBIVAX HB                    |     |
| <i>prednisolone</i>          |          | PROGRAF.....                   | 84     | (PF).....                        | 51  |
| <i>acetate</i> .....         | 144      | PROLASTIN-C.....               | 5      | <i>repaglinide</i> .....         | 16  |
|                              |          | PROLENSA.....                  | 141    | RETACRIT.....                    | 47  |

10/15/2026

|                                   |                                   |                                   |
|-----------------------------------|-----------------------------------|-----------------------------------|
| RETEVMO.....85                    | <i>rosyrah</i> .....139           | <i>sildenafil</i>                 |
| REVCOVI..... 5                    | ROTARIX.....51                    | ( <i>pulm.hypertension</i> )      |
| REVUFORJ..... 85                  | ROTATEQ VACCINE.. 51              | ..... 164                         |
| REXULTI..... 120                  | <i>roweepra</i> ..... 101         | <i>silver sulfadiazine</i> .. 151 |
| REYATAZ..... 33                   | ROZLYTREK..... 85                 | <i>simvastatin</i> ..... 57       |
| REZDIFFRA..... 5                  | RUBRACA..... 85                   | <i>sirolimus</i> ..... 86         |
| REZLIDHIA..... 85                 | <i>rufinamide</i> ..... 101       | SIRTURO.....24                    |
| RHOPRESSA..... 146                | RUKOBIA.....33                    | <i>sitagliptin phos-</i>          |
| <i>ribavirin</i> ..... 33         | RYDAPT .....86                    | <i>metformin</i> .....16          |
| <i>rifabutin</i> .....23          | <i>sacubitril-valsartan</i> ..55  | SKYRIZI..... 43, 149              |
| <i>rifampin</i> ..... 23, 24      | SANTYL.....151                    | <i>sodium chloride</i> ..... 5    |
| <i>rilpivirine hcl</i> ..... 33   | <i>sapropterin</i> ..... 7        | <i>sodium chloride</i>            |
| <i>riluzole</i> ..... 5           | <i>saxagliptin</i> ..... 16       | 0.45 %..... 169                   |
| <i>rimantadine</i> ..... 33       | <i>saxagliptin-</i>               | <i>sodium chloride 0.9</i>        |
| RINVOQ..... 128                   | <i>metformin</i> .....16          | %..... 5                          |
| RINVOQ LQ..... 127                | SCEMBLIX.....86                   | <i>sodium chloride 3 %</i>        |
| <i>risedronate</i> ..... 5, 129   | <i>scopolamine base</i> .... 43   | <i>hypertonic</i> .....169        |
| <i>risperidone</i> .....120, 121  | SECUADO..... 121                  | <i>sodium chloride 5 %</i>        |
| <i>risperidone</i>                | <i>selegiline hcl</i> ..... 92    | <i>hypertonic</i> .....169        |
| <i>microspheres</i> ..... 120     | <i>selenium sulfide</i> ..... 149 | <i>sodium oxybate</i> ..... 121   |
| <i>ritonavir</i> ..... 33         | SELZENTRY..... 33                 | <i>sodium</i>                     |
| <i>rivaroxaban</i> ..... 68       | SEREVENT DISKUS..164              | <i>phenylbutyrate</i> ..... 5     |
| <i>rivastigmine</i> .....106      | <i>sertraline</i> ..... 121       | <i>sodium polystyrene</i>         |
| <i>rivastigmine</i>               | <i>setlakin</i> ..... 139         | <i>sulfonate</i> .....5           |
| <i>tartrate</i> ..... 106         | <i>sevelamer</i>                  | <i>sodium,potassium,</i>          |
| <i>rivelsa</i> ..... 139          | <i>carbonate</i> ..... 5          | <i>mag sulfates</i> ..... 43      |
| <i>rizatriptan</i> ..... 123, 124 | <i>sharobel</i> .....133          | SOFOSBUVIR-                       |
| ROCKLATAN..... 146                | SHINGRIX (PF).... 51, 52          | VELPATASVIR..... 33               |
| <i>roflumilast</i> ..... 164      | SIGNIFOR..... 86                  | <i>solifenacin</i> .....158       |
| ROMVIMZA.....85                   | <i>sildenafil</i> ..... 157       | SOLQUA 100/33.....16              |
| <i>ropinirole</i> ..... 92        |                                   | SOLTAMOX..... 86                  |
| <i>rosuvastatin</i> .....57       |                                   | SOMAVERT..... 8                   |

10/15/2026

|                                    |                                  |                                              |
|------------------------------------|----------------------------------|----------------------------------------------|
| <i>sorafenib</i> .....86           | SUNLENCA..... 34                 | <i>tenofovir disoproxil fumarate</i> .....34 |
| <i>sotalol</i> ..... 54            | <i>syeda</i> ..... 139           | TEPMETKO.....87                              |
| <i>sotalol af</i> ..... 54         | SYMPAZAN.....102                 | <i>terazosin</i> ..... 65                    |
| SPIRIVA RESPIMAT.164               | SYMTUZA..... 34                  | <i>terbinafine hcl</i> .....19               |
| <i>spironolactone</i> ..... 65     | SYNJARDY..... 17                 | <i>terbutaline</i> ..... 164                 |
| <i>spironolacton-</i>              | SYNJARDY XR..... 17              | <i>terconazole</i> ..... 130                 |
| <i>hydrochlorothiaz</i> .....65    | SYNTHROID.....10                 | <i>teriflunomide</i> ..... 106               |
| <i>sprintec (28)</i> .....139      | TABLOID.....86                   | <i>teriparatide</i> .....129                 |
| <i>sps (with sorbitol)</i> ..... 5 | TABRECTA.....86                  | <i>testosterone</i> .....8                   |
| <i>ssd</i> .....151                | <i>tacrolimus</i> .....87, 151   | <i>testosterone</i>                          |
| STEQEYMA.....149                   | <i>tadalafil</i> ..... 158       | <i>cypionate</i> ..... 8                     |
| STIVARGA.....86                    | <i>tadalafil (pulm.</i>          | <i>testosterone</i>                          |
| STOBOCLO..... 129                  | <i>hypertension)</i> .....164    | <i>enanthate</i> ..... 8                     |
| STREPTOMYCIN..... 24               | TAFINLAR..... 87                 | <i>tetrabenazine</i> ..... 106               |
| STRIBILD.....33                    | TAGRISSO.....87                  | <i>tetracycline</i> ..... 38                 |
| SUBVENITE.....102                  | TALZENNA.....87                  | THALOMID..... 87                             |
| <i>sucralfate</i> .....45          | <i>tamoxifen</i> ..... 87        | THEO-24.....165                              |
| <i>sulfacetamide</i>               | <i>tamsulosin</i> ..... 159      | <i>theophylline</i> ..... 165                |
| <i>sodium</i> ..... 144            | <i>tarina 24 fe</i> ..... 139    | <i>thioridazine</i> .....121                 |
| <i>sulfacetamide</i>               | <i>tarina fe 1-20 eq</i>         | <i>thiothixene</i> .....121                  |
| <i>sodium (acne)</i> ..... 155     | <i>(28)</i> ..... 139            | <i>tiadylt er</i> ..... 65                   |
| <i>sulfacetamide-</i>              | TARPEYO.....9                    | <i>tiagabine</i> .....102                    |
| <i>prednisolone</i> ..... 144      | <i>tazarotene</i> ..... 156, 157 | TIBSOVO..... 87                              |
| <i>sulfadiazine</i> .....19        | <i>tazicef</i> ..... 37          | <i>ticagrelor</i> ..... 68                   |
| <i>sulfamethoxazole-</i>           | <i>telmisartan</i> ..... 65      | TICOVAC..... 52                              |
| <i>trimethoprim</i> ..... 19, 20   | <i>telmisartan-</i>              | <i>tigecycline</i> .....24                   |
| <i>sulfasalazine</i> ..... 43      | <i>amlodipine</i> .....65        | <i>tilia fe</i> .....139                     |
| <i>sulindac</i> .....96            | <i>telmisartan-</i>              | <i>timolol maleate</i> 65, 143               |
| <i>sumatriptan</i> ..... 124       | <i>hydrochlorothiazid</i> ...65  | <i>tinidazole</i> ..... 24                   |
| <i>sumatriptan</i>                 | <i>temazepam</i> .....121        | TIVICAY..... 34                              |
| <i>succinate</i> .....124          | TENIVAC (PF)..... 52             | TIVICAY PD..... 34                           |
| <i>sunitinib malate</i> .....86    |                                  |                                              |

10/15/2026

|                               |     |                                |                              |        |
|-------------------------------|-----|--------------------------------|------------------------------|--------|
| <i>tizanidine</i> .....       | 123 | TREMFYA PEN                    | <i>tri-vylibra</i> .....     | 140    |
| TOBRADEX.....                 | 145 | INDUCTION                      | <i>tri-vylibra lo</i> .....  | 140    |
| <i>tobramycin</i> .....       | 143 | PK(2PEN).....                  | TROPHAMINE 10 %              | 167    |
| <i>tobramycin in 0.225</i>    |     | <i>tretinoin</i> .....         | <i>trospium</i> .....        | 158    |
| <i>% nacl</i> .....           | 24  | <i>tretinoin</i>               | TRULICITY.....               | 17     |
| <i>tobramycin sulfate</i> ... | 24  | (antineoplastic).....          | TRUMENBA.....                | 52     |
| <i>tobramycin-</i>            |     | <i>tretinoin</i>               | TRUQAP.....                  | 87     |
| <i>dexamethasone</i> .....    | 145 | <i>microspheres</i> .....      | TUKYSA.....                  | 87, 88 |
| <i>tofacitinib</i> .....      | 128 | <i>triamcinolone</i>           | TURALIO.....                 | 88     |
| <i>tolterodine</i> .....      | 158 | <i>acetonide</i> .....         | <i>turqoz (28)</i> .....     | 140    |
| <i>tolvaptan</i> .....        | 8   | 125, 154                       | TWINRIX (PF).....            | 52     |
| <i>tolvaptan (polycys</i>     |     | <i>triamterene-</i>            | TYENNE.....                  | 128    |
| <i>kidney dis)</i> .....      | 8   | <i>hydrochlorothiazid</i> ...  | TYENNE                       |        |
| <i>topiramate</i> .....       | 102 | ...66                          | AUTOINJECTOR.....            | 128    |
| <i>toremifene</i> .....       | 87  | <i>tridacaine ii</i> .....     | TYPHIM VI.....               | 52     |
| <i>torsemide</i> .....        | 66  | 152                            | <i>unithroid</i> .....       | 10     |
| TRADJENTA.....                | 17  | <i>triderm</i> .....           | <i>ursodiol</i> .....        | 43     |
| <i>tramadol</i> .....         | 96  | 154                            | USTEKINUMAB-                 |        |
| <i>tramadol-</i>              |     | <i>trientine</i> .....         | TTWE.....                    | 150    |
| <i>acetaminophen</i> .....    | 96  | 5                              | <i>valacyclovir</i> .....    | 34     |
| <i>trandolapril</i> .....     | 66  | <i>tri-estarylla</i> .....     | VALCHLOR.....                | 152    |
| <i>tranexamic acid</i> .....  | 130 | 140                            | <i>valganciclovir</i> .....  | 34     |
| <i>tranylcypromine</i> ....   | 121 | <i>trifluoperazine</i> .....   | <i>valproic acid</i> .....   | 102    |
| <i>travasol 10 %</i> .....    | 167 | 121                            | <i>valproic acid (as</i>     |        |
| <i>travoprost</i> .....       | 146 | <i>trifluridine</i> .....      | <i>sodium salt)</i> .....    | 102    |
| <i>trazodone</i> .....        | 121 | 146                            | <i>valsartan</i> .....       | 66     |
| TRELEGY ELLIPTA...            | 165 | <i>trihexyphenidyl</i> .....   | <i>valsartan-</i>            |        |
| TREMFYA.....                  | 150 | 92                             | <i>hydrochlorothiazide</i> . | 66     |
| TREMFYA ONE-                  |     | TRIJARDY XR.....               | VALTOCO.....                 | 102    |
| PRESS.....                    | 149 | 17                             | <i>valtya</i> .....          | 140    |
| TREMFYA PEN.....              | 149 | 165                            | <i>vancomycin</i> .....      | 24     |
|                               |     | <i>tri-legest fe</i> .....     | VANFLYTA.....                | 88     |
|                               |     | 140                            |                              |        |
|                               |     | <i>trilitas</i> .....          |                              |        |
|                               |     | 157                            |                              |        |
|                               |     | <i>tri-lo-estarylla</i> .....  |                              |        |
|                               |     | 140                            |                              |        |
|                               |     | <i>tri-lo-sprintec</i> .....   |                              |        |
|                               |     | 140                            |                              |        |
|                               |     | <i>trimethoprim</i> .....      |                              |        |
|                               |     | 20                             |                              |        |
|                               |     | <i>tri-mili</i> .....          |                              |        |
|                               |     | 140                            |                              |        |
|                               |     | <i>trimipramine</i> .....      |                              |        |
|                               |     | 121                            |                              |        |
|                               |     | TRINTELLIX.....                |                              |        |
|                               |     | 122                            |                              |        |
|                               |     | <i>tri-sprintec (28)</i> ..... |                              |        |
|                               |     | 140                            |                              |        |
|                               |     | TRIUMEQ.....                   |                              |        |
|                               |     | 34                             |                              |        |
|                               |     | TRIUMEQ PD.....                |                              |        |
|                               |     | 34                             |                              |        |

10/15/2026

|                                    |                              |                                  |
|------------------------------------|------------------------------|----------------------------------|
| VAQTA (PF)..... 52                 | VOQUEZNA DUAL                | XIFAXAN..... 24, 25              |
| <i>varidenafil</i> .....158        | PAK..... 45                  | XIGDUO XR..... 17                |
| <i>varenicline tartrate</i> .... 6 | VOQUEZNA TRIPLE              | XOFLUZA..... 35                  |
| VARIVAX (PF)..... 53               | PAK..... 45                  | XOLAIR..... 165, 166             |
| VAXCHORA                           | VORANIGO..... 89             | XOSPATA..... 89                  |
| VACCINE..... 53                    | <i>voriconazole</i> .....19  | XPOVIO..... 90                   |
| <i>velivet triphasic</i>           | VOSEVI..... 35               | XTANDI..... 90                   |
| <i>regimen (28)</i> ..... 140      | VOWST..... 43                | <i>xulane</i> ..... 130          |
| VELSIPITY..... 43                  | VRAYLAR..... 122             | YF-VAX (PF)..... 53              |
| VENCLEXTA..... 88                  | <i>vyfemla (28)</i> .....141 | <i>yulithira</i> ..... 90        |
| VENCLEXTA                          | <i>vylibra</i> ..... 141     | <i>yuvafem</i> ..... 133         |
| STARTING PACK..... 88              | VYZULTA..... 146             | <i>zafemy</i> ..... 131          |
| <i>venlafaxine</i> ..... 122       | <i>warfarin</i> ..... 68     | <i>zafirlukast</i> ..... 166     |
| <i>verapamil</i> ..... 66          | WEGOVY..... 6                | ZEJULA..... 90                   |
| VERQUVO..... 55                    | WELIREG..... 89              | ZELBORAF..... 90                 |
| VERSACLOZ..... 122                 | WINREVAIR..... 165           | <i>zenatane</i> ..... 157        |
| VERZENIO..... 88                   | <i>wymzya fe</i> .....141    | ZENBEXUS..... 90                 |
| <i>vestura (28)</i> ..... 140      | XALKORI..... 89              | ZENPEP..... 44                   |
| <i>vienva</i> ..... 140            | <i>xarah fe</i> .....141     | <i>zidovudine</i> .....35        |
| <i>vigabatrin</i> ..... 102, 103   | XARELTO..... 69              | <i>ziprasidone hcl</i> ..... 122 |
| <i>vigadrone</i> .....103          | XARELTO DVT-PE               | <i>ziprasidone</i>               |
| <i>vilazodone</i> .....122         | TREAT 30D START.... 69       | <i>mesylate</i> ..... 122        |
| VIMKUNYA (PF).....53               | XATMEP..... 89               | ZIRGAN..... 146                  |
| <i>violele (28)</i> .....141       | XCOPRI.....103               | ZOLINZA..... 90                  |
| VIRACEPT..... 34                   | XCOPRI                       | <i>zolmitriptan</i> ..... 124    |
| VIREAD.....34                      | MAINTENANCE                  | <i>zolpidem</i> ..... 122        |
| <i>vitamin d2</i> .....169         | PACK..... 103                | ZONISADE..... 103                |
| VITRAKVI..... 88                   | XCOPRI TITRATION             | <i>zonisamide</i> .....103       |
| VIVOTIF..... 53                    | PACK..... 103                | <i>zovia 1-35 (28)</i> ..... 141 |
| VIZIMPRO..... 89                   | XDEMVY.....144               | ZTALMY.....104                   |
| VONJO..... 89                      | <i>xelria fe</i> .....141    | ZURZUVAE..... 122                |
|                                    | XERMELO..... 89              | ZYKADIA..... 91                  |

10/15/2026

ZYMFENTRA..... 44



## Notice of Availability of Language Assistance Services and Auxiliary Aids and Services

ATTENTION: If you speak a language other than English, free language assistance services are available to you. Appropriate auxiliary aids and services to provide information in accessible formats are also available free of charge. Call 1-844-428-2224 (TTY: 711).

አማርኛ ይነበብ:- ነጻ የቋንቋ እገዛ አገልግሎቶች ለእርስዎ ይገኛሉ። በተጨማሪም አግባብነት ያላቸው ለእርስዎ ተደራሽ በሆኑ ቅርጾች መረጃ የሚያቀርቡልዎ አጋኝ መሳሪያዎች እና አገልግሎቶችን ከክፍያ ነጻ ያገኛሉ። ወደ 1-844-428-2224 (TTY: 711) ይደውሉ።

العربية انتباه: تتوفر لك خدمات مساعدة لغوية مجانية. تتوفر كذلك مجاناً مساعدات وخدمات إضافية ملائمة لتزويد المعلومات بتنسيقات قابلة للوصول إليها. اتصل على الرقم 1-844-428-2224 (TTY: 711).

Հայերեն ՈՒՇԱԴՐՈՒԹՅՈՒՆ. Դուք կարող եք օգտվել անվճար լեզվական ծառայություններից: Անվճար հասանելի են նաև համապատասխան օժանդակ միջոցներ և ծառայություններ՝ մատչելի ձևաչափերով տեղեկություններ տրամադրելու համար: Չանգահարեք 1-844-428-2224 (TTY՝ 711):

বাংলা খেয়াল করুন: আপনার জন্য বিনামূল্যে ভাষা পরিষেবার সুবিধা রয়েছে। বিনামূল্যে অ্যাক্সেসযোগ্য ফর্ম্যাটে তথ্য দিতে উপযুক্ত সহায়ক উপকরণ এবং পরিষেবাও উপলব্ধ রয়েছে। এখানে কল করুন 1-844-428-2224 (TTY: 711)।

Français cadien COMMUNIQUE: Des services d'aide linguistique sans frais sont à votre disposition. Des aides et services auxiliaires appropriés pour fournir des informations en formats accessibles sont également proposés sans frais. Composez le 1-844-428-2224 (TTY : 711).

简体中文 注意：我们为您提供免费的语言协助服务，同时也可免费提供适当的辅助设施与服务，以便提供无障碍格式的信息。请致电 1-844-428-2224 (TTY: 711)。

繁體中文 注意：我們為您提供免費的語言協助服務，還免費提供適當的輔助工具和服務，以無障礙格式提供資訊。請致電 1-844-428-2224 (TTY: 711)。

دري توجه: خدمات رایگان کمک زبانی برای شما فراهم است. وسایل و خدمات کمکی مناسب برای ارائه اطلاعات به شکل قابل دسترس نیز به طور رایگان در دسترس می باشند. لطفاً با شماره 1-844-428-2224 (TTY: 711) تماس بگیرید.

فارسی توجه: خدمات کمک زبانی رایگان برای شما در دسترس است. ابزارها و خدمات کمکی مناسب برای ارائه اطلاعات در قالب های قابل دسترس نیز به صورت رایگان ارائه می شوند. لطفاً با شماره 1-844-428-2224 (TTY: 711) تماس بگیرید.

Français REMARQUE : des services d'assistance linguistique gratuits sont à votre disposition. Des services et aides pour obtenir des informations dans des formats accessibles sont également disponibles gratuitement. Appelez le 1-844-428-2224 (TTY : 711).

Deutsch ACHTUNG: Sprachdienstleistungen stehen Ihnen kostenlos zur Verfügung. Geeignete zusätzliche Unterstützung und Dienstleistungen für Informationen in zugänglichen Formaten stehen Ihnen ebenfalls kostenlos zur Verfügung. Rufen Sie folgende Nummer an: 1-844-428-2224 (TTY: 711).

ગુજરાતી ધ્યાન આપવાની જરૂર છે: તમારા માટે ભાષા સંબંધી સહાયતાની મફત સેવાઓ ઉપલબ્ધ છે. એક્સેસ કરી શકાય તેવાં ફોર્મેટમાં માહિતી પ્રદાન કરવા માટે યોગ્ય સહાયક સહાય અને સેવાઓ પણ મફતમાં ઉપલબ્ધ છે.

1-844-428-2224 (TTY: 711) પર કોલ કરો.

Kreyòl Ayisyen ATANSYON: Sèvis èd gratis pou lang disponib pou ou. Aparèy oksilyè ki bay asistans ak sèvis ki apwopriye pou bay enfòmasyon nan fòma aksesib yo disponib gratis tou. Rele nan 1-844-428-2224 (TTY: 711).

‘Ōlelo Hawai‘i HO‘ĀKAKA: Loa‘a iā ‘oe ke kōkua manuahi no ka unuhi ‘ōlelo. Loa‘a pū kekahi mau pono kōkua kūpono a me nā lawelawe e hā‘awi ai i ka ‘ike i nā ‘ano ‘ano hiki ke ki‘i ‘ia, me ka uku ‘ole. Kelepona i 1-844-428-2224 (TTY: 711).

हिंदी ध्यान दें: आपके लिए निःशुल्क भाषा सहायता सेवाएं उपलब्ध हैं. एक्सेस करने योग्य फ़ॉर्मेट में जानकारी प्रदान करने के लिए उपयुक्त सहायक साधन और सेवाएं भी निःशुल्क उपलब्ध हैं. 1-844-428-2224 (TTY: 711) पर कॉल करें.

Lus Hmoob TSEEM CEEB: Muaj cov kev pab txhais lus pub dawb rau koj. Tsis tas li ntawd, kuj tseem yuav muaj cov kev pab thiab cov kev pab cuam tsim nyog los ua hom ntaub ntawv uas siv tau pub dawb rau koj thiab. Hu rau 1-844-428-2224 (TTY: 711).

Igbo NLERUANYA: A na-enye gi ọrụ enyemaka asụsụ n’efu. Enyemaka na ọrụ ndị kwesiri ekwesị iji nye ozi n’udị ndị di mfe inweta dikrawa n’akwughị ụgwọ. Kpọọ 1-844-428-2224 (TTY: 711).

Iloko PALIIWEN: Adda dagiti libre a serbisio a tulong iti pagsasao. Dagiti maitutop a katulongan ken serbisio a mangipaay iti impormasion kadagiti nalaka a maawatan a pormat ket libre met a magun-odan. Tawagan ti 1-844-428-2224 (TTY: 711).

Italiano ATTENZIONE: sono disponibili servizi di assistenza linguistica gratuiti. Sono inoltre disponibili supporti e servizi ausiliari gratuiti adatti a fornire le informazioni in formati accessibili. Chiamare il numero 1-844-428-2224 (TTY: 711).

日本語 注意：言語支援サービスを無料で提供しています。情報をアクセシビリティに対応した形式で提供する各種補助支援およびサービスも無料です。1-844-428-2224 (TTY: 711) にお電話ください。

ಕನ್ನಡ ನಿಮ್ಮ ಗಮನಕ್ಕೆ: ನಿಮಗೆ ಉಚಿತ ಭಾಷಾ ಸಹಾಯ ಸೇವೆಗಳು ಲಭ್ಯವಿದೆ. ಪ್ರವೇಶಿಸಬಹುದಾದ ಸ್ವರೂಪಗಳಲ್ಲಿ ಮಾಹಿತಿಯನ್ನು ಒದಗಿಸಲು ಸೂಕ್ತವಾದ ಸಹಾಯಕ ಸಾಧನಗಳು ಮತ್ತು ಸೇವೆಗಳು ಸಹ ಉಚಿತವಾಗಿ ಲಭ್ಯವಿದೆ. ಕರೆ ಮಾಡಿ 1-844-428-2224 (TTY: 711).

한국어 주의: 무료 언어 지원 서비스를 이용하실 수 있습니다.  
정보 제공을 위해 적합한 보조 도구 및 서비스 또한 액세스 가능한  
형식으로 무료 이용이 가능합니다. 1-844-428-2224  
(TTY: 711)번으로 전화해 주십시오.

ພາສາລາວ ໝາຍເຫດ: ມີບໍລິການຊ່ວຍເຫຼືອດ້ານພາສາຟຣີສໍາລັບທ່ານ ນອກຈາກນີ້ຍັງມີ  
ບໍລິການຊ່ວຍເຫຼືອ ແລະ ບໍລິການເສີມທີ່ເໝາະສົມເພື່ອໃຫ້ຂໍ້ມູນທີ່ສາມາດເຂົ້າເຖິງໄດ້ໂດຍ  
ບໍ່ຕ້ອງເສຍຄ່າໃຊ້ຈ່າຍເພີ່ມເຕີມ. ໂທ 1-844-428-2224 (TTY: 711).

മലയാളം ശ്രദ്ധിക്കൂ: നിങ്ങൾക്ക് സൗജന്യ ഭാഷാ സഹായ  
സേവനങ്ങൾ ലഭ്യമാണ്. ആക്സസ് ചെയ്യാവുന്ന  
ഫോർമാറ്റുകളിൽ വിവരങ്ങൾ നൽകുന്നതിന്,  
സൗജന്യമായി അനുയോജ്യമായ ഓക്സിലിയറി  
സഹായങ്ങളും സേവനങ്ങളും ലഭ്യമാണ്. 1-844-428-2224  
(TTY: 711) എന്ന നമ്പറിൽ വിളിക്കുക.

तुमच्यासाठी विनामूल्य भाषा सहाय्य सेवा उपलब्ध आहेत. सुलभ स्वरूपात माहिती  
प्रदान करण्यासाठी योग्य अतिरिक्त मदत आणि सेवादेखील विनामूल्य उपलब्ध  
आहेत. 1-844-428-2224 (TTY: 711) वर कॉल करा.

Diné Bizaad BAA NAANISH'AGHA: T'aadoo baabhilinigoo saad 'ahiilka  
'ana'alwo' biniit'aa bineesh'a bil hadlee' goo ni. Ch'idi'nishaah t'aala'i bi'aa  
yilts'ilgo bika 'iishyeed 'aadoo biniit'aa goo bik'inaasdzil bil ch'idaash'a di  
baa honit'l' ya'akogoo bineesh'a aldo' bil hadlee' t'aadoo baabhilinigoo  
'at'e yeel. Bika 'adishni 1-844-428-2224 (TTY: 711).

नेपाली ध्यान दिनुहोस्: तपाईंका लागि भाषासम्बन्धी सहायता सेवाहरू निःशुल्क  
रूपमा उपलब्ध छन्। सुलभ फर्म्याटहरूमा जानकारी प्रदान गर्नका निम्ति उचित  
सहायक सामग्री र सेवाहरू पनि निःशुल्क रूपमा उपलब्ध छन्। 1-844-428-2224  
(TTY: 711) मा कल गर्नुहोस्।

Pennsylvania Deitsch GEB ACHT: Schprooch Hilfe sin meeglich mitaus Koscht. Rechtliche Auxiliary Aids un Hilfe um Information zu gewwe in helfreiche Formats sin aa meeglich mit aus Koscht. Ruf 1-844-428-2224 (TTY: 711).

Polski UWAGA: usługi wsparcia językowego są dostępne nieodpłatnie. Bezpłacie oferowane są również dodatkowe pomoce i usługi pozwalające na przekazanie informacji w formacie przystępnym dla odbiorcy. Zadzwoń pod numer 1-844-428-2224 (TTY: 711).

Português ATENÇÃO: estão disponíveis serviços de assistência gratuitos no seu idioma. Também estão disponíveis apoios auxiliares e serviços adequados que oferecem informações em formatos acessíveis e sem custos. Ligue para 1-844-428-2224 (TTY: 711).

ਮੁਫ਼ਤ ਭਾਸ਼ਾ ਸਹਾਇਤਾ ਸੇਵਾਵਾਂ ਤੁਹਾਡੇ ਲਈ ਉਪਲਬਧ ਹਨ। ਪਹੁੰਚਣਯੋਗ ਫਾਰਮੈਟਾਂ ਵਿੱਚ ਜਾਣਕਾਰੀ ਪ੍ਰਦਾਨ ਕਰਨ ਲਈ ਢੁਕਵੇਂ ਸਹਾਇਕ ਸਾਧਨ ਅਤੇ ਸੇਵਾਵਾਂ ਵੀ ਮੁਫ਼ਤ ਵਿੱਚ ਉਪਲਬਧ ਹਨ। 1-844-428-2224 (TTY: 711) 'ਤੇ ਕਾਲ ਕਰੋ।

Русский ВНИМАНИЕ! Вам доступны бесплатные услуги языковой поддержки. Вы также можете бесплатно получить соответствующие вспомогательные средства и услуги, направленные на предоставление информации в доступных форматах. Позвоните по номеру 1-844-428-2224 (TTY: 711).

Gagana Sāmoa FA'AALIGA: O lo'o avanoa fua ia te oe auaunaga fesoasoani i le gagana. E avanoa fo'i fua fesoasoani ma meafaigaluega talafeagai e tu'uina atu ai fa'amatalaga i auala faigofie ona malamalama ai. Vala'au 1-844-428-2224 (TTY: 711).

Srpski PAŽNJA: Dostupne su vam besplatne usluge jezičke pomoći. Odgovarajuća pomagala i pomoćne usluge koje nude informacije o pristupačnim formatima takođe su besplatne. Pozovite broj 1-844-428-2224 (TTY: 711).

Soomaali DIGNIIN: Adeegyada kaalmada luqadda bilaashka ah ayaa kuu diyaar ah. Sidoo kale, qalab iyo adeegyo kaabayaal ku habboon ayaa diyaar ah si macluumaadka loogu helo qaabab sahlan oo la heli karo, iyadoo aan wax kharash ah lagaaga qaadin. Wac 1-844-428-2224 (TTY: 711).

Español ATENCIÓN: Contamos con servicios de asistencia lingüística que se encuentran disponibles para usted de manera gratuita. También se encuentran disponibles de manera gratuita ayudas y servicios auxiliares adecuados para proporcionar información en formatos accesibles. Llame al 1-844-428-2224 (TTY: 711).

Kiswahili TANBIHI: Huduma za usaidizi wa lugha zinapatikana bila malipo kwako. Nyenzo na huduma sahihi za usaidizi za kutoa maelezo katika miundo inayoweza kufikiwa pia zinapatikana bila malipo. Piga simu 1-844-428-2224 (TTY: 711).

Tagalog ATENSYON: May mga libreng serbisyo ng tulong sa wika na available para sa inyo. Available din nang libre ang mga naaangkop na karagdagang tulong at serbisyo para makapagbigay ng impormasyon sa mga accessible na format. Tumawag sa 1-844-428-2224 (TTY: 711).

**தமிழ் உங்களின் கவனத்திற்கு: உங்களுக்கு மொழி உதவிக்கான இலவச சேவைகள் கிடைக்கின்றன. பயன்படுத்தக்கூடிய வடிவங்களில் தகவல்களை வழங்குவதற்குப் பொருத்தமான புலன் உணர்வுக் கருவிகளும் சேவைகளும் இலவசமாகக் கிடைக்கின்றன. 1-844-428-2224 (TTY: 711) என்ற எண்ணை அழைத்திடுங்கள்.**

తెలుగు గమనిక: మీకు ఉచిత భాష సంబంధ సహాయక సేవలు అందుబాటులో ఉన్నాయి. యాక్సెస్ చేయదగిన ఫార్మాట్లలో సమాచారాన్ని అందించడానికి తగిన సహాయక టూల్స్, సేవలు కూడా ఉచితంగా అందుబాటులో ఉన్నాయి. 1-844-428-2224 (TTY: 711) నంబర్ కి కాల్ చేయండి.

ไทย โปรดทราบ: พร้อมให้บริการความช่วยเหลือทางภาษาฟรีแก่คุณ และมีความช่วยเหลือและบริการเสริมที่เหมาะสมเพื่อให้ข้อมูลในรูปแบบที่เข้าถึงได้โดยไม่มีค่าใช้จ่ายด้วยเช่นกัน โทร 1-844-428-2224 (TTY: 711)

Twi HYE NO NSO: Kasa ho mmoa dwumadie ahodoɔ wo ho ma wo a wontua hwee. Nneɛma a ebeboa wo ama wate nsem ne dwumadie ahodoɔ a ede nsem bema wo wo akwan bebreɛ so nso wo ho a wontua hwee. Frɛ 1-844-428-2224 (TTY: 711).

Українська УВАГА! Вам доступні безкоштовні послуги мовної допомоги. Відповідні допоміжні засоби та послуги для надання інформації у доступних форматах також доступні безкоштовно. Зателефонуйте за номером 1-844-428-2224 (TTY: 711).

اردو توجہ: زبان معاونت کی خدمات آپ کے لیے مفت دستیاب ہیں۔ معلومات کو قابل رسائی شکل میں فراہم کرنے کے لیے مناسب معاون امداد اور خدمات بھی مفت دستیاب ہیں۔ 1-844-428-2224 (TTY: 711) پر کال کریں۔

Tiếng Việt LƯU Ý: Chúng tôi có cung cấp dịch vụ hỗ trợ ngôn ngữ miễn phí. Các dịch vụ và trợ giúp bổ trợ phù hợp để cung cấp thông tin ở các định dạng có thể truy cập cũng được cung cấp miễn phí. Gọi 1-844-428-2224 (TTY: 711).

יידיש אויפֿמערקזאַמקייט: פֿרייע שפּראַך הילף סערוויסעס זענען פֿאַר אײַך פֿאַראַן. פֿאַסיקע הילפֿסמיטלען און סערוויסעס צו צושטעלן אינפֿאָרמאַציע אין צוגענגלעכע פֿאָרמאַטן זענען אויך פֿאַראַן פֿריי פֿון אָפּצאָל. 1-844-428-2224 (TTY: 711).

Yorùbá ÀKÍYÈSÍ: Àwọn ọ̀ṣẹ̀ ìrànṣẹ̀wọ̀ tì èdè wà nílẹ̀ fún ọ̀ lọ́fẹ́ẹ̀. Àwọn ọ̀ṣẹ̀ àtì àwọn ìrànṣẹ̀wọ̀ aranníṣẹ̀wọ̀ tóyẹ̀ láti pèsè ìwífúnni ní àwọn ọ̀nà kíkọ̀sílẹ̀ tóṣeé ráàyẹ̀ sí tún wà nílẹ̀ bákan náà lọ́fẹ́ẹ̀ láisan owó rará. Pe 1-844-428-2224 (TTY: 711).



With



pa health  
& wellness.

42

### **Fòmilè sa a te aktyalize nan dat 10/15/2026.**

Pou plis enfòmasyon ki resan oswa lòt kesyon, tanpri kontakte nou, Sèvis pou Manm Wellcare yo nan **1-833-502-9471** (itilizatè TTY yo ta dwe rele nan **711**), ant 1 Oktòb ak 31 Mas, reprezantan yo disponib sèt jou pa semèn, 8 a.m. jiska 8 p.m., ant 1 Avril ak 30 Septanm, reprezantan yo disponib Lendi jiska Vandredi, 8 a.m. jiska 8 p.m., oswa vizite **[go.wellcare.com/PA](https://go.wellcare.com/PA)**.

10/15/2026

Medicare<sup>R</sup>  
Prescription Drug Coverage X